,sentence_text,e1,e2,relation_type,normalized_sentence
174,Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. ,Barbiturates,coumarin drugs,advise,DRUG glutethimide_be administered_be patients_be receiving_be coumarin_be drugs_be ._be
175,Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. ,glutethimide,coumarin drugs,advise,Barbiturates_bf DRUG administered_be patients_be receiving_be coumarin_be drugs_be ._be
213,Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.,Indinavir,didanosine,advise,DRUG may_be taken_be light_be meal_be 1_be following_be administration_be 400_be mg_be OTHER_DRUG ._af
255,We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.,carbamazepine,tricyclic antidepressants,advise,We_bf report_bf case_bf adolescent_bf altered_bf consciousness_bf caused_bf DRUG overdose_be positive_be tricyclic_be antidepressant_be level_be alert_be clinicians_be cross-reactivity_be DRUG toxicology_af screen_af tricyclic_af antidepressants_af ._af
390,"However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between antiretroviral and antineoplastic drugs. ",antiretroviral drugs,antineoplastic drugs,advise,"However_bf ,_bf careful_bf attention_bf must_bf directed_bf cross_bf toxicity_bf possible_bf pharmacokinetic_bf interactions_bf antiretroviral_bf antineoplastic_bf drugs_bf ._bf"
599,"Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.",sirolimus,diltiazem,advise,"Because_bf pronounced_bf intersubject_bf variability_bf extent_bf sirolimus-diltiazem_bf interaction_bf ,_bf whole_bf blood_bf DRUG concentrations_be monitored_be closely_be patients_be treated_be two_be drugs_be ._be"
849,"Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure. ",Sildenafil,long-acting nitrates,advise,"DRUG contraindicated_be patients_be using_be long-acting_be nitrates_be may_be need_be use_be short-acting_be nitrates_be ,_be combination_be may_be cause_be sharp_be fall_be blood_be pressure_be ._be"
850,"Sildenafil is contraindicated in patients using long-acting nitrates or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure. ",Sildenafil,short-acting nitrates,advise,"DRUG contraindicated_be patients_be using_be long-acting_be nitrates_be may_be need_be use_be short-acting_be nitrates_be ,_be combination_be may_be cause_be sharp_be fall_be blood_be pressure_be ._be"
1626,Concurrent therapy with ORENCIA and TNF antagonists is not recommended.,ORENCIA,TNF antagonists,advise,Concurrent_bf therapy_bf DRUG TNF_be antagonists_be recommended_be ._be
1627,"There is insufficient experience to assess the safety and efficacy of ORENCIA administered concurrently with anakinra, and therefore such use is not recommended.",ORENCIA,anakinra,advise,"There_bf insufficient_bf experience_bf assess_bf safety_bf efficacy_bf DRUG administered_be concurrently_be OTHER_DRUG ,_af therefore_af use_af recommended_af ._af"
1812,"Patients treated with acebutolol plus catecholamine depletors should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.",acebutolol,catecholamine depletors,advise,"Patients_bf treated_bf DRUG plus_be catecholamine_be depletors_be ,_be therefore_be ,_be observed_be closely_be evidence_be marked_be bradycardia_be hypotension_be may_be present_be vertigo_be ,_be syncope/presyncope_be ,_be orthostatic_be changes_be blood_be pressure_be without_be compensatory_be tachycardia_be ._be"
1842,"Caution is advised when beginning, discontinuing, or changing the dose of DIAMOX in patients receiving primidone.",DIAMOX,primidone,advise,"Caution_bf advised_bf beginning_bf ,_bf discontinuing_bf ,_bf changing_bf dose_bf DRUG patients_be receiving_be OTHER_DRUG ._af"
1875,Microdosed minipill progestin preparations are not recommended for use with Soriatane.,progestin,Soriatane,advise,Microdosed_bf minipill_bf DRUG preparations_be recommended_be use_be OTHER_DRUG ._af
1880,"Consequently, the combination of methotrexate with acitretin is also contraindicated.",methotrexate,acitretin,advise,"Consequently_bf ,_bf combination_bf DRUG OTHER_DRUG also_af contraindicated_af ._af"
1898,Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.,vitamin A,acitretin,advise,Vitamin_bf A_bf oral_bf retinoids:_bf Concomitant_bf administration_bf vitamin_bf A_bf and/or_bf oral_bf retinoids_bf OTHER_DRUG must_be avoided_be risk_be hypervitaminosis_be A_be ._be
1899,Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.,retinoids,acitretin,advise,Vitamin_bf A_bf oral_bf retinoids:_bf Concomitant_bf administration_bf vitamin_bf A_bf and/or_bf oral_bf DRUG OTHER_DRUG must_af avoided_af risk_af hypervitaminosis_af A_af ._af
1990,"In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.",methylxanthines,adenosine,advise,"In_bf presence_bf DRUG ,_be larger_be doses_be OTHER_DRUG may_af required_af OTHER_DRUG may_af effective_af ._af"
1991,"In the presence of these methylxanthines, larger doses of adenosine may be required or adenosine may not be effective.",methylxanthines,adenosine,advise,"In_bf presence_bf DRUG ,_be larger_be doses_be OTHER_DRUG may_af required_af OTHER_DRUG may_af effective_af ._af"
2001,"Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).",Nafazodone,Xanax,advise,"DRUG ,_be fluvoxamine_be ,_be cimetidine_be (consider_be OTHER_DRUG dose_af reduction)_af ._af"
2003,"Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).",fluvoxamine,Xanax,advise,"Nafazodone_bf ,_bf DRUG ,_be cimetidine_be (consider_be OTHER_DRUG dose_af reduction)_af ._af"
2004,"Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction).",cimetidine,Xanax,advise,"Nafazodone_bf ,_bf fluvoxamine_bf ,_bf DRUG (consider_be OTHER_DRUG dose_af reduction)_af ._af"
2124,"However, interactions may be expected, and UROXATRAL should NOT be used in combination with other alpha-blockers.",UROXATRAL,alpha-blockers,advise,"However_bf ,_bf interactions_bf may_bf expected_bf ,_bf DRUG NOT_be used_be combination_be OTHER_DRUG ._af"
2298,"In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.",allopurinol,mercaptopurine,advise,"In_bf patients_bf receiving_bf OTHER_DRUG (Purinethol)_be azathioprine_be (Imuran)_be ,_be concomitant_be administration_be 300-600_be mg_be DRUG per_af day_af require_af reduction_af dose_af approximately_af one-third_af one-fourth_af usual_af dose_af OTHER_DRUG azathioprine_af ._af"
2299,"In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.",allopurinol,azathioprine,advise,"In_bf patients_bf receiving_bf mercaptopurine_bf (Purinethol)_bf OTHER_DRUG (Imuran)_be ,_be concomitant_be administration_be 300-600_be mg_be DRUG per_af day_af require_af reduction_af dose_af approximately_af one-third_af one-fourth_af usual_af dose_af mercaptopurine_af OTHER_DRUG ._af"
2325,"Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on thiazide diuretics and allopurinol even in the absence of renal failure, and dosage levels should be even more conservatively adjusted in those patients on such combined therapy if diminished renal function is detected..",thiazide diuretics,allopurinol,advise,"Although_bf causal_bf mechanism_bf cause-and-effect_bf relationship_bf established_bf ,_bf current_bf evidence_bf suggests_bf renal_bf function_bf monitored_bf patients_bf thiazide_bf diuretics_bf OTHER_DRUG even_be absence_be renal_be failure_be ,_be dosage_be levels_be even_be conservatively_be adjusted_be patients_be combined_be therapy_be diminished_be renal_be function_be detected_be ._be ._be"
2375,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",ergotamine,AXERT,advise,"Because_bf theoretical_bf basis_bf effects_bf may_bf additive_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf dihydroergotamine_bf methysergide)_bf OTHER_DRUG within_be 24_be hours_be avoided_be ._be"
2378,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",ergot-type medications,AXERT,advise,"Because_bf theoretical_bf basis_bf effects_bf may_bf additive_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf dihydroergotamine_bf methysergide)_bf OTHER_DRUG within_be 24_be hours_be avoided_be ._be"
2380,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",dihydroergotamine,AXERT,advise,"Because_bf theoretical_bf basis_bf effects_bf may_bf additive_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf DRUG methysergide)_be OTHER_DRUG within_af 24_af hours_af avoided_af ._af"
2381,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.",methysergide,AXERT,advise,"Because_bf theoretical_bf basis_bf effects_bf may_bf additive_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf dihydroergotamine_bf methysergide)_bf OTHER_DRUG within_be 24_be hours_be avoided_be ._be"
2387,Other 5-HT1B/1D Agonists Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with AXERT is contraindicated.,5-HT1B/1D agonists,AXERT,advise,Other_bf 5-HT1B/1D_bf Agonists_bf Concomitant_bf use_bf 5-HT1B/1D_bf agonists_bf within_bf 24_bf hours_bf treatment_bf OTHER_DRUG contraindicated_be ._be
2419,"If concomitant treatment with AXERT and an SSRI is clinically warranted, appropriate observation of the patient is advised.",AXERT,SSRI,advise,"If_bf concomitant_bf treatment_bf DRUG OTHER_DRUG clinically_af warranted_af ,_af appropriate_af observation_af patient_af advised_af ._af"
2437,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.",itraconazole,almotriptan,advise,"Although_bf interaction_bf OTHER_DRUG potent_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be DRUG ,_af ritonavir_af ,_af erythromycin)_af studied_af ,_af increased_af exposures_af OTHER_DRUG may_af expected_af OTHER_DRUG used_af concomitantly_af medications_af ._af"
2440,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.",ritonavir,almotriptan,advise,"Although_bf interaction_bf OTHER_DRUG potent_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be itraconazole_be ,_be DRUG ,_af erythromycin)_af studied_af ,_af increased_af exposures_af OTHER_DRUG may_af expected_af OTHER_DRUG used_af concomitantly_af medications_af ._af"
2442,"Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.",erythromycin,almotriptan,advise,"Although_bf interaction_bf OTHER_DRUG potent_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be itraconazole_be ,_be ritonavir_be ,_be erythromycin)_be studied_be ,_be increased_be exposures_be OTHER_DRUG may_af expected_af OTHER_DRUG used_af concomitantly_af medications_af ._af"
2447,Concomitant administration of alosetron and fluvoxamine is contraindicated.,alosetron,fluvoxamine,advise,Concomitant_bf administration_bf DRUG OTHER_DRUG contraindicated_af ._af
2448,"Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.",alosetron,quinolone antibiotics,advise,"Concomitant_bf administration_bf DRUG moderate_be CYP1A2_be inhibitors_be ,_be including_be quinolone_be antibiotics_be cimetidine_be ,_be evaluated_be ,_be avoided_be unless_be clinically_be necessary_be similar_be potential_be drug_be interactions_be ._be"
2449,"Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions.",alosetron,cimetidine,advise,"Concomitant_bf administration_bf DRUG moderate_be CYP1A2_be inhibitors_be ,_be including_be quinolone_be antibiotics_be OTHER_DRUG ,_af evaluated_af ,_af avoided_af unless_af clinically_af necessary_af similar_af potential_af drug_af interactions_af ._af"
2453,Caution should be used when alosetron and ketoconazole are administered concomitantly.,alosetron,ketoconazole,advise,Caution_bf used_bf DRUG OTHER_DRUG administered_af concomitantly_af ._af
2454,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,clarithromycin,advise,"Coadministration_bf DRUG strong_be CYP3A4_be inhibitors_be ,_be OTHER_DRUG ,_af telithromycin_af ,_af protease_af inhibitors_af ,_af voriconazole_af ,_af itraconazole_af evaluated_af undertaken_af caution_af similar_af potential_af drug_af interactions_af ._af"
2455,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,telithromycin,advise,"Coadministration_bf DRUG strong_be CYP3A4_be inhibitors_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af protease_af inhibitors_af ,_af voriconazole_af ,_af itraconazole_af evaluated_af undertaken_af caution_af similar_af potential_af drug_af interactions_af ._af"
2456,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,protease inhibitors,advise,"Coadministration_bf DRUG strong_be CYP3A4_be inhibitors_be ,_be clarithromycin_be ,_be telithromycin_be ,_be protease_be inhibitors_be ,_be voriconazole_be ,_be itraconazole_be evaluated_be undertaken_be caution_be similar_be potential_be drug_be interactions_be ._be"
2457,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,voriconazole,advise,"Coadministration_bf DRUG strong_be CYP3A4_be inhibitors_be ,_be clarithromycin_be ,_be telithromycin_be ,_be protease_be inhibitors_be ,_be OTHER_DRUG ,_af itraconazole_af evaluated_af undertaken_af caution_af similar_af potential_af drug_af interactions_af ._af"
2458,"Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.",alosetron,itraconazole,advise,"Coadministration_bf DRUG strong_be CYP3A4_be inhibitors_be ,_be clarithromycin_be ,_be telithromycin_be ,_be protease_be inhibitors_be ,_be voriconazole_be ,_be OTHER_DRUG evaluated_af undertaken_af caution_af similar_af potential_af drug_af interactions_af ._af"
2490,Careful observation is required when amantadine is administered concurrently with central nervous system stimulants.,amantadine,central nervous system stimulants,advise,Careful_bf observation_bf required_bf DRUG administered_be concurrently_be central_be nervous_be system_be stimulants_be ._be
2491,Special consideration should be given to the administration of ETHYOL in patients receiving antihypertensive medications or other drugs that could cause or potentiate hypotension.,ETHYOL,antihypertensive medications,advise,Special_bf consideration_bf given_bf administration_bf DRUG patients_be receiving_be antihypertensive_be medications_be drugs_be could_be cause_be potentiate_be hypotension_be ._be
2493,Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.,Lithium,diuretics,advise,DRUG generally_be given_be OTHER_DRUG reduce_af renal_af clearance_af add_af high_af risk_af DRUG toxicity_af ._af
2500,"Therefore, when MIDAMOR and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.",MIDAMOR,non-steroidal anti-inflammatory agents,advise,"Therefore_bf ,_bf DRUG non-steroidal_be anti-inflammatory_be agents_be used_be concomitantly_be ,_be patient_be observed_be closely_be determine_be desired_be effect_be diuretic_be obtained_be ._be"
2515,Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.,amiodarone,protease inhibitor,advise,Monitoring_bf DRUG toxicity_be serial_be measurement_be DRUG serum_af concentration_af concomitant_af protease_af inhibitor_af therapy_af considered_af ._af
2561,"On administration of oral amiodarone, the need for digitalis therapy should be reviewed and the dose reduced by approximately 50% or discontinued.",amiodarone,digitalis,advise,"On_bf administration_bf oral_bf DRUG ,_be need_be OTHER_DRUG therapy_af reviewed_af dose_af reduced_af approximately_af 50%_af discontinued_af ._af"
2750,"Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other.",TCAs,SSRIs,advise,"Nevertheless_bf ,_bf caution_bf indicated_bf coadministration_bf DRUG OTHER_DRUG also_af switching_af one_af class_af ._af"
2890,Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.,Amprenavir,ritonavir,advise,Appropriate_bf laboratory_bf testing_bf considered_bf prior_bf initiating_bf combination_bf therapy_bf DRUG OTHER_DRUG periodic_af intervals_af clinical_af signs_af symptoms_af hyperlipidemia_af elevated_af liver_af function_af tests_af occur_af therapy_af ._af
2971,"Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).",tamoxifen,anastrozole,advise,"Based_bf clinical_bf pharmacokinetic_bf results_bf ATAC_bf trial_bf ,_bf DRUG administered_be OTHER_DRUG (see_af CLINICAL_af PHARMACOLOGY_af Drug_af Interactions_af CLINICAL_af PHARMACOLOGY_af -_af Clinical_af Studies_af -_af Adjuvant_af Treatment_af Breast_af Cancer_af Postmenopausal_af Women_af subsections)_af ._af"
2978,Estrogen-containing therapies should not be used with ARIMIDEX as they may diminish its pharmacologic action.,Estrogen,ARIMIDEX,advise,Estrogen-containing_bf therapies_bf used_bf OTHER_DRUG may_be diminish_be pharmacologic_be action_be ._be
3003,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,5HT3 antagonist class,advise,"5HT3_bf Antagonists:_bf Based_bf reports_bf profound_bf hypotension_bf loss_bf consciousness_bf DRUG administered_be ondansetron_be ,_be concomitant_be use_be DRUG drugs_af 5HT3_af antagonist_af class_af (including_af ,_af example_af ,_af ondansetron_af ,_af granisetron_af ,_af dolasetron_af ,_af palonosetron_af ,_af alosetron)_af contraindicated_af ._af"
3004,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,ondansetron,advise,"5HT3_bf Antagonists:_bf Based_bf reports_bf profound_bf hypotension_bf loss_bf consciousness_bf DRUG administered_be OTHER_DRUG ,_af concomitant_af use_af DRUG drugs_af 5HT3_af antagonist_af class_af (including_af ,_af example_af ,_af OTHER_DRUG ,_af granisetron_af ,_af dolasetron_af ,_af palonosetron_af ,_af alosetron)_af contraindicated_af ._af"
3005,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,granisetron,advise,"5HT3_bf Antagonists:_bf Based_bf reports_bf profound_bf hypotension_bf loss_bf consciousness_bf DRUG administered_be ondansetron_be ,_be concomitant_be use_be DRUG drugs_af 5HT3_af antagonist_af class_af (including_af ,_af example_af ,_af ondansetron_af ,_af OTHER_DRUG ,_af dolasetron_af ,_af palonosetron_af ,_af alosetron)_af contraindicated_af ._af"
3006,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,dolasetron,advise,"5HT3_bf Antagonists:_bf Based_bf reports_bf profound_bf hypotension_bf loss_bf consciousness_bf DRUG administered_be ondansetron_be ,_be concomitant_be use_be DRUG drugs_af 5HT3_af antagonist_af class_af (including_af ,_af example_af ,_af ondansetron_af ,_af granisetron_af ,_af OTHER_DRUG ,_af palonosetron_af ,_af alosetron)_af contraindicated_af ._af"
3007,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,palonosetron,advise,"5HT3_bf Antagonists:_bf Based_bf reports_bf profound_bf hypotension_bf loss_bf consciousness_bf DRUG administered_be ondansetron_be ,_be concomitant_be use_be DRUG drugs_af 5HT3_af antagonist_af class_af (including_af ,_af example_af ,_af ondansetron_af ,_af granisetron_af ,_af dolasetron_af ,_af OTHER_DRUG ,_af alosetron)_af contraindicated_af ._af"
3008,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,alosetron,advise,"5HT3_bf Antagonists:_bf Based_bf reports_bf profound_bf hypotension_bf loss_bf consciousness_bf DRUG administered_be ondansetron_be ,_be concomitant_be use_be DRUG drugs_af 5HT3_af antagonist_af class_af (including_af ,_af example_af ,_af ondansetron_af ,_af granisetron_af ,_af dolasetron_af ,_af palonosetron_af ,_af alosetron)_af contraindicated_af ._af"
3075,"Patients with major psychotic disorders, treated with neuroleptics, should be treated with dopamine agonists only if the potential benefits outweigh the risks.",neuroleptics,dopamine agonists,advise,"Patients_bf major_bf psychotic_bf disorders_bf ,_bf treated_bf DRUG ,_be treated_be dopamine_be agonists_be potential_be benefits_be outweigh_be risks_be ._be"
3076,Apraclonidine should not be used in patients receiving MAO inhibitors..,Apraclonidine,MAO inhibitors,advise,DRUG used_be patients_be receiving_be MAO_be inhibitors_be ._be ._be
3077,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,CNS depressants,advise,"Although_bf specific_bf drug_bf interactions_bf topical_bf glaucoma_bf drugs_bf systemic_bf medications_bf identified_bf clinical_bf studies_bf DRUG 0_be ._be 5%_be Ophthalmic_be Solution_be ,_be possibility_be additive_be potentiating_be effect_be CNS_be depressants_be (alcohol_be ,_be barbiturates_be ,_be opiates_be ,_be sedatives_be ,_be anesthetics)_be considered_be ._be"
3078,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,alcohol,advise,"Although_bf specific_bf drug_bf interactions_bf topical_bf glaucoma_bf drugs_bf systemic_bf medications_bf identified_bf clinical_bf studies_bf DRUG 0_be ._be 5%_be Ophthalmic_be Solution_be ,_be possibility_be additive_be potentiating_be effect_be CNS_be depressants_be (alcohol_be ,_be barbiturates_be ,_be opiates_be ,_be sedatives_be ,_be anesthetics)_be considered_be ._be"
3079,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,barbiturates,advise,"Although_bf specific_bf drug_bf interactions_bf topical_bf glaucoma_bf drugs_bf systemic_bf medications_bf identified_bf clinical_bf studies_bf DRUG 0_be ._be 5%_be Ophthalmic_be Solution_be ,_be possibility_be additive_be potentiating_be effect_be CNS_be depressants_be (alcohol_be ,_be OTHER_DRUG ,_af opiates_af ,_af sedatives_af ,_af anesthetics)_af considered_af ._af"
3080,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,opiates,advise,"Although_bf specific_bf drug_bf interactions_bf topical_bf glaucoma_bf drugs_bf systemic_bf medications_bf identified_bf clinical_bf studies_bf DRUG 0_be ._be 5%_be Ophthalmic_be Solution_be ,_be possibility_be additive_be potentiating_be effect_be CNS_be depressants_be (alcohol_be ,_be barbiturates_be ,_be OTHER_DRUG ,_af sedatives_af ,_af anesthetics)_af considered_af ._af"
3081,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,sedatives,advise,"Although_bf specific_bf drug_bf interactions_bf topical_bf glaucoma_bf drugs_bf systemic_bf medications_bf identified_bf clinical_bf studies_bf DRUG 0_be ._be 5%_be Ophthalmic_be Solution_be ,_be possibility_be additive_be potentiating_be effect_be CNS_be depressants_be (alcohol_be ,_be barbiturates_be ,_be opiates_be ,_be OTHER_DRUG ,_af anesthetics)_af considered_af ._af"
3082,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.",IOPIDINE,anesthetics,advise,"Although_bf specific_bf drug_bf interactions_bf topical_bf glaucoma_bf drugs_bf systemic_bf medications_bf identified_bf clinical_bf studies_bf DRUG 0_be ._be 5%_be Ophthalmic_be Solution_be ,_be possibility_be additive_be potentiating_be effect_be CNS_be depressants_be (alcohol_be ,_be barbiturates_be ,_be opiates_be ,_be sedatives_be ,_be anesthetics)_be considered_be ._be"
3100,"Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.",apraclonidine,beta-blockers,advise,"Since_bf DRUG may_be reduce_be pulse_be blood_be pressure_be ,_be caution_be using_be drugs_be OTHER_DRUG (ophthalmic_af systemic)_af ,_af antihypertensives_af ,_af cardiac_af glycosides_af advised_af ._af"
3101,"Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.",apraclonidine,antihypertensives,advise,"Since_bf DRUG may_be reduce_be pulse_be blood_be pressure_be ,_be caution_be using_be drugs_be beta-blockers_be (ophthalmic_be systemic)_be ,_be OTHER_DRUG ,_af cardiac_af glycosides_af advised_af ._af"
3102,"Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.",apraclonidine,cardiac glycosides,advise,"Since_bf DRUG may_be reduce_be pulse_be blood_be pressure_be ,_be caution_be using_be drugs_be beta-blockers_be (ophthalmic_be systemic)_be ,_be antihypertensives_be ,_be cardiac_be glycosides_be advised_be ._be"
3140,"The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.",dexamethasone,Aprepitant,advise,"The_bf oral_bf DRUG doses_be reduced_be approximately_be 50%_be coadministered_be OTHER_DRUG ,_af achieve_af exposures_af DRUG similar_af obtained_af given_af without_af OTHER_DRUG ._af"
3153,"The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.",methylprednisolone,Aprepitant,advise,"The_bf IV_bf DRUG dose_be reduced_be approximately_be 25%_be ,_be oral_be DRUG dose_af reduced_af approximately_af 50%_af coadministered_af OTHER_DRUG achieve_af exposures_af DRUG similar_af obtained_af given_af without_af OTHER_DRUG ._af"
3156,"The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.",methylprednisolone,Aprepitant,advise,"The_bf IV_bf DRUG dose_be reduced_be approximately_be 25%_be ,_be oral_be DRUG dose_af reduced_af approximately_af 50%_af coadministered_af OTHER_DRUG achieve_af exposures_af DRUG similar_af obtained_af given_af without_af OTHER_DRUG ._af"
3175,"In patients on chronic warfarin therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of Aprepitant with each chemotherapy cycle.",warfarin,Aprepitant,advise,"In_bf patients_bf chronic_bf DRUG therapy_be ,_be prothrombin_be time_be (INR)_be closely_be monitored_be 2-week_be period_be ,_be particularly_be 7_be 10_be days_be ,_be following_be initiation_be 3-day_be regimen_be OTHER_DRUG chemotherapy_af cycle_af ._af"
3208,"Although a 3-day regimen of Aprepitant given concomitantly with oral contraceptives has not been studied, alternative or back-up methods of contraception should be used.",Aprepitant,contraceptives,advise,"Although_bf 3-day_bf regimen_bf DRUG given_be concomitantly_be oral_be OTHER_DRUG studied_af ,_af alternative_af back-up_af methods_af contraception_af used_af ._af"
3222,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",midazolam,Aprepitant,advise,"The_bf potential_bf effects_bf increased_bf plasma_bf concentrations_bf DRUG benzodiazepines_be metabolized_be via_be CYP3A4_be (alprazolam_be ,_be triazolam)_be considered_be coadministering_be agents_be OTHER_DRUG ._af"
3225,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",benzodiazepines,Aprepitant,advise,"The_bf potential_bf effects_bf increased_bf plasma_bf concentrations_bf midazolam_bf DRUG metabolized_be via_be CYP3A4_be (alprazolam_be ,_be triazolam)_be considered_be coadministering_be agents_be OTHER_DRUG ._af"
3227,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",alprazolam,Aprepitant,advise,"The_bf potential_bf effects_bf increased_bf plasma_bf concentrations_bf midazolam_bf benzodiazepines_bf metabolized_bf via_bf CYP3A4_bf (alprazolam_bf ,_bf triazolam)_bf considered_bf coadministering_bf agents_bf OTHER_DRUG ._be"
3228,"The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.",triazolam,Aprepitant,advise,"The_bf potential_bf effects_bf increased_bf plasma_bf concentrations_bf midazolam_bf benzodiazepines_bf metabolized_bf via_bf CYP3A4_bf (alprazolam_bf ,_bf triazolam)_bf considered_bf coadministering_bf agents_bf OTHER_DRUG ._be"
3242,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,ketoconazole,advise,"Consequently_bf ,_bf concomitant_bf administration_bf DRUG strong_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af itraconazole_af ,_af nefazodone_af ,_af troleandomycin_af ,_af clarithromycin_af ,_af ritonavir_af ,_af nelfinavir)_af approached_af caution_af ._af"
3243,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,itraconazole,advise,"Consequently_bf ,_bf concomitant_bf administration_bf DRUG strong_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be OTHER_DRUG ,_af nefazodone_af ,_af troleandomycin_af ,_af clarithromycin_af ,_af ritonavir_af ,_af nelfinavir)_af approached_af caution_af ._af"
3244,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,nefazodone,advise,"Consequently_bf ,_bf concomitant_bf administration_bf DRUG strong_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be OTHER_DRUG ,_af troleandomycin_af ,_af clarithromycin_af ,_af ritonavir_af ,_af nelfinavir)_af approached_af caution_af ._af"
3245,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,troleandomycin,advise,"Consequently_bf ,_bf concomitant_bf administration_bf DRUG strong_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be nefazodone_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af ritonavir_af ,_af nelfinavir)_af approached_af caution_af ._af"
3246,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,clarithromycin,advise,"Consequently_bf ,_bf concomitant_bf administration_bf DRUG strong_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be nefazodone_be ,_be troleandomycin_be ,_be OTHER_DRUG ,_af ritonavir_af ,_af nelfinavir)_af approached_af caution_af ._af"
3247,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,ritonavir,advise,"Consequently_bf ,_bf concomitant_bf administration_bf DRUG strong_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be nefazodone_be ,_be troleandomycin_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af nelfinavir)_af approached_af caution_af ._af"
3248,"Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.",Aprepitant,nelfinavir,advise,"Consequently_bf ,_bf concomitant_bf administration_bf DRUG strong_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be nefazodone_be ,_be troleandomycin_be ,_be clarithromycin_be ,_be ritonavir_be ,_be nelfinavir)_be approached_be caution_be ._be"
3270,"Because moderate CYP3A4 inhibitors (e.g., diltiazem) result in 2-fold increase in plasma concentrations of aprepitant, concomitant administration should also be approached with caution.",diltiazem,aprepitant,advise,"Because_bf moderate_bf CYP3A4_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf diltiazem)_bf result_bf 2-fold_bf increase_bf plasma_bf concentrations_bf OTHER_DRUG ,_be concomitant_be administration_be also_be approached_be caution_be ._be"
3377,"Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.",ABILIFY,centrally acting drugs,advise,"Drug-Drug_bf Interactions_bf Given_bf primary_bf CNS_bf effects_bf aripiprazole_bf ,_bf caution_bf used_bf DRUG taken_be combination_be centrally_be acting_be drugs_be alcohol_be ._be"
3378,"Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.",ABILIFY,alcohol,advise,"Drug-Drug_bf Interactions_bf Given_bf primary_bf CNS_bf effects_bf aripiprazole_bf ,_bf caution_bf used_bf DRUG taken_be combination_be centrally_be acting_be drugs_be OTHER_DRUG ._af"
3399,"When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.",ketoconazole,aripiprazole,advise,"When_bf concomitant_bf administration_bf DRUG OTHER_DRUG occurs_af ,_af OTHER_DRUG dose_af reduced_af one-half_af normal_af dose_af ._af"
3414,Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.,quinidine,aripiprazole,advise,OTHER_DRUG dose_be reduced_be one-half_be normal_be dose_be concomitant_be administration_be DRUG OTHER_DRUG occurs_af ._af
3426,"When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.",carbamazepine,aripiprazole,advise,"When_bf DRUG added_be OTHER_DRUG therapy_af ,_af OTHER_DRUG dose_af doubled_af ._af"
3429,"When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.",carbamazepine,aripiprazole,advise,"When_bf DRUG withdrawn_be combination_be therapy_be ,_be OTHER_DRUG dose_af reduced_af ._af"
3459,"As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY",alcohol,ABILIFY,advise,"As_bf psychoactive_bf medications_bf ,_bf patients_bf advised_bf avoid_bf DRUG taking_be OTHER_DRUG"
3460,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,antiarrhythmics,advise,Caution_bf advised_bf DRUG coadministered_be medications_be prolong_be QT_be interval_be (e_be ._be g_be ._be certain_be OTHER_DRUG thioridazine)_af lead_af electrolyte_af abnormalities_af (such_af diuretics_af amphotericin_af B)_af ._af
3461,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,thioridazine,advise,Caution_bf advised_bf DRUG coadministered_be medications_be prolong_be QT_be interval_be (e_be ._be g_be ._be certain_be antiarrhythmics_be thioridazine)_be lead_be electrolyte_be abnormalities_be (such_be diuretics_be amphotericin_be B)_be ._be
3462,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,diuretics,advise,Caution_bf advised_bf DRUG coadministered_be medications_be prolong_be QT_be interval_be (e_be ._be g_be ._be certain_be antiarrhythmics_be thioridazine)_be lead_be electrolyte_be abnormalities_be (such_be OTHER_DRUG amphotericin_af B)_af ._af
3463,Caution is advised when TRISENOX is coadministered with other medications that can prolong the QT interval (e.g. certain antiarrhythmics or thioridazine) or lead to electrolyte abnormalities (such as diuretics or amphotericin B).,TRISENOX,amphotericin B,advise,Caution_bf advised_bf DRUG coadministered_be medications_be prolong_be QT_be interval_be (e_be ._be g_be ._be certain_be antiarrhythmics_be thioridazine)_be lead_be electrolyte_be abnormalities_be (such_be diuretics_be amphotericin_be B)_be ._be
3473,"These results would seem to dictate against the clinical use of methotrexate with ELSPAR, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.",methotrexate,ELSPAR,advise,"These_bf results_bf would_bf seem_bf dictate_bf clinical_bf use_bf DRUG OTHER_DRUG ,_af period_af following_af OTHER_DRUG therapy_af plasma_af asparagine_af levels_af normal_af ._af"
3500,Nonsteroidal Antiinflammatory Agents: Aspirin is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.,Aspirin,nonsteroidal anti-inflammatory,advise,Nonsteroidal_bf Antiinflammatory_bf Agents:_bf DRUG contraindicated_be patients_be hypersensitive_be nonsteroidal_be anti-inflammatory_be agents_be ._be
3509,"Antacids: Enteric Coated Aspirin should not be given concurrently with antacids, since an increase in the pH of the stomach may effect the enteric coating of the tablets.",Aspirin,antacids,advise,"Antacids:_bf Enteric_bf Coated_bf DRUG given_be concurrently_be OTHER_DRUG ,_af since_af increase_af pH_af stomach_af may_af effect_af enteric_af coating_af tablets_af ._af"
3519,"If the two drugs are coadministered, the beta blocker should be withdrawn several days before the gradual withdrawal of clonidine.",beta blocker,clonidine,advise,"If_bf two_bf drugs_bf coadministered_bf ,_bf beta_bf blocker_bf withdrawn_bf several_bf days_bf gradual_bf withdrawal_bf OTHER_DRUG ._be"
3525,"If replacing clonidine by beta-blocker therapy, the introduction of beta blockers should be delayed for several days after clonidine administration has stopped.",beta blockers,clonidine,advise,"If_bf replacing_bf OTHER_DRUG beta-blocker_be therapy_be ,_be introduction_be beta_be blockers_be delayed_be several_be days_be OTHER_DRUG administration_af stopped_af ._af"
3559,"Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.",azathioprine,allopurinol,advise,"Patients_bf receiving_bf DRUG OTHER_DRUG concomitantly_af dose_af reduction_af DRUG ,_af approximately_af 1/3_af 1/4_af usual_af dose_af ._af"
3569,"Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted.",azithromycin,nelfinavir,advise,"Although_bf dose_bf adjustment_bf DRUG recommended_be administered_be combination_be OTHER_DRUG ,_af close_af monitoring_af known_af side_af effects_af DRUG ,_af liver_af enzyme_af abnormalities_af hearing_af impairment_af ,_af warranted_af ._af"
3573,"However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with azithromycin and warfarin concomitantly.",azithromycin,warfarin,advise,"However_bf ,_bf prudent_bf medical_bf practice_bf dictates_bf careful_bf monitoring_bf prothrombin_bf time_bf patients_bf treated_bf DRUG OTHER_DRUG concomitantly_af ._af"
3705,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,amikacin,advise,"DRUG administered_be concomitantly_be OTHER_DRUG ,_af ciprofloxacin_af ,_af gentamicin_af ,_af netilmicin_af ,_af tobramycin_af ._af"
3706,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,ciprofloxacin,advise,"DRUG administered_be concomitantly_be amikacin_be ,_be OTHER_DRUG ,_af gentamicin_af ,_af netilmicin_af ,_af tobramycin_af ._af"
3707,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,gentamicin,advise,"DRUG administered_be concomitantly_be amikacin_be ,_be ciprofloxacin_be ,_be OTHER_DRUG ,_af netilmicin_af ,_af tobramycin_af ._af"
3708,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,netilmicin,advise,"DRUG administered_be concomitantly_be amikacin_be ,_be ciprofloxacin_be ,_be gentamicin_be ,_be OTHER_DRUG ,_af tobramycin_af ._af"
3709,"Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.",Azlocillin,tobramycin,advise,"DRUG administered_be concomitantly_be amikacin_be ,_be ciprofloxacin_be ,_be gentamicin_be ,_be netilmicin_be ,_be OTHER_DRUG ._af"
3779,The possibility of hypotensive effects with Lotensin can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with Lotensin.,diuretic,Lotensin,advise,The_bf possibility_bf hypotensive_bf effects_bf OTHER_DRUG minimized_be either_be discontinuing_be DRUG increasing_af salt_af intake_af prior_af initiation_af treatment_af OTHER_DRUG ._af
3871,DIDREX should not be used concomitantly with other CNS stimulants.,DIDREX,CNS stimulants,advise,DRUG used_be concomitantly_be CNS_be stimulants_be ._be
3967,"Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.",beta-blockers,clonidine,advise,"Should_bf decided_bf discontinue_bf therapy_bf patients_bf receiving_bf DRUG OTHER_DRUG concurrently_af ,_af beta-blocker_af discontinued_af slowly_af several_af days_af gradual_af withdrawal_af OTHER_DRUG ._af"
3972,"Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.",beta-blocker,clonidine,advise,"Should_bf decided_bf discontinue_bf therapy_bf patients_bf receiving_bf beta-blockers_bf OTHER_DRUG concurrently_be ,_be DRUG discontinued_af slowly_af several_af days_af gradual_af withdrawal_af OTHER_DRUG ._af"
3973,"Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function.",calcium antagonists,beta-adrenergic blocking agents,advise,"Literature_bf reports_bf suggest_bf oral_bf calcium_bf antagonists_bf may_bf used_bf combination_bf beta-adrenergic_bf blocking_bf agents_bf heart_bf function_bf normal_bf ,_bf avoided_bf patients_bf impaired_bf cardiac_bf function_bf ._bf"
4029,Concomitant administration of gemfibrozil with Targretin capsules is not recommended.,gemfibrozil,Targretin,advise,Concomitant_bf administration_bf DRUG OTHER_DRUG capsules_af recommended_af ._af
4040,"For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters",anticoagulant,Bezalip,advise,"For_bf reason_bf ,_bf dose_bf DRUG reduced_be 30_be -_be 50%_be start_be treatment_be OTHER_DRUG OTHER_DRUG retard_af titrated_af according_af blood_af clotting_af parameters_af"
4041,"For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with Bezalip or Bezalip retard and then titrated according to the blood clotting parameters",anticoagulant,Bezalip,advise,"For_bf reason_bf ,_bf dose_bf DRUG reduced_be 30_be -_be 50%_be start_be treatment_be OTHER_DRUG OTHER_DRUG retard_af titrated_af according_af blood_af clotting_af parameters_af"
4051,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip,anion-exchange resins,advise,"-_bf When_bf DRUG DRUG retard_af used_af concurrently_af anion-exchange_af resins_af (e_af ._af g_af ._af cholestryramine)_af ,_af interval_af least_af 2_af hours_af maintained_af two_af medicines_af ,_af since_af absorption_af DRUG DRUG retard_af impaire"
4052,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip,cholestryramine,advise,"-_bf When_bf DRUG DRUG retard_af used_af concurrently_af anion-exchange_af resins_af (e_af ._af g_af ._af cholestryramine)_af ,_af interval_af least_af 2_af hours_af maintained_af two_af medicines_af ,_af since_af absorption_af DRUG DRUG retard_af impaire"
4055,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip retard,anion-exchange resins,advise,"-_bf When_bf Bezalip_bf Bezalip_bf retard_bf used_bf concurrently_bf anion-exchange_bf resins_bf (e_bf ._bf g_bf ._bf cholestryramine)_bf ,_bf interval_bf least_bf 2_bf hours_bf maintained_bf two_bf medicines_bf ,_bf since_bf absorption_bf Bezalip_bf Beza"
4056,"- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired",Bezalip retard,cholestryramine,advise,"-_bf When_bf Bezalip_bf Bezalip_bf retard_bf used_bf concurrently_bf anion-exchange_bf resins_bf (e_bf ._bf g_bf ._bf cholestryramine)_bf ,_bf interval_bf least_bf 2_bf hours_bf maintained_bf two_bf medicines_bf ,_bf since_bf absorption_bf Bezalip_bf Beza"
4066,#NAME?,Perhexiline hydrogen maleate,Bezalip,advise,-_bf Perhexiline_bf hydrogen_bf maleate_bf MAO-inhibitors_bf (with_bf hepatotoxic_bf potential)_bf must_bf administered_bf together_bf OTHER_DRUG OTHER_DRUG retard_af ._af
4067,#NAME?,Perhexiline hydrogen maleate,Bezalip retard,advise,-_bf Perhexiline_bf hydrogen_bf maleate_bf MAO-inhibitors_bf (with_bf hepatotoxic_bf potential)_bf must_bf administered_bf together_bf Bezalip_bf Bezalip_bf retard_bf ._bf
4068,#NAME?,MAO-inhibitors,Bezalip,advise,-_bf Perhexiline_bf hydrogen_bf maleate_bf DRUG (with_be hepatotoxic_be potential)_be must_be administered_be together_be OTHER_DRUG OTHER_DRUG retard_af ._af
4069,#NAME?,MAO-inhibitors,Bezalip retard,advise,-_bf Perhexiline_bf hydrogen_bf maleate_bf DRUG (with_be hepatotoxic_be potential)_be must_be administered_be together_be Bezalip_be Bezalip_be retard_be ._be
4074,"It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.",CASODEX,coumarin anticoagulants,advise,"It_bf recommended_bf DRUG started_be patients_be already_be receiving_be coumarin_be anticoagulants_be ,_be prothrombin_be times_be closely_be monitored_be adjustment_be anticoagulant_be dose_be may_be necessary_be ._be"
4075,"It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.",CASODEX,anticoagulant,advise,"It_bf recommended_bf DRUG started_be patients_be already_be receiving_be coumarin_be anticoagulants_be ,_be prothrombin_be times_be closely_be monitored_be adjustment_be OTHER_DRUG dose_af may_af necessary_af ._af"
4137,Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.,antidiabetic agents,VELCADE,advise,Patients_bf oral_bf antidiabetic_bf agents_bf receiving_bf OTHER_DRUG treatment_be may_be require_be close_be monitoring_be blood_be glucose_be levels_be adjustment_be dose_be antidiabetic_be medication_be ._be
4164,The concomitant administration of bosentan and cyclosporine A is contraindicated.,bosentan,cyclosporine A,advise,The_bf concomitant_bf administration_bf DRUG cyclosporine_be A_be contraindicated_be ._be
4172,Caution should be exercised if tacrolimus and bosentan are used together.,tacrolimus,bosentan,advise,Caution_bf exercised_bf DRUG OTHER_DRUG used_af together_af ._af
4174,"Therefore, the concomitant administration of TRACLEER and glyburide is contraindicated, and alternative hypoglycemic agents should be considered.",TRACLEER,glyburide,advise,"Therefore_bf ,_bf concomitant_bf administration_bf DRUG OTHER_DRUG contraindicated_af ,_af alternative_af hypoglycemic_af agents_af considered_af ._af"
4198,Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after TRACLEER is initiated to see whether the statin dose needs adjustment.,statins,TRACLEER,advise,Patients_bf using_bf CYP3A4_bf metabolized_bf DRUG cholesterol_be levels_be monitored_be OTHER_DRUG initiated_af see_af whether_af statin_af dose_af needs_af adjustment_af ._af
4245,"Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",BOTOX,aminoglycosides,advise,"Co-administration_bf DRUG OTHER_DRUG agents_af interfering_af neuromuscular_af transmission_af (e_af ._af g_af ._af ,_af curare-like_af compounds)_af performed_af caution_af effect_af toxin_af may_af potentiated_af ._af"
4246,"Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",BOTOX,curare-like compounds,advise,"Co-administration_bf DRUG aminoglycosides_be agents_be interfering_be neuromuscular_be transmission_be (e_be ._be g_be ._be ,_be curare-like_be compounds)_be performed_be caution_be effect_be toxin_be may_be potentiated_be ._be"
4252,"Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",MYOBLOC,aminoglycosides,advise,"Co-administration_bf DRUG OTHER_DRUG agents_af interfering_af neuromuscular_af transmission_af (e_af ._af g_af ._af ,_af curare-like_af compounds)_af performed_af caution_af effect_af toxin_af may_af potentiated_af ._af"
4253,"Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.",MYOBLOC,curare-like compounds,advise,"Co-administration_bf DRUG aminoglycosides_be agents_be interfering_be neuromuscular_be transmission_be (e_be ._be g_be ._be ,_be curare-like_be compounds)_be performed_be caution_be effect_be toxin_be may_be potentiated_be ._be"
4266,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,CNS depressants,advise,"Although_bf specific_bf drug_bf interaction_bf studies_bf conducted_bf ALPHAGAN_bf P_bf ,_bf possibility_bf additive_bf potentiating_bf effect_bf CNS_bf depressants_bf (alcohol_bf ,_bf barbiturates_bf ,_bf opiates_bf ,_bf sedatives_bf ,_bf anesthetics)_bf considered_bf ._bf"
4267,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,alcohol,advise,"Although_bf specific_bf drug_bf interaction_bf studies_bf conducted_bf ALPHAGAN_bf P_bf ,_bf possibility_bf additive_bf potentiating_bf effect_bf CNS_bf depressants_bf (alcohol_bf ,_bf barbiturates_bf ,_bf opiates_bf ,_bf sedatives_bf ,_bf anesthetics)_bf considered_bf ._bf"
4268,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,barbiturates,advise,"Although_bf specific_bf drug_bf interaction_bf studies_bf conducted_bf ALPHAGAN_bf P_bf ,_bf possibility_bf additive_bf potentiating_bf effect_bf CNS_bf depressants_bf (alcohol_bf ,_bf OTHER_DRUG ,_be opiates_be ,_be sedatives_be ,_be anesthetics)_be considered_be ._be"
4269,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,opiates,advise,"Although_bf specific_bf drug_bf interaction_bf studies_bf conducted_bf ALPHAGAN_bf P_bf ,_bf possibility_bf additive_bf potentiating_bf effect_bf CNS_bf depressants_bf (alcohol_bf ,_bf barbiturates_bf ,_bf OTHER_DRUG ,_be sedatives_be ,_be anesthetics)_be considered_be ._be"
4270,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,sedatives,advise,"Although_bf specific_bf drug_bf interaction_bf studies_bf conducted_bf ALPHAGAN_bf P_bf ,_bf possibility_bf additive_bf potentiating_bf effect_bf CNS_bf depressants_bf (alcohol_bf ,_bf barbiturates_bf ,_bf opiates_bf ,_bf OTHER_DRUG ,_be anesthetics)_be considered_be ._be"
4271,"Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.",ALPHAGAN P,anesthetics,advise,"Although_bf specific_bf drug_bf interaction_bf studies_bf conducted_bf ALPHAGAN_bf P_bf ,_bf possibility_bf additive_bf potentiating_bf effect_bf CNS_bf depressants_bf (alcohol_bf ,_bf barbiturates_bf ,_bf opiates_bf ,_bf sedatives_bf ,_bf anesthetics)_bf considered_bf ._bf"
4314,Concomitant use of bromocriptine mesylate with other ergot alkaloids is not recommended.,bromocriptine mesylate,ergot alkaloids,advise,Concomitant_bf use_bf bromocriptine_bf mesylate_bf ergot_bf alkaloids_bf recommended_bf ._bf
4385,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",ketoconazole,budesonide,advise,"If_bf treatment_bf inhibitors_bf CYP3A4_bf activity_bf (such_bf DRUG ,_be intraconazole_be ,_be ritonavir_be ,_be indinavir_be ,_be saquinavir_be ,_be erythromycin_be ,_be etc_be ._be )_be indicated_be ,_be reduction_be OTHER_DRUG dose_af considered_af ._af"
4390,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",intraconazole,budesonide,advise,"If_bf treatment_bf inhibitors_bf CYP3A4_bf activity_bf (such_bf ketoconazole_bf ,_bf DRUG ,_be ritonavir_be ,_be indinavir_be ,_be saquinavir_be ,_be erythromycin_be ,_be etc_be ._be )_be indicated_be ,_be reduction_be OTHER_DRUG dose_af considered_af ._af"
4394,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",ritonavir,budesonide,advise,"If_bf treatment_bf inhibitors_bf CYP3A4_bf activity_bf (such_bf ketoconazole_bf ,_bf intraconazole_bf ,_bf DRUG ,_be indinavir_be ,_be saquinavir_be ,_be erythromycin_be ,_be etc_be ._be )_be indicated_be ,_be reduction_be OTHER_DRUG dose_af considered_af ._af"
4397,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",indinavir,budesonide,advise,"If_bf treatment_bf inhibitors_bf CYP3A4_bf activity_bf (such_bf ketoconazole_bf ,_bf intraconazole_bf ,_bf ritonavir_bf ,_bf DRUG ,_be saquinavir_be ,_be erythromycin_be ,_be etc_be ._be )_be indicated_be ,_be reduction_be OTHER_DRUG dose_af considered_af ._af"
4399,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",saquinavir,budesonide,advise,"If_bf treatment_bf inhibitors_bf CYP3A4_bf activity_bf (such_bf ketoconazole_bf ,_bf intraconazole_bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf DRUG ,_be erythromycin_be ,_be etc_be ._be )_be indicated_be ,_be reduction_be OTHER_DRUG dose_af considered_af ._af"
4400,"If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.",erythromycin,budesonide,advise,"If_bf treatment_bf inhibitors_bf CYP3A4_bf activity_bf (such_bf ketoconazole_bf ,_bf intraconazole_bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf saquinavir_bf ,_bf DRUG ,_be etc_be ._be )_be indicated_be ,_be reduction_be OTHER_DRUG dose_af considered_af ._af"
4401,#NAME?,bumetanide,aminoglycoside antibiotics,advise,#NAME?
4406,#NAME?,Lithium,diuretics,advise,-_bf Lithium:_bf DRUG generally_be given_be OTHER_DRUG (such_af bumetanide)_af reduce_af renal_af clearance_af add_af high_af risk_af DRUG toxicity_af ._af
4407,#NAME?,Lithium,bumetanide,advise,-_bf Lithium:_bf DRUG generally_be given_be diuretics_be (such_be bumetanide)_be reduce_be renal_be clearance_be add_be high_be risk_be DRUG toxicity_af ._af
4418,"Thus, probenecid should not be administered concurrently with bumetanide.",probenecid,bumetanide,advise,"Thus_bf ,_bf DRUG administered_be concurrently_be OTHER_DRUG ._af"
4488,"SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.",SUBUTEX,benzodiazepines,advise,"DRUG SUBOXONE_be prescribed_be caution_be patients_be OTHER_DRUG drugs_af act_af central_af nervous_af system_af ,_af regardless_af whether_af drugs_af taken_af advice_af physician_af taken_af drugs_af abuse_af ._af"
4489,"SUBUTEX and SUBOXONE should be prescribed with caution to patients on benzodiazepines or other drugs that act on the central nervous system, regardless of whether these drugs are taken on the advice of a physician or are taken as drugs of abuse.",SUBOXONE,benzodiazepines,advise,"SUBUTEX_bf DRUG prescribed_be caution_be patients_be OTHER_DRUG drugs_af act_af central_af nervous_af system_af ,_af regardless_af whether_af drugs_af taken_af advice_af physician_af taken_af drugs_af abuse_af ._af"
4490,Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.,benzodiazepines,SUBOXONE,advise,Patients_bf warned_bf potential_bf danger_bf intravenous_bf self-administration_bf DRUG treatment_be OTHER_DRUG SUBUTEX_af ._af
4491,Patients should be warned of the potential danger of the intravenous self-administration of benzodiazepines while under treatment with SUBOXONE or SUBUTEX.,benzodiazepines,SUBUTEX,advise,Patients_bf warned_bf potential_bf danger_bf intravenous_bf self-administration_bf DRUG treatment_be SUBOXONE_be OTHER_DRUG ._af
4526,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,antidepressants,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be OTHER_DRUG (e_af ._af g_af ._af ,_af nortriptyline_af ,_af imipramine_af ,_af desipramine_af ,_af paroxetine_af ,_af fluoxetine_af ,_af sertraline)_af ,_af antipsychotics_af (e_af ._af g_af ._af ,_af haloperidol_af ,_af risperidone_af ,_af thioridazine)_af ,_af beta-blockers_af (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
4527,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,nortriptyline,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af imipramine_af ,_af desipramine_af ,_af paroxetine_af ,_af fluoxetine_af ,_af sertraline)_af ,_af antipsychotics_af (e_af ._af g_af ._af ,_af haloperidol_af ,_af risperidone_af ,_af thioridazine)_af ,_af beta-blockers_af (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
4528,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,imipramine,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be OTHER_DRUG ,_af desipramine_af ,_af paroxetine_af ,_af fluoxetine_af ,_af sertraline)_af ,_af antipsychotics_af (e_af ._af g_af ._af ,_af haloperidol_af ,_af risperidone_af ,_af thioridazine)_af ,_af beta-blockers_af (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
4529,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,desipramine,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be OTHER_DRUG ,_af paroxetine_af ,_af fluoxetine_af ,_af sertraline)_af ,_af antipsychotics_af (e_af ._af g_af ._af ,_af haloperidol_af ,_af risperidone_af ,_af thioridazine)_af ,_af beta-blockers_af (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
4530,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,paroxetine,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be OTHER_DRUG ,_af fluoxetine_af ,_af sertraline)_af ,_af antipsychotics_af (e_af ._af g_af ._af ,_af haloperidol_af ,_af risperidone_af ,_af thioridazine)_af ,_af beta-blockers_af (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
4531,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,fluoxetine,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be OTHER_DRUG ,_af sertraline)_af ,_af antipsychotics_af (e_af ._af g_af ._af ,_af haloperidol_af ,_af risperidone_af ,_af thioridazine)_af ,_af beta-blockers_af (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
4532,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,sertraline,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be antipsychotics_be (e_be ._be g_be ._be ,_be haloperidol_be ,_be risperidone_be ,_be thioridazine)_be ,_be beta-blockers_be (e_be ._be g_be ._be ,_be metoprolol)_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be initiated_be lower_be end_be dose_be range_be concomitant_be medication_be ._be"
4533,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,antipsychotics,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af haloperidol_af ,_af risperidone_af ,_af thioridazine)_af ,_af beta-blockers_af (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
4534,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,haloperidol,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be antipsychotics_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af risperidone_af ,_af thioridazine)_af ,_af beta-blockers_af (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
4535,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,risperidone,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be antipsychotics_be (e_be ._be g_be ._be ,_be haloperidol_be ,_be OTHER_DRUG ,_af thioridazine)_af ,_af beta-blockers_af (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
4536,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,thioridazine,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be antipsychotics_be (e_be ._be g_be ._be ,_be haloperidol_be ,_be risperidone_be ,_be thioridazine)_be ,_be beta-blockers_be (e_be ._be g_be ._be ,_be metoprolol)_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be initiated_be lower_be end_be dose_be range_be concomitant_be medication_be ._be"
4537,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,beta-blockers,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be antipsychotics_be (e_be ._be g_be ._be ,_be haloperidol_be ,_be risperidone_be ,_be thioridazine)_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af metoprolol)_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
4538,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,metoprolol,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be antipsychotics_be (e_be ._be g_be ._be ,_be haloperidol_be ,_be risperidone_be ,_be thioridazine)_be ,_be beta-blockers_be (e_be ._be g_be ._be ,_be metoprolol)_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be initiated_be lower_be end_be dose_be range_be concomitant_be medication_be ._be"
4539,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,Type 1C antiarrhythmics,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be antipsychotics_be (e_be ._be g_be ._be ,_be haloperidol_be ,_be risperidone_be ,_be thioridazine)_be ,_be beta-blockers_be (e_be ._be g_be ._be ,_be metoprolol)_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be initiated_be lower_be end_be dose_be range_be concomitant_be medication_be ._be"
4540,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,propafenone,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be antipsychotics_be (e_be ._be g_be ._be ,_be haloperidol_be ,_be risperidone_be ,_be thioridazine)_be ,_be beta-blockers_be (e_be ._be g_be ._be ,_be metoprolol)_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af flecainide)_af ,_af approached_af caution_af initiated_af lower_af end_af dose_af range_af concomitant_af medication_af ._af"
4541,"Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.",bupropion,flecainide,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be CYP2D6_be isoenzyme_be including_be certain_be antidepressants_be (e_be ._be g_be ._be ,_be nortriptyline_be ,_be imipramine_be ,_be desipramine_be ,_be paroxetine_be ,_be fluoxetine_be ,_be sertraline)_be ,_be antipsychotics_be (e_be ._be g_be ._be ,_be haloperidol_be ,_be risperidone_be ,_be thioridazine)_be ,_be beta-blockers_be (e_be ._be g_be ._be ,_be metoprolol)_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be initiated_be lower_be end_be dose_be range_be concomitant_be medication_be ._be"
4678,"Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.",WELLBUTRIN,levodopa,advise,"Administration_bf DRUG Tablets_be patients_be receiving_be either_be OTHER_DRUG amantadine_af concurrently_af undertaken_af caution_af ,_af using_af small_af initial_af doses_af small_af gradual_af dose_af increases_af ._af"
4679,"Administration of WELLBUTRIN Tablets to patients receiving either levodopa or amantadine concurrently should be undertaken with caution, using small initial doses and small gradual dose increases.",WELLBUTRIN,amantadine,advise,"Administration_bf DRUG Tablets_be patients_be receiving_be either_be levodopa_be OTHER_DRUG concurrently_af undertaken_af caution_af ,_af using_af small_af initial_af doses_af small_af gradual_af dose_af increases_af ._af"
4681,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,antipsychotics,advise,"Drugs_bf Lower_bf Seizure_bf Threshold:_bf Concurrent_bf administration_bf DRUG agents_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af antidepressants_af ,_af theophylline_af ,_af systemic_af steroids_af ,_af etc_af ._af )_af lower_af seizure_af threshold_af undertaken_af extreme_af caution_af ._af"
4682,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,antidepressants,advise,"Drugs_bf Lower_bf Seizure_bf Threshold:_bf Concurrent_bf administration_bf DRUG agents_be (e_be ._be g_be ._be ,_be antipsychotics_be ,_be OTHER_DRUG ,_af theophylline_af ,_af systemic_af steroids_af ,_af etc_af ._af )_af lower_af seizure_af threshold_af undertaken_af extreme_af caution_af ._af"
4683,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,theophylline,advise,"Drugs_bf Lower_bf Seizure_bf Threshold:_bf Concurrent_bf administration_bf DRUG agents_be (e_be ._be g_be ._be ,_be antipsychotics_be ,_be antidepressants_be ,_be OTHER_DRUG ,_af systemic_af steroids_af ,_af etc_af ._af )_af lower_af seizure_af threshold_af undertaken_af extreme_af caution_af ._af"
4684,"Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.",WELLBUTRIN,steroids,advise,"Drugs_bf Lower_bf Seizure_bf Threshold:_bf Concurrent_bf administration_bf DRUG agents_be (e_be ._be g_be ._be ,_be antipsychotics_be ,_be antidepressants_be ,_be theophylline_be ,_be systemic_be OTHER_DRUG ,_af etc_af ._af )_af lower_af seizure_af threshold_af undertaken_af extreme_af caution_af ._af"
4697,The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS),alcohol,WELLBUTRIN,advise,The_bf consumption_bf DRUG treatment_be OTHER_DRUG minimized_af avoided_af (also_af see_af href=_af bupropz_od_af ._af htm#CI_af CONTRAINDICATIONS)_af
4698,"It is recommended that buspirone hydrochloride not be used concomitantly with MAO inhibitors Because the effects of concomitant administration of buspirone HCl with most other psychotropic drugs have not been studied, the concomitant use of buspirone HCl with other CNS-active drugs should be approached with caution.",buspirone hydrochloride,MAO inhibitors,advise,"It_bf recommended_bf buspirone_bf hydrochloride_bf used_bf concomitantly_bf MAO_bf inhibitors_bf Because_bf effects_bf concomitant_bf administration_bf buspirone_bf HCl_bf psychotropic_bf drugs_bf studied_bf ,_bf concomitant_bf use_bf buspirone_bf HCl_bf CNS-active_bf drugs_bf approached_bf caution_bf ._bf"
4947,"It is not known if the effects of butorphanol are altered by concomitant medications that affect hepatic metabolism of drugs (erythromycin, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.",butorphanol,erythromycin,advise,"It_bf known_bf effects_bf DRUG altered_be concomitant_be medications_be affect_be hepatic_be metabolism_be drugs_be (erythromycin_be ,_be etc_be ._be )_be ,_be physicians_be alert_be possibility_be smaller_be initial_be dose_be longer_be intervals_be doses_be may_be needed_be ._be"
4953,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,phenothiazines,advise,"DRUG administered_be concurrently_be D2-antagonists_be ,_be OTHER_DRUG ,_af butyrophenones_af ,_af thioxanthines_af ,_af metoclopramide_af ._af"
4954,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,butyrophenones,advise,"DRUG administered_be concurrently_be D2-antagonists_be ,_be phenothiazines_be ,_be OTHER_DRUG ,_af thioxanthines_af ,_af metoclopramide_af ._af"
4955,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,thioxanthines,advise,"DRUG administered_be concurrently_be D2-antagonists_be ,_be phenothiazines_be ,_be butyrophenones_be ,_be OTHER_DRUG ,_af metoclopramide_af ._af"
4956,"DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or metoclopramide.",DOSTINEX,metoclopramide,advise,"DRUG administered_be concurrently_be D2-antagonists_be ,_be phenothiazines_be ,_be butyrophenones_be ,_be thioxanthines_be ,_be OTHER_DRUG ._af"
4964,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,cimetidine,advise,"Based_bf adult_bf data_bf ,_bf lower_bf doses_bf DRUG may_be needed_be following_be coadministration_be drugs_be reported_be decrease_be DRUG elimination_af (e_af ._af g_af ._af ,_af OTHER_DRUG ketoconazole)_af higher_af DRUG doses_af may_af needed_af following_af coadministration_af drugs_af increase_af DRUG elimination_af (e_af ._af g_af ._af ,_af phenobarbital_af phenytoin)_af ._af"
4965,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,ketoconazole,advise,"Based_bf adult_bf data_bf ,_bf lower_bf doses_bf DRUG may_be needed_be following_be coadministration_be drugs_be reported_be decrease_be DRUG elimination_af (e_af ._af g_af ._af ,_af cimetidine_af ketoconazole)_af higher_af DRUG doses_af may_af needed_af following_af coadministration_af drugs_af increase_af DRUG elimination_af (e_af ._af g_af ._af ,_af phenobarbital_af phenytoin)_af ._af"
4986,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,phenobarbital,advise,"Based_bf adult_bf data_bf ,_bf lower_bf doses_bf DRUG may_be needed_be following_be coadministration_be drugs_be reported_be decrease_be DRUG elimination_af (e_af ._af g_af ._af ,_af cimetidine_af ketoconazole)_af higher_af DRUG doses_af may_af needed_af following_af coadministration_af drugs_af increase_af DRUG elimination_af (e_af ._af g_af ._af ,_af OTHER_DRUG phenytoin)_af ._af"
4987,"Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).",caffeine,phenytoin,advise,"Based_bf adult_bf data_bf ,_bf lower_bf doses_bf DRUG may_be needed_be following_be coadministration_be drugs_be reported_be decrease_be DRUG elimination_af (e_af ._af g_af ._af ,_af cimetidine_af ketoconazole)_af higher_af DRUG doses_af may_af needed_af following_af coadministration_af drugs_af increase_af DRUG elimination_af (e_af ._af g_af ._af ,_af phenobarbital_af phenytoin)_af ._af"
5041,"Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.",Vitamin D,digitalis,advise,"Digitalis:_bf Vitamin_bf D_bf dosage_bf must_bf determined_bf care_bf patients_bf undergoing_bf treatment_bf OTHER_DRUG ,_be hypercalcemia_be patients_be may_be precipitate_be cardiac_be arrhythmias_be ._be"
5055,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",Magnesium,vitamin D,advise,"Magnesium:_bf Magnesium-containing_bf preparations_bf (eg_bf ,_bf antacids)_bf may_bf cause_bf hypermagnesemia_bf therefore_bf taken_bf therapy_bf vitamin_bf D_bf patients_bf chronic_bf renal_bf dialysis_bf ._bf"
5056,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",antacids,vitamin D,advise,"Magnesium:_bf Magnesium-containing_bf preparations_bf (eg_bf ,_bf antacids)_bf may_bf cause_bf hypermagnesemia_bf therefore_bf taken_bf therapy_bf vitamin_bf D_bf patients_bf chronic_bf renal_bf dialysis_bf ._bf"
5107,"Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.",Vitamin D,digitalis,advise,"Digitalis:_bf Vitamin_bf D_bf dosage_bf must_bf determined_bf care_bf patients_bf undergoing_bf treatment_bf OTHER_DRUG ,_be hypercalcemia_be patients_be may_be precipitate_be cardiac_be arrhythmias_be ._be"
5121,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",Magnesium,vitamin D,advise,"Magnesium:_bf Magnesium-containing_bf preparations_bf (eg_bf ,_bf antacids)_bf may_bf cause_bf hypermagnesemia_bf therefore_bf taken_bf therapy_bf vitamin_bf D_bf patients_bf chronic_bf renal_bf dialysis_bf ._bf"
5122,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",antacids,vitamin D,advise,"Magnesium:_bf Magnesium-containing_bf preparations_bf (eg_bf ,_bf antacids)_bf may_bf cause_bf hypermagnesemia_bf therefore_bf taken_bf therapy_bf vitamin_bf D_bf patients_bf chronic_bf renal_bf dialysis_bf ._bf"
5196,Patients taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (PT or INR).,coumarin-derivative anticoagulants,capecitabine,advise,Patients_bf taking_bf coumarin-derivative_bf anticoagulants_bf concomitantly_bf OTHER_DRUG monitored_be regularly_be alterations_be coagulation_be parameters_be (PT_be INR)_be ._be
6683,"Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.",EQUETROTM,centrally acting drugs,advise,"Because_bf primary_bf CNS_bf effect_bf ,_bf caution_bf used_bf DRUG taken_be centrally_be acting_be drugs_be alcohol_be ._be"
6684,"Because of its primary CNS effect, caution should be used when EQUETROTM is taken with other centrally acting drugs and alcohol.",EQUETROTM,alcohol,advise,"Because_bf primary_bf CNS_bf effect_bf ,_bf caution_bf used_bf DRUG taken_be centrally_be acting_be drugs_be OTHER_DRUG ._af"
6730,Ocupress should be used with caution in patients who are receiving a beta-adrenergic blocking agent orally because of the potential for additive effects on systemic beta-blockade.,Ocupress,beta-adrenergic blocking agent,advise,DRUG used_be caution_be patients_be receiving_be beta-adrenergic_be blocking_be agent_be orally_be potential_be additive_be effects_be systemic_be beta-blockade_be ._be
6731,"Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope, or postural hypotension.",beta-blocker,reserpine,advise,"Close_bf observation_bf patient_bf recommended_bf DRUG administered_be patients_be receiving_be catecholamine-depleting_be drugs_be OTHER_DRUG ,_af possible_af additive_af effects_af production_af hypotension_af and/or_af marked_af bradycardia_af ,_af may_af produce_af vertigo_af ,_af syncope_af ,_af postural_af hypotension_af ._af"
6759,"When concomitant treatment with agents with b-blocking properties and clonidine is to be terminated, the b-blocking agent should be discontinued first.",agents with b-blocking properties,clonidine,advise,"When_bf concomitant_bf treatment_bf agents_bf b-blocking_bf properties_bf OTHER_DRUG terminated_be ,_be b-blocking_be agent_be discontinued_be first_be ._be"
6766,"Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.",cyclosporine,carvedilol,advise,"Due_bf wide_bf interindividual_bf variability_bf dose_bf adjustment_bf required_bf ,_bf recommended_bf DRUG concentrations_be monitored_be closely_be initiation_be OTHER_DRUG therapy_af dose_af DRUG adjusted_af appropriate_af ._af"
6768,"Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.",carvedilol,cyclosporine,advise,"Due_bf wide_bf interindividual_bf variability_bf dose_bf adjustment_bf required_bf ,_bf recommended_bf OTHER_DRUG concentrations_be monitored_be closely_be initiation_be DRUG therapy_af dose_af OTHER_DRUG adjusted_af appropriate_af ._af"
6776,"Therefore, increased monitoring of digoxin is recommended when initiating, adjusting, or discontinuing COREG.",digoxin,COREG,advise,"Therefore_bf ,_bf increased_bf monitoring_bf DRUG recommended_be initiating_be ,_be adjusting_be ,_be discontinuing_be OTHER_DRUG ._af"
6786,"As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.",COREG,verapamil,advise,"As_bf agents_bf b-blocking_bf properties_bf ,_bf DRUG administered_be orally_be calcium_be channel_be blockers_be OTHER_DRUG diltiazem_af type_af ,_af recommended_af ECG_af blood_af pressure_af monitored_af ._af"
6787,"As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.",COREG,diltiazem,advise,"As_bf agents_bf b-blocking_bf properties_bf ,_bf DRUG administered_be orally_be calcium_be channel_be blockers_be verapamil_be OTHER_DRUG type_af ,_af recommended_af ECG_af blood_af pressure_af monitored_af ._af"
6835,Patients on rifampin should receive 70 mg of CANCIDAS daily.,rifampin,CANCIDAS,advise,Patients_bf DRUG receive_be 70_be mg_be OTHER_DRUG daily_af ._af
6857,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,efavirenz,advise,"When_bf DRUG co-administered_be inducers_be drug_be clearance_be ,_be OTHER_DRUG ,_af nevirapine_af ,_af phenytoin_af ,_af dexamethasone_af ,_af carbamazepine_af ,_af use_af daily_af dose_af 70_af mg_af DRUG considered_af"
6858,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,nevirapine,advise,"When_bf DRUG co-administered_be inducers_be drug_be clearance_be ,_be efavirenz_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af dexamethasone_af ,_af carbamazepine_af ,_af use_af daily_af dose_af 70_af mg_af DRUG considered_af"
6859,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,phenytoin,advise,"When_bf DRUG co-administered_be inducers_be drug_be clearance_be ,_be efavirenz_be ,_be nevirapine_be ,_be OTHER_DRUG ,_af dexamethasone_af ,_af carbamazepine_af ,_af use_af daily_af dose_af 70_af mg_af DRUG considered_af"
6860,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,dexamethasone,advise,"When_bf DRUG co-administered_be inducers_be drug_be clearance_be ,_be efavirenz_be ,_be nevirapine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af carbamazepine_af ,_af use_af daily_af dose_af 70_af mg_af DRUG considered_af"
6861,"When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered",CANCIDAS,carbamazepine,advise,"When_bf DRUG co-administered_be inducers_be drug_be clearance_be ,_be efavirenz_be ,_be nevirapine_be ,_be phenytoin_be ,_be dexamethasone_be ,_be OTHER_DRUG ,_af use_af daily_af dose_af 70_af mg_af DRUG considered_af"
6887,"Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with antacids.",cefditoren pivoxil,antacids,advise,"Although_bf clinical_bf significance_bf known_bf ,_bf recommended_bf cefditoren_bf pivoxil_bf taken_bf concomitantly_bf OTHER_DRUG ._be"
6902,Renal function should be monitored carefully if high doses of aminoglycosides are to be administered with MAXIPIME because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibiotics.,aminoglycosides,MAXIPIME,advise,Renal_bf function_bf monitored_bf carefully_bf high_bf doses_bf DRUG administered_be OTHER_DRUG increased_af potential_af nephrotoxicity_af ototoxicity_af aminoglycoside_af antibiotics_af ._af
6981,This interaction should be given consideration in patients taking CELEBREX concomitantly with ACE-inhibitors.,CELEBREX,ACE-inhibitors,advise,This_bf interaction_bf given_bf consideration_bf patients_bf taking_bf DRUG concomitantly_be OTHER_DRUG ._af
6990,Aspirin: CELEBREX can be used with low dose aspirin.,CELEBREX,aspirin,advise,Aspirin:_bf DRUG used_be low_be dose_be OTHER_DRUG ._af
6999,CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.,CELEBREX,fluconazole,advise,DRUG introduced_be lowest_be recommended_be dose_be patients_be receiving_be OTHER_DRUG ._af
7010,Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.,lithium,CELEBREX,advise,Patients_bf DRUG treatment_be closely_be monitored_be OTHER_DRUG introduced_af withdrawn_af ._af
7024,"However, caution should be used when administering CELEBREX with warfarin since these patients are at increased risk of bleeding complications.",CELEBREX,warfarin,advise,"However_bf ,_bf caution_bf used_bf administering_bf DRUG OTHER_DRUG since_af patients_af increased_af risk_af bleeding_af complications_af ._af"
7039,"Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.",cephalexin,metformin,advise,"Accordingly_bf ,_bf careful_bf patient_bf monitoring_bf dose_bf adjustment_bf OTHER_DRUG recommended_be patients_be concomitantly_be taking_be DRUG OTHER_DRUG ._af"
7158,"Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances.",Cevimeline,beta adrenergic antagonists,advise,"DRUG administered_be caution_be patients_be taking_be beta_be adrenergic_be antagonists_be ,_be possibility_be conduction_be disturbances_be ._be"
7177,"Therefore, chloroprocaine should not be used in any condition in which a sulfonamide drug is being employed.",chloroprocaine,sulfonamide drug,advise,"Therefore_bf ,_bf DRUG used_be condition_be sulfonamide_be drug_be employed_be ._be"
7236,#NAME?,Lithium,diuretics,advise,-_bf Lithium:_bf Generally_bf given_bf OTHER_DRUG ._be
7240,Refer to the package insert for lithium preparations before use of such preparations with chlorothiazide,lithium,chlorothiazide,advise,Refer_bf package_bf insert_bf DRUG preparations_be use_be preparations_be OTHER_DRUG
7251,"Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained",chlorothiazide,non-steroidal anti-inflammatory agents,advise,"Therefore_bf ,_bf DRUG non-steroidal_be anti-inflammatory_be agents_be used_be concomitantly_be ,_be patient_be observed_be closely_be determine_be desired_be effect_be diuretic_be obtained_be"
7564,"If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.",chlorprothixene,opioids,advise,"If_bf DRUG given_be concomitantly_be OTHER_DRUG ,_af opioid_af dose_af reduced_af (by_af approx_af ._af 50%)_af ,_af DRUG amplifies_af therapeutic_af actions_af side-effects_af OTHER_DRUG massively_af ._af"
7574,Avoid the concomitant use of chlorprothixene and tramadol (Ultram).,chlorprothixene,tramadol,advise,Avoid_bf concomitant_bf use_bf DRUG OTHER_DRUG (Ultram)_af ._af
7575,Avoid the concomitant use of chlorprothixene and tramadol (Ultram).,chlorprothixene,Ultram,advise,Avoid_bf concomitant_bf use_bf DRUG tramadol_be (Ultram)_be ._be
7580,"Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",chlorprothixene,anticholinergic drugs,advise,"Exert_bf particular_bf caution_bf combining_bf DRUG anticholinergic_be drugs_be (tricyclic_be antidepressants_be antiparkinsonian_be agents):_be Particularly_be elderly_be may_be develop_be delirium_be ,_be high_be fever_be ,_be severe_be obstipation_be ,_be even_be ileus_be glaucoma_be ._be"
7581,"Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",chlorprothixene,tricyclic antidepressants,advise,"Exert_bf particular_bf caution_bf combining_bf DRUG anticholinergic_be drugs_be (tricyclic_be antidepressants_be antiparkinsonian_be agents):_be Particularly_be elderly_be may_be develop_be delirium_be ,_be high_be fever_be ,_be severe_be obstipation_be ,_be even_be ileus_be glaucoma_be ._be"
7582,"Exert particular caution in combining chlorprothixene with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",chlorprothixene,antiparkinsonian agents,advise,"Exert_bf particular_bf caution_bf combining_bf DRUG anticholinergic_be drugs_be (tricyclic_be antidepressants_be antiparkinsonian_be agents):_be Particularly_be elderly_be may_be develop_be delirium_be ,_be high_be fever_be ,_be severe_be obstipation_be ,_be even_be ileus_be glaucoma_be ._be"
7635,"Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.",Vitamin D,digitalis,advise,"Digitalis:_bf Vitamin_bf D_bf dosage_bf must_bf determined_bf care_bf patients_bf undergoing_bf treatment_bf OTHER_DRUG ,_be hypercalcemia_be patients_be may_be precipitate_be cardiac_be arrhythmias_be ._be"
7780,"Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.",ketoconazole,ciclesonide,advise,"Therefore_bf ,_bf DRUG administered_be caution_be intranasal_be OTHER_DRUG ._af"
7901,Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.,Zidovudine,probenecid,advise,DRUG either_be temporarily_be discontinued_be decreased_be 50%_be coadministered_be OTHER_DRUG day_af VISTIDE_af infusion_af ._af
7904,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,aminoglycosides,advise,"Nephrotoxic_bf agents_bf :_bf Concomitant_bf administration_bf DRUG agents_be nephrotoxic_be potential_be [e_be ._be g_be ._be ,_be intravenous_be OTHER_DRUG (e_af ._af g_af ._af ,_af tobramycin_af ,_af gentamicin_af ,_af amikacin)_af ,_af amphotericin_af B_af ,_af foscarnet_af ,_af intravenous_af pentamidine_af ,_af vancomycin_af ,_af non-steroidal_af anti-inflammatory_af agents]_af contraindicated_af ._af"
7905,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,tobramycin,advise,"Nephrotoxic_bf agents_bf :_bf Concomitant_bf administration_bf DRUG agents_be nephrotoxic_be potential_be [e_be ._be g_be ._be ,_be intravenous_be aminoglycosides_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af gentamicin_af ,_af amikacin)_af ,_af amphotericin_af B_af ,_af foscarnet_af ,_af intravenous_af pentamidine_af ,_af vancomycin_af ,_af non-steroidal_af anti-inflammatory_af agents]_af contraindicated_af ._af"
7906,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,gentamicin,advise,"Nephrotoxic_bf agents_bf :_bf Concomitant_bf administration_bf DRUG agents_be nephrotoxic_be potential_be [e_be ._be g_be ._be ,_be intravenous_be aminoglycosides_be (e_be ._be g_be ._be ,_be tobramycin_be ,_be OTHER_DRUG ,_af amikacin)_af ,_af amphotericin_af B_af ,_af foscarnet_af ,_af intravenous_af pentamidine_af ,_af vancomycin_af ,_af non-steroidal_af anti-inflammatory_af agents]_af contraindicated_af ._af"
7907,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,amikacin,advise,"Nephrotoxic_bf agents_bf :_bf Concomitant_bf administration_bf DRUG agents_be nephrotoxic_be potential_be [e_be ._be g_be ._be ,_be intravenous_be aminoglycosides_be (e_be ._be g_be ._be ,_be tobramycin_be ,_be gentamicin_be ,_be amikacin)_be ,_be amphotericin_be B_be ,_be foscarnet_be ,_be intravenous_be pentamidine_be ,_be vancomycin_be ,_be non-steroidal_be anti-inflammatory_be agents]_be contraindicated_be ._be"
7908,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,amphotericin B,advise,"Nephrotoxic_bf agents_bf :_bf Concomitant_bf administration_bf DRUG agents_be nephrotoxic_be potential_be [e_be ._be g_be ._be ,_be intravenous_be aminoglycosides_be (e_be ._be g_be ._be ,_be tobramycin_be ,_be gentamicin_be ,_be amikacin)_be ,_be amphotericin_be B_be ,_be foscarnet_be ,_be intravenous_be pentamidine_be ,_be vancomycin_be ,_be non-steroidal_be anti-inflammatory_be agents]_be contraindicated_be ._be"
7909,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,foscarnet,advise,"Nephrotoxic_bf agents_bf :_bf Concomitant_bf administration_bf DRUG agents_be nephrotoxic_be potential_be [e_be ._be g_be ._be ,_be intravenous_be aminoglycosides_be (e_be ._be g_be ._be ,_be tobramycin_be ,_be gentamicin_be ,_be amikacin)_be ,_be amphotericin_be B_be ,_be OTHER_DRUG ,_af intravenous_af pentamidine_af ,_af vancomycin_af ,_af non-steroidal_af anti-inflammatory_af agents]_af contraindicated_af ._af"
7910,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,pentamidine,advise,"Nephrotoxic_bf agents_bf :_bf Concomitant_bf administration_bf DRUG agents_be nephrotoxic_be potential_be [e_be ._be g_be ._be ,_be intravenous_be aminoglycosides_be (e_be ._be g_be ._be ,_be tobramycin_be ,_be gentamicin_be ,_be amikacin)_be ,_be amphotericin_be B_be ,_be foscarnet_be ,_be intravenous_be OTHER_DRUG ,_af vancomycin_af ,_af non-steroidal_af anti-inflammatory_af agents]_af contraindicated_af ._af"
7911,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,vancomycin,advise,"Nephrotoxic_bf agents_bf :_bf Concomitant_bf administration_bf DRUG agents_be nephrotoxic_be potential_be [e_be ._be g_be ._be ,_be intravenous_be aminoglycosides_be (e_be ._be g_be ._be ,_be tobramycin_be ,_be gentamicin_be ,_be amikacin)_be ,_be amphotericin_be B_be ,_be foscarnet_be ,_be intravenous_be pentamidine_be ,_be OTHER_DRUG ,_af non-steroidal_af anti-inflammatory_af agents]_af contraindicated_af ._af"
7912,"Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.",VISTIDE,non-steroidal anti-inflammatory agents,advise,"Nephrotoxic_bf agents_bf :_bf Concomitant_bf administration_bf DRUG agents_be nephrotoxic_be potential_be [e_be ._be g_be ._be ,_be intravenous_be aminoglycosides_be (e_be ._be g_be ._be ,_be tobramycin_be ,_be gentamicin_be ,_be amikacin)_be ,_be amphotericin_be B_be ,_be foscarnet_be ,_be intravenous_be pentamidine_be ,_be vancomycin_be ,_be non-steroidal_be anti-inflammatory_be agents]_be contraindicated_be ._be"
7953,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.",PLETAL,ketoconazole,advise,"Since_bf DRUG extensively_be metabolized_be cytochrome_be P-450_be isoenzymes_be ,_be caution_be exercised_be DRUG coadministered_af inhibitors_af C_af ._af P_af ._af A_af ._af OTHER_DRUG erythromycin_af inhibitors_af CYP2C19_af omeprazole_af ._af"
7954,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.",PLETAL,erythromycin,advise,"Since_bf DRUG extensively_be metabolized_be cytochrome_be P-450_be isoenzymes_be ,_be caution_be exercised_be DRUG coadministered_af inhibitors_af C_af ._af P_af ._af A_af ._af ketoconazole_af OTHER_DRUG inhibitors_af CYP2C19_af omeprazole_af ._af"
7955,"Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.",PLETAL,omeprazole,advise,"Since_bf DRUG extensively_be metabolized_be cytochrome_be P-450_be isoenzymes_be ,_be caution_be exercised_be DRUG coadministered_af inhibitors_af C_af ._af P_af ._af A_af ._af ketoconazole_af erythromycin_af inhibitors_af CYP2C19_af OTHER_DRUG ._af"
8019,"therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly.",anticoagulant,Tagamet,advise,"therefore_bf ,_bf close_bf monitoring_bf prothrombin_bf time_bf recommended_bf ,_bf adjustment_bf DRUG dose_be may_be necessary_be OTHER_DRUG administered_af concomitantly_af ._af"
8051,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;",Sensipar,ketoconazole,advise,"Dose_bf adjustment_bf DRUG may_be required_be PTH_be serum_be calcium_be concentrations_be closely_be monitored_be patient_be initiates_be discontinues_be therapy_be strong_be CYP3A4_be inhibitor_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af erythromycin_af ,_af itraconazole;_af"
8052,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;",Sensipar,erythromycin,advise,"Dose_bf adjustment_bf DRUG may_be required_be PTH_be serum_be calcium_be concentrations_be closely_be monitored_be patient_be initiates_be discontinues_be therapy_be strong_be CYP3A4_be inhibitor_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be OTHER_DRUG ,_af itraconazole;_af"
8053,"Dose adjustment of Sensipar may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, erythromycin, itraconazole;",Sensipar,itraconazole,advise,"Dose_bf adjustment_bf DRUG may_be required_be PTH_be serum_be calcium_be concentrations_be closely_be monitored_be patient_be initiates_be discontinues_be therapy_be strong_be CYP3A4_be inhibitor_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be erythromycin_be ,_be itraconazole;_be"
8065,"Although this interaction has not been reported with cinoxacin, caution should be exercised when cinoxacin is given concomitantly with caffeine-containing products.",cinoxacin,caffeine,advise,"Although_bf interaction_bf reported_bf DRUG ,_be caution_be exercised_be DRUG given_af concomitantly_af caffeine-containing_af products_af ._af"
8093,Physicians are provided this information to increase awareness of the potential for serious interactions when cinoxacin and certain nonsteroidal anti-inflammatory agents are administered concomitantly.,cinoxacin,nonsteroidal anti-inflammatory agents,advise,Physicians_bf provided_bf information_bf increase_bf awareness_bf potential_bf serious_bf interactions_bf DRUG certain_be nonsteroidal_be anti-inflammatory_be agents_be administered_be concomitantly_be ._be
8118,"Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.",methotrexate,ciprofloxacin,advise,"Therefore_bf ,_bf patients_bf DRUG therapy_be carefully_be monitored_be concomitant_be OTHER_DRUG therapy_af indicated_af ._af"
8174,"This time window is different than for other oral formulations of ciprofloxacin, which are usually administered 2 hours before or 6 hours after antacids.",ciprofloxacin,antacids,advise,"This_bf time_bf window_bf different_bf oral_bf formulations_bf DRUG ,_be usually_be administered_be 2_be hours_be 6_be hours_be OTHER_DRUG ._af"
8241,"It is advisable to check coagulation time within the first few days after the start and discontinuation of cisapride therapy, with an appropriate adjustment of the anticoagulant dose, if necessary.",cisapride,anticoagulant,advise,"It_bf advisable_bf check_bf coagulation_bf time_bf within_bf first_bf days_bf start_bf discontinuation_bf DRUG therapy_be ,_be appropriate_be adjustment_be OTHER_DRUG dose_af ,_af necessary_af ._af"
8291,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,antiarrhythmics,advise,"DRUG used_be concomitantly_be drugs_be known_be prolong_be QT_be interval:_be certain_be OTHER_DRUG ,_af including_af Class_af IA_af (such_af quinidine_af procainamide)_af Class_af III_af (such_af sotalol);_af"
8292,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,quinidine,advise,"DRUG used_be concomitantly_be drugs_be known_be prolong_be QT_be interval:_be certain_be antiarrhythmics_be ,_be including_be Class_be IA_be (such_be OTHER_DRUG procainamide)_af Class_af III_af (such_af sotalol);_af"
8293,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,procainamide,advise,"DRUG used_be concomitantly_be drugs_be known_be prolong_be QT_be interval:_be certain_be antiarrhythmics_be ,_be including_be Class_be IA_be (such_be quinidine_be procainamide)_be Class_be III_be (such_be sotalol);_be"
8294,"Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);",Cisapride,sotalol,advise,"DRUG used_be concomitantly_be drugs_be known_be prolong_be QT_be interval:_be certain_be antiarrhythmics_be ,_be including_be Class_be IA_be (such_be quinidine_be procainamide)_be Class_be III_be (such_be sotalol);_be"
8350,"In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.",enflurane,NIMBEX,advise,"In_bf long_bf surgical_bf procedures_bf DRUG isoflurane_be anesthesia_be ,_be less_be frequent_be maintenance_be dosing_be ,_be lower_be maintenance_be doses_be ,_be reduced_be infusion_be rates_be OTHER_DRUG may_af necessary_af ._af"
8351,"In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.",isoflurane,NIMBEX,advise,"In_bf long_bf surgical_bf procedures_bf enflurane_bf DRUG anesthesia_be ,_be less_be frequent_be maintenance_be dosing_be ,_be lower_be maintenance_be doses_be ,_be reduced_be infusion_be rates_be OTHER_DRUG may_af necessary_af ._af"
8567,Patients receiving antihistamines should be advised against the concurrent use of other CNS depressant drugs.,antihistamines,CNS depressant drugs,advise,Patients_bf receiving_bf DRUG advised_be concurrent_be use_be CNS_be depressant_be drugs_be ._be
8583,"If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.",dapsone,clofazimine,advise,"If_bf leprosy-associated_bf inflammatory_bf reactions_bf develop_bf patients_bf treated_bf DRUG OTHER_DRUG ,_af still_af advisable_af continue_af treatment_af drugs_af ._af"
8584,Caution should be exercised when anticoagulants are given in conjunction with Atromid-S.,anticoagulants,Atromid-S,advise,Caution_bf exercised_bf DRUG given_be conjunction_be OTHER_DRUG ._af
8597,"Therefore, the combined use of lovastatin with fibrates should generally be avoided.",lovastatin,fibrates,advise,"Therefore_bf ,_bf combined_bf use_bf DRUG OTHER_DRUG generally_af avoided_af ._af"
8634,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.",clozapine,benzodiazepine,advise,"Although_bf established_bf interaction_bf DRUG benzodiazepines_be psychotropics_be ,_be caution_be advised_be DRUG initiated_af patients_af taking_af OTHER_DRUG psychotropic_af drug_af ._af"
8635,"Although it has not been established that there is an interaction between Clozapine and benzodiazepines or other psychotropics, caution is advised when clozapine is initiated in patients taking a benzodiazepine or any other psychotropic drug.",clozapine,psychotropic drug,advise,"Although_bf established_bf interaction_bf DRUG benzodiazepines_be psychotropics_be ,_be caution_be advised_be DRUG initiated_af patients_af taking_af benzodiazepine_af psychotropic_af drug_af ._af"
8657,"Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.",Clozapine,carbamazepine,advise,"Although_bf concomitant_bf use_bf DRUG OTHER_DRUG recommended_af ,_af noted_af discontinuation_af concomitant_af OTHER_DRUG administration_af may_af result_af increase_af DRUG plasma_af levels_af ._af"
8683,"Therefore, such combined treatment should be approached with caution and patients should be monitored closely when Clozapine is combined with these drugs, particularly with fluvoxamine.",Clozapine,fluvoxamine,advise,"Therefore_bf ,_bf combined_bf treatment_bf approached_bf caution_bf patients_bf monitored_bf closely_bf DRUG combined_be drugs_be ,_be particularly_be OTHER_DRUG ._af"
8694,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,antidepressants,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be isozyme_be ,_be including_be OTHER_DRUG ,_af phenothiazines_af ,_af carbamazepine_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide_af encainide)_af ,_af inhibit_af enzyme_af (e_af ._af g_af ._af ,_af quinidine)_af ,_af approached_af caution_af ._af"
8695,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,phenothiazines,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be isozyme_be ,_be including_be antidepressants_be ,_be OTHER_DRUG ,_af carbamazepine_af ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide_af encainide)_af ,_af inhibit_af enzyme_af (e_af ._af g_af ._af ,_af quinidine)_af ,_af approached_af caution_af ._af"
8696,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,carbamazepine,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be isozyme_be ,_be including_be antidepressants_be ,_be phenothiazines_be ,_be OTHER_DRUG ,_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide_af encainide)_af ,_af inhibit_af enzyme_af (e_af ._af g_af ._af ,_af quinidine)_af ,_af approached_af caution_af ._af"
8697,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,Type 1C antiarrhythmics,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be isozyme_be ,_be including_be antidepressants_be ,_be phenothiazines_be ,_be carbamazepine_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide_be encainide)_be ,_be inhibit_be enzyme_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be approached_be caution_be ._be"
8698,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,propafenone,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be isozyme_be ,_be including_be antidepressants_be ,_be phenothiazines_be ,_be carbamazepine_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af flecainide_af encainide)_af ,_af inhibit_af enzyme_af (e_af ._af g_af ._af ,_af quinidine)_af ,_af approached_af caution_af ._af"
8699,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,flecainide,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be isozyme_be ,_be including_be antidepressants_be ,_be phenothiazines_be ,_be carbamazepine_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be OTHER_DRUG encainide)_af ,_af inhibit_af enzyme_af (e_af ._af g_af ._af ,_af quinidine)_af ,_af approached_af caution_af ._af"
8700,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,encainide,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be isozyme_be ,_be including_be antidepressants_be ,_be phenothiazines_be ,_be carbamazepine_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide_be encainide)_be ,_be inhibit_be enzyme_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be approached_be caution_be ._be"
8701,"Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.",clozapine,quinidine,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be metabolized_be isozyme_be ,_be including_be antidepressants_be ,_be phenothiazines_be ,_be carbamazepine_be ,_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide_be encainide)_be ,_be inhibit_be enzyme_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be approached_be caution_be ._be"
8821,The concomitant use of sodium cephalothin and Coly-Mycin M Parenteral should be avoided.,sodium cephalothin,Coly-Mycin M,advise,The_bf concomitant_bf use_bf sodium_bf cephalothin_bf Coly-Mycin_bf M_bf Parenteral_bf avoided_bf ._bf
8838,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenobarbital,corticosteroid,advise,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be phenytoin_be rifampin_be may_be increase_be clearance_be corticosteroids_be may_be require_be increases_be OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
8841,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenytoin,corticosteroid,advise,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf DRUG rifampin_be may_be increase_be clearance_be corticosteroids_be may_be require_be increases_be OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
8843,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",rifampin,corticosteroid,advise,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf phenytoin_bf DRUG may_be increase_be clearance_be corticosteroids_be may_be require_be increases_be OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
8852,Aspirin should be used cautiously in conjunction with cortico-steroids in patients suffering from hypopro-thrombinemia.,Aspirin,cortico-steroids,advise,DRUG used_be cautiously_be conjunction_be OTHER_DRUG patients_af suffering_af hypopro-thrombinemia_af ._af
8922,"It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.",dantrolene sodium,calcium channel blockers,advise,"It_bf recommended_bf combination_bf intravenous_bf dantrolene_bf sodium_bf calcium_bf channel_bf blockers_bf ,_bf verapamil_bf ,_bf used_bf together_bf management_bf malignant_bf hyperthermia_bf crisis_bf relevance_bf findings_bf humans_bf established_bf ._bf"
8923,"It is recommended that the combination of intravenous dantrolene sodium and calcium channel blockers, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.",dantrolene sodium,verapamil,advise,"It_bf recommended_bf combination_bf intravenous_bf dantrolene_bf sodium_bf calcium_bf channel_bf blockers_bf ,_bf OTHER_DRUG ,_be used_be together_be management_be malignant_be hyperthermia_be crisis_be relevance_be findings_be humans_be established_be ._be"
8936,"Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.",HMG-CoA reductase inhibitors,Fentanyl,advise,"Experience_bf co-administration_bf HMG-CoA_bf reductase_bf inhibitors_bf OTHER_DRUG patients_be limited_be ,_be therefore_be ,_be consideration_be given_be temporarily_be suspending_be use_be HMG-CoA_be reductase_be inhibitors_be patients_be receiving_be OTHER_DRUG ._af"
8937,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,ketoconazole,advise,"The_bf daily_bf dose_bf DRUG exceed_be 7_be ._be 5_be mg_be coadministered_be potent_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af itraconazole_af ,_af ritonavir_af ,_af nelfinavir_af ,_af clarithromycin_af nefazadone)_af ._af"
8938,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,itraconazole,advise,"The_bf daily_bf dose_bf DRUG exceed_be 7_be ._be 5_be mg_be coadministered_be potent_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be OTHER_DRUG ,_af ritonavir_af ,_af nelfinavir_af ,_af clarithromycin_af nefazadone)_af ._af"
8939,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,ritonavir,advise,"The_bf daily_bf dose_bf DRUG exceed_be 7_be ._be 5_be mg_be coadministered_be potent_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be OTHER_DRUG ,_af nelfinavir_af ,_af clarithromycin_af nefazadone)_af ._af"
8940,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,nelfinavir,advise,"The_bf daily_bf dose_bf DRUG exceed_be 7_be ._be 5_be mg_be coadministered_be potent_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be ritonavir_be ,_be OTHER_DRUG ,_af clarithromycin_af nefazadone)_af ._af"
8941,"The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .",ENABLEX,clarithromycin,advise,"The_bf daily_bf dose_bf DRUG exceed_be 7_be ._be 5_be mg_be coadministered_be potent_be CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be ritonavir_be ,_be nelfinavir_be ,_be OTHER_DRUG nefazadone)_af ._af"
8952,"Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).",ENABLEX,flecainide,advise,"Caution_bf taken_bf DRUG used_be concomitantly_be medications_be predominantly_be metabolized_be CYP2D6_be narrow_be therapeutic_be window_be ,_be OTHER_DRUG ,_af thioridazine_af tricyclic_af antidepressants_af (see_af CLINICAL_af PHARMACOLOGY)_af ._af"
8953,"Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).",ENABLEX,thioridazine,advise,"Caution_bf taken_bf DRUG used_be concomitantly_be medications_be predominantly_be metabolized_be CYP2D6_be narrow_be therapeutic_be window_be ,_be flecainide_be ,_be OTHER_DRUG tricyclic_af antidepressants_af (see_af CLINICAL_af PHARMACOLOGY)_af ._af"
8954,"Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).",ENABLEX,tricyclic antidepressants,advise,"Caution_bf taken_bf DRUG used_be concomitantly_be medications_be predominantly_be metabolized_be CYP2D6_be narrow_be therapeutic_be window_be ,_be flecainide_be ,_be thioridazine_be tricyclic_be antidepressants_be (see_be CLINICAL_be PHARMACOLOGY)_be ._be"
9052,Simultaneous administration of SPRYCEL with antacids should be avoided.,SPRYCEL,antacids,advise,Simultaneous_bf administration_bf DRUG OTHER_DRUG avoided_af ._af
9053,"If antacid therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of SPRYCEL.",antacid,SPRYCEL,advise,"If_bf DRUG therapy_be needed_be ,_be DRUG dose_af administered_af least_af 2_af hours_af prior_af 2_af hours_af dose_af OTHER_DRUG ._af"
9076,The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.,H2 blockers,SPRYCEL,advise,The_bf concomitant_bf use_bf H2_bf blockers_bf proton_bf pump_bf inhibitors_bf OTHER_DRUG recommended_be ._be
9077,The concomitant use of H2 blockers or proton pump inhibitors with SPRYCEL is not recommended.,proton pump inhibitors,SPRYCEL,advise,The_bf concomitant_bf use_bf H2_bf blockers_bf proton_bf pump_bf inhibitors_bf OTHER_DRUG recommended_be ._be
9082,The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.,H2 blockers,SPRYCEL,advise,The_bf use_bf antacids_bf considered_bf place_bf H2_bf blockers_bf proton_bf pump_bf inhibitors_bf patients_bf receiving_bf OTHER_DRUG therapy_be ._be
9083,The use of antacids should be considered in place of H2 blockers or proton pump inhibitors in patients receiving SPRYCEL therapy.,proton pump inhibitors,SPRYCEL,advise,The_bf use_bf antacids_bf considered_bf place_bf H2_bf blockers_bf proton_bf pump_bf inhibitors_bf patients_bf receiving_bf OTHER_DRUG therapy_be ._be
9097,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",alfentanil,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf DRUG ,_be astemizole_be ,_be terfenadine_be ,_be cisapride_be ,_be cyclosporine_be ,_be fentanyl_be ,_be pimozide_be ,_be quinidine_be ,_be sirolimus_be ,_be tacrolimus_be ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
9109,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",astemizole,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf DRUG ,_be terfenadine_be ,_be cisapride_be ,_be cyclosporine_be ,_be fentanyl_be ,_be pimozide_be ,_be quinidine_be ,_be sirolimus_be ,_be tacrolimus_be ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
9120,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",terfenadine,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf DRUG ,_be cisapride_be ,_be cyclosporine_be ,_be fentanyl_be ,_be pimozide_be ,_be quinidine_be ,_be sirolimus_be ,_be tacrolimus_be ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
9130,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",cisapride,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf DRUG ,_be cyclosporine_be ,_be fentanyl_be ,_be pimozide_be ,_be quinidine_be ,_be sirolimus_be ,_be tacrolimus_be ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
9139,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",cyclosporine,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf cisapride_bf ,_bf DRUG ,_be fentanyl_be ,_be pimozide_be ,_be quinidine_be ,_be sirolimus_be ,_be tacrolimus_be ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
9147,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",fentanyl,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf cisapride_bf ,_bf cyclosporine_bf ,_bf DRUG ,_be pimozide_be ,_be quinidine_be ,_be sirolimus_be ,_be tacrolimus_be ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
9154,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",pimozide,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf cisapride_bf ,_bf cyclosporine_bf ,_bf fentanyl_bf ,_bf DRUG ,_be quinidine_be ,_be sirolimus_be ,_be tacrolimus_be ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
9160,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",quinidine,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf cisapride_bf ,_bf cyclosporine_bf ,_bf fentanyl_bf ,_bf pimozide_bf ,_bf DRUG ,_be sirolimus_be ,_be tacrolimus_be ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
9165,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",sirolimus,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf cisapride_bf ,_bf cyclosporine_bf ,_bf fentanyl_bf ,_bf pimozide_bf ,_bf quinidine_bf ,_bf DRUG ,_be tacrolimus_be ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
9169,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",tacrolimus,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf cisapride_bf ,_bf cyclosporine_bf ,_bf fentanyl_bf ,_bf pimozide_bf ,_bf quinidine_bf ,_bf sirolimus_bf ,_bf DRUG ,_be ergot_be alkaloids_be (ergotamine_be ,_be dihydroergotamine)_be administered_be caution_be patients_be receiving_be OTHER_DRUG ._af"
9172,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",ergot alkaloids,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf cisapride_bf ,_bf cyclosporine_bf ,_bf fentanyl_bf ,_bf pimozide_bf ,_bf quinidine_bf ,_bf sirolimus_bf ,_bf tacrolimus_bf ,_bf ergot_bf alkaloids_bf (ergotamine_bf ,_bf dihydroergotamine)_bf administered_bf caution_bf patients_bf receiving_bf OTHER_DRUG ._be"
9174,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",ergotamine,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf cisapride_bf ,_bf cyclosporine_bf ,_bf fentanyl_bf ,_bf pimozide_bf ,_bf quinidine_bf ,_bf sirolimus_bf ,_bf tacrolimus_bf ,_bf ergot_bf alkaloids_bf (ergotamine_bf ,_bf dihydroergotamine)_bf administered_bf caution_bf patients_bf receiving_bf OTHER_DRUG ._be"
9175,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.",dihydroergotamine,SPRYCEL,advise,"Therefore_bf ,_bf CYP3A4_bf substrates_bf known_bf narrow_bf therapeutic_bf index_bf alfentanil_bf ,_bf astemizole_bf ,_bf terfenadine_bf ,_bf cisapride_bf ,_bf cyclosporine_bf ,_bf fentanyl_bf ,_bf pimozide_bf ,_bf quinidine_bf ,_bf sirolimus_bf ,_bf tacrolimus_bf ,_bf ergot_bf alkaloids_bf (ergotamine_bf ,_bf dihydroergotamine)_bf administered_bf caution_bf patients_bf receiving_bf OTHER_DRUG ._be"
9177,Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine.,Cerubidine,doxorubicin,advise,DRUG used_be patients_be previously_be received_be recommended_be maximum_be cumulative_be doses_be OTHER_DRUG DRUG ._af
9234,"Although deferasirox has a lower affinity for aluminum than for iron, Exjade should not be taken with aluminum-containing antacid preparations.",Exjade,aluminum,advise,"Although_bf deferasirox_bf lower_bf affinity_bf OTHER_DRUG iron_be ,_be DRUG taken_af aluminum-containing_af antacid_af preparations_af ._af"
9290,"Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.",tetracyclines,anticoagulant,advise,"Because_bf DRUG shown_be depress_be plasma_be prothrombin_be activity_be ,_be patients_be OTHER_DRUG therapy_af may_af require_af downward_af adjustment_af OTHER_DRUG dosage_af ._af"
9344,"Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.",corticosteroids,amphotericin B,advise,"Amphotericin_bf B_bf injection_bf potassium-depleting_bf agents:_bf When_bf DRUG administered_be concomitantly_be potassium-depleting_be agents_be (e_be ._be g_be ._be ,_be amphotericin_be B_be ,_be diuretics)_be ,_be patients_be observed_be closely_be development_be hypokalemia_be ._be"
9345,"Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.",corticosteroids,diuretics,advise,"Amphotericin_bf B_bf injection_bf potassium-depleting_bf agents:_bf When_bf DRUG administered_be concomitantly_be potassium-depleting_be agents_be (e_be ._be g_be ._be ,_be amphotericin_be B_be ,_be diuretics)_be ,_be patients_be observed_be closely_be development_be hypokalemia_be ._be"
9354,"If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.",anticholinesterase agents,corticosteroid,advise,"If_bf possible_bf ,_bf anticholinesterase_bf agents_bf withdrawn_bf least_bf 24_bf hours_bf initiating_bf OTHER_DRUG therapy_be ._be"
9422,Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.,Aspirin,corticosteroids,advise,DRUG used_be cautiously_be conjunction_be OTHER_DRUG hypoprothrombinemia_af ._af
9435,Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible.,vaccines,corticosteroid,advise,Routine_bf administration_bf DRUG toxoids_be deferred_be OTHER_DRUG therapy_af discontinued_af possible_af ._af
9510,"Because dexfenfluramine is a serotonin releaser and reuptake inhibitor, dexfenfluramine should not be used concomitantly with a MAO inhibitor.",dexfenfluramine,MAO inhibitor,advise,"Because_bf DRUG serotonin_be releaser_be reuptake_be inhibitor_be ,_be DRUG used_af concomitantly_af MAO_af inhibitor_af ._af"
9511,At least 14 days should elapse between discontinuation of a MAO inhibitor and initiation of treatment with dexfenfluramine.,MAO inhibitor,dexfenfluramine,advise,At_bf least_bf 14_bf days_bf elapse_bf discontinuation_bf MAO_bf inhibitor_bf initiation_bf treatment_bf OTHER_DRUG ._be
9512,At least 3 weeks should elapse between discontinuation of dexfenfluramine and initiation of treatment with a MAO inhibitor.,dexfenfluramine,MAO inhibitor,advise,At_bf least_bf 3_bf weeks_bf elapse_bf discontinuation_bf DRUG initiation_be treatment_be MAO_be inhibitor_be ._be
9523,Dexfenfluramine should not be administered with other serotoninergic agents.,Dexfenfluramine,serotoninergic agents,advise,DRUG administered_be serotoninergic_be agents_be ._be
9585,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,anesthetic,advise,"However_bf ,_bf due_bf possible_bf pharmacodynamic_bf interactions_bf ,_bf co-administered_bf DRUG ,_be reduction_be dosage_be DRUG concomitant_af OTHER_DRUG ,_af sedative_af ,_af hypnotic_af opioid_af may_af required_af ._af"
9586,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,sedative,advise,"However_bf ,_bf due_bf possible_bf pharmacodynamic_bf interactions_bf ,_bf co-administered_bf DRUG ,_be reduction_be dosage_be DRUG concomitant_af anesthetic_af ,_af OTHER_DRUG ,_af hypnotic_af opioid_af may_af required_af ._af"
9587,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,hypnotic,advise,"However_bf ,_bf due_bf possible_bf pharmacodynamic_bf interactions_bf ,_bf co-administered_bf DRUG ,_be reduction_be dosage_be DRUG concomitant_af anesthetic_af ,_af sedative_af ,_af OTHER_DRUG opioid_af may_af required_af ._af"
9588,"However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or opioid may be required.",PRECEDEX,opioid,advise,"However_bf ,_bf due_bf possible_bf pharmacodynamic_bf interactions_bf ,_bf co-administered_bf DRUG ,_be reduction_be dosage_be DRUG concomitant_af anesthetic_af ,_af sedative_af ,_af hypnotic_af OTHER_DRUG may_af required_af ._af"
9760,"Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.",diclofenac,aspirin,advise,"Aspirin:_bf Concomitant_bf administration_bf DRUG OTHER_DRUG recommended_af DRUG displaced_af binding_af sites_af concomitant_af administration_af OTHER_DRUG ,_af resulting_af lower_af plasma_af concentrations_af ,_af peak_af plasma_af levels_af ,_af AUC_af values_af ._af"
9770,"Anticoagulants: While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.",diclofenac,NSAIDs,advise,"Anticoagulants:_bf While_bf studies_bf shown_bf DRUG interact_be anticoagulants_be warfarin_be type_be ,_be caution_be exercised_be ,_be nonetheless_be ,_be since_be interactions_be seen_be OTHER_DRUG ._af"
9777,"Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.",NSAIDs,warfarin,advise,"Because_bf prostaglandins_bf play_bf important_bf role_bf hemostasis_bf ,_bf DRUG affect_be platelet_be function_be well_be ,_be concurrent_be therapy_be DRUG ,_af including_af diclofenac_af ,_af OTHER_DRUG requires_af close_af monitoring_af patients_af certain_af change_af anticoagulant_af dosage_af required_af ._af"
9779,"Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.",diclofenac,warfarin,advise,"Because_bf prostaglandins_bf play_bf important_bf role_bf hemostasis_bf ,_bf NSAIDs_bf affect_bf platelet_bf function_bf well_bf ,_bf concurrent_bf therapy_bf NSAIDs_bf ,_bf including_bf DRUG ,_be OTHER_DRUG requires_af close_af monitoring_af patients_af certain_af change_af anticoagulant_af dosage_af required_af ._af"
9994,Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.,ketoconazole,VIDEX,advise,Drugs_bf Whose_bf Absorption_bf Can_bf Be_bf Affected_bf Level_bf Acidity_bf Stomach:_bf Drugs_bf DRUG itraconazole_be administered_be least_be 2_be hours_be prior_be dosing_be OTHER_DRUG ._af
9995,Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as ketoconazole and itraconazole should be administered at least 2 hours prior to dosing with VIDEX.,itraconazole,VIDEX,advise,Drugs_bf Whose_bf Absorption_bf Can_bf Be_bf Affected_bf Level_bf Acidity_bf Stomach:_bf Drugs_bf ketoconazole_bf DRUG administered_be least_be 2_be hours_be prior_be dosing_be OTHER_DRUG ._af
10012,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",VIDEX,ciprofloxacin,advise,"Quinolone_bf Antibiotics:_bf DRUG administered_be least_be 2_be hours_be 6_be hours_be dosing_be OTHER_DRUG plasma_af concentrations_af OTHER_DRUG decreased_af administered_af antacids_af containing_af magnesium_af ,_af calcium_af ,_af aluminum_af ._af"
10060,"To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.",delavirdine,VIDEX,advise,"To_bf avoid_bf interaction_bf ,_bf DRUG indinavir_be given_be 1_be hour_be prior_be dosing_be OTHER_DRUG ._af"
10061,"To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.",indinavir,VIDEX,advise,"To_bf avoid_bf interaction_bf ,_bf delavirdine_bf DRUG given_be 1_be hour_be prior_be dosing_be OTHER_DRUG ._af"
10090,"Accordingly, when diflunisal is administered with oral anticoagulants, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.",diflunisal,anticoagulants,advise,"Accordingly_bf ,_bf DRUG administered_be oral_be OTHER_DRUG ,_af prothrombin_af time_af closely_af monitored_af several_af days_af concomitant_af drug_af administration_af ._af"
10124,"Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.",diflunisal,acetaminophen,advise,"Since_bf OTHER_DRUG high_be doses_be associated_be hepatotoxicity_be ,_be concomitant_be administration_be DRUG OTHER_DRUG used_af cautiously_af ,_af careful_af monitoring_af patients_af ._af"
10133,Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.,diflunisal,methotrexate,advise,Methotrexate:_bf Caution_bf used_bf DRUG administered_be concomitantly_be OTHER_DRUG ._af
10141,"NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.",NSAIDs,cyclosporine,advise,"DRUG used_be caution_be patients_be taking_be OTHER_DRUG ,_af renal_af function_af carefully_af monitored_af ._af"
10149,"Therefore, indomethacin and diflunisal should not be used concomitantly.",indomethacin,diflunisal,advise,"Therefore_bf ,_bf DRUG OTHER_DRUG used_af concomitantly_af ._af"
10268,"Thyroid administration to a digitalized, hypothyroid patient may increase the dose requirement of digoxin.",Thyroid,digoxin,advise,"DRUG administration_be digitalized_be ,_be hypothyroid_be patient_be may_be increase_be dose_be requirement_be OTHER_DRUG ._af"
10286,"Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..",Sumatriptan,D.H.E. 45,advise,"DRUG D_be ._be H_be ._be E_be ._be 45_be (dihydroergotamine_be mesylate)_be Injection_be ,_be USP_be taken_be within_be 24_be hours_be ._be ._be"
10287,"Sumatriptan and D.H.E. 45  (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..",Sumatriptan,dihydroergotamine mesylate,advise,"DRUG D_be ._be H_be ._be E_be ._be 45_be (dihydroergotamine_be mesylate)_be Injection_be ,_be USP_be taken_be within_be 24_be hours_be ._be ._be"
10371,Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.,diltiazem,cimetidine,advise,Patients_bf currently_bf receiving_bf DRUG therapy_be carefully_be monitored_be change_be pharmacological_be effect_be initiating_be discontinuing_be therapy_be OTHER_DRUG ._af
10377,"Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.",digoxin,diltiazem hydrochloride,advise,"Since_bf conflicting_bf results_bf regarding_bf effect_bf DRUG levels_be ,_be recommended_be DRUG levels_af monitored_af initiating_af ,_af adjusting_af ,_af discontinuing_af diltiazem_af hydrochloride_af therapy_af avoid_af possible_af over-_af under-digitalization_af ._af"
10379,"When used concomitantly, anesthetics and calcium channel blockers should be titrated carefully.",anesthetics,calcium channel blockers,advise,"When_bf used_bf concomitantly_bf ,_bf DRUG calcium_be channel_be blockers_be titrated_be carefully_be ._be"
10384,"If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.",cyclosporine,diltiazem,advise,"If_bf agents_bf administered_bf concurrently_bf ,_bf DRUG concentrations_be monitored_be ,_be especially_be OTHER_DRUG therapy_af initiated_af ,_af adjusted_af ,_af discontinued_af ._af"
10411,"Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.",diltiazem,rifampin,advise,"Coadministration_bf DRUG OTHER_DRUG known_af CYP3A4_af inducer_af avoided_af possible_af ,_af alternative_af therapy_af considered_af ._af"
10512,"In addition, most macrolides are contraindicated in patients receiving terfenadine therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances.",macrolides,terfenadine,advise,"In_bf addition_bf ,_bf DRUG contraindicated_be patients_be receiving_be OTHER_DRUG therapy_af pre-existing_af cardiac_af abnormalities_af (arrhythmia_af ,_af bradycardia_af ,_af QT_af c_af interval_af prolongation_af ,_af ischemic_af heart_af disease_af ,_af congestive_af heart_af failure_af ,_af etc_af ._af )_af electrolyte_af disturbances_af ._af"
10768,Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of dopamine HCl should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.,MAO inhibitors,dopamine HCl,advise,Patients_bf treated_bf MAO_bf inhibitors_bf within_bf two_bf three_bf weeks_bf prior_bf administration_bf dopamine_bf HCl_bf receive_bf initial_bf doses_bf dopamine_bf HCl_bf greater_bf one-tenth_bf (1/10)_bf usual_bf dose_bf ._bf
10794,"Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.",dopamine HCl,cyclopropane,advise,"Therefore_bf ,_bf EXTREME_bf CAUTION_bf exercised_bf administering_bf dopamine_bf HCl_bf patients_bf receiving_bf OTHER_DRUG halogenated_be hydrocarbon_be anesthetics_be ._be"
10795,"Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving cyclopropane or halogenated hydrocarbon anesthetics.",dopamine HCl,halogenated hydrocarbon anesthetics,advise,"Therefore_bf ,_bf EXTREME_bf CAUTION_bf exercised_bf administering_bf dopamine_bf HCl_bf patients_bf receiving_bf cyclopropane_bf halogenated_bf hydrocarbon_bf anesthetics_bf ._bf"
10802,"It is suggested that in patients receiving dopamine HCl, alternatives to phenytoin should be used if anticonvulsant therapy is needed.",dopamine HCl,phenytoin,advise,"It_bf suggested_bf patients_bf receiving_bf dopamine_bf HCl_bf ,_bf alternatives_bf OTHER_DRUG used_be anticonvulsant_be therapy_be needed_be ._be"
11019,"Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.",tetracyclines,anticoagulant,advise,"Because_bf DRUG shown_be depress_be plasma_be prothrombin_be activity_be ,_be patients_be OTHER_DRUG therapy_af may_af require_af downward_af adjustment_af OTHER_DRUG dosage_af ._af"
11024,"Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.",tetracyclines,penicillin,advise,"Since_bf bacteriostatic_bf drugs_bf may_bf interfere_bf bactericidal_bf action_bf OTHER_DRUG ,_be advisable_be avoid_be giving_be DRUG conjunction_af OTHER_DRUG ._af"
11077,"Following the administration of INAPSINE, the dose of other CNS depressant drugs should be reduced.",INAPSINE,CNS depressant drugs,advise,"Following_bf administration_bf DRUG ,_be dose_be CNS_be depressant_be drugs_be reduced_be ._be"
11099,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,antidepressants,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be OTHER_DRUG (tricyclic_af OTHER_DRUG [TCAs]_af ,_af nortriptyline_af ,_af amitriptyline_af ,_af imipramine)_af ,_af phenothiazines_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af ._af"
11100,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,tricyclic antidepressants,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be antidepressants_be (tricyclic_be antidepressants_be [TCAs]_be ,_be nortriptyline_be ,_be amitriptyline_be ,_be imipramine)_be ,_be phenothiazines_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be ._be"
11101,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,TCAs,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be antidepressants_be (tricyclic_be antidepressants_be [TCAs]_be ,_be nortriptyline_be ,_be amitriptyline_be ,_be imipramine)_be ,_be phenothiazines_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be ._be"
11102,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,nortriptyline,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be antidepressants_be (tricyclic_be antidepressants_be [TCAs]_be ,_be OTHER_DRUG ,_af amitriptyline_af ,_af imipramine)_af ,_af phenothiazines_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af ._af"
11103,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,amitriptyline,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be antidepressants_be (tricyclic_be antidepressants_be [TCAs]_be ,_be nortriptyline_be ,_be OTHER_DRUG ,_af imipramine)_af ,_af phenothiazines_af Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af ._af"
11104,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,imipramine,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be antidepressants_be (tricyclic_be antidepressants_be [TCAs]_be ,_be nortriptyline_be ,_be amitriptyline_be ,_be imipramine)_be ,_be phenothiazines_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be ._be"
11105,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,phenothiazines,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be antidepressants_be (tricyclic_be antidepressants_be [TCAs]_be ,_be nortriptyline_be ,_be amitriptyline_be ,_be imipramine)_be ,_be OTHER_DRUG Type_af 1C_af antiarrhythmics_af (e_af ._af g_af ._af ,_af propafenone_af ,_af flecainide)_af ,_af approached_af caution_af ._af"
11106,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,Type 1C antiarrhythmics,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be antidepressants_be (tricyclic_be antidepressants_be [TCAs]_be ,_be nortriptyline_be ,_be amitriptyline_be ,_be imipramine)_be ,_be phenothiazines_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be ._be"
11107,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,propafenone,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be antidepressants_be (tricyclic_be antidepressants_be [TCAs]_be ,_be nortriptyline_be ,_be amitriptyline_be ,_be imipramine)_be ,_be phenothiazines_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af flecainide)_af ,_af approached_af caution_af ._af"
11108,"Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.",Duloxetine,flecainide,advise,"Therefore_bf ,_bf co-administration_bf DRUG drugs_be extensively_be metabolized_be isozyme_be narrow_be therapeutic_be index_be ,_be including_be certain_be antidepressants_be (tricyclic_be antidepressants_be [TCAs]_be ,_be nortriptyline_be ,_be amitriptyline_be ,_be imipramine)_be ,_be phenothiazines_be Type_be 1C_be antiarrhythmics_be (e_be ._be g_be ._be ,_be propafenone_be ,_be flecainide)_be ,_be approached_be caution_be ._be"
11159,Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with Duloxetine.,TCA,Duloxetine,advise,Plasma_bf DRUG concentrations_be may_be need_be monitored_be dose_be DRUG may_af need_af reduced_af DRUG co-administered_af OTHER_DRUG ._af
11162,"Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, Duloxetine and thioridazine should not be co-administered.",Duloxetine,thioridazine,advise,"Because_bf risk_bf serious_bf ventricular_bf arrhythmias_bf sudden_bf death_bf potentially_bf associated_bf elevated_bf plasma_bf levels_bf OTHER_DRUG ,_be DRUG OTHER_DRUG co-administered_af ._af"
11220,RAPTIVA should not be used with other immunosuppressive drugs.,RAPTIVA,immunosuppressive drugs,advise,DRUG used_be immunosuppressive_be drugs_be ._be
11223,"Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.",Acellular vaccines,RAPTIVA,advise,"Acellular_bf ,_bf live_bf live-attenuated_bf vaccines_bf administered_bf OTHER_DRUG treatment_be ._be"
11225,"Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.",live vaccines,RAPTIVA,advise,"Acellular_bf ,_bf live_bf live-attenuated_bf vaccines_bf administered_bf OTHER_DRUG treatment_be ._be"
11226,"Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.",live-attenuated vaccines,RAPTIVA,advise,"Acellular_bf ,_bf live_bf live-attenuated_bf vaccines_bf administered_bf OTHER_DRUG treatment_be ._be"
11276,A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.,lopinavir,SUSTIVA,advise,A_bf dose_bf increase_bf lopinavir/ritonavir_bf 533/133_bf mg_bf (4_bf capsules_bf 6_bf ._bf 5_bf mL)_bf twice_bf daily_bf taken_bf food_bf recommended_bf used_bf combination_bf OTHER_DRUG ._be
11277,A dose increase of lopinavir/ritonavir to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with SUSTIVA.,ritonavir,SUSTIVA,advise,A_bf dose_bf increase_bf lopinavir/ritonavir_bf 533/133_bf mg_bf (4_bf capsules_bf 6_bf ._bf 5_bf mL)_bf twice_bf daily_bf taken_bf food_bf recommended_bf used_bf combination_bf OTHER_DRUG ._be
11280,"Because the potential interaction of efavirenz with oral contraceptives has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral contraceptives.",efavirenz,contraceptives,advise,"Because_bf potential_bf interaction_bf DRUG oral_be OTHER_DRUG fully_af characterized_af ,_af reliable_af method_af barrier_af contraception_af used_af addition_af oral_af OTHER_DRUG ._af"
11284,Monitoring of liver enzymes is recommended when SUSTIVA is used in combination with ritonavir.,SUSTIVA,ritonavir,advise,Monitoring_bf liver_bf enzymes_bf recommended_bf DRUG used_be combination_be OTHER_DRUG ._af
11406,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.,NSAIDs,ACE inhibitors,advise,This_bf interaction_bf given_bf consideration_bf patients_bf taking_bf DRUG concomitantly_be ACE_be inhibitors_be ._be
11470,It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.,enalapril,lithium,advise,It_bf recommended_bf serum_bf OTHER_DRUG levels_be monitored_be frequently_be DRUG administered_af concomitantly_af OTHER_DRUG ._af
11490,"Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.",enoxacin,bismuth subsalicylate,advise,"Thus_bf ,_bf concomitant_bf administration_bf DRUG bismuth_be subsalicylate_be avoided_be ._be"
11576,"Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when warfarin or its derivatives and enoxacin are given concomitantly.",warfarin,enoxacin,advise,"Nevertheless_bf ,_bf prothrombin_bf time_bf suitable_bf coagulation_bf test_bf monitored_bf DRUG derivatives_be OTHER_DRUG given_af concomitantly_af ._af"
11663,All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors.,vasopressors,monoamine oxidase (MAO) inhibitors,advise,All_bf DRUG used_be cautiously_be patients_be taking_be monoamine_be oxidase_be (MAO)_be inhibitors_be ._be
11664,Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.,Epinephrine,sympathomimetic drugs,advise,DRUG administered_be concomitantly_be sympathomimetic_be drugs_be (such_be isoproterenol)_be possible_be additive_be effects_be increased_be toxicity_be ._be
11665,Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.,Epinephrine,isoproterenol,advise,DRUG administered_be concomitantly_be sympathomimetic_be drugs_be (such_be isoproterenol)_be possible_be additive_be effects_be increased_be toxicity_be ._be
11673,"Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.",Epinephrine,digitalis,advise,"DRUG also_be used_be cautiously_be drugs_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af glycosides)_af sensitize_af myocardium_af actions_af sympathomimetic_af drugs_af ._af"
11674,"Epinephrine also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.",Epinephrine,glycosides,advise,"DRUG also_be used_be cautiously_be drugs_be (e_be ._be g_be ._be ,_be digitalis_be ,_be glycosides)_be sensitize_be myocardium_be actions_be sympathomimetic_be drugs_be ._be"
11681,"Concomitant use of ELLENCE with other cardioactive compounds that could cause heart failure (e.g., calcium channel blockers), requires close monitoring of cardiac function throughout treatment.",ELLENCE,calcium channel blockers,advise,"Concomitant_bf use_bf DRUG cardioactive_be compounds_be could_be cause_be heart_be failure_be (e_be ._be g_be ._be ,_be calcium_be channel_be blockers)_be ,_be requires_be close_be monitoring_be cardiac_be function_be throughout_be treatment_be ._be"
11683,Cimetidine treatment should be stopped during treatment with ELLENCE.,Cimetidine,ELLENCE,advise,DRUG treatment_be stopped_be treatment_be OTHER_DRUG ._af
11748,Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.,INSPRA,lithium,advise,Serum_bf OTHER_DRUG levels_be monitored_be frequently_be DRUG administered_af concomitantly_af OTHER_DRUG ._af
11756,"Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.",INSPRA,NSAIDs,advise,"Therefore_bf ,_bf DRUG OTHER_DRUG used_af concomitantly_af ,_af patients_af observed_af determine_af whether_af desired_af effect_af blood_af pressure_af obtained_af ._af"
11863,"Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem is not recommended.",probenecid,ertapenem,advise,"Because_bf small_bf effect_bf half-life_bf ,_bf coadministration_bf DRUG extend_be half-life_be OTHER_DRUG recommended_af ._af"
11881,"In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.",theophylline,erythromycin,advise,"In_bf case_bf DRUG toxicity_be and/or_be elevated_be serum_be DRUG levels_af ,_af dose_af DRUG reduced_af patient_af receiving_af concomitant_af OTHER_DRUG therapy_af ._af"
11999,Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;,lovastatin,erythromycin,advise,Patients_bf receiving_bf concomitant_bf DRUG OTHER_DRUG carefully_af monitored;_af
12013,"Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.",psychotropic medications,LEXAPRO,advise,"Alcohol_bf -_bf Although_bf OTHER_DRUG potentiate_be cognitive_be motor_be effects_be alcohol_be clinical_be trial_be ,_be psychotropic_be medications_be ,_be use_be alcohol_be patients_be taking_be OTHER_DRUG recommended_af ._af"
12014,"Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.",alcohol,LEXAPRO,advise,"DRUG -_be Although_be OTHER_DRUG potentiate_af cognitive_af motor_af effects_af DRUG clinical_af trial_af ,_af psychotropic_af medications_af ,_af use_af DRUG patients_af taking_af OTHER_DRUG recommended_af ._af"
12059,"Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.",LEXAPRO,lithium,advise,"Because_bf OTHER_DRUG may_be enhance_be serotonergic_be effects_be escitalopram_be ,_be caution_be exercised_be DRUG OTHER_DRUG coadministered_af ._af"
12077,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,SSRI,advise,"If_bf concomitant_bf treatment_bf DRUG OTHER_DRUG (e_af ._af g_af ._af ,_af fluoxetine_af ,_af fluvoxamine_af ,_af paroxetine_af ,_af sertraline_af ,_af citalopram_af ,_af escitalopram)_af clinically_af warranted_af ,_af appropriate_af observation_af patient_af advised_af ._af"
12078,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,fluoxetine,advise,"If_bf concomitant_bf treatment_bf DRUG SSRI_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af fluvoxamine_af ,_af paroxetine_af ,_af sertraline_af ,_af citalopram_af ,_af escitalopram)_af clinically_af warranted_af ,_af appropriate_af observation_af patient_af advised_af ._af"
12079,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,fluvoxamine,advise,"If_bf concomitant_bf treatment_bf DRUG SSRI_be (e_be ._be g_be ._be ,_be fluoxetine_be ,_be OTHER_DRUG ,_af paroxetine_af ,_af sertraline_af ,_af citalopram_af ,_af escitalopram)_af clinically_af warranted_af ,_af appropriate_af observation_af patient_af advised_af ._af"
12080,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,paroxetine,advise,"If_bf concomitant_bf treatment_bf DRUG SSRI_be (e_be ._be g_be ._be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be OTHER_DRUG ,_af sertraline_af ,_af citalopram_af ,_af escitalopram)_af clinically_af warranted_af ,_af appropriate_af observation_af patient_af advised_af ._af"
12081,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,sertraline,advise,"If_bf concomitant_bf treatment_bf DRUG SSRI_be (e_be ._be g_be ._be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be paroxetine_be ,_be OTHER_DRUG ,_af citalopram_af ,_af escitalopram)_af clinically_af warranted_af ,_af appropriate_af observation_af patient_af advised_af ._af"
12082,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,citalopram,advise,"If_bf concomitant_bf treatment_bf DRUG SSRI_be (e_be ._be g_be ._be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be paroxetine_be ,_be sertraline_be ,_be OTHER_DRUG ,_af escitalopram)_af clinically_af warranted_af ,_af appropriate_af observation_af patient_af advised_af ._af"
12083,"If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.",sumatriptan,escitalopram,advise,"If_bf concomitant_bf treatment_bf DRUG SSRI_be (e_be ._be g_be ._be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be paroxetine_be ,_be sertraline_be ,_be citalopram_be ,_be escitalopram)_be clinically_be warranted_be ,_be appropriate_be observation_be patient_be advised_be ._be"
12191,"Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.",escitalopram,citalopram,advise,"Concomitant_bf Administration_bf Racemic_bf OTHER_DRUG OTHER_DRUG -_af Since_af DRUG active_af isomer_af racemic_af OTHER_DRUG (Celexa)_af ,_af two_af agents_af coadministered_af ._af"
12192,"Concomitant Administration with Racemic Citalopram Citalopram - Since escitalopram is the active isomer of racemic citalopram (Celexa), the two agents should not be coadministered.",escitalopram,Celexa,advise,"Concomitant_bf Administration_bf Racemic_bf Citalopram_bf Citalopram_bf -_bf Since_bf DRUG active_be isomer_be racemic_be citalopram_be (Celexa)_be ,_be two_be agents_be coadministered_be ._be"
12223,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,digoxin,advise,"Although_bf interactions_bf observed_bf studies_bf appear_bf major_bf clinical_bf importance_bf ,_bf DRUG titrated_be caution_be patients_be treated_be concurrently_be OTHER_DRUG ,_af morphine_af ,_af succinylcholine_af warfarin_af ._af"
12224,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,morphine,advise,"Although_bf interactions_bf observed_bf studies_bf appear_bf major_bf clinical_bf importance_bf ,_bf DRUG titrated_be caution_be patients_be treated_be concurrently_be digoxin_be ,_be OTHER_DRUG ,_af succinylcholine_af warfarin_af ._af"
12225,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,succinylcholine,advise,"Although_bf interactions_bf observed_bf studies_bf appear_bf major_bf clinical_bf importance_bf ,_bf DRUG titrated_be caution_be patients_be treated_be concurrently_be digoxin_be ,_be morphine_be ,_be OTHER_DRUG warfarin_af ._af"
12226,"Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.",BREVIBLOC,warfarin,advise,"Although_bf interactions_bf observed_bf studies_bf appear_bf major_bf clinical_bf importance_bf ,_bf DRUG titrated_be caution_be patients_be treated_be concurrently_be digoxin_be ,_be morphine_be ,_be succinylcholine_be OTHER_DRUG ._af"
12233,Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.,BREVIBLOC,verapamil,advise,Caution_bf exercised_bf considering_bf use_bf DRUG OTHER_DRUG patients_af depressed_af myocardial_af function_af ._af
12234,"Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.",BREVIBLOC,dopamine,advise,"Additionally_bf ,_bf DRUG used_be control_be supraventricular_be tachycardia_be presence_be agents_be vasoconstrictive_be inotropic_be OTHER_DRUG ,_af epinephrine_af ,_af norepinephrine_af danger_af blocking_af cardiac_af contractility_af systemic_af vascular_af resistance_af high_af ._af"
12235,"Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.",BREVIBLOC,epinephrine,advise,"Additionally_bf ,_bf DRUG used_be control_be supraventricular_be tachycardia_be presence_be agents_be vasoconstrictive_be inotropic_be dopamine_be ,_be OTHER_DRUG ,_af norepinephrine_af danger_af blocking_af cardiac_af contractility_af systemic_af vascular_af resistance_af high_af ._af"
12236,"Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.",BREVIBLOC,norepinephrine,advise,"Additionally_bf ,_bf DRUG used_be control_be supraventricular_be tachycardia_be presence_be agents_be vasoconstrictive_be inotropic_be dopamine_be ,_be epinephrine_be ,_be OTHER_DRUG danger_af blocking_af cardiac_af contractility_af systemic_af vascular_af resistance_af high_af ._af"
12277,Concomitant administration of clarithromycin with pimozide is contraindicated.,clarithromycin,pimozide,advise,Concomitant_bf administration_bf DRUG OTHER_DRUG contraindicated_af ._af
12399,Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.,PEGANONE,Phenurone,advise,Considerable_bf caution_bf exercised_bf DRUG administered_be concurrently_be OTHER_DRUG (phenacemide)_af since_af paranoid_af symptoms_af reported_af therapy_af combination_af ._af
12400,Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.,PEGANONE,phenacemide,advise,Considerable_bf caution_bf exercised_bf DRUG administered_be concurrently_be Phenurone_be (phenacemide)_be since_be paranoid_be symptoms_be reported_be therapy_be combination_be ._be
12410,Caution is therefore advised when administering PEGANONE to patients receiving coumarin anticoagulants.,PEGANONE,coumarin anticoagulants,advise,Caution_bf therefore_bf advised_bf administering_bf DRUG patients_be receiving_be coumarin_be anticoagulants_be ._be
12415,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors.,NSAIDs,ACE-inhibitors,advise,This_bf interaction_bf given_bf consideration_bf patients_bf taking_bf DRUG concomitantly_be OTHER_DRUG ._af
12427,"however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.",Lodine,aspirin,advise,"however_bf ,_bf NSAIDs_bf ,_bf concomitant_bf administration_bf DRUG OTHER_DRUG generally_af recommended_af potential_af increased_af adverse_af effects_af ._af"
12460,"Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.",etodolac,phenylbutazone,advise,"Although_bf vivo_bf studies_bf done_bf see_bf DRUG clearance_be changed_be coadministration_be OTHER_DRUG ,_af recommended_af coadministered_af ._af"
13521,"In order to maintain phenytoin levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.",felbamate,phenytoin,advise,"In_bf order_bf maintain_bf OTHER_DRUG levels_be ,_be limit_be adverse_be experiences_be ,_be achieve_be DRUG dose_af 3600_af mg/day_af ,_af OTHER_DRUG dose_af reduction_af approximately_af 40%_af necessary_af eight_af 10_af subjects_af ._af"
13746,"Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.",Nalfon,salicylates,advise,"Because_bf DRUG shown_be produce_be additional_be effect_be beyond_be obtained_be aspirin_be alone_be aspirin_be increases_be rate_be excretion_be DRUG ,_af concomitant_af use_af DRUG OTHER_DRUG recommended_af ._af"
13748,"When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.",phenobarbital,Nalfon,advise,"When_bf DRUG added_be withdrawn_be treatment_be ,_be dosage_be adjustment_be OTHER_DRUG may_af required_af ._af"
13754,"In patients receiving Nalfon and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.",Nalfon,steroid,advise,"In_bf patients_bf receiving_bf DRUG OTHER_DRUG concomitantly_af ,_af reduction_af OTHER_DRUG dosage_af gradual_af order_af avoid_af possible_af complications_af sudden_af OTHER_DRUG withdrawal_af ._af"
13877,MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics,DURAGESIC,MAOI,advise,MAO_bf Inhibitors:_bf DRUG recommended_be use_be patients_be received_be OTHER_DRUG within_af 14_af days_af severe_af unpredictable_af potentiation_af MAO_af inhibitors_af reported_af opioid_af analgesics_af
13882,MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics,MAO inhibitors,opioid analgesics,advise,MAO_bf Inhibitors:_bf DURAGESIC_bf recommended_bf use_bf patients_bf received_bf MAOI_bf within_bf 14_bf days_bf severe_bf unpredictable_bf potentiation_bf MAO_bf inhibitors_bf reported_bf opioid_bf analgesics_bf
13932,ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.,ALLEGRA,aluminum,advise,DRUG taken_be closely_be time_be OTHER_DRUG magnesium_af containing_af antacids_af ._af
13933,ALLEGRA should not be taken closely in time with aluminum and magnesium containing antacids.,ALLEGRA,magnesium,advise,DRUG taken_be closely_be time_be aluminum_be OTHER_DRUG containing_af antacids_af ._af
14111,"Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.",disopyramide,TAMBOCOR,advise,"Because_bf drugs_bf negative_bf inotropic_bf properties_bf effects_bf coadministration_bf OTHER_DRUG unknown_be ,_be neither_be DRUG verapamil_af administered_af concurrently_af OTHER_DRUG unless_af ,_af judgment_af physician_af ,_af benefits_af combination_af outweigh_af risks_af ._af"
14112,"Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.",verapamil,TAMBOCOR,advise,"Because_bf drugs_bf negative_bf inotropic_bf properties_bf effects_bf coadministration_bf OTHER_DRUG unknown_be ,_be neither_be disopyramide_be DRUG administered_af concurrently_af OTHER_DRUG unless_af ,_af judgment_af physician_af ,_af benefits_af combination_af outweigh_af risks_af ._af"
14199,Wait 5 weeks after stopping escitalopram before starting a non-selective MAO inhibitor.,escitalopram,non-selective MAO inhibitor,advise,Wait_bf 5_bf weeks_bf stopping_bf DRUG starting_be non-selective_be MAO_be inhibitor_be ._be
14200,Wait 2 weeks after stopping an MAO inhibitor before starting escitalopram.,MAO inhibitor,escitalopram,advise,Wait_bf 2_bf weeks_bf stopping_bf MAO_bf inhibitor_bf starting_bf OTHER_DRUG ._be
14427,"Therefore, close monitoring of prothrombin time is recommended and adjustment of the anticoagulant dose may be necessary when EULEXIN Capsules are administered concomitantly with warfarin.",EULEXIN,warfarin,advise,"Therefore_bf ,_bf close_bf monitoring_bf prothrombin_bf time_bf recommended_bf adjustment_bf anticoagulant_bf dose_bf may_bf necessary_bf DRUG Capsules_be administered_be concomitantly_be OTHER_DRUG ._af"
14431,"Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.",Fluvoxamine,MAOIs,advise,"Therefore_bf ,_bf recommended_bf DRUG Tablets_be used_be combination_be OTHER_DRUG ,_af within_af 14_af days_af discontinuing_af treatment_af MAOI_af ._af"
14432,"Therefore, it is recommended that Fluvoxamine Tablets not be used in combination with MAOIs, or within 14 days of discontinuing treatment with a MAOI.",Fluvoxamine,MAOI,advise,"Therefore_bf ,_bf recommended_bf DRUG Tablets_be used_be combination_be MAOIs_be ,_be within_be 14_be days_be discontinuing_be treatment_be OTHER_DRUG ._af"
14434,"After stopping Fluvoxamine Tablets, at least 2 weeks should be allowed before starting a MAOI.",Fluvoxamine,MAOI,advise,"After_bf stopping_bf DRUG Tablets_be ,_be least_be 2_be weeks_be allowed_be starting_be OTHER_DRUG ._af"
14451,"Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.",fluvoxamine,terbinafine,advise,"Consequently_bf ,_bf recommended_bf DRUG used_be combination_be either_be OTHER_DRUG ,_af astemizole_af ,_af cisapride_af ._af"
14452,"Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.",fluvoxamine,astemizole,advise,"Consequently_bf ,_bf recommended_bf DRUG used_be combination_be either_be terbinafine_be ,_be OTHER_DRUG ,_af cisapride_af ._af"
14453,"Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.",fluvoxamine,cisapride,advise,"Consequently_bf ,_bf recommended_bf DRUG used_be combination_be either_be terbinafine_be ,_be astemizole_be ,_be OTHER_DRUG ._af"
14499,"This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is co-administered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If alprazolam is co-administered with Fluvoxamine Tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended.",alprazolam,Fluvoxamine,advise,"This_bf interaction_bf ,_bf investigated_bf using_bf higher_bf doses_bf OTHER_DRUG ,_be may_be pronounced_be 300_be mg_be daily_be dose_be co-administered_be ,_be particularly_be since_be OTHER_DRUG exhibits_af non-linear_af pharmacokinetics_af dosage_af range_af 100-300_af mg_af ._af If_af DRUG co-administered_af OTHER_DRUG Tablets_af ,_af initial_af DRUG dosage_af least_af halved_af titration_af lowest_af effective_af dose_af recommended_af ._af"
14504,Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.,Fluvoxamine,diazepam,advise,Diazepam:_bf The_bf co-administration_bf DRUG Tablets_be OTHER_DRUG generally_af advisable_af ._af
14508,Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.,fluvoxamine,diazepam,advise,Evidence_bf supporting_bf conclusion_bf inadvisable_bf co-administer_bf DRUG OTHER_DRUG derived_af study_af healthy_af volunteers_af taking_af 150_af mg/day_af DRUG administered_af single_af oral_af dose_af 10_af mg_af OTHER_DRUG ._af
14516,"Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.",diazepam,fluvoxamine,advise,"Accordingly_bf ,_bf DRUG OTHER_DRUG ordinarily_af co-administered_af ._af"
14523,"Therefore, if theophylline is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.",theophylline,fluvoxamine maleate,advise,"Therefore_bf ,_bf DRUG co-administered_be fluvoxamine_be maleate_be ,_be dose_be reduced_be one_be third_be usual_be daily_be maintenance_be dose_be plasma_be concentrations_be DRUG monitored_af ._af"
14532,Thus patients receiving oral anticoagulants and Fluvoxamine Tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly.,anticoagulants,Fluvoxamine,advise,Thus_bf patients_bf receiving_bf oral_bf DRUG OTHER_DRUG Tablets_af prothrombin_af time_af monitored_af anticoagulant_af dose_af adjusted_af accordingly_af ._af
14595,Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.,FORADIL,monoamine oxidase inhibitors,advise,Monoamine_bf Oxidase_bf Inhibitors_bf Tricyclic_bf Antidepressants:_bf DRUG administered_be extreme_be caution_be patients_be treated_be monoamine_be oxidase_be inhibitors_be tricyclic_be antidepressants_be action_be formoterol_be cardiovascular_be system_be may_be potentiated_be agents_be ._be
14596,Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.,FORADIL,tricyclic antidepressants,advise,Monoamine_bf Oxidase_bf Inhibitors_bf Tricyclic_bf Antidepressants:_bf DRUG administered_be extreme_be caution_be patients_be treated_be monoamine_be oxidase_be inhibitors_be tricyclic_be antidepressants_be action_be formoterol_be cardiovascular_be system_be may_be potentiated_be agents_be ._be
14647,"Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.",FOSCAVIR,aminoglycosides,advise,"Because_bf foscarnets_bf tendency_bf cause_bf renal_bf impairment_bf ,_bf use_bf DRUG avoided_be combination_be potentially_be nephrotoxic_be drugs_be OTHER_DRUG ,_af amphotericin_af B_af intravenous_af pentamidine_af unless_af potential_af benefits_af outweigh_af risks_af patient_af ._af"
14648,"Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.",FOSCAVIR,amphotericin B,advise,"Because_bf foscarnets_bf tendency_bf cause_bf renal_bf impairment_bf ,_bf use_bf DRUG avoided_be combination_be potentially_be nephrotoxic_be drugs_be aminoglycosides_be ,_be amphotericin_be B_be intravenous_be pentamidine_be unless_be potential_be benefits_be outweigh_be risks_be patient_be ._be"
14649,"Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.",FOSCAVIR,pentamidine,advise,"Because_bf foscarnets_bf tendency_bf cause_bf renal_bf impairment_bf ,_bf use_bf DRUG avoided_be combination_be potentially_be nephrotoxic_be drugs_be aminoglycosides_be ,_be amphotericin_be B_be intravenous_be OTHER_DRUG unless_af potential_af benefits_af outweigh_af risks_af patient_af ._af"
14671,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",ergotamine,FROVA,advise,"Due_bf theoretical_bf risk_bf pharmacodynamic_bf interaction_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf dihydroergotamine_bf methysergide)_bf OTHER_DRUG within_be 24_be hours_be avoided_be (see_be href=_be frova_od_be ._be htm#CI_be CONTRAINDICATIONS)_be ._be"
14674,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",ergot-type medications,FROVA,advise,"Due_bf theoretical_bf risk_bf pharmacodynamic_bf interaction_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf dihydroergotamine_bf methysergide)_bf OTHER_DRUG within_be 24_be hours_be avoided_be (see_be href=_be frova_od_be ._be htm#CI_be CONTRAINDICATIONS)_be ._be"
14676,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",dihydroergotamine,FROVA,advise,"Due_bf theoretical_bf risk_bf pharmacodynamic_bf interaction_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf DRUG methysergide)_be OTHER_DRUG within_af 24_af hours_af avoided_af (see_af href=_af frova_od_af ._af htm#CI_af CONTRAINDICATIONS)_af ._af"
14677,"Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).",methysergide,FROVA,advise,"Due_bf theoretical_bf risk_bf pharmacodynamic_bf interaction_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf dihydroergotamine_bf methysergide)_bf OTHER_DRUG within_be 24_be hours_be avoided_be (see_be href=_be frova_od_be ._be htm#CI_be CONTRAINDICATIONS)_be ._be"
14699,"If concomitant treatment with frovatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.",frovatriptan,SSRI,advise,"If_bf concomitant_bf treatment_bf DRUG OTHER_DRUG clinically_af warranted_af ,_af appropriate_af observation_af patient_af advised_af ._af"
14702,Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.,Furosemide,ethacrynic acid,advise,DRUG used_be concomitantly_be ethacrynic_be acid_be possibility_be ototoxicity_be ._be
14709,Lithium generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of lithium toxicity.,Lithium,diuretics,advise,DRUG generally_be given_be OTHER_DRUG reduce_af lithiums_af renal_af clearance_af add_af high_af risk_af DRUG toxicity_af ._af
14721,The intake of furosemide and sucralfate should be separated by at least two hours.,furosemide,sucralfate,advise,The_bf intake_bf DRUG OTHER_DRUG separated_af least_af two_af hours_af ._af
14725,Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.,indomethacin,furosemide,advise,Patients_bf receiving_bf DRUG OTHER_DRUG observed_af closely_af determine_af desired_af diuretic_af and/or_af antihypertensive_af effect_af OTHER_DRUG achieved_af ._af
14821,It is recommended that gabapentin be taken at least 2 hours following Maalox administration.,gabapentin,Maalox,advise,It_bf recommended_bf DRUG taken_be least_be 2_be hours_be following_be OTHER_DRUG administration_af ._af
14896,"However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.",quinolone antimicrobial,warfarin,advise,"However_bf ,_bf quinolones_bf reported_bf enhance_bf anticoagulant_bf effects_bf OTHER_DRUG derivatives_be patients_be ,_be prothrombin_be time_be suitable_be coagulation_be test_be closely_be monitored_be quinolone_be antimicrobial_be administered_be concomitantly_be OTHER_DRUG derivatives_af ._af"
14911,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",Magnesium,FACTIVE,advise,"Magnesium-_bf and/or_bf aluminum-containing_bf antacids_bf ,_bf products_bf containing_bf ferrous_bf sulfate_bf (iron)_bf ,_bf multivitamin_bf preparations_bf containing_bf zinc_bf metal_bf cations_bf ,_bf Videx_bf (didanosine)_bf chewable/buffered_bf tablets_bf pediatric_bf powder_bf oral_bf solution_bf taken_bf within_bf 3_bf hours_bf 2_bf hours_bf OTHER_DRUG ._be"
14919,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",aluminum,FACTIVE,advise,"Magnesium-_bf and/or_bf aluminum-containing_bf antacids_bf ,_bf products_bf containing_bf ferrous_bf sulfate_bf (iron)_bf ,_bf multivitamin_bf preparations_bf containing_bf zinc_bf metal_bf cations_bf ,_bf Videx_bf (didanosine)_bf chewable/buffered_bf tablets_bf pediatric_bf powder_bf oral_bf solution_bf taken_bf within_bf 3_bf hours_bf 2_bf hours_bf OTHER_DRUG ._be"
14932,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",ferrous sulfate,FACTIVE,advise,"Magnesium-_bf and/or_bf aluminum-containing_bf antacids_bf ,_bf products_bf containing_bf ferrous_bf sulfate_bf (iron)_bf ,_bf multivitamin_bf preparations_bf containing_bf zinc_bf metal_bf cations_bf ,_bf Videx_bf (didanosine)_bf chewable/buffered_bf tablets_bf pediatric_bf powder_bf oral_bf solution_bf taken_bf within_bf 3_bf hours_bf 2_bf hours_bf OTHER_DRUG ._be"
14937,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",iron,FACTIVE,advise,"Magnesium-_bf and/or_bf aluminum-containing_bf antacids_bf ,_bf products_bf containing_bf ferrous_bf sulfate_bf (iron)_bf ,_bf multivitamin_bf preparations_bf containing_bf zinc_bf metal_bf cations_bf ,_bf Videx_bf (didanosine)_bf chewable/buffered_bf tablets_bf pediatric_bf powder_bf oral_bf solution_bf taken_bf within_bf 3_bf hours_bf 2_bf hours_bf OTHER_DRUG ._be"
14941,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",multivitamin preparations,FACTIVE,advise,"Magnesium-_bf and/or_bf aluminum-containing_bf antacids_bf ,_bf products_bf containing_bf ferrous_bf sulfate_bf (iron)_bf ,_bf multivitamin_bf preparations_bf containing_bf zinc_bf metal_bf cations_bf ,_bf Videx_bf (didanosine)_bf chewable/buffered_bf tablets_bf pediatric_bf powder_bf oral_bf solution_bf taken_bf within_bf 3_bf hours_bf 2_bf hours_bf OTHER_DRUG ._be"
14944,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",zinc,FACTIVE,advise,"Magnesium-_bf and/or_bf aluminum-containing_bf antacids_bf ,_bf products_bf containing_bf ferrous_bf sulfate_bf (iron)_bf ,_bf multivitamin_bf preparations_bf containing_bf DRUG metal_be cations_be ,_be Videx_be (didanosine)_be chewable/buffered_be tablets_be pediatric_be powder_be oral_be solution_be taken_be within_be 3_be hours_be 2_be hours_be OTHER_DRUG ._af"
14946,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",Videx,FACTIVE,advise,"Magnesium-_bf and/or_bf aluminum-containing_bf antacids_bf ,_bf products_bf containing_bf ferrous_bf sulfate_bf (iron)_bf ,_bf multivitamin_bf preparations_bf containing_bf zinc_bf metal_bf cations_bf ,_bf DRUG (didanosine)_be chewable/buffered_be tablets_be pediatric_be powder_be oral_be solution_be taken_be within_be 3_be hours_be 2_be hours_be OTHER_DRUG ._af"
14947,"Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.",didanosine,FACTIVE,advise,"Magnesium-_bf and/or_bf aluminum-containing_bf antacids_bf ,_bf products_bf containing_bf ferrous_bf sulfate_bf (iron)_bf ,_bf multivitamin_bf preparations_bf containing_bf zinc_bf metal_bf cations_bf ,_bf Videx_bf (didanosine)_bf chewable/buffered_bf tablets_bf pediatric_bf powder_bf oral_bf solution_bf taken_bf within_bf 3_bf hours_bf 2_bf hours_bf OTHER_DRUG ._be"
14948,Sucralfate should not be taken within 2 hours of FACTIVE.,Sucralfate,FACTIVE,advise,DRUG taken_be within_be 2_be hours_be OTHER_DRUG ._af
15042,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,aspirin,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be OTHER_DRUG another_af salicylate_af magnesium/choline_af salicylate_af (Trilisate)_af ,_af salsalate_af (Disalcid_af ,_af others)_af ,_af choline_af salicylate_af (Arthropan)_af ,_af magnesium_af salicylate_af (Magan)_af ,_af bismuth_af subsalicylate_af (Pepto-Bismol);_af"
15043,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,salicylate,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be OTHER_DRUG magnesium/choline_af OTHER_DRUG (Trilisate)_af ,_af salsalate_af (Disalcid_af ,_af others)_af ,_af choline_af OTHER_DRUG (Arthropan)_af ,_af magnesium_af OTHER_DRUG (Magan)_af ,_af bismuth_af subsalicylate_af (Pepto-Bismol);_af"
15044,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,magnesium/choline salicylate,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be salsalate_be (Disalcid_be ,_be others)_be ,_be choline_be salicylate_be (Arthropan)_be ,_be magnesium_be salicylate_be (Magan)_be ,_be bismuth_be subsalicylate_be (Pepto-Bismol);_be"
15045,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Trilisate,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be salsalate_be (Disalcid_be ,_be others)_be ,_be choline_be salicylate_be (Arthropan)_be ,_be magnesium_be salicylate_be (Magan)_be ,_be bismuth_be subsalicylate_be (Pepto-Bismol);_be"
15046,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,salsalate,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be OTHER_DRUG (Disalcid_af ,_af others)_af ,_af choline_af salicylate_af (Arthropan)_af ,_af magnesium_af salicylate_af (Magan)_af ,_af bismuth_af subsalicylate_af (Pepto-Bismol);_af"
15047,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Disalcid,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be salsalate_be (Disalcid_be ,_be others)_be ,_be choline_be salicylate_be (Arthropan)_be ,_be magnesium_be salicylate_be (Magan)_be ,_be bismuth_be subsalicylate_be (Pepto-Bismol);_be"
15048,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,choline salicylate,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be salsalate_be (Disalcid_be ,_be others)_be ,_be choline_be salicylate_be (Arthropan)_be ,_be magnesium_be salicylate_be (Magan)_be ,_be bismuth_be subsalicylate_be (Pepto-Bismol);_be"
15049,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Arthropan,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be salsalate_be (Disalcid_be ,_be others)_be ,_be choline_be salicylate_be (Arthropan)_be ,_be magnesium_be salicylate_be (Magan)_be ,_be bismuth_be subsalicylate_be (Pepto-Bismol);_be"
15050,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,magnesium salicylate,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be salsalate_be (Disalcid_be ,_be others)_be ,_be choline_be salicylate_be (Arthropan)_be ,_be magnesium_be salicylate_be (Magan)_be ,_be bismuth_be subsalicylate_be (Pepto-Bismol);_be"
15051,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Magan,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be salsalate_be (Disalcid_be ,_be others)_be ,_be choline_be salicylate_be (Arthropan)_be ,_be magnesium_be salicylate_be (Magan)_be ,_be bismuth_be subsalicylate_be (Pepto-Bismol);_be"
15052,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,bismuth subsalicylate,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be salsalate_be (Disalcid_be ,_be others)_be ,_be choline_be salicylate_be (Arthropan)_be ,_be magnesium_be salicylate_be (Magan)_be ,_be bismuth_be subsalicylate_be (Pepto-Bismol);_be"
15053,"Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);",glimepiride,Pepto-Bismol,advise,"Before_bf taking_bf DRUG ,_be tell_be doctor_be taking_be following_be medicines:_be -_be aspirin_be another_be salicylate_be magnesium/choline_be salicylate_be (Trilisate)_be ,_be salsalate_be (Disalcid_be ,_be others)_be ,_be choline_be salicylate_be (Arthropan)_be ,_be magnesium_be salicylate_be (Magan)_be ,_be bismuth_be subsalicylate_be (Pepto-Bismol);_be"
15873,"When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.",theophylline,grepafloxacin,advise,"When_bf initiating_bf multi-day_bf course_bf OTHER_DRUG patient_be maintained_be DRUG ,_af DRUG maintenance_af dose_af halved_af period_af concurrent_af use_af OTHER_DRUG monitoring_af serum_af DRUG concentrations_af initiated_af guide_af dosage_af adjustments_af ._af"
15884,"However, because some quinolones have been reported to enhance the effects of warfarin or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a quinolone antimicrobial is administered with warfarin or its derivatives.",quinolone antimicrobial,warfarin,advise,"However_bf ,_bf quinolones_bf reported_bf enhance_bf effects_bf OTHER_DRUG derivatives_be ,_be prothrombin_be time_be suitable_be anticoagulation_be test_be monitored_be closely_be quinolone_be antimicrobial_be administered_be OTHER_DRUG derivatives_af ._af"
15912,Patients on warfarin-type anticoagulant therapy may require dosage adjustment of the anticoagulant during and after griseofulvin therapy.,warfarin-type anticoagulant,griseofulvin,advise,Patients_bf warfarin-type_bf anticoagulant_bf therapy_bf may_bf require_bf dosage_bf adjustment_bf anticoagulant_bf OTHER_DRUG therapy_be ._be
16023,"Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.",rifampin,haloperidol,advise,"Thus_bf ,_bf careful_bf monitoring_bf clinical_bf status_bf warranted_bf DRUG administered_be discontinued_be haloperidol-treated_be patients_be ._be"
16028,Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.,adrenaline,FLUOTHANE,advise,Caution_bf exercised_bf administration_bf DRUG patients_be anaesthetised_be OTHER_DRUG arrhythmias_af may_af precipitated_af ._af
16039,"Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.",heparin sodium,dicumarol,advise,"Therefore_bf ,_bf heparin_bf sodium_bf given_bf OTHER_DRUG warfarin_be sodium_be ,_be period_be least_be 5_be hours_be last_be intravenous_be dose_be 24_be hours_be last_be subcutaneous_be dose_be elapse_be blood_be drawn_be valid_be prothrombin_be time_be obtained_be ._be"
16040,"Therefore, when heparin sodium is given with dicumarol or warfarin sodium, a period of at least 5 hours after the last intravenous dose or 24 hours after the last subcutaneous dose should elapse before blood is drawn if a valid prothrombin time is to be obtained.",heparin sodium,warfarin sodium,advise,"Therefore_bf ,_bf heparin_bf sodium_bf given_bf dicumarol_bf warfarin_bf sodium_bf ,_bf period_bf least_bf 5_bf hours_bf last_bf intravenous_bf dose_bf 24_bf hours_bf last_bf subcutaneous_bf dose_bf elapse_bf blood_bf drawn_bf valid_bf prothrombin_bf time_bf obtained_bf ._bf"
16079,"Thus in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with antithrombin III (human).",heparin,antithrombin III,advise,"Thus_bf order_bf avoid_bf bleeding_bf ,_bf reduced_bf dosage_bf DRUG recommended_be treatment_be antithrombin_be III_be (human)_be ._be"
16135,MAO inhibitors should be used with caution in patients receiving hydralazine.,MAO inhibitors,hydralazine,advise,MAO_bf inhibitors_bf used_bf caution_bf patients_bf receiving_bf OTHER_DRUG ._be
16174,Lithium: generally should not be given with diuretics.,Lithium,diuretics,advise,Lithium:_bf generally_bf given_bf OTHER_DRUG ._be
16178,Refer to the package insert for lithium preparations before use of such preparations with Hydrochlorothiazide.,lithium,Hydrochlorothiazide,advise,Refer_bf package_bf insert_bf DRUG preparations_be use_be preparations_be OTHER_DRUG ._af
16189,"Therefore, when Hydrochlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.",Hydrochlorothiazide,non-steroidal anti-inflammatory agents,advise,"Therefore_bf ,_bf DRUG non-steroidal_be anti-inflammatory_be agents_be used_be concomitantly_be ,_be patient_be observed_be closely_be determine_be desired_be effect_be diuretic_be obtained_be ._be"
16237,"for adult-onset diabetics, dosage adjustment of hypoglycemic medications may be necessary during and after thiazide diuretic therapy;",hypoglycemic medications,thiazide diuretic,advise,"adult-onset_bf diabetics_bf ,_bf dosage_bf adjustment_bf hypoglycemic_bf medications_bf may_bf necessary_bf thiazide_bf diuretic_bf therapy;_bf"
16245,"Therefore, when hydroflumethiazide and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)",hydroflumethiazide,nonsteroidal anti-inflammatory agents,advise,"Therefore_bf ,_bf DRUG nonsteroidal_be anti-inflammatory_be agents_be used_be concomitantly_be ,_be patient_be observed_be closely_be determine_be desired_be effect_be diuretic_be obtained_be ._be )_be"
16297,Therefore when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced.,central nervous system depressants,hydroxyzine,advise,Therefore_bf central_bf nervous_bf system_bf depressants_bf administered_bf concomitantly_bf OTHER_DRUG dosage_be reduced_be ._be
16310,"Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).",Ibandronate,antacids,advise,"DRUG taken_be least_be 60_be minutes_be oral_be medications_be containing_be multivalent_be cations_be (including_be OTHER_DRUG ,_af supplements_af vitamins)_af ._af"
16311,"Ibandronate should be taken at least 60 minutes before any oral medications containing multivalent cations (including antacids, supplements or vitamins).",Ibandronate,vitamins,advise,"DRUG taken_be least_be 60_be minutes_be oral_be medications_be containing_be multivalent_be cations_be (including_be antacids_be ,_be supplements_be vitamins)_be ._be"
16344,"However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.",aspirin,Ibandronate,advise,"However_bf ,_bf since_bf DRUG ,_be NSAIDs_be ,_be bisphosphonates_be associated_be gastrointestinal_be irritation_be ,_be caution_be exercised_be concomitant_be use_be DRUG NSAIDs_af OTHER_DRUG ._af"
16345,"However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.",NSAIDs,Ibandronate,advise,"However_bf ,_bf since_bf aspirin_bf ,_bf DRUG ,_be bisphosphonates_be associated_be gastrointestinal_be irritation_be ,_be caution_be exercised_be concomitant_be use_be aspirin_be DRUG OTHER_DRUG ._af"
16370,"However, appropriate monitoring of blood glucose should be performed when initiating EXTRANEAL in diabetic patients and insulin dosage should be adjusted if needed.",EXTRANEAL,insulin,advise,"However_bf ,_bf appropriate_bf monitoring_bf blood_bf glucose_bf performed_bf initiating_bf DRUG diabetic_be patients_be OTHER_DRUG dosage_af adjusted_af needed_af ._af"
16420,"When you are using idoxuridine, it is especially important that your health care professional know if you are using the following: Eye product containing boric acid.",idoxuridine,boric acid,advise,"When_bf using_bf DRUG ,_be especially_be important_be health_be care_be professional_be know_be using_be following:_be Eye_be product_be containing_be boric_be acid_be ._be"
16484,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,ketoconazole,advise,"Drugs_bf may_bf alter_bf imatinib_bf plasma_bf concentrations_bf Drugs_bf may_bf increase_bf imatinib_bf plasma_bf concentrations:_bf Caution_bf recommended_bf administering_bf DRUG inhibitors_be CYP3A4_be family_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af itraconazole_af ,_af erythromycin_af ,_af clarithromycin)_af ._af"
16485,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,itraconazole,advise,"Drugs_bf may_bf alter_bf imatinib_bf plasma_bf concentrations_bf Drugs_bf may_bf increase_bf imatinib_bf plasma_bf concentrations:_bf Caution_bf recommended_bf administering_bf DRUG inhibitors_be CYP3A4_be family_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be OTHER_DRUG ,_af erythromycin_af ,_af clarithromycin)_af ._af"
16486,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,erythromycin,advise,"Drugs_bf may_bf alter_bf imatinib_bf plasma_bf concentrations_bf Drugs_bf may_bf increase_bf imatinib_bf plasma_bf concentrations:_bf Caution_bf recommended_bf administering_bf DRUG inhibitors_be CYP3A4_be family_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be OTHER_DRUG ,_af clarithromycin)_af ._af"
16487,"Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).",Gleevec,clarithromycin,advise,"Drugs_bf may_bf alter_bf imatinib_bf plasma_bf concentrations_bf Drugs_bf may_bf increase_bf imatinib_bf plasma_bf concentrations:_bf Caution_bf recommended_bf administering_bf DRUG inhibitors_be CYP3A4_be family_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be clarithromycin)_be ._be"
16517,"Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).",Gleevec,cyclosporine,advise,"Particular_bf caution_bf recommended_bf administering_bf DRUG CYP3A4_be substrates_be narrow_be therapeutic_be window_be (e_be ._be g_be ._be ,_be OTHER_DRUG pimozide)_af ._af"
16518,"Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).",Gleevec,pimozide,advise,"Particular_bf caution_bf recommended_bf administering_bf DRUG CYP3A4_be substrates_be narrow_be therapeutic_be window_be (e_be ._be g_be ._be ,_be cyclosporine_be pimozide)_be ._be"
16532,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",decongestants,tricyclic antidepressants,advise,"Avoid_bf use_bf preparations_bf DRUG local_be anesthetics_be contain_be sympathomimetic_be amine_be (e_be ._be g_be ._be ,_be epinephrine_be ,_be norepinephrine)_be ,_be since_be reported_be tricyclic_be antidepressants_be potentiate_be effects_be catecholamines_be ._be"
16536,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",anesthetics,tricyclic antidepressants,advise,"Avoid_bf use_bf preparations_bf decongestants_bf local_bf DRUG contain_be sympathomimetic_be amine_be (e_be ._be g_be ._be ,_be epinephrine_be ,_be norepinephrine)_be ,_be since_be reported_be tricyclic_be antidepressants_be potentiate_be effects_be catecholamines_be ._be"
16539,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",sympathomimetic amine,tricyclic antidepressants,advise,"Avoid_bf use_bf preparations_bf decongestants_bf local_bf anesthetics_bf contain_bf sympathomimetic_bf amine_bf (e_bf ._bf g_bf ._bf ,_bf epinephrine_bf ,_bf norepinephrine)_bf ,_bf since_bf reported_bf tricyclic_bf antidepressants_bf potentiate_bf effects_bf catecholamines_bf ._bf"
16541,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",epinephrine,tricyclic antidepressants,advise,"Avoid_bf use_bf preparations_bf decongestants_bf local_bf anesthetics_bf contain_bf sympathomimetic_bf amine_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be norepinephrine)_be ,_be since_be reported_be tricyclic_be antidepressants_be potentiate_be effects_be catecholamines_be ._be"
16542,"Avoid the use of preparations such as decongestants and local anesthetics which contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.",norepinephrine,tricyclic antidepressants,advise,"Avoid_bf use_bf preparations_bf decongestants_bf local_bf anesthetics_bf contain_bf sympathomimetic_bf amine_bf (e_bf ._bf g_bf ._bf ,_bf epinephrine_bf ,_bf norepinephrine)_bf ,_bf since_bf reported_bf tricyclic_bf antidepressants_bf potentiate_bf effects_bf catecholamines_bf ._bf"
16618,Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.,CRIXIVAN,atazanavir,advise,Combinations_bf drugs_bf studied_bf coadministration_bf DRUG OTHER_DRUG recommended_af ._af
16619,Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.,CRIXIVAN,delavirdine,advise,Dose_bf reduction_bf DRUG 600_be mg_be every_be 8_be hours_be considered_be taking_be OTHER_DRUG 400_af mg_af three_af times_af day_af ._af
16620,Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.,Indinavir,didanosine,advise,DRUG OTHER_DRUG formulations_af containing_af buffer_af administered_af least_af one_af hour_af apart_af empty_af stomach_af ._af
16636,Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when coadministered with CRIXIVAN.,antiarrhythmics,CRIXIVAN,advise,Caution_bf warranted_bf therapeutic_bf concentration_bf monitoring_bf recommended_bf DRUG coadministered_be OTHER_DRUG ._af
16660,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.",atorvastatin,CRIXIVAN,advise,"Use_bf lowest_bf possible_bf dose_bf DRUG careful_be monitoring_be ,_be consider_be HMG-CoA_be reductase_be inhibitors_be primarily_be metabolized_be CYP3A4_be ,_be pravastatin_be ,_be fluvastatin_be ,_be rosuvastatin_be combination_be OTHER_DRUG ._af"
16664,"Use lowest possible dose of atorvastatin with careful monitoring, or consider HMG-CoA reductase inhibitors that are not primarily metabolized by CYP3A4, such as pravastatin, fluvastatin, or rosuvastatin in combination with CRIXIVAN.",HMG-CoA reductase inhibitors,CRIXIVAN,advise,"Use_bf lowest_bf possible_bf dose_bf atorvastatin_bf careful_bf monitoring_bf ,_bf consider_bf HMG-CoA_bf reductase_bf inhibitors_bf primarily_bf metabolized_bf CYP3A4_bf ,_bf pravastatin_bf ,_bf fluvastatin_bf ,_bf rosuvastatin_bf combination_bf OTHER_DRUG ._be"
16677,Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering itraconazole concurrently.,CRIXIVAN,itraconazole,advise,Dose_bf reduction_bf DRUG 600_be mg_be every_be 8_be hours_be recommended_be administering_be OTHER_DRUG concurrently_af ._af
16684,Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.,rifabutin,CRIXIVAN,advise,Dose_bf reduction_bf DRUG half_be standard_be dose_be dose_be increase_be OTHER_DRUG 1000_af mg_af (three_af 333-mg_af capsules)_af every_af 8_af hours_af recommended_af DRUG OTHER_DRUG coadministered_af ._af
16685,Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.,Sildenafil,indinavir,advise,DRUG dose_be exceed_be maximum_be 25_be mg_be 48-_be hour_be period_be patients_be receiving_be concomitant_be OTHER_DRUG therapy_af ._af
16686,Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.,Tadalafil,indinavir,advise,DRUG dose_be exceed_be maximum_be 10_be mg_be 72-_be hour_be period_be patients_be receiving_be concomitant_be OTHER_DRUG therapy_af ._af
16687,Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.,Vardenafil,indinavir,advise,DRUG dose_be exceed_be maximum_be 2_be ._be 5_be mg_be 24-hour_be period_be patients_be receiving_be concomitant_be OTHER_DRUG therapy_af ._af
16692,"Therefore, diflunisal and INDOCIN should not be used concomitantly.",diflunisal,INDOCIN,advise,"Therefore_bf ,_bf DRUG OTHER_DRUG used_af concomitantly_af ._af"
16694,"The concomitant use of INDOCIN with other NSAIDs is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.",INDOCIN,NSAIDs,advise,"The_bf concomitant_bf use_bf DRUG OTHER_DRUG recommended_af due_af increased_af possibility_af gastrointestinal_af toxicity_af ,_af little_af increase_af efficacy_af ._af"
16696,"However, when any additional drug, including INDOCIN, is added to the treatment of patients on anticoagulant therapy, the patients should be observed for alterations of the prothrombin time.",INDOCIN,anticoagulant,advise,"However_bf ,_bf additional_bf drug_bf ,_bf including_bf DRUG ,_be added_be treatment_be patients_be OTHER_DRUG therapy_af ,_af patients_af observed_af alterations_af prothrombin_af time_af ._af"
16698,Caution should be exercised when INDOCIN and anticoagulants are administered concomitantly.,INDOCIN,anticoagulants,advise,Caution_bf exercised_bf DRUG OTHER_DRUG administered_af concomitantly_af ._af
16702,Caution should be used if INDOCIN is administered simultaneously with methotrexate.,INDOCIN,methotrexate,advise,Caution_bf used_bf DRUG administered_be simultaneously_be OTHER_DRUG ._af
16707,"NSAIDs should be used with caution in patients taking cyclosporine, and renal function should be carefully monitored.",NSAIDs,cyclosporine,advise,"DRUG used_be caution_be patients_be taking_be OTHER_DRUG ,_af renal_af function_af carefully_af monitored_af ._af"
16714,"As a consequence, when INDOCIN and lithium are given concomitantly, the patient should be carefully observed for signs of lithium toxicity.",INDOCIN,lithium,advise,"As_bf consequence_bf ,_bf DRUG OTHER_DRUG given_af concomitantly_af ,_af patient_af carefully_af observed_af signs_af OTHER_DRUG toxicity_af ._af"
16720,"Therefore, when INDOCIN and digoxin are used concomitantly, serum digoxin levels should be closely monitored.",INDOCIN,digoxin,advise,"Therefore_bf ,_bf DRUG OTHER_DRUG used_af concomitantly_af ,_af serum_af OTHER_DRUG levels_af closely_af monitored_af ._af"
16735,INDOCIN and triamterene should not be administered together.,INDOCIN,triamterene,advise,DRUG OTHER_DRUG administered_af together_af ._af
16804,Caution is therefore advised in the coadministration of ATROVENT Inhalation Aerosol with other anticholinergic-containing drugs.,ATROVENT,anticholinergic,advise,Caution_bf therefore_bf advised_bf coadministration_bf DRUG Inhalation_be Aerosol_be anticholinergic-containing_be drugs_be ._be
16840,"Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).",Isocarboxazid,Antabuse,advise,"DRUG administered_be caution_be patients_be receiving_be OTHER_DRUG (disulfiram_af ,_af Wyeth-Ayerst_af Laboratories)_af ._af"
16841,"Isocarboxazid should be administered with caution to patients receiving Antabuse (disulfiram, Wyeth-Ayerst Laboratories).",Isocarboxazid,disulfiram,advise,"DRUG administered_be caution_be patients_be receiving_be Antabuse_be (disulfiram_be ,_be Wyeth-Ayerst_be Laboratories)_be ._be"
16844,Concomitant use of Isocarboxazid and other psychotropic agents is generally not recommended because of possible potentiating effects.,Isocarboxazid,psychotropic agents,advise,Concomitant_bf use_bf DRUG psychotropic_be agents_be generally_be recommended_be possible_be potentiating_be effects_be ._be
16884,"Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.",Carbamazepine,isoniazid,advise,"Carbamazepine:_bf OTHER_DRUG known_be slow_be metabolism_be DRUG increase_af serum_af levels_af DRUG levels_af determined_af prior_af concurrent_af administration_af OTHER_DRUG ,_af signs_af symptoms_af DRUG toxicity_af monitored_af closely_af ,_af appropriate_af dosage_af adjustment_af anticonvulsant_af made_af ._af"
16912,"Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.",isoniazid,valproate,advise,"Plasma_bf OTHER_DRUG concentration_be monitored_be DRUG OTHER_DRUG co_af administered_af ,_af appropriate_af dosage_af adjustments_af OTHER_DRUG made_af ._af"
16915,Isoproterenol hydrochloride injection and epinephrine should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias.,Isoproterenol hydrochloride,epinephrine,advise,Isoproterenol_bf hydrochloride_bf injection_bf OTHER_DRUG administered_be simultaneously_be drugs_be direct_be cardiac_be stimulants_be combined_be effects_be may_be induce_be serious_be arrhythmias_be ._be
16916,"ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.",ISUPREL,anesthetics,advise,"DRUG used_be caution_be ,_be ,_be potent_be inhalational_be OTHER_DRUG halothane_af employed_af potential_af sensitize_af myocardium_af effects_af sympathomimetic_af amines_af ._af"
16917,"ISUPREL should be used with caution, if at all, when potent inhalational anesthetics such as halothane are employed because of potential to sensitize the myocardium to effects of sympathomimetic amines.",ISUPREL,halothane,advise,"DRUG used_be caution_be ,_be ,_be potent_be inhalational_be anesthetics_be OTHER_DRUG employed_af potential_af sensitize_af myocardium_af effects_af sympathomimetic_af amines_af ._af"
16936,"Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines",Accutane,tetracyclines,advise,"Tetracyclines:_bf Concomitant_bf treatment_bf DRUG OTHER_DRUG avoided_af DRUG use_af associated_af number_af cases_af pseudotumor_af cerebri_af (benign_af intracranial_af hypertension)_af ,_af involved_af concomitant_af use_af OTHER_DRUG"
16990,If isradipine therapy is initiated in a patient currently receiving cimetidine careful monitoring for adverse reactions is advised and downward dose adjustment may be required.,isradipine,cimetidine,advise,If_bf DRUG therapy_be initiated_be patient_be currently_be receiving_be OTHER_DRUG careful_af monitoring_af adverse_af reactions_af advised_af downward_af dose_af adjustment_af may_af required_af ._af
17050,"Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of astemizole with itraconazole is contraindicated.",astemizole,itraconazole,advise,"Based_bf chemical_bf resemblance_bf OTHER_DRUG ketoconazole_be ,_be coadministration_be DRUG OTHER_DRUG contraindicated_af ._af"
17056,therefore concomitant administration of Itraconazole with cisapride is contraindicated.,Itraconazole,cisapride,advise,therefore_bf concomitant_bf administration_bf DRUG OTHER_DRUG contraindicated_af ._af
17068,"Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",Cyclosporine,Itraconazole,advise,"DRUG ,_be tacrolimus_be digoxin_be concentrations_be monitored_be initiation_be OTHER_DRUG therapy_af frequently_af thereafter_af ,_af dose_af three_af drug_af products_af adjusted_af appropriately_af ._af"
17070,"Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",tacrolimus,Itraconazole,advise,"Cyclosporine_bf ,_bf DRUG digoxin_be concentrations_be monitored_be initiation_be OTHER_DRUG therapy_af frequently_af thereafter_af ,_af dose_af three_af drug_af products_af adjusted_af appropriately_af ._af"
17071,"Cyclosporine, tacrolimus and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.",digoxin,Itraconazole,advise,"Cyclosporine_bf ,_bf tacrolimus_bf DRUG concentrations_be monitored_be initiation_be OTHER_DRUG therapy_af frequently_af thereafter_af ,_af dose_af three_af drug_af products_af adjusted_af appropriately_af ._af"
17085,"therefore, plasma concentrations of phenytoin should also be monitored when it is given concurrently with Itraconazole.",phenytoin,Itraconazole,advise,"therefore_bf ,_bf plasma_bf concentrations_bf DRUG also_be monitored_be given_be concurrently_be OTHER_DRUG ._af"
17087,"Therefore, prothrombin time should be carefully monitored in patients receiving Itraconazole and coumarin-like drugs simultaneously.",Itraconazole,coumarin,advise,"Therefore_bf ,_bf prothrombin_bf time_bf carefully_bf monitored_bf patients_bf receiving_bf DRUG coumarin-like_be drugs_be simultaneously_be ._be"
17091,Itraconazole plasma concentrations should be monitored when Itraconazole and isoniazid are coadministered.,Itraconazole,isoniazid,advise,DRUG plasma_be concentrations_be monitored_be DRUG OTHER_DRUG coadministered_af ._af
17093,Blood glucose concentrations should be carefully monitored when Itraconazole and oral hypoglycemic agents are coadministered.,Itraconazole,hypoglycemic agents,advise,Blood_bf glucose_bf concentrations_bf carefully_bf monitored_bf DRUG oral_be hypoglycemic_be agents_be coadministered_be ._be
17120,Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.,astemizole,ketoconazole,advise,Coadministration_bf DRUG OTHER_DRUG tablets_af therefore_af contraindicated_af ._af
17125,Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.,ketoconazole,cisapride,advise,Therefore_bf concomitant_bf administration_bf DRUG tablets_be OTHER_DRUG contraindicated_af ._af
17141,"It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.",digoxin,ketoconazole,advise,"It_bf ,_bf therefore_bf ,_bf advisable_bf monitor_bf DRUG concentrations_be patients_be receiving_be OTHER_DRUG ._af"
17145,"In simultaneous treatment with imidazole drugs and coumarin drugs, the anticoagulant effect should be carefully titrated and monitored.",imidazole drugs,coumarin drugs,advise,"In_bf simultaneous_bf treatment_bf imidazole_bf drugs_bf coumarin_bf drugs_bf ,_bf anticoagulant_bf effect_bf carefully_bf titrated_bf monitored_bf ._bf"
17157,It is suggested to monitor both ketoconazole and phenytoin.,ketoconazole,phenytoin,advise,It_bf suggested_bf monitor_bf DRUG OTHER_DRUG ._af
17230,"Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.",TORADOL,anticoagulants,advise,"Although_bf results_bf indicate_bf significant_bf interaction_bf DRUG warfarin_be heparin_be ,_be administration_be DRUG patients_af taking_af OTHER_DRUG done_af extremely_af cautiously_af ,_af patients_af closely_af monitored_af ._af"
17247,"Therefore, concomitant use of TORADOL and probenecid is contraindicated.",TORADOL,probenecid,advise,"Therefore_bf ,_bf concomitant_bf use_bf DRUG OTHER_DRUG contraindicated_af ._af"
17465,Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.,labetalol,calcium antagonist,advise,Care_bf taken_bf DRUG used_be concomitantly_be calcium_be antagonists_be verapamil_be type_be ._be
17477,"Therefore, use of lamivudine in combination with zalcitabine is not recommended",lamivudine,zalcitabine,advise,"Therefore_bf ,_bf use_bf DRUG combination_be OTHER_DRUG recommended_af"
17536,"Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.",theophylline,lansoprazole,advise,"Nonetheless_bf ,_bf individual_bf patients_bf may_bf require_bf additional_bf titration_bf DRUG dosage_be OTHER_DRUG started_af stopped_af ensure_af clinically_af effective_af blood_af levels_af ._af"
17548,"Therefore, proton pump inhibitors should be taken at least 30 minutes prior to sucralfate.",proton pump inhibitors,sucralfate,advise,"Therefore_bf ,_bf proton_bf pump_bf inhibitors_bf taken_bf least_bf 30_bf minutes_bf prior_bf OTHER_DRUG ._be"
17596,"Because of the potential for ARAVA levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both ARAVA and rifampin.",ARAVA,rifampin,advise,"Because_bf potential_bf DRUG levels_be continue_be increase_be multiple_be dosing_be ,_be caution_be used_be patients_be receiving_be DRUG OTHER_DRUG ._af"
17630,"Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent levamisole and warfarin sodium, it is suggested that the prothrombin time be monitored carefully, and the dose of warfarin sodium or other coumarin-like drugs should be adjusted accordingly, in patients taking both drugs.",levamisole,warfarin sodium,advise,"Because_bf reports_bf prolongation_bf prothrombin_bf time_bf beyond_bf therapeutic_bf range_bf patients_bf taking_bf concurrent_bf DRUG warfarin_be sodium_be ,_be suggested_be prothrombin_be time_be monitored_be carefully_be ,_be dose_be warfarin_be sodium_be coumarin-like_be drugs_be adjusted_be accordingly_be ,_be patients_be taking_be drugs_be ._be"
17775,"Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.",beta-blocker,reserpine,advise,"Close_bf observation_bf patient_bf recommended_bf DRUG administered_be patients_be receiving_be catecholamine-depleting_be drugs_be OTHER_DRUG ,_af possible_af additive_af effects_af production_af hypotension_af and/or_af marked_af bradycardia_af ,_af may_af produce_af vertigo_af ,_af syncope_af postural_af hypotension_af ._af"
17776,"Patients receiving beta-adrenergic blocking agents along with either oral or intravenous calcium antagonists should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.",beta-adrenergic blocking agents,calcium antagonists,advise,"Patients_bf receiving_bf beta-adrenergic_bf blocking_bf agents_bf along_bf either_bf oral_bf intravenous_bf calcium_bf antagonists_bf monitored_bf possible_bf atrioventricular_bf conduction_bf disturbances_bf ,_bf left_bf ventricular_bf failure_bf hypotension_bf ._bf"
17781,Chirocaine   should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive.,Chirocaine,anesthetics,advise,DRUG used_be caution_be patients_be receiving_be local_be OTHER_DRUG agents_af structurally_af related_af amide-type_af local_af OTHER_DRUG since_af toxic_af effects_af drugs_af could_af additive_af ._af
17903,"Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors.",Levo-Dromoran,MAO inhibitors,advise,"Although_bf interaction_bf MAO_bf inhibitors_bf DRUG observed_be ,_be recommended_be use_be MAO_be inhibitors_be ._be"
17919,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",Agonist/antagonist analgesics,Levo-Dromoran,advise,"Interactions_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (eg_bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf butorphanol_bf ,_bf dezocine_bf buprenorphine)_bf NOT_bf administered_bf patient_bf received_bf receiving_bf course_bf therapy_bf pure_bf agonist_bf opioid_bf analgesic_bf OTHER_DRUG ._be"
17925,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",pentazocine,Levo-Dromoran,advise,"Interactions_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (eg_bf ,_bf DRUG ,_be nalbuphine_be ,_be butorphanol_be ,_be dezocine_be buprenorphine)_be NOT_be administered_be patient_be received_be receiving_be course_be therapy_be pure_be agonist_be opioid_be analgesic_be OTHER_DRUG ._af"
17930,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",nalbuphine,Levo-Dromoran,advise,"Interactions_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (eg_bf ,_bf pentazocine_bf ,_bf DRUG ,_be butorphanol_be ,_be dezocine_be buprenorphine)_be NOT_be administered_be patient_be received_be receiving_be course_be therapy_be pure_be agonist_be opioid_be analgesic_be OTHER_DRUG ._af"
17934,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",butorphanol,Levo-Dromoran,advise,"Interactions_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (eg_bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf DRUG ,_be dezocine_be buprenorphine)_be NOT_be administered_be patient_be received_be receiving_be course_be therapy_be pure_be agonist_be opioid_be analgesic_be OTHER_DRUG ._af"
17937,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",dezocine,Levo-Dromoran,advise,"Interactions_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (eg_bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf butorphanol_bf ,_bf DRUG buprenorphine)_be NOT_be administered_be patient_be received_be receiving_be course_be therapy_be pure_be agonist_be opioid_be analgesic_be OTHER_DRUG ._af"
17939,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",buprenorphine,Levo-Dromoran,advise,"Interactions_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (eg_bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf butorphanol_bf ,_bf dezocine_bf buprenorphine)_bf NOT_bf administered_bf patient_bf received_bf receiving_bf course_bf therapy_bf pure_bf agonist_bf opioid_bf analgesic_bf OTHER_DRUG ._be"
17940,"Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.",pure agonist opioid analgesic,Levo-Dromoran,advise,"Interactions_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (eg_bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf butorphanol_bf ,_bf dezocine_bf buprenorphine)_bf NOT_bf administered_bf patient_bf received_bf receiving_bf course_bf therapy_bf pure_bf agonist_bf opioid_bf analgesic_bf OTHER_DRUG ._be"
18004,Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started.,anticoagulants,thyroid,advise,Patients_bf stabilized_bf oral_bf DRUG found_be require_be OTHER_DRUG replacement_af therapy_af watched_af closely_af OTHER_DRUG started_af ._af
18022,"Therefore, 4 to 5 hours should elapse between administration of cholestyramine and thyroid hormones.",cholestyramine,thyroid hormones,advise,"Therefore_bf ,_bf 4_bf 5_bf hours_bf elapse_bf administration_bf DRUG thyroid_be hormones_be ._be"
18029,"Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.",thyroid,estrogens,advise,"Therefore_bf ,_bf patients_bf without_bf functioning_bf DRUG gland_be DRUG replacement_af therapy_af may_af need_af increase_af DRUG dose_af OTHER_DRUG estrogen-containing_af oral_af contraceptives_af given_af ._af"
18031,"Therefore, patients without a functioning thyroid gland who are on thyroid replacement therapy may need to increase their thyroid dose if estrogens or estrogen-containing oral contraceptives are given.",thyroid,contraceptives,advise,"Therefore_bf ,_bf patients_bf without_bf functioning_bf DRUG gland_be DRUG replacement_af therapy_af may_af need_af increase_af DRUG dose_af estrogens_af estrogen-containing_af oral_af OTHER_DRUG given_af ._af"
18163,"If it is necessary to continue the diuretic, initiate therapy with PRINIVIL at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized.",diuretic,PRINIVIL,advise,"If_bf necessary_bf continue_bf DRUG ,_be initiate_be therapy_be OTHER_DRUG dose_af 5_af mg_af daily_af ,_af provide_af close_af medical_af supervision_af initial_af dose_af blood_af pressure_af stabilized_af ._af"
18170,Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.,ACE inhibitor,diuretic,advise,Studies_bf ACE_bf inhibitors_bf combination_bf diuretics_bf indicate_bf dose_bf ACE_bf inhibitor_bf reduced_bf given_bf OTHER_DRUG ._be
18177,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.,NSAIDs,ACE inhibitors,advise,This_bf interaction_bf given_bf consideration_bf patients_bf taking_bf DRUG concomitantly_be ACE_be inhibitors_be ._be
18217,It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.,PRINIVIL,lithium,advise,It_bf recommended_bf serum_bf OTHER_DRUG levels_be monitored_be frequently_be DRUG administered_af concomitantly_af OTHER_DRUG ._af
18494,"It is recommended that in patients taking anticoagulants, prothrombin time be determined before starting lovastatin and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs.",anticoagulants,lovastatin,advise,"It_bf recommended_bf patients_bf taking_bf DRUG ,_be prothrombin_be time_be determined_be starting_be OTHER_DRUG frequently_af enough_af early_af therapy_af insure_af significant_af alteration_af prothrombin_af time_af occurs_af ._af"
18519,"Therefore, when meclofenamate sodium is given to a patient receiving warfarin, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.",meclofenamate sodium,warfarin,advise,"Therefore_bf ,_bf meclofenamate_bf sodium_bf given_bf patient_bf receiving_bf OTHER_DRUG ,_be dosage_be OTHER_DRUG reduced_af prevent_af excessive_af prolongation_af prothrombin_af time_af ._af"
18542,"Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.",NSAIDs,aspirin,advise,"Aspirin:_bf As_bf DRUG ,_be concomitant_be administration_be Ponstel_be OTHER_DRUG generally_af recommended_af potential_af increased_af adverse_af effects_af ._af"
18543,"Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.",Ponstel,aspirin,advise,"Aspirin:_bf As_bf NSAIDs_bf ,_bf concomitant_bf administration_bf DRUG OTHER_DRUG generally_af recommended_af potential_af increased_af adverse_af effects_af ._af"
18547,Caution should be used when NSAIDs are administered concomitantly with methotrexate.,NSAIDs,methotrexate,advise,Caution_bf used_bf DRUG administered_be concomitantly_be OTHER_DRUG ._af
18551,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.,NSAIDs,ACE inhibitors,advise,This_bf interaction_bf given_bf consideration_bf patients_bf taking_bf DRUG concomitantly_be ACE_be inhibitors_be ._be
18558,"During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.",Ponstel,furosemide,advise,"During_bf concomitant_bf therapy_bf DRUG OTHER_DRUG ,_af patient_af observed_af closely_af signs_af renal_af failure_af ,_af well_af assure_af diuretic_af efficacy_af ._af"
18565,"Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.",NSAIDs,lithium,advise,"Thus_bf ,_bf DRUG OTHER_DRUG administered_af concurrently_af ,_af subjects_af observed_af carefully_af signs_af OTHER_DRUG toxicity_af ._af"
18600,"Because of the danger of a potentially fatal prolongation of the QTc interval, halofantrine must not be given simultaneously with or subsequent to Mefloquine.",halofantrine,Mefloquine,advise,"Because_bf danger_bf potentially_bf fatal_bf prolongation_bf QTc_bf interval_bf ,_bf DRUG must_be given_be simultaneously_be subsequent_be OTHER_DRUG ._af"
18657,"Nevertheless, the effects of Mefloquine on travelers receiving comedication, particularly diabetics or patients using anticoagulants, should be checked before departure.",Mefloquine,anticoagulants,advise,"Nevertheless_bf ,_bf effects_bf DRUG travelers_be receiving_be comedication_be ,_be particularly_be diabetics_be patients_be using_be OTHER_DRUG ,_af checked_af departure_af ._af"
18715,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,psychoactive drugs,advise,"DRUG administered_be caution_be patients_be taking_be psychoactive_be drugs_be CNS_be depressants_be ,_be including_be alcohol_be ,_be barbiturates_be narcotic_be analgesics_be ,_be history_be psychiatric_be disorder_be (including_be manic-depressive_be illness_be schizophrenia)_be ._be"
18716,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,CNS depressants,advise,"DRUG administered_be caution_be patients_be taking_be psychoactive_be drugs_be CNS_be depressants_be ,_be including_be alcohol_be ,_be barbiturates_be narcotic_be analgesics_be ,_be history_be psychiatric_be disorder_be (including_be manic-depressive_be illness_be schizophrenia)_be ._be"
18717,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,alcohol,advise,"DRUG administered_be caution_be patients_be taking_be psychoactive_be drugs_be CNS_be depressants_be ,_be including_be OTHER_DRUG ,_af barbiturates_af narcotic_af analgesics_af ,_af history_af psychiatric_af disorder_af (including_af manic-depressive_af illness_af schizophrenia)_af ._af"
18718,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,barbiturates,advise,"DRUG administered_be caution_be patients_be taking_be psychoactive_be drugs_be CNS_be depressants_be ,_be including_be alcohol_be ,_be OTHER_DRUG narcotic_af analgesics_af ,_af history_af psychiatric_af disorder_af (including_af manic-depressive_af illness_af schizophrenia)_af ._af"
18719,"Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).",Nabilone,narcotic analgesics,advise,"DRUG administered_be caution_be patients_be taking_be psychoactive_be drugs_be CNS_be depressants_be ,_be including_be alcohol_be ,_be barbiturates_be narcotic_be analgesics_be ,_be history_be psychiatric_be disorder_be (including_be manic-depressive_be illness_be schizophrenia)_be ._be"
18740,Caution should be exercised when administering nabumetone with warfarin since interactions have been seen with other NSAIDs.,nabumetone,warfarin,advise,Caution_bf exercised_bf administering_bf DRUG OTHER_DRUG since_af interactions_af seen_af NSAIDs_af ._af
18792,"Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.",naproxen,aspirin,advise,"Concomitant_bf administration_bf DRUG OTHER_DRUG recommended_af DRUG displaced_af binding_af sites_af concomitant_af administration_af OTHER_DRUG ,_af resulting_af lower_af plasma_af concentrations_af peak_af plasma_af levels_af ._af"
18797,"Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.",naproxen,aspirin,advise,"Concomitant_bf administration_bf DRUG OTHER_DRUG recommended_af DRUG displaced_af binding_af sites_af concomitant_af administration_af OTHER_DRUG ,_af resulting_af lower_af plasma_af concentrations_af peak_af plasma_af levels_af ._af"
18806,Caution should be used if naproxen is administered concomitantly with methotrexate.,naproxen,methotrexate,advise,Caution_bf used_bf DRUG administered_be concomitantly_be OTHER_DRUG ._af
18820,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",ergotamine,naratriptan,advise,"Because_bf theoretical_bf basis_bf effects_bf may_bf additive_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf dihydroergotamine_bf methysergide)_bf OTHER_DRUG within_be 24_be hours_be contraindicated_be ._be"
18823,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",ergot-type medications,naratriptan,advise,"Because_bf theoretical_bf basis_bf effects_bf may_bf additive_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf dihydroergotamine_bf methysergide)_bf OTHER_DRUG within_be 24_be hours_be contraindicated_be ._be"
18825,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",dihydroergotamine,naratriptan,advise,"Because_bf theoretical_bf basis_bf effects_bf may_bf additive_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf DRUG methysergide)_be OTHER_DRUG within_af 24_af hours_af contraindicated_af ._af"
18826,"Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.",methysergide,naratriptan,advise,"Because_bf theoretical_bf basis_bf effects_bf may_bf additive_bf ,_bf use_bf ergotamine-containing_bf ergot-type_bf medications_bf (like_bf dihydroergotamine_bf methysergide)_bf OTHER_DRUG within_be 24_be hours_be contraindicated_be ._be"
18828,"Because their vasospastic effects may be additive, coadministration of naratriptan and other 5-HT1 agonists within 24 hours of each other is not recommended.",naratriptan,5-HT1 agonists,advise,"Because_bf vasospastic_bf effects_bf may_bf additive_bf ,_bf coadministration_bf DRUG 5-HT1_be agonists_be within_be 24_be hours_be recommended_be ._be"
18844,"If concomitant treatment with naratriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.",naratriptan,SSRI,advise,"If_bf concomitant_bf treatment_bf DRUG OTHER_DRUG clinically_af warranted_af ,_af appropriate_af observation_af patient_af advised_af ._af"
19049,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Antiarrhythmics,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be terfenadine_be Antimigraine:_be ergot_be derivatives_be Antimycobacterial_be agents:_be rifampin_be Benzodiazepines_be midazolam_be ,_be triazolam_be GI_be motility_be agents:_be cisapride_be"
19050,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,amiodarone,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be OTHER_DRUG ,_af quinidine_af Antihistamines:_af astemizole_af ,_af terfenadine_af Antimigraine:_af ergot_af derivatives_af Antimycobacterial_af agents:_af rifampin_af Benzodiazepines_af midazolam_af ,_af triazolam_af GI_af motility_af agents:_af cisapride_af"
19051,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,quinidine,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be OTHER_DRUG Antihistamines:_af astemizole_af ,_af terfenadine_af Antimigraine:_af ergot_af derivatives_af Antimycobacterial_af agents:_af rifampin_af Benzodiazepines_af midazolam_af ,_af triazolam_af GI_af motility_af agents:_af cisapride_af"
19052,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Antihistamines,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be terfenadine_be Antimigraine:_be ergot_be derivatives_be Antimycobacterial_be agents:_be rifampin_be Benzodiazepines_be midazolam_be ,_be triazolam_be GI_be motility_be agents:_be cisapride_be"
19053,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,astemizole,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be OTHER_DRUG ,_af terfenadine_af Antimigraine:_af ergot_af derivatives_af Antimycobacterial_af agents:_af rifampin_af Benzodiazepines_af midazolam_af ,_af triazolam_af GI_af motility_af agents:_af cisapride_af"
19054,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,terfenadine,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be OTHER_DRUG Antimigraine:_af ergot_af derivatives_af Antimycobacterial_af agents:_af rifampin_af Benzodiazepines_af midazolam_af ,_af triazolam_af GI_af motility_af agents:_af cisapride_af"
19055,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,ergot derivatives,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be terfenadine_be Antimigraine:_be ergot_be derivatives_be Antimycobacterial_be agents:_be rifampin_be Benzodiazepines_be midazolam_be ,_be triazolam_be GI_be motility_be agents:_be cisapride_be"
19056,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Antimycobacterial agents,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be terfenadine_be Antimigraine:_be ergot_be derivatives_be Antimycobacterial_be agents:_be rifampin_be Benzodiazepines_be midazolam_be ,_be triazolam_be GI_be motility_be agents:_be cisapride_be"
19057,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,rifampin,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be terfenadine_be Antimigraine:_be ergot_be derivatives_be Antimycobacterial_be agents:_be OTHER_DRUG Benzodiazepines_af midazolam_af ,_af triazolam_af GI_af motility_af agents:_af cisapride_af"
19058,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,Benzodiazepines,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be terfenadine_be Antimigraine:_be ergot_be derivatives_be Antimycobacterial_be agents:_be rifampin_be OTHER_DRUG midazolam_af ,_af triazolam_af GI_af motility_af agents:_af cisapride_af"
19059,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,midazolam,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be terfenadine_be Antimigraine:_be ergot_be derivatives_be Antimycobacterial_be agents:_be rifampin_be Benzodiazepines_be OTHER_DRUG ,_af triazolam_af GI_af motility_af agents:_af cisapride_af"
19060,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,triazolam,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be terfenadine_be Antimigraine:_be ergot_be derivatives_be Antimycobacterial_be agents:_be rifampin_be Benzodiazepines_be midazolam_be ,_be OTHER_DRUG GI_af motility_af agents:_af cisapride_af"
19061,"Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride",VIRACEPT,cisapride,advise,"Drugs_bf That_bf Should_bf Not_bf Be_bf Coadministered_bf With_bf DRUG Antiarrhythmics:_be amiodarone_be ,_be quinidine_be Antihistamines:_be astemizole_be ,_be terfenadine_be Antimigraine:_be ergot_be derivatives_be Antimycobacterial_be agents:_be rifampin_be Benzodiazepines_be midazolam_be ,_be triazolam_be GI_be motility_be agents:_be OTHER_DRUG"
19140,Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin,VIRACEPT,Antimycobacterial agents,advise,Drugs_bf Which_bf Require_bf Dose_bf Reduction_bf When_bf Coadminstered_bf With_bf DRUG Antimycobacterial_be agents:_be rifabutin_be
19141,Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT Antimycobacterial agents: rifabutin,VIRACEPT,rifabutin,advise,Drugs_bf Which_bf Require_bf Dose_bf Reduction_bf When_bf Coadminstered_bf With_bf DRUG Antimycobacterial_be agents:_be OTHER_DRUG
19150,"therefore, VIRACEPT should not be administered concurrently with terfenadine because of the potential for serious and/or life-threatening cardiac arrhythmias.",VIRACEPT,terfenadine,advise,"therefore_bf ,_bf DRUG administered_be concurrently_be OTHER_DRUG potential_af serious_af and/or_af life-threatening_af cardiac_af arrhythmias_af ._af"
19151,"Because a similar interaction is likely, VIRACEPT should also not be administered concurrently with astemizole.",VIRACEPT,astemizole,advise,"Because_bf similar_bf interaction_bf likely_bf ,_bf DRUG also_be administered_be concurrently_be OTHER_DRUG ._af"
19195,"therefore, nelfinavir should be administered (with food) one hour after or more than two hours before didanosine.",nelfinavir,didanosine,advise,"therefore_bf ,_bf DRUG administered_be (with_be food)_be one_be hour_be two_be hours_be OTHER_DRUG ._af"
19196,A dose adjustment is not needed when zidovudine is administered with VIRACEPT.,zidovudine,VIRACEPT,advise,A_bf dose_bf adjustment_bf needed_bf DRUG administered_be OTHER_DRUG ._af
19210,It is recommended that the dose of rifabutin be reduced to one-half the usual dose when administered with VIRACEPT.,rifabutin,VIRACEPT,advise,It_bf recommended_bf dose_bf DRUG reduced_be one-half_be usual_be dose_be administered_be OTHER_DRUG ._af
19217,VIRACEPT and rifampin should not be coadministered.,VIRACEPT,rifampin,advise,DRUG OTHER_DRUG coadministered_af ._af
19239,"These antibiotics should be used in the myasthenic patient only where definitely indicated, and then careful adjustment should be made of adjunctive anticholinesterase dosage.",antibiotics,anticholinesterase,advise,"These_bf DRUG used_be myasthenic_be patient_be definitely_be indicated_be ,_be careful_be adjustment_be made_be adjunctive_be OTHER_DRUG dosage_af ._af"
19262,Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.,Netilmicin,loop diuretics,advise,DRUG administered_be concomitantly_be potent_be loop_be diuretics_be furosemide_be ethacrynic_be acid_be potential_be ototoxicity_be enhanced_be combination_be ._be
19263,Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.,Netilmicin,furosemide,advise,DRUG administered_be concomitantly_be potent_be loop_be diuretics_be OTHER_DRUG ethacrynic_af acid_af potential_af ototoxicity_af enhanced_af combination_af ._af
19264,Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.,Netilmicin,ethacrynic acid,advise,DRUG administered_be concomitantly_be potent_be loop_be diuretics_be furosemide_be ethacrynic_be acid_be potential_be ototoxicity_be enhanced_be combination_be ._be
19271,"When warfarin is co-administered with nevirapine, anticoagulation levels should be monitored frequently.",warfarin,nevirapine,advise,"When_bf DRUG co-administered_be OTHER_DRUG ,_af anticoagulation_af levels_af monitored_af frequently_af ._af"
19276,"Oral contraceptives and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking nevirapine, since nevirapinemay lower the plasma levels of thesemedications.",contraceptives,nevirapine,advise,"Oral_bf DRUG hormonalmethods_be birth_be control_be usedas_be sole_be method_be contraception_be inwomen_be taking_be OTHER_DRUG ,_af since_af nevirapinemay_af lower_af plasma_af levels_af thesemedications_af ._af"
19277,Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.,Nevirapine,ketoconazole,advise,DRUG OTHER_DRUG beadministered_af concomitantly_af becausedecreases_af OTHER_DRUG plasmaconcentrations_af may_af reduce_af efficacy_af drug_af ._af
19282,A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.,lopinavir,nevirapine,advise,A_bf dose_bf increase_bf lopinavir/ritonavir_bf 533/133_bf mg_bf twice_bf daily_bf food_bf isrecommended_bf combination_bf OTHER_DRUG ._be
19283,A dose increase of lopinavir/ritonavir to 533/133 mg twice daily with food isrecommended in combination with nevirapine.,ritonavir,nevirapine,advise,A_bf dose_bf increase_bf lopinavir/ritonavir_bf 533/133_bf mg_bf twice_bf daily_bf food_bf isrecommended_bf combination_bf OTHER_DRUG ._be
19291,Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.,Methadone,nevirapine,advise,DRUG levels_be may_be decreased;_be increased_be dosages_be may_be required_be prevent_be symptoms_be opiate_be withdrawal_be ._be DRUG maintained_af patients_af beginning_af OTHER_DRUG therapy_af monitored_af forevidence_af withdrawal_af DRUG dose_af adjusted_af accordingly_af ._af
19295,Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.,Nevirapine,rifampin,advise,DRUG OTHER_DRUG beadministered_af concomitantly_af becausedecreases_af DRUG plasmaconcentrations_af may_af reduce_af efficacy_af ofthe_af drug_af ._af
19341,"Nicardipine HCl usually does not alter the plasma levels of digoxin, however, serum digoxin levels should be evaluated after concomitant therapy with nicardipine HCl is initiated.",digoxin,nicardipine HCl,advise,"Nicardipine_bf HCl_bf usually_bf alter_bf plasma_bf levels_bf DRUG ,_be however_be ,_be serum_be DRUG levels_af evaluated_af concomitant_af therapy_af nicardipine_af HCl_af initiated_af ._af"
19348,"Plasma concentrations of cyclosporine should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with nicardipine.",cyclosporine,nicardipine,advise,"Plasma_bf concentrations_bf DRUG therefore_be closely_be monitored_be ,_be dosage_be reduced_be accordingly_be ,_be patients_be treated_be OTHER_DRUG ._af"
19393,"Digitalis: Immediate Release Capsules: Since there have been isolated reports of patients with elevated digoxin levels, and there is a possible interaction between digoxin and nifedipine, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.",digoxin,nifedipine,advise,"Digitalis:_bf Immediate_bf Release_bf Capsules:_bf Since_bf isolated_bf reports_bf patients_bf elevated_bf DRUG levels_be ,_be possible_be interaction_be DRUG OTHER_DRUG ,_af recommended_af DRUG levels_af monitored_af initiating_af ,_af adjusting_af ,_af discontinuing_af OTHER_DRUG avoid_af possible_af over-_af under-digitalization_af ._af"
19399,"Since there have been isolated reports of patients with elevated digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing nifedipine to avoid possible over- or under-digitalization.",digoxin,nifedipine,advise,"Since_bf isolated_bf reports_bf patients_bf elevated_bf DRUG levels_be ,_be recommended_be DRUG levels_af monitored_af initiating_af ,_af adjusting_af ,_af discontinuing_af OTHER_DRUG avoid_af possible_af over-_af under-digitalization_af ._af"
19416,"If nifedipine therapy is initiated in a patient currently receiving cimetidine, cautious titration is advised.",nifedipine,cimetidine,advise,"If_bf DRUG therapy_be initiated_be patient_be currently_be receiving_be OTHER_DRUG ,_af cautious_af titration_af advised_af ._af"
19420,"For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.",vitamin K antagonists,nilutamide,advise,"For_bf example_bf ,_bf vitamin_bf K_bf antagonists_bf administered_bf concomitantly_bf OTHER_DRUG ,_be prothrombin_be time_be carefully_be monitored_be necessary_be ,_be dosage_be vitamin_be K_be antagonists_be reduced_be ._be"
19428,Coadministration of SULAR with phenytoin or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.,SULAR,phenytoin,advise,Coadministration_bf DRUG OTHER_DRUG known_af CYP3A4_af inducer_af avoided_af alternative_af antihypertensive_af therapy_af considered_af ._af
19571,Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.,nortriptyline hydrochloride,anticholinergic drugs,advise,Close_bf supervision_bf careful_bf adjustment_bf dosage_bf required_bf nortriptyline_bf hydrochloride_bf used_bf anticholinergic_bf drugs_bf sympathomimetic_bf drugs_bf ._bf
19572,Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other anticholinergic drugs or sympathomimetic drugs.,nortriptyline hydrochloride,sympathomimetic drugs,advise,Close_bf supervision_bf careful_bf adjustment_bf dosage_bf required_bf nortriptyline_bf hydrochloride_bf used_bf anticholinergic_bf drugs_bf sympathomimetic_bf drugs_bf ._bf
19581,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,antidepressants,advise,"Therefore_bf ,_bf co-administration_bf tricyclic_bf OTHER_DRUG drugs_be metabolized_be isoenzyme_be ,_be including_be OTHER_DRUG ,_af phenothiazines_af ,_af carbamazepine_af ,_af Type_af 1C_af antiarrhythmics_af (eg_af ,_af propafenone_af ,_af flecainide_af ,_af encainide)_af ,_af inhibit_af enzyme_af (eg_af ,_af quinidine)_af ,_af approached_af caution_af ._af"
19582,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,phenothiazines,advise,"Therefore_bf ,_bf co-administration_bf tricyclic_bf antidepressants_bf drugs_bf metabolized_bf isoenzyme_bf ,_bf including_bf antidepressants_bf ,_bf OTHER_DRUG ,_be carbamazepine_be ,_be Type_be 1C_be antiarrhythmics_be (eg_be ,_be propafenone_be ,_be flecainide_be ,_be encainide)_be ,_be inhibit_be enzyme_be (eg_be ,_be quinidine)_be ,_be approached_be caution_be ._be"
19583,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,carbamazepine,advise,"Therefore_bf ,_bf co-administration_bf tricyclic_bf antidepressants_bf drugs_bf metabolized_bf isoenzyme_bf ,_bf including_bf antidepressants_bf ,_bf phenothiazines_bf ,_bf OTHER_DRUG ,_be Type_be 1C_be antiarrhythmics_be (eg_be ,_be propafenone_be ,_be flecainide_be ,_be encainide)_be ,_be inhibit_be enzyme_be (eg_be ,_be quinidine)_be ,_be approached_be caution_be ._be"
19584,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,Type 1C antiarrhythmics,advise,"Therefore_bf ,_bf co-administration_bf tricyclic_bf antidepressants_bf drugs_bf metabolized_bf isoenzyme_bf ,_bf including_bf antidepressants_bf ,_bf phenothiazines_bf ,_bf carbamazepine_bf ,_bf Type_bf 1C_bf antiarrhythmics_bf (eg_bf ,_bf propafenone_bf ,_bf flecainide_bf ,_bf encainide)_bf ,_bf inhibit_bf enzyme_bf (eg_bf ,_bf quinidine)_bf ,_bf approached_bf caution_bf ._bf"
19585,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,propafenone,advise,"Therefore_bf ,_bf co-administration_bf tricyclic_bf antidepressants_bf drugs_bf metabolized_bf isoenzyme_bf ,_bf including_bf antidepressants_bf ,_bf phenothiazines_bf ,_bf carbamazepine_bf ,_bf Type_bf 1C_bf antiarrhythmics_bf (eg_bf ,_bf OTHER_DRUG ,_be flecainide_be ,_be encainide)_be ,_be inhibit_be enzyme_be (eg_be ,_be quinidine)_be ,_be approached_be caution_be ._be"
19586,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,flecainide,advise,"Therefore_bf ,_bf co-administration_bf tricyclic_bf antidepressants_bf drugs_bf metabolized_bf isoenzyme_bf ,_bf including_bf antidepressants_bf ,_bf phenothiazines_bf ,_bf carbamazepine_bf ,_bf Type_bf 1C_bf antiarrhythmics_bf (eg_bf ,_bf propafenone_bf ,_bf OTHER_DRUG ,_be encainide)_be ,_be inhibit_be enzyme_be (eg_be ,_be quinidine)_be ,_be approached_be caution_be ._be"
19587,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,encainide,advise,"Therefore_bf ,_bf co-administration_bf tricyclic_bf antidepressants_bf drugs_bf metabolized_bf isoenzyme_bf ,_bf including_bf antidepressants_bf ,_bf phenothiazines_bf ,_bf carbamazepine_bf ,_bf Type_bf 1C_bf antiarrhythmics_bf (eg_bf ,_bf propafenone_bf ,_bf flecainide_bf ,_bf encainide)_bf ,_bf inhibit_bf enzyme_bf (eg_bf ,_bf quinidine)_bf ,_bf approached_bf caution_bf ._bf"
19588,"Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.",tricyclic antidepressants,quinidine,advise,"Therefore_bf ,_bf co-administration_bf tricyclic_bf antidepressants_bf drugs_bf metabolized_bf isoenzyme_bf ,_bf including_bf antidepressants_bf ,_bf phenothiazines_bf ,_bf carbamazepine_bf ,_bf Type_bf 1C_bf antiarrhythmics_bf (eg_bf ,_bf propafenone_bf ,_bf flecainide_bf ,_bf encainide)_bf ,_bf inhibit_bf enzyme_bf (eg_bf ,_bf quinidine)_bf ,_bf approached_bf caution_bf ._bf"
19641,"Therefore, when using doses of Trileptal greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required.",Trileptal,phenytoin,advise,"Therefore_bf ,_bf using_bf doses_bf DRUG greater_be 1200_be mg/day_be adjunctive_be therapy_be ,_be decrease_be dose_be OTHER_DRUG may_af required_af ._af"
19713,"Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.",cyclosporin,TAXOL,advise,"Hypersensitivity_bf Reactions:_bf Patients_bf history_bf severe_bf hypersensitivity_bf reactions_bf products_bf containing_bf Cremophor_bf EL_bf (eg_bf ,_bf DRUG injection_be concentrate_be teniposide_be injection_be concentrate)_be treated_be OTHER_DRUG ._af"
19714,"Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and teniposide for injection concentrate) should not be treated with TAXOL.",teniposide,TAXOL,advise,"Hypersensitivity_bf Reactions:_bf Patients_bf history_bf severe_bf hypersensitivity_bf reactions_bf products_bf containing_bf Cremophor_bf EL_bf (eg_bf ,_bf cyclosporin_bf injection_bf concentrate_bf DRUG injection_be concentrate)_be treated_be OTHER_DRUG ._af"
19734,Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.,theophylline,PEGASYS,advise,DRUG serum_be levels_be monitored_be appropriate_be dose_be adjustments_be considered_be patients_be given_be DRUG OTHER_DRUG ._af
19743,Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.,COPEGUS,didanosine,advise,Nucleoside_bf Analogues_bf OTHER_DRUG Co-administration_be DRUG OTHER_DRUG recommended_af ._af
19812,This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors.,VIOXX,ACE inhibitors,advise,This_bf interaction_bf given_bf consideration_bf patients_bf taking_bf DRUG concomitantly_be ACE_be inhibitors_be ._be
19847,"Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.",VIOXX,lithium,advise,"Thus_bf ,_bf DRUG OTHER_DRUG administered_af concurrently_af ,_af subjects_af observed_af carefully_af signs_af OTHER_DRUG toxicity_af ._af"
19865,Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.,VIOXX,methotrexate,advise,Standard_bf monitoring_bf methotrexate-related_bf toxicity_bf continued_bf DRUG OTHER_DRUG administered_af concomitantly_af ._af
19897,Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.,VIOXX,theophylline,advise,Adequate_bf monitoring_bf OTHER_DRUG plasma_be concentrations_be considered_be therapy_be DRUG initiated_af changed_af patients_af receiving_af OTHER_DRUG ._af
19903,"Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.",VIOXX,warfarin,advise,"Warfarin:_bf Anticoagulant_bf activity_bf monitored_bf ,_bf particularly_bf first_bf days_bf initiating_bf changing_bf DRUG therapy_be patients_be receiving_be OTHER_DRUG similar_af agents_af ,_af since_af patients_af increased_af risk_af bleeding_af complications_af ._af"
20111,"Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.",INVIRASE,ritonavir,advise,"Since_bf DRUG coadministered_be OTHER_DRUG ,_af OTHER_DRUG label_af reviewed_af additional_af drugs_af coadministered_af ._af"
20651,"Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.",ethanol,tiagabine,advise,"Because_bf possible_bf additive_bf effects_bf drugs_bf may_bf depress_bf nervous_bf system_bf ,_bf DRUG triazolam_be used_be cautiously_be combination_be OTHER_DRUG ._af"
20652,"Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.",triazolam,tiagabine,advise,"Because_bf possible_bf additive_bf effects_bf drugs_bf may_bf depress_bf nervous_bf system_bf ,_bf ethanol_bf DRUG used_be cautiously_be combination_be OTHER_DRUG ._af"
20678,This interaction should be given consideration in patients taking BEXTRA concomitantly with ACE-inhibitors.,BEXTRA,ACE-inhibitors,advise,This_bf interaction_bf given_bf consideration_bf patients_bf taking_bf DRUG concomitantly_be OTHER_DRUG ._af
20691,Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.,valdecoxib,phenytoin,advise,Patients_bf already_bf stabilized_bf DRUG closely_be monitored_be loss_be symptom_be control_be OTHER_DRUG coadministration_af ._af
20706,Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.,BEXTRA,lithium,advise,OTHER_DRUG serum_be concentrations_be monitored_be closely_be initiating_be changing_be therapy_be DRUG patients_af receiving_af OTHER_DRUG ._af
20722,"Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving warfarin or similar agents.",BEXTRA,warfarin,advise,"Anticoagulant_bf therapy_bf monitored_bf ,_bf particularly_bf first_bf weeks_bf ,_bf initiating_bf therapy_bf DRUG patients_be receiving_be OTHER_DRUG similar_af agents_af ._af"
20757,"Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.",glyburide,valdecoxib,advise,"Because_bf changes_bf glucose_bf concentrations_bf OTHER_DRUG coadministration_be within_be normal_be variability_be individual_be glucose_be concentrations_be near_be 70_be mg/dL_be ,_be dose_be adjustment_be DRUG (5_af mg_af QD_af 10_af mg_af BID)_af OTHER_DRUG coadministration_af (up_af 40_af mg_af QD)_af indicated_af ._af"
20791,These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.,contraceptive,valdecoxib,advise,These_bf increased_bf exposures_bf norethindrone_bf ethinyl_bf estradiol_bf taken_bf consideration_bf selecting_bf oral_bf DRUG women_be taking_be OTHER_DRUG ._af
20813,It is recommended not to exceed a single 5 mg dose of Vardenafil in a 24-hour period when used in combination with erythromycin.,Vardenafil,erythromycin,advise,It_bf recommended_bf exceed_bf single_bf 5_bf mg_bf dose_bf DRUG 24-hour_be period_be used_be combination_be OTHER_DRUG ._af
20817,A 5-mg Vardenafil dose should not be exceeded when used in combination with 200 mg once daily ketoconazole.,Vardenafil,ketoconazole,advise,A_bf 5-mg_bf DRUG dose_be exceeded_be used_be combination_be 200_be mg_be daily_be OTHER_DRUG ._af
20820,"Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.",Vardenafil,ketoconazole,advise,"Since_bf higher_bf doses_bf OTHER_DRUG (400_be mg_be daily)_be may_be result_be higher_be increases_be Cmax_be AUC_be ,_be single_be 2_be ._be 5_be mg_be dose_be DRUG exceeded_af 24-hour_af period_af used_af combination_af OTHER_DRUG 400_af mg_af daily_af ._af"
20836,It is recommended not to exceed a single 2.5 mg Vardenafil dose in a 24-hour period when used in combination with indinavir.,Vardenafil,indinavir,advise,It_bf recommended_bf exceed_bf single_bf 2_bf ._bf 5_bf mg_bf DRUG dose_be 24-hour_be period_be used_be combination_be OTHER_DRUG ._af
20845,"Consequently, it is recommended not to exceed a single 2.5 mg Vardenafil dose in a 72-hour period when used in combination with ritonavir.",Vardenafil,ritonavir,advise,"Consequently_bf ,_bf recommended_bf exceed_bf single_bf 2_bf ._bf 5_bf mg_bf DRUG dose_be 72-hour_be period_be used_be combination_be OTHER_DRUG ._af"
20871,"Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and nitrates is contraindicated.",Vardenafil,nitrates,advise,"Potentiation_bf hypotensive_bf effects_bf OTHER_DRUG patients_be ischemic_be heart_be disease_be evaluated_be ,_be concomitant_be use_be DRUG OTHER_DRUG contraindicated_af ._af"
20893,"Based on these data, Vardenafil should not be used in patients on alpha-blocker therapy.",Vardenafil,alpha-blocker,advise,"Based_bf data_bf ,_bf DRUG used_be patients_be OTHER_DRUG therapy_af ._af"
20943,Concomitant use of zalcitabine and lamivudine is not recommended.,zalcitabine,lamivudine,advise,Concomitant_bf use_bf DRUG OTHER_DRUG recommended_af ._af
21070,Concomitant use of HIVID with didanosine is not recommended.,HIVID,didanosine,advise,Concomitant_bf use_bf DRUG OTHER_DRUG recommended_af ._af
21073,"If intravenous pentamidine is required to treat Pneumocystis carinii pneumonia, treatment with HIVID should be interrupted.",pentamidine,HIVID,advise,"If_bf intravenous_bf DRUG required_be treat_be Pneumocystis_be carinii_be pneumonia_be ,_be treatment_be OTHER_DRUG interrupted_af ._af"
21139,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.",zalcitabine,magnesium,advise,"The_bf clinical_bf significance_bf reduction_bf known_bf ,_bf hence_bf DRUG recommended_be ingested_be simultaneously_be magnesium/aluminum-containing_be antacids_be ._be"
21140,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.",zalcitabine,aluminum,advise,"The_bf clinical_bf significance_bf reduction_bf known_bf ,_bf hence_bf DRUG recommended_be ingested_be simultaneously_be magnesium/aluminum-containing_be antacids_be ._be"
21141,"The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/aluminum-containing antacids.",zalcitabine,antacids,advise,"The_bf clinical_bf significance_bf reduction_bf known_bf ,_bf hence_bf DRUG recommended_be ingested_be simultaneously_be magnesium/aluminum-containing_be OTHER_DRUG ._af"
34,"The antimicrobial combinations of GL with four antibiotics resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances. ",GL,antibiotics,effect,"The_bf antimicrobial_bf combinations_bf DRUG four_be OTHER_DRUG resulted_af additive_af effect_af instances_af ,_af synergism_af two_af instances_af ,_af antagonism_af two_af instances_af ._af"
35,Synergism was observed when GL was combined with cefazolin against Bacillus subtilis and Klebsiella oxytoca.,GL,cefazolin,effect,Synergism_bf observed_bf DRUG combined_be OTHER_DRUG Bacillus_af subtilis_af Klebsiella_af oxytoca_af ._af
46,"Echistatin alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of contortrostatin when both are added simultaneously. ",Echistatin,contortrostatin,effect,"DRUG alone_be effect_be tyrosine_be phosphorylation_be T24_be cells_be ,_be dose-dependently_be inhibits_be effects_be OTHER_DRUG added_af simultaneously_af ._af"
47,"Flavoridin alone was found to have no effect on CAS, but can completely block contortrostatin-induced phosphorylation of this protein in MDA-MB-435 cells. ",Flavoridin,contortrostatin,effect,"DRUG alone_be found_be effect_be CAS_be ,_be completely_be block_be contortrostatin-induced_be phosphorylation_be protein_be MDA-MB-435_be cells_be ._be"
71,"Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. ",METH,SCH-23390,effect,"Using_bf situ_bf hybridization_bf ,_bf observed_bf DRUG caused_be rapid_be transient_be dose-dependent_be increase_be arc_be mRNA_be level_be striatum_be cortex_be abolished_be pretreatment_be specific_be dopamine_be D1_be receptor_be antagonist_be OTHER_DRUG atypical_af neuroleptic_af clozapine_af ._af"
87,The effects of DCG-IV were very strong and completely depressed the PCP-induced hyperlocomotion. ,DCG-IV,PCP,effect,The_bf effects_bf DRUG strong_be completely_be depressed_be PCP-induced_be hyperlocomotion_be ._be
122,Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ,ibogaine,morphine,effect,Both_bf DRUG 18-MC_be block_be morphine-induced_be nicotine-induced_be dopamine_be release_be nucleus_be accumbens;_be
123,Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ,ibogaine,nicotine,effect,Both_bf DRUG 18-MC_be block_be morphine-induced_be nicotine-induced_be dopamine_be release_be nucleus_be accumbens;_be
124,Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ,18-MC,morphine,effect,Both_bf ibogaine_bf DRUG block_be morphine-induced_be nicotine-induced_be dopamine_be release_be nucleus_be accumbens;_be
125,Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ,18-MC,nicotine,effect,Both_bf ibogaine_bf DRUG block_be morphine-induced_be nicotine-induced_be dopamine_be release_be nucleus_be accumbens;_be
127,only ibogaine enhances cocaine-induced increases in accumbal dopamine. ,ibogaine,cocaine,effect,DRUG enhances_be cocaine-induced_be increases_be accumbal_be dopamine_be ._be
130,"Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine; ",Ibogaine,morphine,effect,"DRUG attenuates_be ,_be 18-MC_be potentiates_be ,_be acute_be locomotor_be effects_be morphine;_be"
131,"Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine; ",18-MC,morphine,effect,"Ibogaine_bf attenuates_bf ,_bf DRUG potentiates_be ,_be acute_be locomotor_be effects_be morphine;_be"
214,"Cytochalasin D at 10 microM preferentially blocked the secretory effect of carbachol and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within 15 min. ",Cytochalasin D,carbachol,effect,"Cytochalasin_bf D_bf 10_bf microM_bf preferentially_bf blocked_bf secretory_bf effect_bf OTHER_DRUG synergism_be cAMP_be ,_be whereas_be effect_be histamine-_be cAMP-stimulated_be acid_be secretion_be within_be 15_be min_be ._be"
215,Cytochalasin D inhibited the carbachol-stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due to release from the Ca(2+) store. ,Cytochalasin D,carbachol,effect,Cytochalasin_bf D_bf inhibited_bf carbachol-stimulated_bf intracellular_bf Ca(2+)_bf concentration_bf ([Ca(2+)](i))_bf increase_bf due_bf release_bf Ca(2+)_bf store_bf ._bf
219,"Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
",verapamil,bombesin,effect,Suppression_bf DRUG bombesin-enhanced_be peritoneal_be metastasis_be intestinal_be adenocarcinomas_be induced_be azoxymethane_be wistar_be rats_be ._be
241,"Verapamil also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by bombesin. ",Verapamil,bombesin,effect,"DRUG also_be significantly_be decreased_be incidence_be lymphatic_be invasion_be adenocarcinomas_be ,_be enhanced_be OTHER_DRUG ._af"
247,PGF2alpha produced significantly increased vasoconstriction after a single administration of oxytocin. ,PGF2alpha,oxytocin,effect,DRUG produced_be significantly_be increased_be vasoconstriction_be single_be administration_be OTHER_DRUG ._af
248,There is thus an enhancement effect of PGF2alpha upon the reaction of placental vessels to oxytocin in vitro.,PGF2alpha,oxytocin,effect,There_bf thus_bf enhancement_bf effect_bf DRUG upon_be reaction_be placental_be vessels_be OTHER_DRUG vitro_af ._af
250,We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.,carbamazepine,tricyclic antidepressant,effect,We_bf report_bf case_bf adolescent_bf altered_bf consciousness_bf caused_bf DRUG overdose_be positive_be tricyclic_be antidepressant_be level_be alert_be clinicians_be cross-reactivity_be DRUG toxicology_af screen_af tricyclic_af antidepressants_af ._af
288,"When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ",ofloxacin,KRM-1648,effect,"When_bf combined_bf DRUG ,_be OTHER_DRUG exhibited_af strong_af synergistic_af activity_af additive_af effects_af observed_af combination_af rifampicin_af (or_af rifabutin)_af DRUG ._af"
296,"When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ",rifampicin,ofloxacin,effect,"When_bf combined_bf OTHER_DRUG ,_be KRM-1648_be exhibited_be strong_be synergistic_be activity_be additive_be effects_be observed_be combination_be DRUG (or_af rifabutin)_af OTHER_DRUG ._af"
297,"When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ",rifabutin,ofloxacin,effect,"When_bf combined_bf OTHER_DRUG ,_be KRM-1648_be exhibited_be strong_be synergistic_be activity_be additive_be effects_be observed_be combination_be rifampicin_be (or_be rifabutin)_be OTHER_DRUG ._af"
304,Administering InsP(3) together with RR (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion. ,InsP(3),RR,effect,Administering_bf DRUG together_be OTHER_DRUG (100-500_af microM)_af inhibited_af InsP(3)-induced_af responses_af (both_af Ca(2+)_af current_af responses)_af dose-dependent_af fashion_af ._af
305,Pretreatment of megakaryocytes with extracellular RR (50 microM) also inhibited InsP(3)-induced responses. ,RR,InsP(3),effect,Pretreatment_bf megakaryocytes_bf extracellular_bf DRUG (50_be microM)_be also_be inhibited_be InsP(3)-induced_be responses_be ._be
417,Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.,Buforin II,azithromycin,effect,Buforin_bf II_bf may_bf active_bf inhibiting_bf Cryptosporidium_bf parvum_bf growth_bf vitro_bf upon_bf combination_bf either_bf OTHER_DRUG minocycline_be ._be
418,Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.,Buforin II,minocycline,effect,Buforin_bf II_bf may_bf active_bf inhibiting_bf Cryptosporidium_bf parvum_bf growth_bf vitro_bf upon_bf combination_bf either_bf azithromycin_bf OTHER_DRUG ._be
434,It is concluded that ketamine is not a short-acting drug and that concomitant use with halothane would be expected to prolong further the duration of its action on the central nervous system.,ketamine,halothane,effect,It_bf concluded_bf DRUG short-acting_be drug_be concomitant_be use_be OTHER_DRUG would_af expected_af prolong_af duration_af action_af central_af nervous_af system_af ._af
443,The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ,rifampin,warfarin,effect,The_bf effect_bf DRUG OTHER_DRUG requirement_af patient_af appeared_af maximal_af 5_af 7_af days_af initiation_af DRUG extended_af similar_af length_af time_af DRUG withdrawal_af ._af
542,"Amprenavir plus rifabutin was poorly tolerated, and 5 of 11 subjects discontinued therapy. ",Amprenavir,rifabutin,effect,"DRUG plus_be OTHER_DRUG poorly_af tolerated_af ,_af 5_af 11_af subjects_af discontinued_af therapy_af ._af"
568,Etofibrate elicited 62% enhancement of post-heparin lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment. ,Etofibrate,heparin,effect,DRUG elicited_be 62%_be enhancement_be post-heparin_be lipolytic_be activity_be 100%_be increase_be 3H-triglyceride_be fractional_be clearance_be rate_be compared_be placebo_be treatment_be ._be
630,"ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia.
",ADL 8-2698,morphine,effect,"ADL_bf 8-2698_bf ,_bf trans-3_bf ,_bf 4-dimethyl-4-(3-hydroxyphenyl)_bf piperidine_bf ,_bf prevents_bf gastrointestinal_bf effects_bf intravenous_bf OTHER_DRUG without_be affecting_be analgesia_be ._be"
632,ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. ,ADL-8-2698,opioid,effect,DRUG novel_be peripherally_be restricted_be OTHER_DRUG antagonist_af may_af selectively_af prevent_af opioid-induced_af gastrointestinal_af effects_af without_af reversing_af analgesia_af ._af
637,Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by ADL 8-2698 (P = .004). ,Morphine,ADL 8-2698,effect,DRUG prolonged_be gastrointestinal_be transit_be time_be 69_be 103_be minutes_be (P_be =_be ._be 005);_be prevented_be ADL_be 8-2698_be (P_be =_be ._be 004)_be ._be
640,We conclude that ADL 8-2698 prevents morphine-induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.,ADL 8-2698,morphine,effect,We_bf conclude_bf ADL_bf 8-2698_bf prevents_bf morphine-induced_bf increases_bf gastrointestinal_bf transit_bf time_bf means_bf selective_bf peripheral_bf opioid_bf anitagonism_bf without_bf affecting_bf central_bf opioid_bf analgesia_bf ._bf
641,"Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
",simvastatin,clarithromycin,effect,Rhabdomyolysis_bf secondary_bf drug_bf interaction_bf DRUG OTHER_DRUG ._af
644,The concomitant administration of macrolide antibiotics and other hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have resulted in previous reports of rhabdomyolysis. ,macrolide antibiotics,hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors,effect,The_bf concomitant_bf administration_bf macrolide_bf antibiotics_bf hydroxymethylglutaryl_bf coenzyme_bf A_bf (HMG-CoA)_bf reductase_bf inhibitors_bf resulted_bf previous_bf reports_bf rhabdomyolysis_bf ._bf
781,"Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ",acetaminophen,theophylline,effect,"Coingestion_bf DRUG OTHER_DRUG ,_af phenobarbital_af DRUG ,_af valproic_af acid_af phenobarbital_af high_af toxic_af concentrations_af decreases_af binding_af target_af drug_af ._af"
790,"Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ",phenobarbital,acetaminophen,effect,"Coingestion_bf OTHER_DRUG theophylline_be ,_be DRUG OTHER_DRUG ,_af valproic_af acid_af DRUG high_af toxic_af concentrations_af decreases_af binding_af target_af drug_af ._af"
795,"Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. ",valproic acid,phenobarbital,effect,"Coingestion_bf acetaminophen_bf theophylline_bf ,_bf OTHER_DRUG acetaminophen_be ,_be valproic_be acid_be OTHER_DRUG high_af toxic_af concentrations_af decreases_af binding_af target_af drug_af ._af"
818,Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of morphine. ,Diazepam,morphine,effect,DRUG doses_be 0_be ._be 25_be mg/kg_be 2_be ._be 5_be mg/kg_be injected_be OTHER_DRUG found_af decrease_af antinociceptive_af effect_af OTHER_DRUG ._af
821,"Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. ",diazepam,metamizol,effect,"Similarly_bf ,_bf DRUG decreased_be antinociceptive_be effect_be OTHER_DRUG (only_af tail-flick_af test)_af indomethacin_af ._af"
822,"Similarly, diazepam decreased the antinociceptive effect of metamizol (only in the tail-flick test) and indomethacin. ",diazepam,indomethacin,effect,"Similarly_bf ,_bf DRUG decreased_be antinociceptive_be effect_be metamizol_be (only_be tail-flick_be test)_be OTHER_DRUG ._af"
824,"Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.",Midazolam,morphine,effect,"DRUG used_be doses_be 1_be ._be 25_be mg/kg_be 2_be ._be 5_be mg/kg_be decreased_be antinociceptive_be effect_be OTHER_DRUG ,_af metamizol_af (only_af tail-flick_af test)_af indomethacin_af ._af"
825,"Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.",Midazolam,metamizol,effect,"DRUG used_be doses_be 1_be ._be 25_be mg/kg_be 2_be ._be 5_be mg/kg_be decreased_be antinociceptive_be effect_be morphine_be ,_be OTHER_DRUG (only_af tail-flick_af test)_af indomethacin_af ._af"
826,"Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and indomethacin.",Midazolam,indomethacin,effect,"DRUG used_be doses_be 1_be ._be 25_be mg/kg_be 2_be ._be 5_be mg/kg_be decreased_be antinociceptive_be effect_be morphine_be ,_be metamizol_be (only_be tail-flick_be test)_be OTHER_DRUG ._af"
837,"Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) estradiol group were supersensitive to noradrenaline compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). ",estradiol,noradrenaline,effect,"Aortic_bf rings_bf intact_bf endothelium_bf high-dose_bf (4_bf mg/kg/day)_bf DRUG group_be supersensitive_be OTHER_DRUG compared_af vehicle_af low-dose_af (10_af microg/kg/day)_af DRUG groups_af (pD2_af values_af =_af 7_af ._af 86+/-0_af ._af 09_af ,_af 7_af ._af 30+/-0_af ._af 11_af 7_af ._af 35+/-0_af ._af 04_af ,_af respectively)_af ._af"
838,"Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). ",estradiol,noradrenaline,effect,"Endothelium-intact_bf aortic_bf rings_bf high-estradiol_bf rats_bf supersensitive_bf OTHER_DRUG compared_be vehicle-_be ,_be progesterone-_be progesterone_be +_be high-estradiol-treated_be rats_be (pD2_be values_be =_be 7_be ._be 77+/-0_be ._be 12_be ,_be 7_be ._be 21+/-0_be ._be 13_be ,_be 6_be ._be 93+/-0_be ._be 04_be 7_be ._be 22+/-0_be ._be 18_be ,_be respectively)_be ._be"
913,"however, patients with moderate to severe cardiovascular disease or those taking nitrate therapy are at increased risk for potentially serious cardiovascular adverse effects with sildenafil therapy. ",nitrate,sildenafil,effect,"however_bf ,_bf patients_bf moderate_bf severe_bf cardiovascular_bf disease_bf taking_bf DRUG therapy_be increased_be risk_be potentially_be serious_be cardiovascular_be adverse_be effects_be OTHER_DRUG therapy_af ._af"
934,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ",ketamine,ouabain,effect,"In_bf comparison_bf digitalis_bf tolerance_bf dogs_bf anesthetized_bf DRUG ,_be Innovar_be Vet_be ,_be pentobarbital_be ,_be dosage_be OTHER_DRUG needed_af cause_af ventricular_af tachycardia_af significantly_af higher_af ,_af LD50_af OTHER_DRUG ,_af DRUG Innovar_af pentobarbital_af ._af"
940,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ",Innovar Vet,ouabain,effect,"In_bf comparison_bf digitalis_bf tolerance_bf dogs_bf anesthetized_bf ketamine_bf ,_bf Innovar_bf Vet_bf ,_bf pentobarbital_bf ,_bf dosage_bf OTHER_DRUG needed_be cause_be ventricular_be tachycardia_be significantly_be higher_be ,_be LD50_be OTHER_DRUG ,_af ketamine_af Innovar_af pentobarbital_af ._af"
945,"In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. ",pentobarbital,ouabain,effect,"In_bf comparison_bf digitalis_bf tolerance_bf dogs_bf anesthetized_bf ketamine_bf ,_bf Innovar_bf Vet_bf ,_bf DRUG ,_be dosage_be OTHER_DRUG needed_af cause_af ventricular_af tachycardia_af significantly_af higher_af ,_af LD50_af OTHER_DRUG ,_af ketamine_af Innovar_af DRUG ._af"
960,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.",ouabain,Innovar,effect,"Ventricular_bf tachycardia_bf induced_bf DRUG generally_be converted_be sinus_be rhythm_be following_be administration_be OTHER_DRUG ,_af ketamine_af ,_af droperidol_af administration_af fentayl_af alone_af pentobarbital_af ._af"
961,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.",ouabain,ketamine,effect,"Ventricular_bf tachycardia_bf induced_bf DRUG generally_be converted_be sinus_be rhythm_be following_be administration_be Innovar_be ,_be OTHER_DRUG ,_af droperidol_af administration_af fentayl_af alone_af pentobarbital_af ._af"
962,"Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.",ouabain,droperidol,effect,"Ventricular_bf tachycardia_bf induced_bf DRUG generally_be converted_be sinus_be rhythm_be following_be administration_be Innovar_be ,_be ketamine_be ,_be OTHER_DRUG administration_af fentayl_af alone_af pentobarbital_af ._af"
978,Combinations of clindamycin and gentamicin were indifferent for 29 strains and synergistic for 33 strains. ,clindamycin,gentamicin,effect,Combinations_bf DRUG OTHER_DRUG indifferent_af 29_af strains_af synergistic_af 33_af strains_af ._af
980,Combinations of clindamycin and gentamicin were indifferent for 16 and synergistic for 11 of the resistant strains. ,clindamycin,gentamicin,effect,Combinations_bf DRUG OTHER_DRUG indifferent_af 16_af synergistic_af 11_af resistant_af strains_af ._af
1035,"Although this effect was noted even when cholestyramine was given 4 hours prior to fluvastatin, this regimen did not result in diminished efficacy. ",cholestyramine,fluvastatin,effect,"Although_bf effect_bf noted_bf even_bf DRUG given_be 4_be hours_be prior_be OTHER_DRUG ,_af regimen_af result_af diminished_af efficacy_af ._af"
1080,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ",picrotoxin,diazepam,effect,"[The_bf GABA-ergic_bf system_bf brain_bf edema]_bf It_bf shown_bf rats_bf experimental_bf toxic_bf traumatic_bf edemas_bf DRUG (1_be mg/kg)_be removes_be antiedematous_be action_be OTHER_DRUG ,_af phenazepam_af ,_af phenibut_af amizyl_af reduces_af action_af phentolamine_af ._af"
1081,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ",picrotoxin,phenazepam,effect,"[The_bf GABA-ergic_bf system_bf brain_bf edema]_bf It_bf shown_bf rats_bf experimental_bf toxic_bf traumatic_bf edemas_bf DRUG (1_be mg/kg)_be removes_be antiedematous_be action_be diazepam_be ,_be OTHER_DRUG ,_af phenibut_af amizyl_af reduces_af action_af phentolamine_af ._af"
1082,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ",picrotoxin,phenibut,effect,"[The_bf GABA-ergic_bf system_bf brain_bf edema]_bf It_bf shown_bf rats_bf experimental_bf toxic_bf traumatic_bf edemas_bf DRUG (1_be mg/kg)_be removes_be antiedematous_be action_be diazepam_be ,_be phenazepam_be ,_be OTHER_DRUG amizyl_af reduces_af action_af phentolamine_af ._af"
1083,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ",picrotoxin,amizyl,effect,"[The_bf GABA-ergic_bf system_bf brain_bf edema]_bf It_bf shown_bf rats_bf experimental_bf toxic_bf traumatic_bf edemas_bf DRUG (1_be mg/kg)_be removes_be antiedematous_be action_be diazepam_be ,_be phenazepam_be ,_be phenibut_be OTHER_DRUG reduces_af action_af phentolamine_af ._af"
1084,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of phentolamine. ",picrotoxin,phentolamine,effect,"[The_bf GABA-ergic_bf system_bf brain_bf edema]_bf It_bf shown_bf rats_bf experimental_bf toxic_bf traumatic_bf edemas_bf DRUG (1_be mg/kg)_be removes_be antiedematous_be action_be diazepam_be ,_be phenazepam_be ,_be phenibut_be amizyl_be reduces_be action_be OTHER_DRUG ._af"
1139,"In the presence of ouabain (10(-5) M), PTX (10(-8) M) failed to cause the first contraction; ",ouabain,PTX,effect,"In_bf presence_bf DRUG (10(-5)_be M)_be ,_be OTHER_DRUG (10(-8)_af M)_af failed_af cause_af first_af contraction;_af"
1140,"When ouabain was applied to the muscle in the presence of phentolamine, both first and second contractile responses to PTX were abolished. ",ouabain,phentolamine,effect,"When_bf DRUG applied_be muscle_be presence_be OTHER_DRUG ,_af first_af second_af contractile_af responses_af PTX_af abolished_af ._af"
1143,Exposure of the muscle to ouabain (10(-5) M) markedly increased the PTX-induced release. ,ouabain,PTX,effect,Exposure_bf muscle_bf DRUG (10(-5)_be M)_be markedly_be increased_be PTX-induced_be release_be ._be
1167,"Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). ",naloxone,beta-endorphin,effect,"Intrathecal_bf injection_bf DRUG doses_be 0_be ._be 4_be 40_be micrograms_be caused_be dose-related_be blockade_be inhibition_be tail-flick_be response_be induced_be intraventricular_be injection_be OTHER_DRUG ,_af high_af dose_af DRUG (40_af micrograms)_af completely_af blocked_af tail-flick_af inhibition_af induced_af intraventricular_af OTHER_DRUG (16_af micrograms)_af ._af"
1172,"Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). ",naloxone,beta-endorphin,effect,"Intrathecal_bf injection_bf DRUG doses_be 0_be ._be 4_be 40_be micrograms_be caused_be dose-related_be blockade_be inhibition_be tail-flick_be response_be induced_be intraventricular_be injection_be OTHER_DRUG ,_af high_af dose_af DRUG (40_af micrograms)_af completely_af blocked_af tail-flick_af inhibition_af induced_af intraventricular_af OTHER_DRUG (16_af micrograms)_af ._af"
1173,"On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms). ",naloxone,morphine,effect,"On_bf hand_bf ,_bf intrathecal_bf DRUG (12-120_be micrograms)_be weak_be effect_be tail-flick_be inhibition_be induced_be intraventricular_be OTHER_DRUG (40_af micrograms)_af ._af"
1174,Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. ,naloxone,beta-endorphin,effect,Intraventricular_bf injection_bf DRUG doses_be 1_be ._be 2_be 12_be micrograms_be equally_be antagonized_be dose-dependent_be manner_be tail-flick_be inhibition_be induced_be intraventricular_be OTHER_DRUG morphine_af ._af
1175,Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. ,naloxone,morphine,effect,Intraventricular_bf injection_bf DRUG doses_be 1_be ._be 2_be 12_be micrograms_be equally_be antagonized_be dose-dependent_be manner_be tail-flick_be inhibition_be induced_be intraventricular_be beta-endorphin_be OTHER_DRUG ._af
1192,It was observed that MPTP induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by pargyline pretreatment. ,MPTP,pargyline,effect,It_bf observed_bf DRUG induced_be long_be lasting_be depletions_be striatal_be dopamine_be concentrations_be neurotoxic_be effect_be could_be prevented_be OTHER_DRUG pretreatment_af ._af
1193,The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. ,MPTP,amphetamine,effect,The_bf MPTP-induced_bf neuronal_bf damage_bf produced_bf tolerance_bf disruptive_bf effects_bf OTHER_DRUG supersensitivity_be disruptive_be effects_be apomorphine_be rats_be responding_be schedule_be controlled_be paradigm_be ._be
1194,The MPTP-induced neuronal damage produced a tolerance to the disruptive effects of amphetamine and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. ,MPTP,apomorphine,effect,The_bf MPTP-induced_bf neuronal_bf damage_bf produced_bf tolerance_bf disruptive_bf effects_bf amphetamine_bf supersensitivity_bf disruptive_bf effects_bf OTHER_DRUG rats_be responding_be schedule_be controlled_be paradigm_be ._be
1197,"Methamphetamine, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. ",Methamphetamine,pargyline,effect,"DRUG ,_be like_be MPTP_be ,_be produced_be depletions_be striatal_be dopamine_be actions_be potentiated_be OTHER_DRUG pretreatment_af ._af"
1200,Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.,Dexamethasone,EGF,effect,DRUG retinyl_be acetate_be similarly_be inhibit_be stimulate_be EGF-_be insulin-induced_be proliferation_be prostatic_be epithelium_be ._be
1201,Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.,Dexamethasone,insulin,effect,DRUG retinyl_be acetate_be similarly_be inhibit_be stimulate_be EGF-_be insulin-induced_be proliferation_be prostatic_be epithelium_be ._be
1202,Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.,retinyl acetate,EGF,effect,Dexamethasone_bf retinyl_bf acetate_bf similarly_bf inhibit_bf stimulate_bf EGF-_bf insulin-induced_bf proliferation_bf prostatic_bf epithelium_bf ._bf
1203,Dexamethasone and retinyl acetate similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.,retinyl acetate,insulin,effect,Dexamethasone_bf retinyl_bf acetate_bf similarly_bf inhibit_bf stimulate_bf EGF-_bf insulin-induced_bf proliferation_bf prostatic_bf epithelium_bf ._bf
1210,"Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ",dexamethasone,EGF,effect,"Although_bf neither_bf DRUG retinyl_be acetate_be affected_be proliferation_be prostatic_be epithelium_be RPMI1640_be containing_be transferrin_be alone_be ,_be modify_be mitogenic_be effect_be OTHER_DRUG insulin_af ._af"
1211,"Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ",dexamethasone,insulin,effect,"Although_bf neither_bf DRUG retinyl_be acetate_be affected_be proliferation_be prostatic_be epithelium_be RPMI1640_be containing_be transferrin_be alone_be ,_be modify_be mitogenic_be effect_be EGF_be OTHER_DRUG ._af"
1213,"Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ",retinyl acetate,EGF,effect,"Although_bf neither_bf dexamethasone_bf retinyl_bf acetate_bf affected_bf proliferation_bf prostatic_bf epithelium_bf RPMI1640_bf containing_bf transferrin_bf alone_bf ,_bf modify_bf mitogenic_bf effect_bf OTHER_DRUG insulin_be ._be"
1214,"Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. ",retinyl acetate,insulin,effect,"Although_bf neither_bf dexamethasone_bf retinyl_bf acetate_bf affected_bf proliferation_bf prostatic_bf epithelium_bf RPMI1640_bf containing_bf transferrin_bf alone_bf ,_bf modify_bf mitogenic_bf effect_bf EGF_bf OTHER_DRUG ._be"
1219,Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF. ,Dexamethasone,EGF,effect,DRUG 10(-10)_be M_be retinyl_be acetate_be 3_be X_be 10(-9)_be M_be inhibits_be proliferation_be stimulated_be OTHER_DRUG ._af
1220,Dexamethasone at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by EGF. ,retinyl acetate,EGF,effect,Dexamethasone_bf 10(-10)_bf M_bf retinyl_bf acetate_bf 3_bf X_bf 10(-9)_bf M_bf inhibits_bf proliferation_bf stimulated_bf OTHER_DRUG ._be
1222,Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. ,dexamethasone,EGF,effect,Higher_bf concentrations_bf DRUG (10(-8)_be -_be 10(-6)_be M)_be retinyl_be acetate_be (3_be X_be 10(-8)_be -_be 10(-7)_be M)_be enhance_be mitogenic_be activity_be OTHER_DRUG ._af
1223,Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF. ,retinyl acetate,EGF,effect,Higher_bf concentrations_bf dexamethasone_bf (10(-8)_bf -_bf 10(-6)_bf M)_bf retinyl_bf acetate_bf (3_bf X_bf 10(-8)_bf -_bf 10(-7)_bf M)_bf enhance_bf mitogenic_bf activity_bf OTHER_DRUG ._be
1225,"However, retinyl acetate stimulated, but did not significantly inhibit, proliferation in the presence of insulin. ",retinyl acetate,insulin,effect,"However_bf ,_bf retinyl_bf acetate_bf stimulated_bf ,_bf significantly_bf inhibit_bf ,_bf proliferation_bf presence_bf OTHER_DRUG ._be"
1229,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",dexamethasone,insulin,effect,"These_bf results_bf suggest_bf DRUG retinyl_be acetate_be ,_be possibly_be glucocorticoids_be retinoids_be ,_be may_be regulate_be proliferation_be prostate_be epithelium_be dose-dependent_be modification_be activity_be OTHER_DRUG EGF_af ._af"
1230,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",dexamethasone,EGF,effect,"These_bf results_bf suggest_bf DRUG retinyl_be acetate_be ,_be possibly_be glucocorticoids_be retinoids_be ,_be may_be regulate_be proliferation_be prostate_be epithelium_be dose-dependent_be modification_be activity_be insulin_be OTHER_DRUG ._af"
1233,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",retinyl acetate,insulin,effect,"These_bf results_bf suggest_bf dexamethasone_bf retinyl_bf acetate_bf ,_bf possibly_bf glucocorticoids_bf retinoids_bf ,_bf may_bf regulate_bf proliferation_bf prostate_bf epithelium_bf dose-dependent_bf modification_bf activity_bf OTHER_DRUG EGF_be ._be"
1234,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",retinyl acetate,EGF,effect,"These_bf results_bf suggest_bf dexamethasone_bf retinyl_bf acetate_bf ,_bf possibly_bf glucocorticoids_bf retinoids_bf ,_bf may_bf regulate_bf proliferation_bf prostate_bf epithelium_bf dose-dependent_bf modification_bf activity_bf insulin_bf OTHER_DRUG ._be"
1236,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",glucocorticoids,insulin,effect,"These_bf results_bf suggest_bf dexamethasone_bf retinyl_bf acetate_bf ,_bf possibly_bf DRUG retinoids_be ,_be may_be regulate_be proliferation_be prostate_be epithelium_be dose-dependent_be modification_be activity_be OTHER_DRUG EGF_af ._af"
1237,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",glucocorticoids,EGF,effect,"These_bf results_bf suggest_bf dexamethasone_bf retinyl_bf acetate_bf ,_bf possibly_bf DRUG retinoids_be ,_be may_be regulate_be proliferation_be prostate_be epithelium_be dose-dependent_be modification_be activity_be insulin_be OTHER_DRUG ._af"
1238,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",retinoids,insulin,effect,"These_bf results_bf suggest_bf dexamethasone_bf retinyl_bf acetate_bf ,_bf possibly_bf glucocorticoids_bf DRUG ,_be may_be regulate_be proliferation_be prostate_be epithelium_be dose-dependent_be modification_be activity_be OTHER_DRUG EGF_af ._af"
1239,"These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.",retinoids,EGF,effect,"These_bf results_bf suggest_bf dexamethasone_bf retinyl_bf acetate_bf ,_bf possibly_bf glucocorticoids_bf DRUG ,_be may_be regulate_be proliferation_be prostate_be epithelium_be dose-dependent_be modification_be activity_be insulin_be OTHER_DRUG ._af"
1254,"Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in pentazocine and tripelennamine, addicts) were completely inhibited by the drug combination. ",pentazocine,tripelennamine,effect,"Twelve_bf strains_bf Staphylococcus_bf aureus_bf (a_bf frequent_bf cause_bf infection_bf heroin_bf ,_bf DRUG OTHER_DRUG ,_af addicts)_af completely_af inhibited_af drug_af combination_af ._af"
1255,"Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that tripelennamine was responsible for the inhibitory activity, which was partially antagonized by pentazocine. ",tripelennamine,pentazocine,effect,"Dose-response_bf curves_bf (derived_bf results_bf using_bf tablets_bf well_bf pure_bf powders)_bf showed_bf DRUG responsible_be inhibitory_be activity_be ,_be partially_be antagonized_be OTHER_DRUG ._af"
1267,"Misonidazole protects mouse tumour and normal tissues from the toxicity of oral CCNU.
",Misonidazole,CCNU,effect,DRUG protects_be mouse_be tumour_be normal_be tissues_be toxicity_be oral_be OTHER_DRUG ._af
1274,Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71. ,Misonidazole,CCNU,effect,DRUG reduced_be antitumour_be activity_be oral_be OTHER_DRUG dose_af modifying_af factors_af (DMF)_af 0_af ._af 58-0_af ._af 71_af ._af
1279,"With combined use, clinicians should be aware, when phenytoin is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum theophylline concentrations.",phenytoin,theophylline,effect,"With_bf combined_bf use_bf ,_bf clinicians_bf aware_bf ,_bf DRUG added_be ,_be potential_be reexacerbation_be pulmonary_be symptomatology_be due_be lowered_be serum_be OTHER_DRUG concentrations_af ._af"
1294,"In both species, (-)-NANM, but not (+)-NANM, antagonized the rate-decreasing effects of morphine on FI and FR responding. ",(-)-NANM,morphine,effect,"In_bf species_bf ,_bf DRUG ,_be (+)-NANM_be ,_be antagonized_be rate-decreasing_be effects_be OTHER_DRUG FI_af FR_af responding_af ._af"
1298,"In monkeys, the effects of (-)-NANM, but not (+)-NANM or PCP, were antagonized by naloxone; ",(-)-NANM,naloxone,effect,"In_bf monkeys_bf ,_bf effects_bf DRUG ,_be (+)-NANM_be PCP_be ,_be antagonized_be naloxone;_be"
1302,the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. ,naloxone,(-)-NANM,effect,doses_bf DRUG required_be antagonize_be effects_be OTHER_DRUG 100_af times_af higher_af required_af antagonize_af effects_af morphine_af ._af
1303,the doses of naloxone required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of morphine. ,naloxone,morphine,effect,doses_bf DRUG required_be antagonize_be effects_be (-)-NANM_be 100_be times_be higher_be required_be antagonize_be effects_be OTHER_DRUG ._af
1311,"Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. ",Haloperidol,(+)-NANM,effect,"DRUG reduced_be eliminated_be increases_be FI_be responding_be produced_be intermediate_be doses_be either_be OTHER_DRUG PCP_af pigeons_af ,_af antagonize_af decreases_af FI_af FR_af responding_af produced_af high_af doses_af PCP_af either_af stereoisomer_af NANM_af ._af"
1312,"Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. ",Haloperidol,PCP,effect,"DRUG reduced_be eliminated_be increases_be FI_be responding_be produced_be intermediate_be doses_be either_be (+)-NANM_be OTHER_DRUG pigeons_af ,_af antagonize_af decreases_af FI_af FR_af responding_af produced_af high_af doses_af OTHER_DRUG either_af stereoisomer_af NANM_af ._af"
1317,Increased hepatotoxicity of acetaminophen by concomitant administration of caffeine in the rat.,acetaminophen,caffeine,effect,Increased_bf hepatotoxicity_bf DRUG concomitant_be administration_be OTHER_DRUG rat_af ._af
1324,Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.,acetaminophen,caffeine,effect,Careful_bf observations_bf hepatotoxicity_bf suggested_bf DRUG prescribed_be OTHER_DRUG ._af
1325,"High-dose cisplatin with sodium thiosulfate protection.
",cisplatin,sodium thiosulfate,effect,High-dose_bf DRUG sodium_be thiosulfate_be protection_be ._be
1326,Sodium thiosulfate is a neutralizing agent for cisplatin that protects against renal damage. ,Sodium thiosulfate,cisplatin,effect,Sodium_bf thiosulfate_bf neutralizing_bf agent_bf OTHER_DRUG protects_be renal_be damage_be ._be
1367,"The treatment of ewes with an intravenous (IV) injection of trichlorfon, insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of coumaphos/kg/day. ",trichlorfon,coumaphos,effect,"The_bf treatment_bf ewes_bf intravenous_bf (IV)_bf injection_bf DRUG ,_be insufficient_be produce_be significant_be inhibition_be erythrocyte_be acetylcholinesterase_be (AChE)_be activity_be ,_be appeared_be produce_be additive_be effects_be produced_be subsequent_be treatment_be 4_be mg_be coumaphos/kg/day_be ._be"
1368,"In ewes given 40 mg of phenobarbital sodium/kg for 5 days intraperitoneally (IP), the anticholinesterase effect of 4 mg of coumaphos/kg was significantly reduced and signs of toxicity were not present. ",phenobarbital sodium,coumaphos,effect,"In_bf ewes_bf given_bf 40_bf mg_bf phenobarbital_bf sodium/kg_bf 5_bf days_bf intraperitoneally_bf (IP)_bf ,_bf anticholinesterase_bf effect_bf 4_bf mg_bf coumaphos/kg_bf significantly_bf reduced_bf signs_bf toxicity_bf present_bf ._bf"
1371,"Studies in rats have shown that neomycin administration attenuates certain types of adrenocortical steroid dependent hypertension, including ACTH hypertension. ",neomycin,ACTH,effect,"Studies_bf rats_bf shown_bf DRUG administration_be attenuates_be certain_be types_be adrenocortical_be steroid_be dependent_be hypertension_be ,_be including_be OTHER_DRUG hypertension_af ._af"
1380,These results suggest that exposure to environmental lead may alter the biological and behavioral responsiveness of an animal to alcohol.,lead,alcohol,effect,These_bf results_bf suggest_bf exposure_bf environmental_bf DRUG may_be alter_be biological_be behavioral_be responsiveness_be animal_be OTHER_DRUG ._af
1385,"Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. ",Physostigmine,alcohol,effect,"DRUG pretreatment_be augmented_be depressant_be effect_be OTHER_DRUG early_af components_af P1_af N1_af ,_af attenuating_af alcohol's_af influence_af components_af P2_af P3_af ._af"
1386,"Physostigmine pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. ",Physostigmine,alcohol,effect,"DRUG pretreatment_be augmented_be depressant_be effect_be OTHER_DRUG early_af components_af P1_af N1_af ,_af attenuating_af alcohol's_af influence_af components_af P2_af P3_af ._af"
1391,Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with disulfiram 8 hours before the ethanol challenge. ,ethanol,disulfiram,effect,Core_bf temperature_bf decreased_bf rats_bf dose-dependent_bf manner_bf DRUG administered_be rats_be treated_be OTHER_DRUG 8_af hours_af DRUG challenge_af ._af
1396,"Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
",neurotensin,enkephalins,effect,Interaction_bf antinociceptive_bf effect_bf DRUG OTHER_DRUG tuftsin_af ._af
1397,"Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
",neurotensin,tuftsin,effect,Interaction_bf antinociceptive_bf effect_bf DRUG enkephalins_be OTHER_DRUG ._af
1405,It was shown that neurotensin antagonized evidently the antinociceptive effect of enkephalins and their analogue. ,neurotensin,enkephalins,effect,It_bf shown_bf DRUG antagonized_be evidently_be antinociceptive_be effect_be OTHER_DRUG analogue_af ._af
1406,"On the contrary, neurotensin and tuftsin were agonists in induction of analgesia. ",neurotensin,tuftsin,effect,"On_bf contrary_bf ,_bf DRUG OTHER_DRUG agonists_af induction_af analgesia_af ._af"
1407,It is concluded that neurotensin modulates in an opposite way the function of the enkephalinergic neurons and the central action of tuftsin.,neurotensin,tuftsin,effect,It_bf concluded_bf DRUG modulates_be opposite_be way_be function_be enkephalinergic_be neurons_be central_be action_be OTHER_DRUG ._af
1408,"Among the risk factors studied, two appear to increase the risk of ARE: the prescription of thiabendazole to treat strongyloidiasis during the melarsoprol cure and the bad general clinical conditions of patients. ",thiabendazole,melarsoprol,effect,"Among_bf risk_bf factors_bf studied_bf ,_bf two_bf appear_bf increase_bf risk_bf ARE:_bf prescription_bf DRUG treat_be strongyloidiasis_be OTHER_DRUG cure_af bad_af general_af clinical_af conditions_af patients_af ._af"
1432,"Therapeutic drug monitoring can avoid iatrogenic alterations caused by 99mTc-methylene diphosphonate (MDP)-gentamicin interaction.
",99mTc-methylene diphosphonate,gentamicin,effect,Therapeutic_bf drug_bf monitoring_bf avoid_bf iatrogenic_bf alterations_bf caused_bf 99mTc-methylene_bf diphosphonate_bf (MDP)-gentamicin_bf interaction_bf ._bf
1461,These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde; ,ethanol,acetaldehyde,effect,These_bf results_bf suggest_bf hepatoxicity_bf DRUG alcoholic_be beverages_be enhanced_be interaction_be congeners_be acetaldehyde;_be
1525,"Interaction between glycine and glutamate in the development of spontaneous motility in chick embryos.
",glycine,glutamate,effect,Interaction_bf DRUG OTHER_DRUG development_af spontaneous_af motility_af chick_af embryos_af ._af
1526,The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone. ,glycine,glutamate,effect,The_bf successive_bf application_bf DRUG (5_be 10_be mg/kg_be egg_be weight_be (e_be ._be w_be ._be )_be OTHER_DRUG (15_af mg/kg_af ._af w_af ._af )_af 10_af min_af interval_af significantly_af increased_af activation_af spontaneous_af motility_af 17-day-old_af chick_af embryos_af comparison_af effect_af OTHER_DRUG alone_af ._af
1531,The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. ,cocaine,norepinephrine,effect,The_bf uptake_bf inhibitors_bf DRUG desipramine_be (3_be mumol/liter)_be potentiated_be positive_be inotropic_be effects_be OTHER_DRUG nonfailing_af myocardium_af (p_af <_af 0_af ._af 05)_af functional_af class_af IV_af myocardium_af ._af
1532,The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. ,desipramine,norepinephrine,effect,The_bf uptake_bf inhibitors_bf cocaine_bf DRUG (3_be mumol/liter)_be potentiated_be positive_be inotropic_be effects_be OTHER_DRUG nonfailing_af myocardium_af (p_af <_af 0_af ._af 05)_af functional_af class_af IV_af myocardium_af ._af
1623,Concurrent administration of a TNF antagonist with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.,TNF antagonist,ORENCIA,effect,Concurrent_bf administration_bf TNF_bf antagonist_bf OTHER_DRUG associated_be increased_be risk_be serious_be infections_be significant_be additional_be efficacy_be use_be TNF_be antagonists_be alone_be ._be
1693,"Patients taking Acamprosate concomitantly with antidepressants more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.",Acamprosate,antidepressants,effect,"Patients_bf taking_bf DRUG concomitantly_be OTHER_DRUG commonly_af reported_af weight_af gain_af weight_af loss_af ,_af compared_af patients_af taking_af either_af medication_af alone_af ._af"
1810,"Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.",Catecholamine-depleting drugs,beta-blocking agents,effect,"Catecholamine-depleting_bf drugs_bf ,_bf reserpine_bf ,_bf may_bf additive_bf effect_bf given_bf beta-blocking_bf agents_bf ._bf"
1811,"Catecholamine-depleting drugs, such as reserpine, may have an additive effect when given with beta-blocking agents.",reserpine,beta-blocking agents,effect,"Catecholamine-depleting_bf drugs_bf ,_bf DRUG ,_be may_be additive_be effect_be given_be beta-blocking_be agents_be ._be"
1813,"Exaggerated hypertensive responses have been reported from the combined use of beta-adrenergic antagonists and alpha-adrenergic stimulants, including those contained in proprietary cold remedies and vasoconstrictive nasal drops.",beta-adrenergic antagonists,alpha-adrenergic stimulants,effect,"Exaggerated_bf hypertensive_bf responses_bf reported_bf combined_bf use_bf beta-adrenergic_bf antagonists_bf alpha-adrenergic_bf stimulants_bf ,_bf including_bf contained_bf proprietary_bf cold_bf remedies_bf vasoconstrictive_bf nasal_bf drops_bf ._bf"
1814,Blunting of the antihypertensive effect of beta-adrenoceptor blocking agents by nonsteroidal anti-inflammatory drugs has been reported.,beta-adrenoceptor blocking agents,nonsteroidal anti-inflammatory drugs,effect,Blunting_bf antihypertensive_bf effect_bf beta-adrenoceptor_bf blocking_bf agents_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf reported_bf ._bf
1843,Acetazolamide may increase the effects of other folic acid antagonists.,Acetazolamide,folic acid antagonists,effect,DRUG may_be increase_be effects_be folic_be acid_be antagonists_be ._be
1846,Acetazolamide may prevent the urinary antiseptic effect of methenamine.,Acetazolamide,methenamine,effect,DRUG may_be prevent_be urinary_be antiseptic_be effect_be OTHER_DRUG ._af
1850,Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation.,Acetazolamide,sodium bicarbonate,effect,DRUG sodium_be bicarbonate_be used_be concurrently_be increases_be risk_be renal_be calculus_be formation_be ._be
1864,"Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.",acitretin,glibenclamide,effect,"Glibenclamide:_bf In_bf study_bf 7_bf healthy_bf male_bf volunteers_bf ,_bf DRUG treatment_be potentiated_be blood_be glucose_be lowering_be effect_be OTHER_DRUG (a_af sulfonylurea_af similar_af chlorpropamide)_af 3_af 7_af subjects_af ._af"
1874,"However, it has been established that acitretin interferes with the contraceptive effect of microdosed progestin minipill preparations.",acitretin,progestin,effect,"However_bf ,_bf established_bf DRUG interferes_be contraceptive_be effect_be microdosed_be OTHER_DRUG minipill_af preparations_af ._af"
1879,Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.,methotrexate,etretinate,effect,Methotrexate:_bf An_bf increased_bf risk_bf hepatitis_bf reported_bf result_bf combined_bf use_bf DRUG OTHER_DRUG ._af
1889,"Tetracyclines: Since both acitretin and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.",acitretin,tetracyclines,effect,"Tetracyclines:_bf Since_bf DRUG OTHER_DRUG cause_af increased_af intracranial_af pressure_af ,_af combined_af use_af contraindicated_af ._af"
1917,"Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.",anakinra,TNF-blocking agent,effect,"Anakinra:_bf Concurrent_bf administration_bf DRUG (an_be interleukin-1_be antagonist)_be another_be TNF-blocking_be agent_be associated_be increased_be risk_be serious_be infections_be ,_be increased_be risk_be neutropenia_be additional_be benefit_be compared_be medicinal_be products_be alone_be ._be"
1918,"Anakinra: Concurrent administration of anakinra (an interleukin-1 antagonist) and another TNF-blocking agent has been associated with an increased risk of serious infections, an increased risk of neutropenia and no additional benefit compared to these medicinal products alone.",interleukin-1 antagonist,TNF-blocking agent,effect,"Anakinra:_bf Concurrent_bf administration_bf anakinra_bf (an_bf interleukin-1_bf antagonist)_bf another_bf TNF-blocking_bf agent_bf associated_bf increased_bf risk_bf serious_bf infections_bf ,_bf increased_bf risk_bf neutropenia_bf additional_bf benefit_bf compared_bf medicinal_bf products_bf alone_bf ._bf"
1920,"Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.",anakinra,TNF-blocking agents,effect,"Therefore_bf ,_bf combination_bf DRUG TNF-blocking_be agents_be ,_be including_be HUMIRA_be ,_be may_be also_be result_be n_be similar_be toxicities_be ._be"
1921,"Therefore the, combination of anakinra with other TNF-blocking agents, including HUMIRA, may also result i n similar toxicities.",anakinra,HUMIRA,effect,"Therefore_bf ,_bf combination_bf DRUG TNF-blocking_be agents_be ,_be including_be OTHER_DRUG ,_af may_af also_af result_af n_af similar_af toxicities_af ._af"
1981,Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.,Digoxin,Adenocard,effect,DRUG verapamil_be use_be may_be rarely_be associated_be ventricular_be fibrillation_be combined_be OTHER_DRUG ._af
1982,Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.,verapamil,Adenocard,effect,Digoxin_bf DRUG use_be may_be rarely_be associated_be ventricular_be fibrillation_be combined_be OTHER_DRUG ._af
1983,The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation.,Adenocard,digitalis,effect,The_bf use_bf DRUG patients_be receiving_be OTHER_DRUG may_af rarely_af associated_af ventricular_af fibrillation_af ._af
1984,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.,adenosine,methylxanthines,effect,The_bf effects_bf DRUG antagonized_be OTHER_DRUG caffeine_af theophylline_af ._af
1985,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.,adenosine,caffeine,effect,The_bf effects_bf DRUG antagonized_be methylxanthines_be OTHER_DRUG theophylline_af ._af
1986,The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.,adenosine,theophylline,effect,The_bf effects_bf DRUG antagonized_be methylxanthines_be caffeine_be OTHER_DRUG ._af
1993,Adenosine effects are potentiated by dipyridamole.,Adenosine,dipyridamole,effect,DRUG effects_be potentiated_be OTHER_DRUG ._af
1994,"Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.",adenosine,dipyridamole,effect,"Thus_bf ,_bf smaller_bf doses_bf DRUG may_be effective_be presence_be OTHER_DRUG ._af"
1995,"As the primary effect of adenosine is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of carbamazepine.",adenosine,carbamazepine,effect,"As_bf primary_bf effect_bf DRUG decrease_be conduction_be A-V_be node_be ,_be higher_be degrees_be heart_be block_be may_be produced_be presence_be OTHER_DRUG ._af"
2060,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",aminoglycosides,PROLEUKIN,effect,"Concurrent_bf administration_bf drugs_bf possessing_bf nephrotoxic_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be indomethacin)_be ,_be myelotoxic_be (e_be ._be g_be ._be ,_be cytotoxic_be chemotherapy)_be ,_be cardiotoxic_be (e_be ._be g_be ._be ,_be doxorubicin)_be hepatotoxic_be (e_be ._be g_be ._be ,_be methotrexate_be ,_be asparaginase)_be effects_be OTHER_DRUG may_af increase_af toxicity_af organ_af systems_af ._af"
2065,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",indomethacin,PROLEUKIN,effect,"Concurrent_bf administration_bf drugs_bf possessing_bf nephrotoxic_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf indomethacin)_bf ,_bf myelotoxic_bf (e_bf ._bf g_bf ._bf ,_bf cytotoxic_bf chemotherapy)_bf ,_bf cardiotoxic_bf (e_bf ._bf g_bf ._bf ,_bf doxorubicin)_bf hepatotoxic_bf (e_bf ._bf g_bf ._bf ,_bf methotrexate_bf ,_bf asparaginase)_bf effects_bf OTHER_DRUG may_be increase_be toxicity_be organ_be systems_be ._be"
2069,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",cytotoxic,PROLEUKIN,effect,"Concurrent_bf administration_bf drugs_bf possessing_bf nephrotoxic_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf indomethacin)_bf ,_bf myelotoxic_bf (e_bf ._bf g_bf ._bf ,_bf DRUG chemotherapy)_be ,_be cardiotoxic_be (e_be ._be g_be ._be ,_be doxorubicin)_be hepatotoxic_be (e_be ._be g_be ._be ,_be methotrexate_be ,_be asparaginase)_be effects_be OTHER_DRUG may_af increase_af toxicity_af organ_af systems_af ._af"
2072,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",doxorubicin,PROLEUKIN,effect,"Concurrent_bf administration_bf drugs_bf possessing_bf nephrotoxic_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf indomethacin)_bf ,_bf myelotoxic_bf (e_bf ._bf g_bf ._bf ,_bf cytotoxic_bf chemotherapy)_bf ,_bf cardiotoxic_bf (e_bf ._bf g_bf ._bf ,_bf doxorubicin)_bf hepatotoxic_bf (e_bf ._bf g_bf ._bf ,_bf methotrexate_bf ,_bf asparaginase)_bf effects_bf OTHER_DRUG may_be increase_be toxicity_be organ_be systems_be ._be"
2074,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",methotrexate,PROLEUKIN,effect,"Concurrent_bf administration_bf drugs_bf possessing_bf nephrotoxic_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf indomethacin)_bf ,_bf myelotoxic_bf (e_bf ._bf g_bf ._bf ,_bf cytotoxic_bf chemotherapy)_bf ,_bf cardiotoxic_bf (e_bf ._bf g_bf ._bf ,_bf doxorubicin)_bf hepatotoxic_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be asparaginase)_be effects_be OTHER_DRUG may_af increase_af toxicity_af organ_af systems_af ._af"
2075,"Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.",asparaginase,PROLEUKIN,effect,"Concurrent_bf administration_bf drugs_bf possessing_bf nephrotoxic_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf indomethacin)_bf ,_bf myelotoxic_bf (e_bf ._bf g_bf ._bf ,_bf cytotoxic_bf chemotherapy)_bf ,_bf cardiotoxic_bf (e_bf ._bf g_bf ._bf ,_bf doxorubicin)_bf hepatotoxic_bf (e_bf ._bf g_bf ._bf ,_bf methotrexate_bf ,_bf asparaginase)_bf effects_bf OTHER_DRUG may_be increase_be toxicity_be organ_be systems_be ._be"
2077,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,antineoplastic agents,effect,"Hypersensitivity_bf reactions_bf reported_bf patients_bf receiving_bf combination_bf regimens_bf containing_bf sequential_bf high_bf dose_bf DRUG antineoplastic_be agents_be ,_be specifically_be ,_be dacarbazine_be ,_be cis-platinum_be ,_be tamoxifen_be interferon-alfa_be ._be"
2078,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,dacarbazine,effect,"Hypersensitivity_bf reactions_bf reported_bf patients_bf receiving_bf combination_bf regimens_bf containing_bf sequential_bf high_bf dose_bf DRUG antineoplastic_be agents_be ,_be specifically_be ,_be OTHER_DRUG ,_af cis-platinum_af ,_af tamoxifen_af interferon-alfa_af ._af"
2079,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,cis-platinum,effect,"Hypersensitivity_bf reactions_bf reported_bf patients_bf receiving_bf combination_bf regimens_bf containing_bf sequential_bf high_bf dose_bf DRUG antineoplastic_be agents_be ,_be specifically_be ,_be dacarbazine_be ,_be OTHER_DRUG ,_af tamoxifen_af interferon-alfa_af ._af"
2080,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,tamoxifen,effect,"Hypersensitivity_bf reactions_bf reported_bf patients_bf receiving_bf combination_bf regimens_bf containing_bf sequential_bf high_bf dose_bf DRUG antineoplastic_be agents_be ,_be specifically_be ,_be dacarbazine_be ,_be cis-platinum_be ,_be OTHER_DRUG interferon-alfa_af ._af"
2081,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.",PROLEUKIN,interferon-alfa,effect,"Hypersensitivity_bf reactions_bf reported_bf patients_bf receiving_bf combination_bf regimens_bf containing_bf sequential_bf high_bf dose_bf DRUG antineoplastic_be agents_be ,_be specifically_be ,_be dacarbazine_be ,_be cis-platinum_be ,_be tamoxifen_be OTHER_DRUG ._af"
2092,"Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving PROLEUKIN and interferon-alfa concurrently.",PROLEUKIN,interferon-alfa,effect,"Myocardial_bf injury_bf ,_bf including_bf myocardial_bf infarction_bf ,_bf myocarditis_bf ,_bf ventricular_bf hypokinesia_bf ,_bf severe_bf rhabdomyolysis_bf appear_bf increased_bf patients_bf receiving_bf DRUG OTHER_DRUG concurrently_af ._af"
2093,"Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of interferon-alfa and PROLEUKIN, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.",interferon-alfa,PROLEUKIN,effect,"Exacerbation_bf initial_bf presentation_bf number_bf autoimmune_bf inflammatory_bf disorders_bf observed_bf following_bf concurrent_bf use_bf DRUG OTHER_DRUG ,_af including_af crescentic_af IgA_af glomerulonephritis_af ,_af oculo-bulbar_af myasthenia_af gravis_af ,_af inflammatory_af arthritis_af ,_af thyroiditis_af ,_af bullous_af pemphigoid_af ,_af Stevens-Johnson_af syndrome_af ._af"
2094,"Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.",glucocorticoids,PROLEUKIN,effect,"Although_bf DRUG shown_be reduce_be PROLEUKIN-induced_be side_be effects_be including_be fever_be ,_be renal_be insufficiency_be ,_be hyperbilirubinemia_be ,_be confusion_be ,_be dyspnea_be ,_be concomitant_be administration_be agents_be OTHER_DRUG may_af reduce_af antitumor_af effectiveness_af OTHER_DRUG thus_af avoided_af ._af 12_af Beta-blockers_af antihypertensives_af may_af potentiate_af hypotension_af seen_af OTHER_DRUG ._af"
2113,"Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.",Beta-blockers,PROLEUKIN,effect,"Although_bf glucocorticoids_bf shown_bf reduce_bf PROLEUKIN-induced_bf side_bf effects_bf including_bf fever_bf ,_bf renal_bf insufficiency_bf ,_bf hyperbilirubinemia_bf ,_bf confusion_bf ,_bf dyspnea_bf ,_bf concomitant_bf administration_bf agents_bf OTHER_DRUG may_be reduce_be antitumor_be effectiveness_be OTHER_DRUG thus_af avoided_af ._af 12_af DRUG antihypertensives_af may_af potentiate_af hypotension_af seen_af OTHER_DRUG ._af"
2114,"Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.",antihypertensives,PROLEUKIN,effect,"Although_bf glucocorticoids_bf shown_bf reduce_bf PROLEUKIN-induced_bf side_bf effects_bf including_bf fever_bf ,_bf renal_bf insufficiency_bf ,_bf hyperbilirubinemia_bf ,_bf confusion_bf ,_bf dyspnea_bf ,_bf concomitant_bf administration_bf agents_bf OTHER_DRUG may_be reduce_be antitumor_be effectiveness_be OTHER_DRUG thus_af avoided_af ._af 12_af Beta-blockers_af DRUG may_af potentiate_af hypotension_af seen_af OTHER_DRUG ._af"
2117,"Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.",interleukin-2,radiographic iodinated contrast media,effect,"Delayed_bf Adverse_bf Reactions_bf Iodinated_bf Contrast_bf Media:_bf A_bf review_bf literature_bf revealed_bf 12_bf ._bf 6%_bf (range_bf 11-28%)_bf 501_bf patients_bf treated_bf various_bf DRUG containing_be regimens_be subsequently_be administered_be radiographic_be iodinated_be contrast_be media_be experienced_be acute_be ,_be atypical_be adverse_be reactions_be ._be"
2322,Thiazide Diuretics: The reports that the concomitant use of allopurinol and thiazide diuretics may contribute to the enhancement of allopurinol toxicity in some patients have been reviewed in an attempt to establish a cause-and-effect relationship and a mechanism of causation.,allopurinol,thiazide diuretics,effect,Thiazide_bf Diuretics:_bf The_bf reports_bf concomitant_bf use_bf DRUG thiazide_be diuretics_be may_be contribute_be enhancement_be DRUG toxicity_af patients_af reviewed_af attempt_af establish_af cause-and-effect_af relationship_af mechanism_af causation_af ._af
2334,Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.,ampicillin,allopurinol,effect,Ampicillin/Amoxicillin:_bf An_bf increase_bf frequency_bf skin_bf rash_bf reported_bf among_bf patients_bf receiving_bf DRUG amoxicillin_be concurrently_be OTHER_DRUG compared_af patients_af receiving_af drugs_af ._af
2335,Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.,amoxicillin,allopurinol,effect,Ampicillin/Amoxicillin:_bf An_bf increase_bf frequency_bf skin_bf rash_bf reported_bf among_bf patients_bf receiving_bf ampicillin_bf DRUG concurrently_be OTHER_DRUG compared_af patients_af receiving_af drugs_af ._af
2340,"Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.",cyclophosphamide,allopurinol,effect,"Cytotoxic_bf Agents:_bf Enhanced_bf bone_bf marrow_bf suppression_bf DRUG cytotoxic_be agents_be reported_be among_be patients_be neoplastic_be disease_be ,_be except_be leukemia_be ,_be presence_be OTHER_DRUG ._af"
2341,"Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.",cytotoxic agents,allopurinol,effect,"Cytotoxic_bf Agents:_bf Enhanced_bf bone_bf marrow_bf suppression_bf cyclophosphamide_bf cytotoxic_bf agents_bf reported_bf among_bf patients_bf neoplastic_bf disease_bf ,_bf except_bf leukemia_bf ,_bf presence_bf OTHER_DRUG ._be"
2367,The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.,allopurinol,chlorpropamide,effect,The_bf risk_bf hypoglycemia_bf secondary_bf mechanism_bf may_bf increased_bf DRUG OTHER_DRUG given_af concomitantly_af presence_af renal_af insufficiency_af ._af
2408,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",SSRIs,5-HT1 agonists,effect,"Selective_bf Serotonin_bf Reuptake_bf Inhibitors_bf (SSRIs):_bf DRUG (e_be ._be g_be ._be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be paroxetine_be ,_be sertraline)_be rarely_be reported_be cause_be weakness_be ,_be hyperreflexia_be ,_be incoordination_be coadministered_be 5-HT1_be agonists_be ._be"
2412,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",fluoxetine,5-HT1 agonists,effect,"Selective_bf Serotonin_bf Reuptake_bf Inhibitors_bf (SSRIs):_bf SSRIs_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be fluvoxamine_be ,_be paroxetine_be ,_be sertraline)_be rarely_be reported_be cause_be weakness_be ,_be hyperreflexia_be ,_be incoordination_be coadministered_be 5-HT1_be agonists_be ._be"
2415,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",fluvoxamine,5-HT1 agonists,effect,"Selective_bf Serotonin_bf Reuptake_bf Inhibitors_bf (SSRIs):_bf SSRIs_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf DRUG ,_be paroxetine_be ,_be sertraline)_be rarely_be reported_be cause_be weakness_be ,_be hyperreflexia_be ,_be incoordination_be coadministered_be 5-HT1_be agonists_be ._be"
2417,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",paroxetine,5-HT1 agonists,effect,"Selective_bf Serotonin_bf Reuptake_bf Inhibitors_bf (SSRIs):_bf SSRIs_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf DRUG ,_be sertraline)_be rarely_be reported_be cause_be weakness_be ,_be hyperreflexia_be ,_be incoordination_be coadministered_be 5-HT1_be agonists_be ._be"
2418,"Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.",sertraline,5-HT1 agonists,effect,"Selective_bf Serotonin_bf Reuptake_bf Inhibitors_bf (SSRIs):_bf SSRIs_bf (e_bf ._bf g_bf ._bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf paroxetine_bf ,_bf sertraline)_bf rarely_bf reported_bf cause_bf weakness_bf ,_bf hyperreflexia_bf ,_bf incoordination_bf coadministered_bf 5-HT1_bf agonists_bf ._bf"
2469,"Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.",alosetron,isoniazid,effect,"Although_bf studied_bf DRUG ,_be inhibition_be N-acetyltransferase_be may_be clinically_be relevant_be consequences_be drugs_be OTHER_DRUG ,_af procainamide_af ,_af hydralazine_af ._af"
2470,"Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.",alosetron,procainamide,effect,"Although_bf studied_bf DRUG ,_be inhibition_be N-acetyltransferase_be may_be clinically_be relevant_be consequences_be drugs_be isoniazid_be ,_be OTHER_DRUG ,_af hydralazine_af ._af"
2471,"Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine.",alosetron,hydralazine,effect,"Although_bf studied_bf DRUG ,_be inhibition_be N-acetyltransferase_be may_be clinically_be relevant_be consequences_be drugs_be isoniazid_be ,_be procainamide_be ,_be OTHER_DRUG ._af"
2492,"When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, the risk of hyperkalemia may be increased.",amiloride,angiotensin-converting enzyme inhibitor,effect,"When_bf DRUG HCl_be administered_be concomitantly_be angiotensin-converting_be enzyme_be inhibitor_be ,_be risk_be hyperkalemia_be may_be increased_be ._be"
2494,"In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,loop diuretics,effect,"In_bf patients_bf ,_bf administration_bf non-steroidal_bf anti-inflammatory_bf agent_bf reduce_bf diuretic_bf ,_bf natriuretic_bf ,_bf antihypertensive_bf effects_bf loop_bf ,_bf potassium-sparing_bf thiazide_bf diuretics_bf ._bf"
2495,"In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,potassium-sparing diuretics,effect,"In_bf patients_bf ,_bf administration_bf non-steroidal_bf anti-inflammatory_bf agent_bf reduce_bf diuretic_bf ,_bf natriuretic_bf ,_bf antihypertensive_bf effects_bf loop_bf ,_bf potassium-sparing_bf thiazide_bf diuretics_bf ._bf"
2496,"In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.",non-steroidal anti-inflammatory agent,thiazide diuretics,effect,"In_bf patients_bf ,_bf administration_bf non-steroidal_bf anti-inflammatory_bf agent_bf reduce_bf diuretic_bf ,_bf natriuretic_bf ,_bf antihypertensive_bf effects_bf loop_bf ,_bf potassium-sparing_bf thiazide_bf diuretics_bf ._bf"
2503,"Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.",indomethacin,potassium-sparing diuretics,effect,"Since_bf DRUG potassium-sparing_be diuretics_be ,_be including_be MIDAMOR_be ,_be may_be associated_be increased_be serum_be potassium_be levels_be ,_be potential_be effects_be potassium_be kinetics_be renal_be function_be considered_be agents_be administered_be concurrently_be ._be"
2504,"Since indomethacin and potassium-sparing diuretics, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.",indomethacin,MIDAMOR,effect,"Since_bf DRUG potassium-sparing_be diuretics_be ,_be including_be OTHER_DRUG ,_af may_af associated_af increased_af serum_af potassium_af levels_af ,_af potential_af effects_af potassium_af kinetics_af renal_af function_af considered_af agents_af administered_af concurrently_af ._af"
2747,The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.,SSRI,TCA,effect,The_bf extent_bf SSRI-TCA_bf interactions_bf may_bf pose_bf clinical_bf problems_bf depend_bf degree_bf inhibition_bf pharmacokinetics_bf DRUG involved_be ._be
2772,"Hyperpyrexia has been reported when amitriptyline HCl is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.",amitriptyline HCl,anticholinergic,effect,"Hyperpyrexia_bf reported_bf amitriptyline_bf HCl_bf administered_bf OTHER_DRUG agents_be neuroleptic_be drugs_be ,_be particularly_be hot_be weather_be ._be"
2775,Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic-type drugs.,tricyclic antidepressants,anticholinergic,effect,Paralytic_bf ileus_bf may_bf occur_bf patients_bf taking_bf tricyclic_bf antidepressants_bf combination_bf anticholinergic-type_bf drugs_bf ._bf
2779,Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine.,tricyclic antidepressants,cimetidine,effect,Clinically_bf significant_bf effects_bf reported_bf tricyclic_bf antidepressants_bf used_bf concomitantly_bf OTHER_DRUG ._be
2792,Transient delirium has been reported in patients who were treated with one gram of ethchlorvynol and 75 - 150 mg of amitriptyline HCl.,ethchlorvynol,amitriptyline HCl,effect,Transient_bf delirium_bf reported_bf patients_bf treated_bf one_bf gram_bf DRUG 75_be -_be 150_be mg_be amitriptyline_be HCl_be ._be
2793,"When administered concurrently, the following drugs may interact with amphotericin B: Antineoplastic agents: may enhance the potential for renal toxicity, bronchospasm and hypotension.",amphotericin B,Antineoplastic agents,effect,"When_bf administered_bf concurrently_bf ,_bf following_bf drugs_bf may_bf interact_bf amphotericin_bf B:_bf Antineoplastic_bf agents:_bf may_bf enhance_bf potential_bf renal_bf toxicity_bf ,_bf bronchospasm_bf hypotension_bf ._bf"
2797,Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.,Corticosteroids,amphotericin B,effect,DRUG Corticotropin_be (ACTH):_be may_be potentiate_be amphotericin_be B-_be induced_be hypokalemia_be may_be predispose_be patient_be cardiac_be dysfunction_be ._be
2799,Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.,Corticotropin,amphotericin B,effect,Corticosteroids_bf DRUG (ACTH):_be may_be potentiate_be amphotericin_be B-_be induced_be hypokalemia_be may_be predispose_be patient_be cardiac_be dysfunction_be ._be
2800,Corticosteroids and Corticotropin (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.,ACTH,amphotericin B,effect,Corticosteroids_bf Corticotropin_bf (ACTH):_bf may_bf potentiate_bf amphotericin_bf B-_bf induced_bf hypokalemia_bf may_bf predispose_bf patient_bf cardiac_bf dysfunction_bf ._bf
2803,Digitalis glycosides: amphotericin B-induced hypokalemia may potentiate digitalis toxicity.,amphotericin B,digitalis,effect,OTHER_DRUG glycosides:_be amphotericin_be B-induced_be hypokalemia_be may_be potentiate_be OTHER_DRUG toxicity_af ._af
2806,"Flucytosine: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.",amphotericin B,flucytosine,effect,"Flucytosine:_bf synergistic_bf relationship_bf amphotericin_bf B_bf reported_bf ,_bf concomitant_bf use_bf may_bf increase_bf toxicity_bf OTHER_DRUG possibly_be increasing_be cellular_be uptake_be and/or_be impairing_be renal_be excretion_be ._be"
2842,"Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.",imidazoles,amphotericin B,effect,"DRUG (e_be ._be g_be ._be ,_be ketoconazole_be ,_be miconazole_be ,_be clotrimazole_be ,_be fluconazole_be ,_be etc_be ._be ):_be vitro_be animal_be studies_be combination_be amphotericin_be B_be DRUG suggest_af DRUG may_af induce_af fungal_af resistance_af amphotericin_af B_af ._af"
2849,"Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).",amphotericin B,skeletal muscle relaxants,effect,"Skeletal_bf muscle_bf relaxants:_bf amphotericin_bf B-induced_bf hypokalemia_bf may_bf enhance_bf curariform_bf effect_bf skeletal_bf muscle_bf relaxants_bf (e_bf ._bf g_bf ._bf ,_bf tubocurarine)_bf ._bf"
2850,"Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).",amphotericin B,tubocurarine,effect,"Skeletal_bf muscle_bf relaxants:_bf amphotericin_bf B-induced_bf hypokalemia_bf may_bf enhance_bf curariform_bf effect_bf skeletal_bf muscle_bf relaxants_bf (e_bf ._bf g_bf ._bf ,_bf tubocurarine)_bf ._bf"
2854,Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and leukocyte transfusions.,amphotericin B,leukocyte transfusions,effect,Leukocyte_bf transfusions:_bf acute_bf pulmonary_bf toxicity_bf reported_bf patients_bf receiving_bf intravenous_bf amphotericin_bf B_bf leukocyte_bf transfusions_bf ._bf
2863,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",Chloramphenicol,penicillins,effect,"Bacteriostatic_bf Antibiotics:_bf DRUG ,_be erythromycins_be ,_be sulfonamides_be ,_be tetracyclines_be may_be interfere_be bactericidal_be effect_be OTHER_DRUG ._af"
2866,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",erythromycins,penicillins,effect,"Bacteriostatic_bf Antibiotics:_bf Chloramphenicol_bf ,_bf DRUG ,_be sulfonamides_be ,_be tetracyclines_be may_be interfere_be bactericidal_be effect_be OTHER_DRUG ._af"
2868,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",sulfonamides,penicillins,effect,"Bacteriostatic_bf Antibiotics:_bf Chloramphenicol_bf ,_bf erythromycins_bf ,_bf DRUG ,_be tetracyclines_be may_be interfere_be bactericidal_be effect_be OTHER_DRUG ._af"
2869,"Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.",tetracyclines,penicillins,effect,"Bacteriostatic_bf Antibiotics:_bf Chloramphenicol_bf ,_bf erythromycins_bf ,_bf sulfonamides_bf ,_bf DRUG may_be interfere_be bactericidal_be effect_be OTHER_DRUG ._af"
2883,Methadone: Coadministration of amprenavir and methadone can decrease plasma levels of methadone.,amprenavir,methadone,effect,Methadone:_bf Coadministration_bf DRUG OTHER_DRUG decrease_af plasma_af levels_af OTHER_DRUG ._af
2889,"Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.",Amprenavir,ritonavir,effect,"Laboratory_bf Tests:_bf The_bf combination_bf DRUG low-dose_be OTHER_DRUG associated_af elevations_af cholesterol_af triglycerides_af ,_af SGOT_af (AST)_af ,_af SGPT_af (ALT)_af patients_af ._af"
2939,"Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.",Anagrelide,aspirin,effect,"DRUG alone_be effect_be platelet_be aggregation_be ,_be slightly_be enhance_be inhibition_be platelet_be aggregation_be OTHER_DRUG ._af"
2946,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",milrinone,anagrelide,effect,"The_bf effects_bf medicinal_bf products_bf similar_bf properties_bf inotropes_bf DRUG ,_be enoximone_be ,_be amrinone_be ,_be olprinone_be cilostazol_be may_be exacerbated_be OTHER_DRUG ._af"
2950,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",enoximone,anagrelide,effect,"The_bf effects_bf medicinal_bf products_bf similar_bf properties_bf inotropes_bf milrinone_bf ,_bf DRUG ,_be amrinone_be ,_be olprinone_be cilostazol_be may_be exacerbated_be OTHER_DRUG ._af"
2953,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",amrinone,anagrelide,effect,"The_bf effects_bf medicinal_bf products_bf similar_bf properties_bf inotropes_bf milrinone_bf ,_bf enoximone_bf ,_bf DRUG ,_be olprinone_be cilostazol_be may_be exacerbated_be OTHER_DRUG ._af"
2955,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",olprinone,anagrelide,effect,"The_bf effects_bf medicinal_bf products_bf similar_bf properties_bf inotropes_bf milrinone_bf ,_bf enoximone_bf ,_bf amrinone_bf ,_bf DRUG cilostazol_be may_be exacerbated_be OTHER_DRUG ._af"
2956,"The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.",cilostazol,anagrelide,effect,"The_bf effects_bf medicinal_bf products_bf similar_bf properties_bf inotropes_bf milrinone_bf ,_bf enoximone_bf ,_bf amrinone_bf ,_bf olprinone_bf DRUG may_be exacerbated_be OTHER_DRUG ._af"
2959,"In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).",Kineret,etanercept,effect,"In_bf study_bf patients_bf active_bf RA_bf treated_bf 24_bf weeks_bf concurrent_bf DRUG OTHER_DRUG therapy_af ,_af 7%_af rate_af serious_af infections_af observed_af ,_af higher_af observed_af OTHER_DRUG alone_af (0%)_af ._af"
2962,Two percent of patients treated concurrently with Kineret and etanercept developed neutropenia (ANC  1 x 109/L).,Kineret,etanercept,effect,Two_bf percent_bf patients_bf treated_bf concurrently_bf DRUG OTHER_DRUG developed_af neutropenia_af (ANC_af 1_af x_af 109/L)_af ._af
2988,"5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .",apomorphine,ondansetron,effect,"5HT3_bf Antagonists:_bf Based_bf reports_bf profound_bf hypotension_bf loss_bf consciousness_bf DRUG administered_be OTHER_DRUG ,_af concomitant_af use_af DRUG drugs_af 5HT3_af antagonist_af class_af (including_af ,_af example_af ,_af OTHER_DRUG ,_af granisetron_af ,_af dolasetron_af ,_af palonosetron_af ,_af alosetron)_af contraindicated_af ._af"
3029,"Antihypertensive Medications and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.",antihypertensive medications,vasodilators,effect,"Antihypertensive_bf Medications_bf Vasodilators:_bf The_bf following_bf adverse_bf events_bf experienced_bf commonly_bf patients_bf receiving_bf concomitant_bf antihypertensive_bf medications_bf OTHER_DRUG (n_be =_be 94)_be compared_be patients_be receiving_be concomitant_be drugs_be (n_be =_be 456):_be hypotension_be 10%_be vs_be 4%_be ,_be myocardial_be infarction_be 3%_be vs_be 1%_be ,_be serious_be pneumonia_be 5%_be vs_be 3%_be ,_be serious_be falls_be 9%_be vs_be 3%_be ,_be bone_be joint_be injuries_be 6%_be vs_be 2%_be ._be"
3058,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",dopamine antagonists,metoclopramide,effect,"Dopamine_bf Antagonists:_bf Since_bf apomorphine_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf OTHER_DRUG ,_be may_be diminish_be effectiveness_be APOKYN_be ._be"
3068,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",phenothiazines,APOKYN,effect,"Dopamine_bf Antagonists:_bf Since_bf apomorphine_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf OTHER_DRUG ._be"
3071,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",butyrophenones,APOKYN,effect,"Dopamine_bf Antagonists:_bf Since_bf apomorphine_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf DRUG ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be OTHER_DRUG ._af"
3073,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",thioxanthenes,APOKYN,effect,"Dopamine_bf Antagonists:_bf Since_bf apomorphine_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf OTHER_DRUG ._be"
3074,"Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.",metoclopramide,APOKYN,effect,"Dopamine_bf Antagonists:_bf Since_bf apomorphine_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf DRUG ,_be may_be diminish_be effectiveness_be OTHER_DRUG ._af"
3098,Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.,Tricyclic antidepressants,clonidine,effect,Tricyclic_bf antidepressants_bf reported_bf blunt_bf hypotensive_bf effect_bf systemic_bf OTHER_DRUG ._be
3099,An additive hypotensive effect has been reported with the combination of systemic clonidine and neuroleptic therapy.,clonidine,neuroleptic,effect,An_bf additive_bf hypotensive_bf effect_bf reported_bf combination_bf systemic_bf DRUG OTHER_DRUG therapy_af ._af
3207,"therefore, the efficacy of oral contraceptives during administration of Aprepitant may be reduced.",contraceptives,Aprepitant,effect,"therefore_bf ,_bf efficacy_bf oral_bf DRUG administration_be OTHER_DRUG may_af reduced_af ._af"
3361,"However, the concomitant use of Argatroban and warfarin (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).",Argatroban,warfarin,effect,"However_bf ,_bf concomitant_bf use_bf DRUG OTHER_DRUG (5-7_af ._af 5_af mg_af initial_af oral_af dose_af followed_af 2_af ._af 5-6_af mg/day_af orally_af 6-10_af days)_af results_af prolongation_af prothrombin_af time_af (PT)_af International_af Normalized_af Ratio_af (INR)_af ._af"
3365,"Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.",Argatroban,antiplatelet agents,effect,"Co-administration:_bf Concomitant_bf use_bf DRUG antiplatelet_be agents_be ,_be thrombolytics_be ,_be anticoagulants_be may_be increase_be risk_be bleeding_be ._be"
3366,"Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.",Argatroban,thrombolytics,effect,"Co-administration:_bf Concomitant_bf use_bf DRUG antiplatelet_be agents_be ,_be OTHER_DRUG ,_af anticoagulants_af may_af increase_af risk_af bleeding_af ._af"
3367,"Co-administration: Concomitant use of Argatroban with antiplatelet agents, thrombolytics, and other anticoagulants may increase the risk of bleeding.",Argatroban,anticoagulants,effect,"Co-administration:_bf Concomitant_bf use_bf DRUG antiplatelet_be agents_be ,_be thrombolytics_be ,_be OTHER_DRUG may_af increase_af risk_af bleeding_af ._af"
3380,"1- adrenergic receptor antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.",aripiprazole,antihypertensive agents,effect,"1-_bf adrenergic_bf receptor_bf antagonism_bf ,_bf DRUG potential_be enhance_be effect_be certain_be antihypertensive_be agents_be ._be"
3470,Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.,ELSPAR,methotrexate,effect,Tissue_bf culture_bf animal_bf studies_bf indicate_bf DRUG diminish_be abolish_be effect_be OTHER_DRUG malignant_af cells_af ._af 14_af This_af effect_af OTHER_DRUG activity_af persists_af long_af plasma_af asparagine_af levels_af suppressed_af ._af
3480,"Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.",Aspirin,probenecid,effect,"Uricosuric_bf Agents:_bf DRUG may_be decrease_be effects_be OTHER_DRUG ,_af sulfinpyrazone_af ,_af phenylbutazone_af ._af"
3481,"Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.",Aspirin,sulfinpyrazone,effect,"Uricosuric_bf Agents:_bf DRUG may_be decrease_be effects_be probenecid_be ,_be OTHER_DRUG ,_af phenylbutazone_af ._af"
3482,"Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.",Aspirin,phenylbutazone,effect,"Uricosuric_bf Agents:_bf DRUG may_be decrease_be effects_be probenecid_be ,_be sulfinpyrazone_be ,_be OTHER_DRUG ._af"
3486,Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.,Alcohol,aspirin,effect,Alcohol:_bf Has_bf synergistic_bf effect_bf OTHER_DRUG causing_be gastrointestinal_be bleeding_be ._be
3487,Corticosteroids: Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels.,Corticosteroids,aspirin,effect,Corticosteroids:_bf Concomitant_bf administration_bf OTHER_DRUG may_be increase_be risk_be gastrointestinal_be ulceration_be may_be reduce_be serum_be salicylate_be levels_be ._be
3491,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",Pyrazolone Derivatives,aspirin,effect,"Pyrazolone_bf Derivatives_bf (phenylbutazone_bf ,_bf oxyphenbutazone_bf ,_bf possibly_bf dipyrone):_bf Concomitant_bf administration_bf OTHER_DRUG may_be increase_be risk_be gastrointestinal_be ulceration_be ._be"
3494,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",phenylbutazone,aspirin,effect,"Pyrazolone_bf Derivatives_bf (phenylbutazone_bf ,_bf oxyphenbutazone_bf ,_bf possibly_bf dipyrone):_bf Concomitant_bf administration_bf OTHER_DRUG may_be increase_be risk_be gastrointestinal_be ulceration_be ._be"
3496,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",oxyphenbutazone,aspirin,effect,"Pyrazolone_bf Derivatives_bf (phenylbutazone_bf ,_bf DRUG ,_be possibly_be dipyrone):_be Concomitant_be administration_be OTHER_DRUG may_af increase_af risk_af gastrointestinal_af ulceration_af ._af"
3497,"Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.",dipyrone,aspirin,effect,"Pyrazolone_bf Derivatives_bf (phenylbutazone_bf ,_bf oxyphenbutazone_bf ,_bf possibly_bf dipyrone):_bf Concomitant_bf administration_bf OTHER_DRUG may_be increase_be risk_be gastrointestinal_be ulceration_be ._be"
3505,Phenytoin: Serum phenytoin levels may be increased by aspirin.,phenytoin,aspirin,effect,Phenytoin:_bf Serum_bf DRUG levels_be may_be increased_be OTHER_DRUG ._af
3506,Propranolol: May decrease aspirins anti-inflammatory action by competing for the same receptors.,Propranolol,aspirins,effect,Propranolol:_bf May_bf decrease_bf OTHER_DRUG anti-inflammatory_be action_be competing_be receptors_be ._be
3516,"Catecholamine-depleting drugs (eg, reserpine) may have an additive effect when given with beta-blocking agents.",reserpine,beta-blocking agent,effect,"Catecholamine-depleting_bf drugs_bf (eg_bf ,_bf reserpine)_bf may_bf additive_bf effect_bf given_bf beta-blocking_bf agents_bf ._bf"
3517,Calcium channel blockers may also have an additive effect when given with TENORMIN .,Calcium channel blockers,TENORMIN,effect,Calcium_bf channel_bf blockers_bf may_bf also_bf additive_bf effect_bf given_bf OTHER_DRUG ._be
3518,Beta blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine.,Beta blockers,clonidine,effect,Beta_bf blockers_bf may_bf exacerbate_bf rebound_bf hypertension_bf follow_bf withdrawal_bf OTHER_DRUG ._be
3526,"Concomitant use of prostaglandin synthase inhibiting drugs, eg, indomethacin, may decrease the hypotensive effects of beta blockers.",indomethacin,beta blockers,effect,"Concomitant_bf use_bf prostaglandin_bf synthase_bf inhibiting_bf drugs_bf ,_bf eg_bf ,_bf DRUG ,_be may_be decrease_be hypotensive_be effects_be beta_be blockers_be ._be"
3529,MAO inhibitors prolong and intensify the effects of antihistamines.,MAO inhibitors,antihistamines,effect,MAO_bf inhibitors_bf prolong_bf intensify_bf effects_bf OTHER_DRUG ._be
3530,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,alcohol,effect,"Concomitant_bf use_bf DRUG OTHER_DRUG ,_af tricyclic_af antidepressants_af ,_af barbiturates_af ,_af central_af nervous_af system_af depressants_af may_af additive_af effect_af ._af"
3531,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,tricyclic antidepressants,effect,"Concomitant_bf use_bf DRUG alcohol_be ,_be tricyclic_be antidepressants_be ,_be barbiturates_be ,_be central_be nervous_be system_be depressants_be may_be additive_be effect_be ._be"
3532,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,barbiturates,effect,"Concomitant_bf use_bf DRUG alcohol_be ,_be tricyclic_be antidepressants_be ,_be OTHER_DRUG ,_af central_af nervous_af system_af depressants_af may_af additive_af effect_af ._af"
3533,"Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.",antihistamines,central nervous system depressants,effect,"Concomitant_bf use_bf DRUG alcohol_be ,_be tricyclic_be antidepressants_be ,_be barbiturates_be ,_be central_be nervous_be system_be depressants_be may_be additive_be effect_be ._be"
3540,"When sympathomimetic drugs are given to patients receiving monoamine oxidase inhibitors, hypertensive reactions, including hypertensive crises, may occur.",sympathomimetic drugs,monoamine oxidase inhibitors,effect,"When_bf sympathomimetic_bf drugs_bf given_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf ,_bf hypertensive_bf reactions_bf ,_bf including_bf hypertensive_bf crises_bf ,_bf may_bf occur_bf ._bf"
3544,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",methyldopa,sympathomimetics,effect,"The_bf antihypertensive_bf effects_bf DRUG ,_be mecamylamine_be ,_be reserpine_be ,_be veratrum_be alkaloids_be may_be reduced_be OTHER_DRUG ._af"
3547,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",mecamylamine,sympathomimetics,effect,"The_bf antihypertensive_bf effects_bf methyldopa_bf ,_bf DRUG ,_be reserpine_be ,_be veratrum_be alkaloids_be may_be reduced_be OTHER_DRUG ._af"
3549,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",reserpine,sympathomimetics,effect,"The_bf antihypertensive_bf effects_bf methyldopa_bf ,_bf mecamylamine_bf ,_bf DRUG ,_be veratrum_be alkaloids_be may_be reduced_be OTHER_DRUG ._af"
3550,"The antihypertensive effects of methyldopa, mecamylamine, reserpine, and veratrum alkaloids may be reduced by sympathomimetics.",veratrum alkaloids,sympathomimetics,effect,"The_bf antihypertensive_bf effects_bf methyldopa_bf ,_bf mecamylamine_bf ,_bf reserpine_bf ,_bf veratrum_bf alkaloids_bf may_bf reduced_bf OTHER_DRUG ._be"
3552,Increased ectopic pacemaker activity can occur when pseudoephedrine is used concomitantly with digitalis.,pseudoephedrine,digitalis,effect,Increased_bf ectopic_bf pacemaker_bf activity_bf occur_bf DRUG used_be concomitantly_be OTHER_DRUG ._af
3564,Use with Angiotensln Converting Enzyme Inhibitors: The use of angiotensin converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.,angiotensin converting enzyme inhibitors,azathioprine,effect,Use_bf Angiotensln_bf Converting_bf Enzyme_bf Inhibitors:_bf The_bf use_bf angiotensin_bf converting_bf enzyme_bf inhibitors_bf control_bf hypertension_bf patients_bf OTHER_DRUG reported_be induce_be severe_be leukopenia_be ._be
3566,Co-administration of nelfinavir at steady-state with a single dose of azithromycin (2 x 600 mg tablets) results in increased azithromycin serum concentrations.,nelfinavir,azithromycin,effect,Co-administration_bf DRUG steady-state_be single_be dose_be OTHER_DRUG (2_af x_af 600_af mg_af tablets)_af results_af increased_af OTHER_DRUG serum_af concentrations_af ._af
3574,Concurrent use of macrolides and warfarin in clinical practice has been associated with increased anticoagulant effects.,macrolides,warfarin,effect,Concurrent_bf use_bf DRUG OTHER_DRUG clinical_af practice_af associated_af increased_af anticoagulant_af effects_af ._af
3720,Interactions attributed to the combined use of baclofen injection and epidural morphine include hypotension and dyspnea.,baclofen,morphine,effect,Interactions_bf attributed_bf combined_bf use_bf DRUG injection_be epidural_be OTHER_DRUG include_af hypotension_af dyspnea_af ._af
3776,"Diuretics: Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Lotensin.",diuretics,Lotensin,effect,"Diuretics:_bf Patients_bf DRUG ,_be especially_be diuretic_be therapy_be recently_be instituted_be ,_be may_be occasionally_be experience_be excessive_be reduction_be blood_be pressure_be initiation_be therapy_be OTHER_DRUG ._af"
3782,Potassium Supplements and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by thiazide diuretics.,Potassium-Sparing Diuretics,thiazide diuretics,effect,Potassium_bf Supplements_bf Potassium-Sparing_bf Diuretics_bf Lotensin_bf attenuate_bf potassium_bf loss_bf caused_bf thiazide_bf diuretics_bf ._bf
3809,"If a diuretic is also used, the risk of lithium toxicity may be increased.",diuretic,lithium,effect,"If_bf DRUG also_be used_be ,_be risk_be OTHER_DRUG toxicity_af may_af increased_af ._af"
3862,"Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system",Benazepril,beta-adrenergic blockers,effect,"DRUG ,_be like_be ACE_be inhibitors_be ,_be less_be additive_be effects_be beta-adrenergic_be blockers_be ,_be presumably_be drugs_be lower_be blood_be pressure_be inhibiting_be parts_be renin-angiotensin_be system_be"
3863,"Benazepril, like other ACE inhibitors, has had less than additive effects with beta-adrenergic blockers, presumably because both drugs lower blood pressure by inhibiting parts of the renin-angiotensin system",ACE inhibitors,beta-adrenergic blockers,effect,"Benazepril_bf ,_bf like_bf ACE_bf inhibitors_bf ,_bf less_bf additive_bf effects_bf beta-adrenergic_bf blockers_bf ,_bf presumably_bf drugs_bf lower_bf blood_bf pressure_bf inhibiting_bf parts_bf renin-angiotensin_bf system_bf"
3865,"May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;",cholestyramine,thiazide diuretics,effect,"May_bf interact_bf following:_bf DRUG ,_be colestipol_be (use_be thiazide_be diuretics_be may_be prevent_be diuretic_be working_be properly;_be"
3867,"May interact with the following: cholestyramine, colestipol (use with thiazide diuretics may prevent the diuretic from working properly;",colestipol,thiazide diuretics,effect,"May_bf interact_bf following:_bf cholestyramine_bf ,_bf DRUG (use_be thiazide_be diuretics_be may_be prevent_be diuretic_be working_be properly;_be"
3870,Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly within14 days following use of monoamine oxidase inhibitors.,sympathomimetic amines,monoamine oxidase inhibitors,effect,Hypertensive_bf crises_bf resulted_bf sympathomimetic_bf amines_bf used_bf concomitantly_bf within14_bf days_bf following_bf use_bf monoamine_bf oxidase_bf inhibitors_bf ._bf
3872,Amphetamines may decrease the hypotensive effect of antihypertensives.,Amphetamines,antihypertensives,effect,DRUG may_be decrease_be hypotensive_be effect_be OTHER_DRUG ._af
3873,Amphetamines may enhance the effects of tricyclic antidepressants.,Amphetamines,tricyclic antidepressants,effect,DRUG may_be enhance_be effects_be tricyclic_be antidepressants_be ._be
3947,Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.,Anti-arrhythmics,bepridil hydrochloride,effect,DRUG tricyclic_be anti-depressants_be could_be exaggerate_be prolongation_be QT_be interval_be observed_be bepridil_be hydrochloride_be ._be
3948,Anti-arrhythmics and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.,tricyclic anti-depressants,bepridil hydrochloride,effect,Anti-arrhythmics_bf tricyclic_bf anti-depressants_bf could_bf exaggerate_bf prolongation_bf QT_bf interval_bf observed_bf bepridil_bf hydrochloride_bf ._bf
3949,Cardiac glycosides could exaggerate the depression of AV nodal conduction observed with bepridil hydrochloride.,Cardiac glycosides,bepridil hydrochloride,effect,Cardiac_bf glycosides_bf could_bf exaggerate_bf depression_bf AV_bf nodal_bf conduction_bf observed_bf bepridil_bf hydrochloride_bf ._bf
3966,"Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.",reserpine,beta-blocking,effect,"Catecholamine-depleting_bf drugs_bf (e_bf ._bf g_bf ._bf ,_bf reserpine)_bf may_bf additive_bf effect_bf given_bf OTHER_DRUG agents_be ._be"
3974,"Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving beta-adrenergic blocking agents when an oral calcium antagonist was added to the treatment regimen.",beta-adrenergic blocking agents,calcium antagonist,effect,"Hypotension_bf ,_bf AV_bf conduction_bf disturbances_bf ,_bf left_bf ventricular_bf failure_bf reported_bf patients_bf receiving_bf beta-adrenergic_bf blocking_bf agents_bf oral_bf calcium_bf antagonist_bf added_bf treatment_bf regimen_bf ._bf"
3985,"Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to epinephrine in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.",beta-blockers,epinephrine,effect,"Risk_bf Anaphylactic_bf Reaction:_bf Although_bf known_bf patients_bf DRUG may_be refractory_be OTHER_DRUG treatment_af anaphylactic_af shock_af ,_af DRUG ,_af addition_af ,_af interfere_af modulation_af allergic_af reaction_af lead_af increased_af severity_af and/or_af frequency_af attacks_af ._af"
4038,When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.,Bezalip,anticoagulants of the coumarin type,effect,When_bf DRUG DRUG retard_af used_af time_af medicines_af substances_af following_af interactions_af must_af taken_af account:_af -_af DRUG DRUG retard_af may_af enhance_af action_af anticoagulants_af coumarin_af type_af ._af
4039,When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.,Bezalip retard,anticoagulants of the coumarin type,effect,When_bf Bezalip_bf Bezalip_bf retard_bf used_bf time_bf medicines_bf substances_bf following_bf interactions_bf must_bf taken_bf account:_bf -_bf Bezalip_bf Bezalip_bf retard_bf may_bf enhance_bf action_bf anticoagulants_bf coumarin_bf type_bf ._bf
4044,#NAME?,sulphonylureas,Bezalip,effect,-_bf The_bf action_bf DRUG insulin_be may_be enhanced_be OTHER_DRUG OTHER_DRUG retard_af ._af
4045,#NAME?,sulphonylureas,Bezalip retard,effect,-_bf The_bf action_bf DRUG insulin_be may_be enhanced_be Bezalip_be Bezalip_be retard_be ._be
4046,#NAME?,insulin,Bezalip,effect,-_bf The_bf action_bf sulphonylureas_bf DRUG may_be enhanced_be OTHER_DRUG OTHER_DRUG retard_af ._af
4047,#NAME?,insulin,Bezalip retard,effect,-_bf The_bf action_bf sulphonylureas_bf DRUG may_be enhanced_be Bezalip_be Bezalip_be retard_be ._be
4049,#NAME?,immuno-suppressant,bezafibrate,effect,"-_bf In_bf isolated_bf cases_bf ,_bf pronounced_bf though_bf reversible_bf ,_bf impairment_bf renal_bf function_bf (accompanied_bf corresponding_bf increase_bf serum_bf creatinine_bf level)_bf reported_bf organ_bf transplant_bf patients_bf receiving_bf DR"
4078,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,narcotic analgesics,effect,"Drug_bf Interactions:_bf The_bf central_bf DRUG syndrome_be occur_be DRUG agents_af AKINETON_af administered_af concomitantly_af drugs_af secondary_af DRUG actions_af ,_af ._af g_af ._af ,_af certain_af narcotic_af analgesics_af meperidine_af ,_af phenothiazines_af antipsychotics_af ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af quinidine_af salts_af ,_af antihistamines_af ._af"
4079,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,meperidine,effect,"Drug_bf Interactions:_bf The_bf central_bf DRUG syndrome_be occur_be DRUG agents_af AKINETON_af administered_af concomitantly_af drugs_af secondary_af DRUG actions_af ,_af ._af g_af ._af ,_af certain_af narcotic_af analgesics_af OTHER_DRUG ,_af phenothiazines_af antipsychotics_af ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af quinidine_af salts_af ,_af antihistamines_af ._af"
4080,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,phenothiazines,effect,"Drug_bf Interactions:_bf The_bf central_bf DRUG syndrome_be occur_be DRUG agents_af AKINETON_af administered_af concomitantly_af drugs_af secondary_af DRUG actions_af ,_af ._af g_af ._af ,_af certain_af narcotic_af analgesics_af meperidine_af ,_af OTHER_DRUG antipsychotics_af ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af quinidine_af salts_af ,_af antihistamines_af ._af"
4081,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,antipsychotics,effect,"Drug_bf Interactions:_bf The_bf central_bf DRUG syndrome_be occur_be DRUG agents_af AKINETON_af administered_af concomitantly_af drugs_af secondary_af DRUG actions_af ,_af ._af g_af ._af ,_af certain_af narcotic_af analgesics_af meperidine_af ,_af phenothiazines_af OTHER_DRUG ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af quinidine_af salts_af ,_af antihistamines_af ._af"
4082,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,tricyclic antidepressants,effect,"Drug_bf Interactions:_bf The_bf central_bf DRUG syndrome_be occur_be DRUG agents_af AKINETON_af administered_af concomitantly_af drugs_af secondary_af DRUG actions_af ,_af ._af g_af ._af ,_af certain_af narcotic_af analgesics_af meperidine_af ,_af phenothiazines_af antipsychotics_af ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af quinidine_af salts_af ,_af antihistamines_af ._af"
4083,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,antiarrhythmics,effect,"Drug_bf Interactions:_bf The_bf central_bf DRUG syndrome_be occur_be DRUG agents_af AKINETON_af administered_af concomitantly_af drugs_af secondary_af DRUG actions_af ,_af ._af g_af ._af ,_af certain_af narcotic_af analgesics_af meperidine_af ,_af phenothiazines_af antipsychotics_af ,_af tricyclic_af antidepressants_af ,_af certain_af OTHER_DRUG quinidine_af salts_af ,_af antihistamines_af ._af"
4084,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,quinidine,effect,"Drug_bf Interactions:_bf The_bf central_bf DRUG syndrome_be occur_be DRUG agents_af AKINETON_af administered_af concomitantly_af drugs_af secondary_af DRUG actions_af ,_af ._af g_af ._af ,_af certain_af narcotic_af analgesics_af meperidine_af ,_af phenothiazines_af antipsychotics_af ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af OTHER_DRUG salts_af ,_af antihistamines_af ._af"
4085,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",anticholinergic,antihistamines,effect,"Drug_bf Interactions:_bf The_bf central_bf DRUG syndrome_be occur_be DRUG agents_af AKINETON_af administered_af concomitantly_af drugs_af secondary_af DRUG actions_af ,_af ._af g_af ._af ,_af certain_af narcotic_af analgesics_af meperidine_af ,_af phenothiazines_af antipsychotics_af ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af quinidine_af salts_af ,_af OTHER_DRUG ._af"
4086,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,narcotic analgesics,effect,"Drug_bf Interactions:_bf The_bf central_bf anticholinergic_bf syndrome_bf occur_bf anticholinergic_bf agents_bf DRUG administered_be concomitantly_be drugs_be secondary_be anticholinergic_be actions_be ,_be ._be g_be ._be ,_be certain_be narcotic_be analgesics_be meperidine_be ,_be phenothiazines_be antipsychotics_be ,_be tricyclic_be antidepressants_be ,_be certain_be antiarrhythmics_be quinidine_be salts_be ,_be antihistamines_be ._be"
4087,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,meperidine,effect,"Drug_bf Interactions:_bf The_bf central_bf anticholinergic_bf syndrome_bf occur_bf anticholinergic_bf agents_bf DRUG administered_be concomitantly_be drugs_be secondary_be anticholinergic_be actions_be ,_be ._be g_be ._be ,_be certain_be narcotic_be analgesics_be OTHER_DRUG ,_af phenothiazines_af antipsychotics_af ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af quinidine_af salts_af ,_af antihistamines_af ._af"
4088,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,phenothiazines,effect,"Drug_bf Interactions:_bf The_bf central_bf anticholinergic_bf syndrome_bf occur_bf anticholinergic_bf agents_bf DRUG administered_be concomitantly_be drugs_be secondary_be anticholinergic_be actions_be ,_be ._be g_be ._be ,_be certain_be narcotic_be analgesics_be meperidine_be ,_be OTHER_DRUG antipsychotics_af ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af quinidine_af salts_af ,_af antihistamines_af ._af"
4089,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,antipsychotics,effect,"Drug_bf Interactions:_bf The_bf central_bf anticholinergic_bf syndrome_bf occur_bf anticholinergic_bf agents_bf DRUG administered_be concomitantly_be drugs_be secondary_be anticholinergic_be actions_be ,_be ._be g_be ._be ,_be certain_be narcotic_be analgesics_be meperidine_be ,_be phenothiazines_be OTHER_DRUG ,_af tricyclic_af antidepressants_af ,_af certain_af antiarrhythmics_af quinidine_af salts_af ,_af antihistamines_af ._af"
4090,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,tricyclic antidepressants,effect,"Drug_bf Interactions:_bf The_bf central_bf anticholinergic_bf syndrome_bf occur_bf anticholinergic_bf agents_bf DRUG administered_be concomitantly_be drugs_be secondary_be anticholinergic_be actions_be ,_be ._be g_be ._be ,_be certain_be narcotic_be analgesics_be meperidine_be ,_be phenothiazines_be antipsychotics_be ,_be tricyclic_be antidepressants_be ,_be certain_be antiarrhythmics_be quinidine_be salts_be ,_be antihistamines_be ._be"
4091,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,antiarrhythmics,effect,"Drug_bf Interactions:_bf The_bf central_bf anticholinergic_bf syndrome_bf occur_bf anticholinergic_bf agents_bf DRUG administered_be concomitantly_be drugs_be secondary_be anticholinergic_be actions_be ,_be ._be g_be ._be ,_be certain_be narcotic_be analgesics_be meperidine_be ,_be phenothiazines_be antipsychotics_be ,_be tricyclic_be antidepressants_be ,_be certain_be OTHER_DRUG quinidine_af salts_af ,_af antihistamines_af ._af"
4092,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,quinidine,effect,"Drug_bf Interactions:_bf The_bf central_bf anticholinergic_bf syndrome_bf occur_bf anticholinergic_bf agents_bf DRUG administered_be concomitantly_be drugs_be secondary_be anticholinergic_be actions_be ,_be ._be g_be ._be ,_be certain_be narcotic_be analgesics_be meperidine_be ,_be phenothiazines_be antipsychotics_be ,_be tricyclic_be antidepressants_be ,_be certain_be antiarrhythmics_be OTHER_DRUG salts_af ,_af antihistamines_af ._af"
4093,"Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.",AKINETON,antihistamines,effect,"Drug_bf Interactions:_bf The_bf central_bf anticholinergic_bf syndrome_bf occur_bf anticholinergic_bf agents_bf DRUG administered_be concomitantly_be drugs_be secondary_be anticholinergic_be actions_be ,_be ._be g_be ._be ,_be certain_be narcotic_be analgesics_be meperidine_be ,_be phenothiazines_be antipsychotics_be ,_be tricyclic_be antidepressants_be ,_be certain_be antiarrhythmics_be quinidine_be salts_be ,_be OTHER_DRUG ._af"
4161,"Therefore, hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when TRACLEER is co-administered.",hormonal contraceptives,TRACLEER,effect,"Therefore_bf ,_bf hormonal_bf contraceptives_bf ,_bf including_bf oral_bf ,_bf injectable_bf ,_bf transdermal_bf ,_bf implantable_bf forms_bf ,_bf may_bf reliable_bf OTHER_DRUG co-administered_be ._be"
4251,Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.,botulinum toxin,botulinum toxin,effect,Excessive_bf neuromuscular_bf weakness_bf may_bf exacerbated_bf administration_bf another_bf botulinum_bf toxin_bf prior_bf resolution_bf effects_bf previously_bf administered_bf botulinum_bf toxin_bf ._bf
4258,Digitalis toxicity may be aggravated by the initial release of norepinephrine caused by Bretylium Tosylate Injection.,Digitalis,Bretylium Tosylate,effect,DRUG toxicity_be may_be aggravated_be initial_be release_be norepinephrine_be caused_be Bretylium_be Tosylate_be Injection_be ._be
4261,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.,catecholamines,Bretylium Tosylate,effect,The_bf pressor_bf effects_bf DRUG dopamine_be norepinephrine_be enhanced_be Bretylium_be Tosylate_be ._be
4263,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.,dopamine,Bretylium Tosylate,effect,The_bf pressor_bf effects_bf catecholamines_bf DRUG norepinephrine_be enhanced_be Bretylium_be Tosylate_be ._be
4264,The pressor effects of catecholamines such as dopamine or norepinephrine are enhanced by Bretylium Tosylate.,norepinephrine,Bretylium Tosylate,effect,The_bf pressor_bf effects_bf catecholamines_bf dopamine_bf DRUG enhanced_be Bretylium_be Tosylate_be ._be
4290,Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.,Tricyclic antidepressants,clonidine,effect,Tricyclic_bf antidepressants_bf reported_bf blunt_bf hypotensive_bf effect_bf systemic_bf OTHER_DRUG ._be It_be known_be whether_be concurrent_be use_be agents_be ALPHAGAN_be P_be humans_be lead_be resulting_be interference_be IOP_be lowering_be effect_be ._be
4300,"The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of bromocriptine mesylate.",alcohol,bromocriptine mesylate,effect,"The_bf risk_bf using_bf bromocriptine_bf mesylate_bf combination_bf drugs_bf systematically_bf evaluated_bf ,_bf DRUG may_be potentiate_be side_be effects_be bromocriptine_be mesylate_be ._be"
4304,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,phenothiazines,effect,"Compounds_bf categories_bf result_bf decreased_bf efficacy_bf bromocriptine_bf mesylate:_bf OTHER_DRUG ,_be haloperidol_be ,_be metoclopramide_be ,_be pimozide_be ._be"
4305,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,haloperidol,effect,"Compounds_bf categories_bf result_bf decreased_bf efficacy_bf bromocriptine_bf mesylate:_bf phenothiazines_bf ,_bf OTHER_DRUG ,_be metoclopramide_be ,_be pimozide_be ._be"
4306,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,metoclopramide,effect,"Compounds_bf categories_bf result_bf decreased_bf efficacy_bf bromocriptine_bf mesylate:_bf phenothiazines_bf ,_bf haloperidol_bf ,_bf OTHER_DRUG ,_be pimozide_be ._be"
4307,"Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, metoclopramide, pimozide.",bromocriptine mesylate,pimozide,effect,"Compounds_bf categories_bf result_bf decreased_bf efficacy_bf bromocriptine_bf mesylate:_bf phenothiazines_bf ,_bf haloperidol_bf ,_bf metoclopramide_bf ,_bf OTHER_DRUG ._be"
4315,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,alcohol,effect,"DRUG interact_be OTHER_DRUG CNS_af depressants_af (may_af potentiate_af CNS_af depressant_af effects_af either_af medications_af antihistamines)_af ,_af anticholinergics_af medications_af anticholinergic_af activity_af (anticholinergic_af effects_af may_af potentiated_af medications_af used_af concurrently_af antihistamines)_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af (concurrent_af use_af antihistamines_af may_af prolong_af intensify_af anticholinergic_af CNS_af depressant_af effects_af antihistamines)_af ._af"
4316,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,CNS depressants,effect,"DRUG interact_be alcohol_be CNS_be depressants_be (may_be potentiate_be CNS_be depressant_be effects_be either_be medications_be antihistamines)_be ,_be anticholinergics_be medications_be anticholinergic_be activity_be (anticholinergic_be effects_be may_be potentiated_be medications_be used_be concurrently_be antihistamines)_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be (concurrent_be use_be antihistamines_be may_be prolong_be intensify_be anticholinergic_be CNS_be depressant_be effects_be antihistamines)_be ._be"
4318,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,anticholinergics,effect,"DRUG interact_be alcohol_be CNS_be depressants_be (may_be potentiate_be CNS_be depressant_be effects_be either_be medications_be antihistamines)_be ,_be OTHER_DRUG medications_af anticholinergic_af activity_af (anticholinergic_af effects_af may_af potentiated_af medications_af used_af concurrently_af antihistamines)_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af (concurrent_af use_af antihistamines_af may_af prolong_af intensify_af anticholinergic_af CNS_af depressant_af effects_af antihistamines)_af ._af"
4320,"Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).",Dexbrompheniramine,monoamine oxidase (MAO) inhibitors,effect,"DRUG interact_be alcohol_be CNS_be depressants_be (may_be potentiate_be CNS_be depressant_be effects_be either_be medications_be antihistamines)_be ,_be anticholinergics_be medications_be anticholinergic_be activity_be (anticholinergic_be effects_be may_be potentiated_be medications_be used_be concurrently_be antihistamines)_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be (concurrent_be use_be antihistamines_be may_be prolong_be intensify_be anticholinergic_be CNS_be depressant_be effects_be antihistamines)_be ._be"
4414,#NAME?,probenecid,bumetanide,effect,-_bf Probenecid:_bf Pretreatment_bf DRUG reduces_be natriuresis_be hyperreninemia_be produced_be OTHER_DRUG ._af
4423,#NAME?,Indomethacin,bumetanide,effect,-_bf Indomethacin:_bf DRUG blunts_be increases_be urine_be volume_be sodium_be excretion_be seen_be OTHER_DRUG treatment_af inhibits_af bumetanide-induced_af increase_af plasma_af renin_af activity_af ._af
4427,#NAME?,Bumetanide,antihypertensive drugs,effect,"-_bf Antihypertensives:_bf DRUG may_be potentiate_be effect_be various_be antihypertensive_be drugs_be ,_be necessitating_be reduction_be dosage_be drugs_be ._be"
4437,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",epinephrine,monoamine oxidase inhibitors,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf DRUG norepinephrine_be patients_be receiving_be monoamine_be oxidase_be inhibitors_be tricyclic_be antidepressants_be may_be produce_be severe_be ,_be prolonged_be hypertension_be ._be"
4438,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",epinephrine,tricyclic antidepressants,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf DRUG norepinephrine_be patients_be receiving_be monoamine_be oxidase_be inhibitors_be tricyclic_be antidepressants_be may_be produce_be severe_be ,_be prolonged_be hypertension_be ._be"
4439,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",norepinephrine,monoamine oxidase inhibitors,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf epinephrine_bf DRUG patients_be receiving_be monoamine_be oxidase_be inhibitors_be tricyclic_be antidepressants_be may_be produce_be severe_be ,_be prolonged_be hypertension_be ._be"
4440,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.",norepinephrine,tricyclic antidepressants,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf epinephrine_bf DRUG patients_be receiving_be monoamine_be oxidase_be inhibitors_be tricyclic_be antidepressants_be may_be produce_be severe_be ,_be prolonged_be hypertension_be ._be"
4444,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.,Phenothiazines,epinephrine,effect,DRUG butyrophenones_be may_be reduce_be reverse_be pressor_be effect_be OTHER_DRUG ._af
4445,Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.,butyrophenones,epinephrine,effect,Phenothiazines_bf DRUG may_be reduce_be reverse_be pressor_be effect_be OTHER_DRUG ._af
4485,There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of buprenorphine and benzodiazepines by addicts.,buprenorphine,benzodiazepines,effect,There_bf number_bf reports_bf post-marketing_bf experience_bf coma_bf death_bf associated_bf concomitant_bf intravenous_bf misuse_bf DRUG OTHER_DRUG addicts_af ._af
4666,MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine .,bupropion,phenelzine,effect,MAO_bf Inhibitors:_bf Studies_bf animals_bf demonstrate_bf acute_bf toxicity_bf DRUG enhanced_be MAO_be inhibitor_be OTHER_DRUG ._af
4675,Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.,bupropion,levodopa,effect,OTHER_DRUG Amantadine:_be Limited_be clinical_be data_be suggest_be higher_be incidence_be adverse_be experiences_be patients_be receiving_be DRUG concurrently_af either_af OTHER_DRUG amantadine_af ._af
4676,Levodopa and Amantadine: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving bupropion concurrently with either levodopa or amantadine.,bupropion,amantadine,effect,Levodopa_bf Amantadine:_bf Limited_bf clinical_bf data_bf suggest_bf higher_bf incidence_bf adverse_bf experiences_bf patients_bf receiving_bf DRUG concurrently_be either_be levodopa_be OTHER_DRUG ._af
4696,"Alcohol: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN.",alcohol,WELLBUTRIN,effect,"Alcohol:_bf In_bf post-marketing_bf experience_bf ,_bf rare_bf reports_bf adverse_bf neuropsychiatric_bf events_bf reduced_bf DRUG tolerance_be patients_be drinking_be DRUG treatment_af OTHER_DRUG ._af"
4709,There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.,trazodone hydrochloride,buspirone HCl,effect,There_bf one_bf report_bf suggesting_bf concomitant_bf use_bf trazodone_bf hydrochloride_bf (Desyrel)_bf buspirone_bf HCl_bf may_bf caused_bf 3-_bf 6-fold_bf elevations_bf SGPT_bf (ALT)_bf patients_bf ._bf
4710,There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.,Desyrel,buspirone HCl,effect,There_bf one_bf report_bf suggesting_bf concomitant_bf use_bf trazodone_bf hydrochloride_bf (Desyrel)_bf buspirone_bf HCl_bf may_bf caused_bf 3-_bf 6-fold_bf elevations_bf SGPT_bf (ALT)_bf patients_bf ._bf
4720,"However, there has been one report of prolonged prothrombin time when buspirone was added to the regimen of a patient treated with warfarin.",buspirone,warfarin,effect,"However_bf ,_bf one_bf report_bf prolonged_bf prothrombin_bf time_bf DRUG added_be regimen_be patient_be treated_be OTHER_DRUG ._af"
4857,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).",barbiturates,contraceptives,effect,"Interactions_bf may_bf occur_bf following:_bf adrenocorticoids_bf (cortisone-like_bf medicine)_bf ,_bf anticoagulants_bf (blood_bf thinners)_bf ,_bf carbamazepine_bf ,_bf corticotropin_bf (barbiturates_bf may_bf decrease_bf effects_bf medicines)_bf ,_bf central_bf nervous_bf system_bf (CNS)_bf depressants_bf (using_bf medicines_bf DRUG may_be result_be increased_be CNS_be depressant_be effects)_be ,_be divalproex_be sodium_be ,_be valproic_be acid_be (using_be medicines_be DRUG may_af change_af amount_af either_af medicine_af need_af take)_af ,_af oral_af OTHER_DRUG containing_af estrogens_af (barbiturates_af may_af decrease_af effectiveness_af oral_af OTHER_DRUG ,_af may_af need_af change_af different_af type_af birth_af control)_af ._af"
4858,The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.,butalbital,monoamine oxidase (MAO) inhibitors,effect,The_bf CNS_bf effects_bf DRUG may_be enhanced_be monoamine_be oxidase_be (MAO)_be inhibitors_be ._be
4861,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,narcotic analgesic,effect,"DRUG ,_be acetaminophen_be caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be chlordiazepoxide_be ,_be sedative-hypnotics_be ,_be CNS_be depressants_be ,_be causing_be increased_be CNS_be depression_be ._be"
4862,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,alcohol,effect,"DRUG ,_be acetaminophen_be caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be OTHER_DRUG ,_af general_af anesthetics_af ,_af tranquilizers_af chlordiazepoxide_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
4863,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,anesthetics,effect,"DRUG ,_be acetaminophen_be caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be OTHER_DRUG ,_af tranquilizers_af chlordiazepoxide_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
4864,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,tranquilizers,effect,"DRUG ,_be acetaminophen_be caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be OTHER_DRUG chlordiazepoxide_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
4865,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,chlordiazepoxide,effect,"DRUG ,_be acetaminophen_be caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be OTHER_DRUG ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
4866,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,sedative-hypnotics,effect,"DRUG ,_be acetaminophen_be caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be chlordiazepoxide_be ,_be OTHER_DRUG ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
4867,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",Butalbital,CNS depressants,effect,"DRUG ,_be acetaminophen_be caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be chlordiazepoxide_be ,_be sedative-hypnotics_be ,_be CNS_be depressants_be ,_be causing_be increased_be CNS_be depression_be ._be"
4869,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,narcotic analgesic,effect,"Butalbital_bf ,_bf DRUG caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be chlordiazepoxide_be ,_be sedative-hypnotics_be ,_be CNS_be depressants_be ,_be causing_be increased_be CNS_be depression_be ._be"
4870,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,alcohol,effect,"Butalbital_bf ,_bf DRUG caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be OTHER_DRUG ,_af general_af anesthetics_af ,_af tranquilizers_af chlordiazepoxide_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
4871,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,anesthetics,effect,"Butalbital_bf ,_bf DRUG caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be OTHER_DRUG ,_af tranquilizers_af chlordiazepoxide_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
4872,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,tranquilizers,effect,"Butalbital_bf ,_bf DRUG caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be OTHER_DRUG chlordiazepoxide_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
4873,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,chlordiazepoxide,effect,"Butalbital_bf ,_bf DRUG caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be OTHER_DRUG ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
4874,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,sedative-hypnotics,effect,"Butalbital_bf ,_bf DRUG caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be chlordiazepoxide_be ,_be OTHER_DRUG ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
4875,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",acetaminophen,CNS depressants,effect,"Butalbital_bf ,_bf DRUG caffeine_be may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be chlordiazepoxide_be ,_be sedative-hypnotics_be ,_be CNS_be depressants_be ,_be causing_be increased_be CNS_be depression_be ._be"
4876,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,narcotic analgesic,effect,"Butalbital_bf ,_bf acetaminophen_bf DRUG may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be chlordiazepoxide_be ,_be sedative-hypnotics_be ,_be CNS_be depressants_be ,_be causing_be increased_be CNS_be depression_be ._be"
4877,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,alcohol,effect,"Butalbital_bf ,_bf acetaminophen_bf DRUG may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be OTHER_DRUG ,_af general_af anesthetics_af ,_af tranquilizers_af chlordiazepoxide_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
4878,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,anesthetics,effect,"Butalbital_bf ,_bf acetaminophen_bf DRUG may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be OTHER_DRUG ,_af tranquilizers_af chlordiazepoxide_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
4879,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,tranquilizers,effect,"Butalbital_bf ,_bf acetaminophen_bf DRUG may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be OTHER_DRUG chlordiazepoxide_af ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
4880,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,chlordiazepoxide,effect,"Butalbital_bf ,_bf acetaminophen_bf DRUG may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be OTHER_DRUG ,_af sedative-hypnotics_af ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
4881,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,sedative-hypnotics,effect,"Butalbital_bf ,_bf acetaminophen_bf DRUG may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be chlordiazepoxide_be ,_be OTHER_DRUG ,_af CNS_af depressants_af ,_af causing_af increased_af CNS_af depression_af ._af"
4882,"Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.",caffeine,CNS depressants,effect,"Butalbital_bf ,_bf acetaminophen_bf DRUG may_be enhance_be effects_be of:_be narcotic_be analgesics_be ,_be alcohol_be ,_be general_be anesthetics_be ,_be tranquilizers_be chlordiazepoxide_be ,_be sedative-hypnotics_be ,_be CNS_be depressants_be ,_be causing_be increased_be CNS_be depression_be ._be"
4905,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,central nervous system depressants,effect,"Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (e_be ._be g_be ._be ,_be alcohol_be ,_be barbiturates_be ,_be tranquilizers_be ,_be antihistamines)_be may_be result_be increased_be central_be nervous_be system_be depressant_be effects_be ._be"
4906,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,alcohol,effect,"Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af barbiturates_af ,_af tranquilizers_af ,_af antihistamines)_af may_af result_af increased_af central_af nervous_af system_af depressant_af effects_af ._af"
4907,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,barbiturates,effect,"Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (e_be ._be g_be ._be ,_be alcohol_be ,_be OTHER_DRUG ,_af tranquilizers_af ,_af antihistamines)_af may_af result_af increased_af central_af nervous_af system_af depressant_af effects_af ._af"
4908,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,tranquilizers,effect,"Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (e_be ._be g_be ._be ,_be alcohol_be ,_be barbiturates_be ,_be OTHER_DRUG ,_af antihistamines)_af may_af result_af increased_af central_af nervous_af system_af depressant_af effects_af ._af"
4909,"Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.",butorphanol,antihistamines,effect,"Concurrent_bf use_bf DRUG central_be nervous_be system_be depressants_be (e_be ._be g_be ._be ,_be alcohol_be ,_be barbiturates_be ,_be tranquilizers_be ,_be antihistamines)_be may_be result_be increased_be central_be nervous_be system_be depressant_be effects_be ._be"
4937,"These results suggest that the analgesic effect of STADOL NS may be diminished when it is administered shortly after sumatriptan nasal spray, but by 30 minutes any such reduction in effect should be minimal.",STADOL NS,sumatriptan,effect,"These_bf results_bf suggest_bf analgesic_bf effect_bf STADOL_bf NS_bf may_bf diminished_bf administered_bf shortly_bf OTHER_DRUG nasal_be spray_be ,_be 30_be minutes_be reduction_be effect_be minimal_be ._be"
4951,"Therefore, a slower onset can be anticipated if STADOL NS is administered concomitantly with, or immediately following, a nasal vasoconstrictor.",STADOL NS,nasal vasoconstrictor,effect,"Therefore_bf ,_bf slower_bf onset_bf anticipated_bf STADOL_bf NS_bf administered_bf concomitantly_bf ,_bf immediately_bf following_bf ,_bf nasal_bf vasoconstrictor_bf ._bf"
4991,Caffeine administered concurrently with ketoprofen reduced the urine volume in 4 healthy volunteers.,Caffeine,ketoprofen,effect,DRUG administered_be concurrently_be OTHER_DRUG reduced_af urine_af volume_af 4_af healthy_af volunteers_af ._af
5038,Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.,thiazides,vitamin D,effect,Some_bf reports_bf shown_bf concomitant_bf administration_bf DRUG vitamin_be D_be causes_be hypercalcemia_be ._be
5104,Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.,thiazides,vitamin D,effect,Some_bf reports_bf shown_bf concomitant_bf administration_bf DRUG vitamin_be D_be causes_be hypercalcemia_be ._be
5190,Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.,capecitabine,coumarin-derivative anticoagulants,effect,Coumarin_bf Anticoagulants_bf Altered_bf coagulation_bf parameters_bf and/or_bf bleeding_bf reported_bf patients_bf taking_bf DRUG concomitantly_be coumarin-derivative_be anticoagulants_be warfarin_be phenprocoumon_be ._be
5192,Coumarin Anticoagulants Altered coagulation parameters and/or bleeding have been reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such as warfarin and phenprocoumon.,capecitabine,phenprocoumon,effect,Coumarin_bf Anticoagulants_bf Altered_bf coagulation_bf parameters_bf and/or_bf bleeding_bf reported_bf patients_bf taking_bf DRUG concomitantly_be coumarin-derivative_be anticoagulants_be warfarin_be OTHER_DRUG ._af
5200,"Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.",leucovorin,fluorouracil,effect,"Deaths_bf severe_bf enterocolitis_bf ,_bf diarrhea_bf ,_bf dehydration_bf reported_bf elderly_bf patients_bf receiving_bf weekly_bf DRUG OTHER_DRUG ._af"
6673,Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.,carbamazepine,lithium,effect,Pharmacological/Pharmacodynamic_bf Interactions_bf DRUG Concomitant_be administration_be DRUG OTHER_DRUG may_af increase_af risk_af neurotoxic_af side_af effects_af ._af
6679,"Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.",anti-malarial drugs,carbamazepine,effect,"Additionally_bf ,_bf anti-malarial_bf drugs_bf ,_bf chloroquine_bf mefloquine_bf ,_bf may_bf antagonize_bf activity_bf OTHER_DRUG ._be"
6681,"Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.",chloroquine,carbamazepine,effect,"Additionally_bf ,_bf anti-malarial_bf drugs_bf ,_bf DRUG mefloquine_be ,_be may_be antagonize_be activity_be OTHER_DRUG ._af"
6682,"Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.",mefloquine,carbamazepine,effect,"Additionally_bf ,_bf anti-malarial_bf drugs_bf ,_bf chloroquine_bf DRUG ,_be may_be antagonize_be activity_be OTHER_DRUG ._af"
6690,"Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.",Iodine,Carbimazole,effect,"DRUG DRUG excess_af may_af decrease_af effect_af OTHER_DRUG ,_af DRUG deficiency_af increase_af effect_af OTHER_DRUG ._af"
6698,"Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.",iodine,Carbimazole,effect,"DRUG DRUG excess_af may_af decrease_af effect_af OTHER_DRUG ,_af DRUG deficiency_af increase_af effect_af OTHER_DRUG ._af"
6702,"Antithyroid agents may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole.",Antithyroid agents,sodium iodide I131,effect,"Antithyroid_bf agents_bf may_bf decrease_bf thyroidal_bf uptake_bf sodium_bf iodide_bf I131_bf ,_bf rebound_bf uptake_bf may_bf occur_bf 5_bf days_bf sudden_bf withdrawal_bf Carbimazole_bf ._bf"
6705,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,tricyclic antidepressants,effect,"DRUG may_be enhance_be effects_be tricyclic_be antidepressants_be ,_be barbiturates_be ,_be alcohol_be ,_be CNS_be depressants_be ._be"
6706,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,barbiturates,effect,"DRUG may_be enhance_be effects_be tricyclic_be antidepressants_be ,_be OTHER_DRUG ,_af alcohol_af ,_af CNS_af depressants_af ._af"
6707,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,alcohol,effect,"DRUG may_be enhance_be effects_be tricyclic_be antidepressants_be ,_be barbiturates_be ,_be OTHER_DRUG ,_af CNS_af depressants_af ._af"
6708,"Antihistamines may enhance the effects of tricyclic antidepressants, barbiturates, alcohol, and other CNS depressants.",Antihistamines,CNS depressants,effect,"DRUG may_be enhance_be effects_be tricyclic_be antidepressants_be ,_be barbiturates_be ,_be alcohol_be ,_be CNS_be depressants_be ._be"
6715,MAO inhibitors prolong and intensify the anticholinergic effects of antihistamines.,MAO inhibitors,antihistamines,effect,MAO_bf inhibitors_bf prolong_bf intensify_bf anticholinergic_bf effects_bf OTHER_DRUG ._be
6716,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,reserpine,effect,"Sympathomimetic_bf amines_bf may_bf reduce_bf antihypertensive_bf effects_bf OTHER_DRUG ,_be veratrum_be alkaloids_be ,_be methyldopa_be mecamylamine_be ._be"
6717,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,veratrum alkaloids,effect,"Sympathomimetic_bf amines_bf may_bf reduce_bf antihypertensive_bf effects_bf reserpine_bf ,_bf veratrum_bf alkaloids_bf ,_bf methyldopa_bf mecamylamine_bf ._bf"
6718,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,methyldopa,effect,"Sympathomimetic_bf amines_bf may_bf reduce_bf antihypertensive_bf effects_bf reserpine_bf ,_bf veratrum_bf alkaloids_bf ,_bf OTHER_DRUG mecamylamine_be ._be"
6719,"Sympathomimetic amines may reduce the antihypertensive effects of reserpine, veratrum alkaloids, methyldopa and mecamylamine.",Sympathomimetic amines,mecamylamine,effect,"Sympathomimetic_bf amines_bf may_bf reduce_bf antihypertensive_bf effects_bf reserpine_bf ,_bf veratrum_bf alkaloids_bf ,_bf methyldopa_bf OTHER_DRUG ._be"
6726,Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.,sympathomimetics,MAO inhibitors,effect,Effects_bf DRUG increased_be MAO_be inhibitors_be beta_be adrenergic_be blockers_be ._be
6727,Effects of sympathomimetics are increased with MAO inhibitors and beta adrenergic blockers.,sympathomimetics,beta adrenergic blockers,effect,Effects_bf DRUG increased_be MAO_be inhibitors_be beta_be adrenergic_be blockers_be ._be
6729,HEMABATE may augment the activity of other oxytocic agents.,HEMABATE,oxytocic agents,effect,DRUG may_be augment_be activity_be oxytocic_be agents_be ._be
6746,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",quinidine,carvedilol,effect,"poor_bf metabolizers_bf debrisoquin:_bf Interactions_bf OTHER_DRUG strong_be inhibitors_be CYP2D6_be (such_be DRUG ,_af fluoxetine_af ,_af paroxetine_af ,_af propafenone)_af studied_af ,_af drugs_af would_af expected_af increase_af blood_af levels_af R(+)_af enantiomer_af OTHER_DRUG ._af"
6749,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",fluoxetine,carvedilol,effect,"poor_bf metabolizers_bf debrisoquin:_bf Interactions_bf OTHER_DRUG strong_be inhibitors_be CYP2D6_be (such_be quinidine_be ,_be DRUG ,_af paroxetine_af ,_af propafenone)_af studied_af ,_af drugs_af would_af expected_af increase_af blood_af levels_af R(+)_af enantiomer_af OTHER_DRUG ._af"
6751,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",paroxetine,carvedilol,effect,"poor_bf metabolizers_bf debrisoquin:_bf Interactions_bf OTHER_DRUG strong_be inhibitors_be CYP2D6_be (such_be quinidine_be ,_be fluoxetine_be ,_be DRUG ,_af propafenone)_af studied_af ,_af drugs_af would_af expected_af increase_af blood_af levels_af R(+)_af enantiomer_af OTHER_DRUG ._af"
6752,"poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .",propafenone,carvedilol,effect,"poor_bf metabolizers_bf debrisoquin:_bf Interactions_bf OTHER_DRUG strong_be inhibitors_be CYP2D6_be (such_be quinidine_be ,_be fluoxetine_be ,_be paroxetine_be ,_be propafenone)_be studied_be ,_be drugs_be would_be expected_be increase_be blood_be levels_be R(+)_be enantiomer_be OTHER_DRUG ._af"
6753,"Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.",agents with b-blocking properties,reserpine,effect,"Catecholamine-depleting_bf Agents:_bf Patients_bf taking_bf agents_bf b-blocking_bf properties_bf drug_bf deplete_bf catecholamines_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG monoamine_be oxidase_be inhibitors)_be observed_be closely_be signs_be hypotension_be and/or_be severe_be bradycardia_be ._be"
6754,"Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., reserpine and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.",agents with b-blocking properties,monoamine oxidase inhibitors,effect,"Catecholamine-depleting_bf Agents:_bf Patients_bf taking_bf agents_bf b-blocking_bf properties_bf drug_bf deplete_bf catecholamines_bf (e_bf ._bf g_bf ._bf ,_bf reserpine_bf monoamine_bf oxidase_bf inhibitors)_bf observed_bf closely_bf signs_bf hypotension_bf and/or_bf severe_bf bradycardia_bf ._bf"
6758,Clonidine: Concomitant administration of clonidine with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.,clonidine,agents with b-blocking properties,effect,Clonidine:_bf Concomitant_bf administration_bf DRUG agents_be b-blocking_be properties_be may_be potentiate_be blood-pressure-_be heart-rate-lowering_be effects_be ._be
6775,Both digoxin and COREG slow AV conduction.,digoxin,COREG,effect,Both_bf DRUG OTHER_DRUG slow_af AV_af conduction_af ._af
6780,Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with diltiazem.,COREG,diltiazem,effect,Calcium_bf Channel_bf Blockers:_bf Isolated_bf cases_bf conduction_bf disturbance_bf (rarely_bf hemodynamic_bf compromise)_bf observed_bf DRUG co-administered_be OTHER_DRUG ._af
6798,Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.,Agents with b-blocking properties,insulin,effect,OTHER_DRUG Oral_be Hypoglycemics:_be Agents_be b-blocking_be properties_be may_be enhance_be blood-sugar-reducing_be effect_be OTHER_DRUG oral_af hypoglycemics_af ._af
6799,Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.,Agents with b-blocking properties,hypoglycemics,effect,Insulin_bf Oral_bf Hypoglycemics:_bf Agents_bf b-blocking_bf properties_bf may_bf enhance_bf blood-sugar-reducing_bf effect_bf insulin_bf oral_bf OTHER_DRUG ._be
6833,There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.,CANCIDAS,cyclosporine,effect,There_bf transient_bf increases_bf liver_bf ALT_bf AST_bf DRUG OTHER_DRUG co-administered_af ._af
6905,Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.,cephalosporins,diuretics,effect,Nephrotoxicity_bf reported_bf following_bf concomitant_bf administration_bf DRUG potent_be OTHER_DRUG furosemide_af ._af
6906,Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide.,cephalosporins,furosemide,effect,Nephrotoxicity_bf reported_bf following_bf concomitant_bf administration_bf DRUG potent_be diuretics_be OTHER_DRUG ._af
6912,"Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.",Warfarin,cefixime,effect,"DRUG Anticoagulants:_be Increased_be prothrombin_be time_be ,_be without_be clinical_be bleeding_be ,_be reported_be OTHER_DRUG administered_af concomitantly_af ._af"
6913,"Warfarin and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.",Anticoagulants,cefixime,effect,"Warfarin_bf Anticoagulants:_bf Increased_bf prothrombin_bf time_bf ,_bf without_bf clinical_bf bleeding_bf ,_bf reported_bf OTHER_DRUG administered_be concomitantly_be ._be"
6915,Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.,cephalosporins,aminoglycoside antibiotics,effect,Increased_bf nephrotoxicity_bf reported_bf following_bf concomitant_bf administration_bf DRUG aminoglycoside_be antibiotics_be ._be
6917,"If CEFOTAN and an aminoglycoside are used concomitantly, renal function should be carefully monitored, because nephrotoxicity may be potentiated.",CEFOTAN,aminoglycoside,effect,"If_bf DRUG OTHER_DRUG used_af concomitantly_af ,_af renal_af function_af carefully_af monitored_af ,_af nephrotoxicity_af may_af potentiated_af ._af"
6919,Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.,cephalosporins,aminoglycoside antibiotics,effect,Increased_bf nephrotoxicity_bf reported_bf following_bf concomitant_bf administration_bf DRUG aminoglycoside_be antibiotics_be ._be
6921,Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics.,aminoglycoside antibiotics,cephalosporin antibiotics,effect,Nephrotoxicity_bf reported_bf following_bf concomitant_bf administration_bf aminoglycoside_bf antibiotics_bf cephalosporin_bf antibiotics_bf ._bf
6924,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.,cephalosporins,aminoglycoside antibiotics,effect,Nephrotoxicity_bf reported_bf following_bf concomitant_bf administration_bf DRUG aminoglycoside_be antibiotics_be potent_be diuretics_be furosemide_be ._be
6925,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.,cephalosporins,diuretics,effect,Nephrotoxicity_bf reported_bf following_bf concomitant_bf administration_bf DRUG aminoglycoside_be antibiotics_be potent_be OTHER_DRUG furosemide_af ._af
6926,Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.,cephalosporins,furosemide,effect,Nephrotoxicity_bf reported_bf following_bf concomitant_bf administration_bf DRUG aminoglycoside_be antibiotics_be potent_be diuretics_be OTHER_DRUG ._af
6931,"Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.",Chloramphenicol,beta-lactam antibiotics,effect,"DRUG shown_be antagonistic_be beta-lactam_be antibiotics_be ,_be including_be ceftazidime_be ,_be based_be vitro_be studies_be time_be kill_be curves_be enteric_be gram-negative_be bacilli_be ._be"
6932,"Chloramphenicol has been shown to be antagonistic to beta-lactam antibiotics, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.",Chloramphenicol,ceftazidime,effect,"DRUG shown_be antagonistic_be beta-lactam_be antibiotics_be ,_be including_be OTHER_DRUG ,_af based_af vitro_af studies_af time_af kill_af curves_af enteric_af gram-negative_af bacilli_af ._af"
6947,"Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other cephalosporins and aminoglycosides.",cephalosporins,aminoglycosides,effect,"Although_bf occurrence_bf reported_bf Cefizox_bf ,_bf nephrotoxicity_bf reported_bf following_bf concomitant_bf administration_bf DRUG OTHER_DRUG ._af"
6980,ACE inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.,NSAIDs,Angiotensin Converting Enzyme (ACE) inhibitors,effect,ACE_bf inhibitors:_bf Reports_bf suggest_bf DRUG may_be diminish_be antihypertensive_be effect_be Angiotensin_be Converting_be Enzyme_be (ACE)_be inhibitors_be ._be
6985,"Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,furosemide,effect,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post_bf marketing_bf observations_bf ,_bf shown_bf DRUG reduce_be natriuretic_be effect_be OTHER_DRUG thiazides_af patients_af ._af"
6986,"Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients.",NSAIDs,thiazides,effect,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post_bf marketing_bf observations_bf ,_bf shown_bf DRUG reduce_be natriuretic_be effect_be furosemide_be OTHER_DRUG patients_af ._af"
6991,"However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.",aspirin,CELEBREX,effect,"However_bf ,_bf concomitant_bf administration_bf DRUG OTHER_DRUG may_af result_af increased_af rate_af GI_af ulceration_af complications_af ,_af compared_af use_af OTHER_DRUG alone_af ._af"
7159,"Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral anticoagulants and chlordiazepoxide.",anticoagulants,chlordiazepoxide,effect,"Although_bf clinical_bf studies_bf established_bf cause_bf effect_bf relationship_bf ,_bf physicians_bf aware_bf variable_bf effects_bf blood_bf coagulation_bf reported_bf rarely_bf patients_bf receiving_bf oral_bf DRUG OTHER_DRUG ._af"
7164,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",anesthetic solutions,tricyclic antidepressants,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf epinephrine_bf norepinephrine_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf ,_bf tricyclic_bf antidepressants_bf phenothiazines_bf may_bf produce_bf severe_bf ,_bf prolonged_bf hypotension_bf hypertension_bf ._bf"
7165,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",anesthetic solutions,phenothiazines,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf epinephrine_bf norepinephrine_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf ,_bf tricyclic_bf antidepressants_bf OTHER_DRUG may_be produce_be severe_be ,_be prolonged_be hypotension_be hypertension_be ._be"
7167,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",epinephrine,monoamine oxidase inhibitors,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf DRUG norepinephrine_be patients_be receiving_be monoamine_be oxidase_be inhibitors_be ,_be tricyclic_be antidepressants_be phenothiazines_be may_be produce_be severe_be ,_be prolonged_be hypotension_be hypertension_be ._be"
7168,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",epinephrine,tricyclic antidepressants,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf DRUG norepinephrine_be patients_be receiving_be monoamine_be oxidase_be inhibitors_be ,_be tricyclic_be antidepressants_be phenothiazines_be may_be produce_be severe_be ,_be prolonged_be hypotension_be hypertension_be ._be"
7169,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",epinephrine,phenothiazines,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf DRUG norepinephrine_be patients_be receiving_be monoamine_be oxidase_be inhibitors_be ,_be tricyclic_be antidepressants_be OTHER_DRUG may_af produce_af severe_af ,_af prolonged_af hypotension_af hypertension_af ._af"
7170,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",norepinephrine,monoamine oxidase inhibitors,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf epinephrine_bf DRUG patients_be receiving_be monoamine_be oxidase_be inhibitors_be ,_be tricyclic_be antidepressants_be phenothiazines_be may_be produce_be severe_be ,_be prolonged_be hypotension_be hypertension_be ._be"
7171,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",norepinephrine,tricyclic antidepressants,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf epinephrine_bf DRUG patients_be receiving_be monoamine_be oxidase_be inhibitors_be ,_be tricyclic_be antidepressants_be phenothiazines_be may_be produce_be severe_be ,_be prolonged_be hypotension_be hypertension_be ._be"
7172,"The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.",norepinephrine,phenothiazines,effect,"The_bf administration_bf local_bf anesthetic_bf solutions_bf containing_bf epinephrine_bf DRUG patients_be receiving_be monoamine_be oxidase_be inhibitors_be ,_be tricyclic_be antidepressants_be OTHER_DRUG may_af produce_af severe_af ,_af prolonged_af hypotension_af hypertension_af ._af"
7176,"Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.",vasopressor drugs,ergot-type oxytocic drugs,effect,"Concurrent_bf administration_bf vasopressor_bf drugs_bf (for_bf treatment_bf hypotension_bf related_bf obstetric_bf blocks)_bf ergot-type_bf oxytocic_bf drugs_bf may_bf cause_bf severe_bf ,_bf persistent_bf hypertension_bf cerebrovascular_bf accidents_bf ._bf"
7245,#NAME?,non-steroidal anti-inflammatory agent,loop diuretics,effect,#NAME?
7246,#NAME?,non-steroidal anti-inflammatory agent,potassium-sparing diuretics,effect,#NAME?
7247,#NAME?,non-steroidal anti-inflammatory agent,thiazide diuretics,effect,#NAME?
7443,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,antiparkinsonian drug,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
7444,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,trihexyphenidyl,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
7445,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,tricyclic antidepressant,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
7446,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antipsychotic drug,amitriptyline,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
7447,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,antiparkinsonian drug,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
7448,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,trihexyphenidyl,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
7449,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,tricyclic antidepressant,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
7450,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",chlorpromazine,amitriptyline,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
7452,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antiparkinsonian drug,tricyclic antidepressant,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
7453,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",antiparkinsonian drug,amitriptyline,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
7454,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",trihexyphenidyl,tricyclic antidepressant,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
7455,"The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.",trihexyphenidyl,amitriptyline,effect,"The_bf concurrent_bf use_bf two_bf drugs_bf anticholinergic_bf activity--such_bf antipsychotic_bf drug_bf (eg_bf ,_bf chlorpromazine)_bf ,_bf antiparkinsonian_bf drug_bf (eg_bf ,_bf trihexyphenidyl)_bf ,_bf and/or_bf tricyclic_bf antidepressant_bf (eg_bf ,_bf amitriptyline)--commonly_bf results_bf excessive_bf anticholinergic_bf effects_bf ,_bf including_bf dry_bf mouth_bf associated_bf dental_bf complications_bf ,_bf blurred_bf vision_bf ,_bf ,_bf patients_bf exposed_bf high_bf temperature_bf humidity_bf ,_bf hyperpyrexia_bf ._bf"
7573,"If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.",chlorprothixene,opioids,effect,"If_bf DRUG given_be concomitantly_be OTHER_DRUG ,_af opioid_af dose_af reduced_af (by_af approx_af ._af 50%)_af ,_af DRUG amplifies_af therapeutic_af actions_af side-effects_af OTHER_DRUG massively_af ._af"
7577,"Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.",chlorprothixene,benzodiazepines,effect,"Consider_bf additive_bf sedative_bf effects_bf confusional_bf states_bf emerge_bf ,_bf DRUG given_be OTHER_DRUG barbituates_af ._af"
7578,"Consider additive sedative effects and confusional states to emerge, if chlorprothixene is given with benzodiazepines or barbituates.",chlorprothixene,barbituates,effect,"Consider_bf additive_bf sedative_bf effects_bf confusional_bf states_bf emerge_bf ,_bf DRUG given_be benzodiazepines_be OTHER_DRUG ._af"
7632,Some reports have shown that the concomitant administration of thiazides with vitamin D causes hypercalcemia.,thiazides,vitamin D,effect,Some_bf reports_bf shown_bf concomitant_bf administration_bf DRUG vitamin_be D_be causes_be hypercalcemia_be ._be
7642,"Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.",vitamin D,corticosteroids,effect,"Corticosteroids:_bf A_bf relationship_bf functional_bf antagonism_bf exists_bf vitamin_bf D_bf analogues_bf ,_bf promote_bf calcium_bf absorption_bf ,_bf OTHER_DRUG ,_be inhibit_be calcium_be absorption_be ._be"
7649,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",Magnesium,vitamin D,effect,"Magnesium:_bf Magnesium-containing_bf preparations_bf (eg_bf ,_bf antacids)_bf may_bf cause_bf hypermagnesemia_bf therefore_bf taken_bf therapy_bf vitamin_bf D_bf patients_bf chronic_bf renal_bf dialysis_bf ._bf"
7650,"Magnesium: Magnesium-containing preparations (eg, antacids) may cause hypermagnesemia and should therefore not be taken during therapy with vitamin D by patients on chronic renal dialysis.",antacids,vitamin D,effect,"Magnesium:_bf Magnesium-containing_bf preparations_bf (eg_bf ,_bf antacids)_bf may_bf cause_bf hypermagnesemia_bf therefore_bf taken_bf therapy_bf vitamin_bf D_bf patients_bf chronic_bf renal_bf dialysis_bf ._bf"
8060,There have been reports of theophylline-related side-effects in patients on concomitant theophylline-quinolone therapy.,theophylline,quinolone,effect,There_bf reports_bf theophylline-related_bf side-effects_bf patients_bf concomitant_bf theophylline-quinolone_bf therapy_bf ._bf
8085,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",Quinolones,anticoagulants,effect,"DRUG ,_be including_be cinoxacin_be ,_be may_be enhance_be effects_be oral_be OTHER_DRUG ,_af warfarin_af derivatives_af ._af"
8086,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",Quinolones,warfarin,effect,"DRUG ,_be including_be cinoxacin_be ,_be may_be enhance_be effects_be oral_be anticoagulants_be ,_be OTHER_DRUG derivatives_af ._af"
8087,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",cinoxacin,anticoagulants,effect,"Quinolones_bf ,_bf including_bf DRUG ,_be may_be enhance_be effects_be oral_be OTHER_DRUG ,_af warfarin_af derivatives_af ._af"
8088,"Quinolones, including cinoxacin, may enhance the effects of oral anticoagulants, such as warfarin or its derivatives.",cinoxacin,warfarin,effect,"Quinolones_bf ,_bf including_bf DRUG ,_be may_be enhance_be effects_be oral_be anticoagulants_be ,_be OTHER_DRUG derivatives_af ._af"
8090,Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.,quinolone class antimicrobial,nonsteroidal anti-inflammatory drug,effect,Seizures_bf reported_bf patients_bf taking_bf another_bf quinolone_bf class_bf antimicrobial_bf nonsteroidal_bf anti-inflammatory_bf drug_bf fenbufen_bf concurrently_bf ._bf
8091,Seizures have been reported in patients taking another quinolone class antimicrobial and the nonsteroidal anti-inflammatory drug fenbufen concurrently.,quinolone class antimicrobial,fenbufen,effect,Seizures_bf reported_bf patients_bf taking_bf another_bf quinolone_bf class_bf antimicrobial_bf nonsteroidal_bf anti-inflammatory_bf drug_bf OTHER_DRUG concurrently_be ._be
8101,"Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.",quinolones,cyclosporine,effect,"Some_bf DRUG ,_be including_be ciprofloxacin_be ,_be associated_be transient_be elevations_be serum_be creatinine_be patients_be receiving_be OTHER_DRUG concomitantly_af ._af"
8102,"Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.",ciprofloxacin,cyclosporine,effect,"Some_bf quinolones_bf ,_bf including_bf DRUG ,_be associated_be transient_be elevations_be serum_be creatinine_be patients_be receiving_be OTHER_DRUG concomitantly_af ._af"
8106,"Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.",ciprofloxacin,sulfonylurea,effect,"Glyburide:_bf The_bf concomitant_bf administration_bf DRUG OTHER_DRUG glyburide_af ,_af rare_af occasions_af ,_af resulted_af severe_af hypoglycemia_af ._af"
8107,"Glyburide: The concomitant administration of ciprofloxacin with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.",ciprofloxacin,glyburide,effect,"Glyburide:_bf The_bf concomitant_bf administration_bf DRUG sulfonylurea_be OTHER_DRUG ,_af rare_af occasions_af ,_af resulted_af severe_af hypoglycemia_af ._af"
8212,Warfarin: Quinolones have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.,Quinolones,warfarin,effect,Warfarin:_bf DRUG reported_be enhance_be effects_be oral_be anticoagulant_be OTHER_DRUG derivatives_af ._af
8236,"Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.",anticholinergic compounds,cisapride,effect,"Anticholinergics:_bf Concurrent_bf administration_bf certain_bf anticholinergic_bf compounds_bf ,_bf belladonna_bf alkaloids_bf dicyclomine_bf ,_bf would_bf expected_bf compromise_bf beneficial_bf effects_bf OTHER_DRUG ._be"
8238,"Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.",belladonna alkaloids,cisapride,effect,"Anticholinergics:_bf Concurrent_bf administration_bf certain_bf anticholinergic_bf compounds_bf ,_bf belladonna_bf alkaloids_bf dicyclomine_bf ,_bf would_bf expected_bf compromise_bf beneficial_bf effects_bf OTHER_DRUG ._be"
8239,"Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.",dicyclomine,cisapride,effect,"Anticholinergics:_bf Concurrent_bf administration_bf certain_bf anticholinergic_bf compounds_bf ,_bf belladonna_bf alkaloids_bf DRUG ,_be would_be expected_be compromise_be beneficial_be effects_be OTHER_DRUG ._af"
8266,A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.,cisapride,ketoconazole,effect,A_bf study_bf 14_bf normal_bf male_bf female_bf volunteers_bf suggests_bf coadministration_bf DRUG OTHER_DRUG result_af prolongation_af QT_af interval_af ECG_af ._af
8310,Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced  95% neuromuscular block.,NIMBEX,succinylcholine,effect,Administration_bf 0_bf ._bf 1-mg/kg_bf (2_bf x_bf ED95)_bf DRUG 10%_be 95%_be recovery_be following_be intubating_be dose_be OTHER_DRUG (1_af mg/kg)_af produced_af 95%_af neuromuscular_af block_af ._af
8311,The time to onset of maximum block following NIMBEX is approximately 2 minutes faster with prior administration of succinylcholine.,NIMBEX,succinylcholine,effect,The_bf time_bf onset_bf maximum_bf block_bf following_bf DRUG approximately_be 2_be minutes_be faster_be prior_be administration_be OTHER_DRUG ._af
8316,Infusion requirements of NIMBEX in patients administered succinylcholine prior to infusions of NIMBEX were comparable to or slightly greater than when succinylcholine was not administered.,succinylcholine,NIMBEX,effect,Infusion_bf requirements_bf OTHER_DRUG patients_be administered_be DRUG prior_af infusions_af OTHER_DRUG comparable_af slightly_af greater_af DRUG administered_af ._af
8331,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,Isoflurane,NIMBEX,effect,DRUG enflurane_be administered_be nitrous_be oxide/oxygen_be achieve_be 1_be ._be 25_be MAC_be [Minimum_be Alveolar_be Concentration]_be may_be prolong_be clinically_be effective_be duration_be action_be initial_be maintenance_be doses_be OTHER_DRUG decrease_af required_af infusion_af rate_af OTHER_DRUG ._af
8332,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,Isoflurane,NIMBEX,effect,DRUG enflurane_be administered_be nitrous_be oxide/oxygen_be achieve_be 1_be ._be 25_be MAC_be [Minimum_be Alveolar_be Concentration]_be may_be prolong_be clinically_be effective_be duration_be action_be initial_be maintenance_be doses_be OTHER_DRUG decrease_af required_af infusion_af rate_af OTHER_DRUG ._af
8335,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,enflurane,NIMBEX,effect,Isoflurane_bf DRUG administered_be nitrous_be oxide/oxygen_be achieve_be 1_be ._be 25_be MAC_be [Minimum_be Alveolar_be Concentration]_be may_be prolong_be clinically_be effective_be duration_be action_be initial_be maintenance_be doses_be OTHER_DRUG decrease_af required_af infusion_af rate_af OTHER_DRUG ._af
8336,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,enflurane,NIMBEX,effect,Isoflurane_bf DRUG administered_be nitrous_be oxide/oxygen_be achieve_be 1_be ._be 25_be MAC_be [Minimum_be Alveolar_be Concentration]_be may_be prolong_be clinically_be effective_be duration_be action_be initial_be maintenance_be doses_be OTHER_DRUG decrease_af required_af infusion_af rate_af OTHER_DRUG ._af
8338,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,nitrous oxide,NIMBEX,effect,Isoflurane_bf enflurane_bf administered_bf nitrous_bf oxide/oxygen_bf achieve_bf 1_bf ._bf 25_bf MAC_bf [Minimum_bf Alveolar_bf Concentration]_bf may_bf prolong_bf clinically_bf effective_bf duration_bf action_bf initial_bf maintenance_bf doses_bf OTHER_DRUG decrease_be required_be infusion_be rate_be OTHER_DRUG ._af
8339,Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.,nitrous oxide,NIMBEX,effect,Isoflurane_bf enflurane_bf administered_bf nitrous_bf oxide/oxygen_bf achieve_bf 1_bf ._bf 25_bf MAC_bf [Minimum_bf Alveolar_bf Concentration]_bf may_bf prolong_bf clinically_bf effective_bf duration_bf action_bf initial_bf maintenance_bf doses_bf OTHER_DRUG decrease_be required_be infusion_be rate_be OTHER_DRUG ._af
8353,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,NIMBEX,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf OTHER_DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
8354,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,antibiotics,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf OTHER_DRUG (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
8355,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,aminoglycosides,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
8356,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,tetracyclines,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf OTHER_DRUG ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
8357,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,bacitracin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf OTHER_DRUG ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
8358,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,polymyxins,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf OTHER_DRUG ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
8359,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,lincomycin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf OTHER_DRUG ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
8360,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,clindamycin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf OTHER_DRUG ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
8361,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,colistin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf OTHER_DRUG ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
8362,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,sodium colistemethate,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistemethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf anesthetics_bf ,_bf procainamide_bf ,_bf quinidine_bf ._bf"
8363,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,magnesium,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistemethate)_bf ,_bf OTHER_DRUG salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
8364,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,lithium,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistemethate)_bf ,_bf magnesium_bf salts_bf ,_bf OTHER_DRUG ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
8365,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,anesthetics,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistemethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf OTHER_DRUG ,_be procainamide_be ,_be quinidine_be ._be"
8366,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,procainamide,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistemethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf anesthetics_bf ,_bf OTHER_DRUG ,_be quinidine_be ._be"
8367,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",nondepolarizing agents,quinidine,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf NIMBEX_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistemethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf anesthetics_bf ,_bf procainamide_bf ,_bf OTHER_DRUG ._be"
8368,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,antibiotics,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be OTHER_DRUG (e_af ._af g_af ._af ,_af aminoglycosides_af ,_af tetracyclines_af ,_af bacitracin_af ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistemethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
8369,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,aminoglycosides,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af tetracyclines_af ,_af bacitracin_af ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistemethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
8370,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,tetracyclines,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be OTHER_DRUG ,_af bacitracin_af ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistemethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
8371,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,bacitracin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be OTHER_DRUG ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistemethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
8372,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,polymyxins,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be OTHER_DRUG ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistemethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
8373,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,lincomycin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be OTHER_DRUG ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistemethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
8374,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,clindamycin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be OTHER_DRUG ,_af colistin_af ,_af sodium_af colistemethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
8375,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,colistin,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be OTHER_DRUG ,_af sodium_af colistemethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
8376,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,sodium colistemethate,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
8377,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,magnesium,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be OTHER_DRUG salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
8378,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,lithium,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be OTHER_DRUG ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
8379,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,anesthetics,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be OTHER_DRUG ,_af procainamide_af ,_af quinidine_af ._af"
8380,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,procainamide,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
8381,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.",NIMBEX,quinidine,effect,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistemethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be OTHER_DRUG ._af"
8473,Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.,nondepolarizing neuromuscular blocking agents,phenytoin,effect,Resistance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf neuromuscular_bf blocking_bf agents_bf demonstrated_bf patients_bf chronically_bf administered_bf OTHER_DRUG carbamazepine_be ._be
8474,Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.,nondepolarizing neuromuscular blocking agents,carbamazepine,effect,Resistance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf neuromuscular_bf blocking_bf agents_bf demonstrated_bf patients_bf chronically_bf administered_bf phenytoin_bf OTHER_DRUG ._be
8477,"While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.",phenytoin,NIMBEX,effect,"While_bf effects_bf chronic_bf DRUG carbamazepine_be therapy_be action_be OTHER_DRUG unknown_af ,_af slightly_af shorter_af durations_af neuromuscular_af block_af may_af anticipated_af infusion_af rate_af requirements_af may_af higher_af ._af"
8478,"While the effects of chronic phenytoin or carbamazepine therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.",carbamazepine,NIMBEX,effect,"While_bf effects_bf chronic_bf phenytoin_bf DRUG therapy_be action_be OTHER_DRUG unknown_af ,_af slightly_af shorter_af durations_af neuromuscular_af block_af may_af anticipated_af infusion_af rate_af requirements_af may_af higher_af ._af"
8546,The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.,allopurinol,ampicillin,effect,The_bf concurrent_bf administration_bf DRUG OTHER_DRUG increases_af substantially_af incidence_af rashes_af patients_af receiving_af drugs_af compared_af patients_af receiving_af OTHER_DRUG alone_af ._af
8549,It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricemia present in these patients.,ampicillin,allopurinol,effect,It_bf known_bf whether_bf potentiation_bf DRUG rashes_be due_be OTHER_DRUG hyperuricemia_af present_af patients_af ._af
8555,"In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives",broad-spectrum antibiotics,contraceptives,effect,"In_bf common_bf broad-spectrum_bf antibiotics_bf ,_bf AUGMENTIN_bf XR_bf may_bf reduce_bf efficacy_bf oral_bf OTHER_DRUG"
8556,"In common with other broad-spectrum antibiotics, AUGMENTIN XR may reduce the efficacy of oral contraceptives",AUGMENTIN XR,contraceptives,effect,"In_bf common_bf broad-spectrum_bf antibiotics_bf ,_bf AUGMENTIN_bf XR_bf may_bf reduce_bf efficacy_bf oral_bf OTHER_DRUG"
8557,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,CNS depressants,effect,"Additive_bf CNS_bf depression_bf may_bf occur_bf DRUG administered_be concomitantly_be CNS_be depressants_be including_be barbiturates_be ,_be tranquilizers_be ,_be alcohol_be ._be"
8558,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,barbiturates,effect,"Additive_bf CNS_bf depression_bf may_bf occur_bf DRUG administered_be concomitantly_be CNS_be depressants_be including_be OTHER_DRUG ,_af tranquilizers_af ,_af alcohol_af ._af"
8559,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,tranquilizers,effect,"Additive_bf CNS_bf depression_bf may_bf occur_bf DRUG administered_be concomitantly_be CNS_be depressants_be including_be barbiturates_be ,_be OTHER_DRUG ,_af alcohol_af ._af"
8560,"Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and alcohol.",antihistamines,alcohol,effect,"Additive_bf CNS_bf depression_bf may_bf occur_bf DRUG administered_be concomitantly_be CNS_be depressants_be including_be barbiturates_be ,_be tranquilizers_be ,_be OTHER_DRUG ._af"
8568,Monoamine oxidase (MAO) inhibitors prolong and intensify the anticholinergic effects of antihistamines.,Monoamine oxidase (MAO) inhibitors,antihistamines,effect,Monoamine_bf oxidase_bf (MAO)_bf inhibitors_bf prolong_bf intensify_bf anticholinergic_bf effects_bf OTHER_DRUG ._be
8571,"Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.",Amantadine,clidinium,effect,"DRUG ,_be tricyclic_be antidepressants_be ,_be MAOIs_be may_be increase_be anticholinergic_be effect_be OTHER_DRUG ._af"
8573,"Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.",tricyclic antidepressants,clidinium,effect,"Amantadine_bf ,_bf tricyclic_bf antidepressants_bf ,_bf MAOIs_bf may_bf increase_bf anticholinergic_bf effect_bf OTHER_DRUG ._be"
8574,"Amantadine, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of clidinium.",MAOIs,clidinium,effect,"Amantadine_bf ,_bf tricyclic_bf antidepressants_bf ,_bf DRUG may_be increase_be anticholinergic_be effect_be OTHER_DRUG ._af"
8575,"Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.",Clidinium,phenothiazines,effect,"DRUG may_be decrease_be effect_be OTHER_DRUG ,_af levodopa_af ,_af ketoconazole_af ._af"
8576,"Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.",Clidinium,levodopa,effect,"DRUG may_be decrease_be effect_be phenothiazines_be ,_be OTHER_DRUG ,_af ketoconazole_af ._af"
8577,"Clidinium may decrease the effect of phenothiazines, levodopa, and ketoconazole.",Clidinium,ketoconazole,effect,"DRUG may_be decrease_be effect_be phenothiazines_be ,_be levodopa_be ,_be OTHER_DRUG ._af"
8582,Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene have not been confirmed.,dapsone,Lamprene,effect,Preliminary_bf data_bf suggest_bf DRUG may_be inhibit_be anti-inflammatory_be activity_be OTHER_DRUG confirmed_af ._af
8588,The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.,tolbutamide,Atromid-S,effect,The_bf hypoglycemic_bf effect_bf DRUG reported_be increase_be OTHER_DRUG given_af concurrently_af ._af
8589,Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another fibrate and lovastatin but may be seen after several months.,fibrate,lovastatin,effect,Fulminant_bf rhabdomyolysis_bf seen_bf early_bf three_bf weeks_bf initiation_bf combined_bf therapy_bf another_bf DRUG OTHER_DRUG may_af seen_af several_af months_af ._af
8590,"For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with lovastatin and a fibrate do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.",lovastatin,fibrate,effect,"For_bf reasons_bf ,_bf felt_bf ,_bf subjects_bf unsatisfactory_bf lipid_bf response_bf either_bf drug_bf alone_bf ,_bf possible_bf benefits_bf combined_bf therapy_bf DRUG OTHER_DRUG outweigh_af risks_af severe_af myopathy_af ,_af rhabdomyolysis_af ,_af acute_af renal_af failure_af ._af"
8598,"Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",clorazepate dipotassium,hexobarbital,effect,"Animal_bf experience_bf indicates_bf clorazepate_bf dipotassium_bf prolongs_bf sleeping_bf time_bf OTHER_DRUG ethyl_be alcohol_be ,_be increases_be inhibitory_be effects_be chlorpromazine_be ,_be exhibit_be monoamine_be oxidase_be inhibition_be ._be"
8599,"Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",clorazepate dipotassium,ethyl alcohol,effect,"Animal_bf experience_bf indicates_bf clorazepate_bf dipotassium_bf prolongs_bf sleeping_bf time_bf hexobarbital_bf ethyl_bf alcohol_bf ,_bf increases_bf inhibitory_bf effects_bf chlorpromazine_bf ,_bf exhibit_bf monoamine_bf oxidase_bf inhibition_bf ._bf"
8600,"Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.",clorazepate dipotassium,chlorpromazine,effect,"Animal_bf experience_bf indicates_bf clorazepate_bf dipotassium_bf prolongs_bf sleeping_bf time_bf hexobarbital_bf ethyl_bf alcohol_bf ,_bf increases_bf inhibitory_bf effects_bf OTHER_DRUG ,_be exhibit_be monoamine_be oxidase_be inhibition_be ._be"
8604,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,barbiturates,effect,"The_bf actions_bf DRUG may_be potentiated_be OTHER_DRUG ,_af narcotics_af ,_af phenothiazines_af ,_af monoamine_af oxidase_af inhibitors_af antidepressants_af ._af"
8605,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,narcotics,effect,"The_bf actions_bf DRUG may_be potentiated_be barbiturates_be ,_be OTHER_DRUG ,_af phenothiazines_af ,_af monoamine_af oxidase_af inhibitors_af antidepressants_af ._af"
8606,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,phenothiazines,effect,"The_bf actions_bf DRUG may_be potentiated_be barbiturates_be ,_be narcotics_be ,_be OTHER_DRUG ,_af monoamine_af oxidase_af inhibitors_af antidepressants_af ._af"
8607,"The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.",benzodiazepines,monoamine oxidase inhibitors,effect,"The_bf actions_bf DRUG may_be potentiated_be barbiturates_be ,_be narcotics_be ,_be phenothiazines_be ,_be monoamine_be oxidase_be inhibitors_be antidepressants_be ._be"
196,"Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ",indinavir,didanosine,mechanism,"Concurrent_bf administration_bf DRUG OTHER_DRUG significantly_af reduces_af level_af exposure_af DRUG ,_af unclear_af soon_af OTHER_DRUG administration_af DRUG may_af given_af safely_af ._af"
212,Median gastric pH was significantly higher when indinavir was taken after didanosine administration; ,indinavir,didanosine,mechanism,Median_bf gastric_bf pH_bf significantly_bf higher_bf DRUG taken_be OTHER_DRUG administration;_af
429,"However, halothane anesthetic requirement (i.e., MAC) was depressed in a dose-dependent fashion as much as 56% 1-2 hours and as much as 14% 5-6 hours after injection of ketamine, 50 mg/kg, im. ",halothane,ketamine,mechanism,"However_bf ,_bf DRUG anesthetic_be requirement_be (i_be ._be ._be ,_be MAC)_be depressed_be dose-dependent_be fashion_be much_be 56%_be 1-2_be hours_be much_be 14%_be 5-6_be hours_be injection_be OTHER_DRUG ,_af 50_af mg/kg_af ,_af im_af ._af"
431,The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone. ,ketamine,halothane,mechanism,The_bf half-life_bf DRUG plasma_be brain_be longer_be presence_be OTHER_DRUG DRUG given_af alone_af ._af
437,Rifampin has been reported to increase the warfarin requirements in human subjects ingesting these agents simultaneously. ,Rifampin,warfarin,mechanism,DRUG reported_be increase_be OTHER_DRUG requirements_af human_af subjects_af ingesting_af agents_af simultaneously_af ._af
438,The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. ,rifampin,warfarin,mechanism,The_bf concomitant_bf administration_bf DRUG OTHER_DRUG resulted_af need_af unusually_af high_af maintenance_af dose_af OTHER_DRUG (20_af mg_af per_af day)_af order_af produce_af therapeutic_af effect_af ._af
441,Withdrawal of rifampin decreased the warfarin requirement by 50%. ,rifampin,warfarin,mechanism,Withdrawal_bf DRUG decreased_be OTHER_DRUG requirement_af 50%_af ._af
442,"This effect may be mediated by the ability of rifampin to induce microsomal enzymes and, thus, the catabolism of warfarin. ",rifampin,warfarin,mechanism,"This_bf effect_bf may_bf mediated_bf ability_bf DRUG induce_be microsomal_be enzymes_be ,_be thus_be ,_be catabolism_be OTHER_DRUG ._af"
531,Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. ,Amprenavir,rifabutin,mechanism,DRUG significantly_be increased_be area_be curve_be steady_be state_be (AUC(ss))_be OTHER_DRUG 2_af ._af 93-fold_af AUC(ss)_af 25-O-desacetylrifabutin_af 13_af ._af 3-fold_af ._af
532,Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. ,Amprenavir,25-O-desacetylrifabutin,mechanism,DRUG significantly_be increased_be area_be curve_be steady_be state_be (AUC(ss))_be rifabutin_be 2_be ._be 93-fold_be AUC(ss)_be OTHER_DRUG 13_af ._af 3-fold_af ._af
534,"Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. ",Rifampin,amprenavir,mechanism,"DRUG significantly_be decreased_be AUC(ss)_be OTHER_DRUG 82%_af ,_af OTHER_DRUG effect_af DRUG pharmacokinetics_af ._af"
543,"Rifampin markedly increases the metabolic clearance of amprenavir, and coadministration is contraindicated. ",Rifampin,amprenavir,mechanism,"DRUG markedly_be increases_be metabolic_be clearance_be OTHER_DRUG ,_af coadministration_af contraindicated_af ._af"
544,"Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. ",Amprenavir,rifabutin,mechanism,"DRUG significantly_be decreases_be clearance_be OTHER_DRUG 25-O-desacetylrifabutin_af ,_af combination_af poorly_af tolerated_af ._af"
545,"Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. ",Amprenavir,25-O-desacetylrifabutin,mechanism,"DRUG significantly_be decreases_be clearance_be rifabutin_be OTHER_DRUG ,_af combination_af poorly_af tolerated_af ._af"
571,"Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers.
",diltiazem,sirolimus,mechanism,Pharmacokinetic_bf interaction_bf single_bf oral_bf doses_bf DRUG OTHER_DRUG healthy_af volunteers_af ._af
580,"RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. ",sirolimus,diltiazem,mechanism,"RESULTS:_bf The_bf geometric_bf mean_bf (90%_bf confidence_bf interval)_bf whole_bf blood_bf DRUG area_be plasma_be concentration_be time-curve_be increased_be 60%_be (35%-90%)_be ,_be 736_be 1178_be ng_be x_be h/mL_be ,_be maximum_be concentration_be increased_be 43%_be (14%-81%)_be ,_be 67_be 96_be ng/mL_be ,_be OTHER_DRUG coadministration_af ,_af whereas_af mean_af elimination_af half-life_af DRUG decreased_af slightly_af ,_af 79_af 67_af hours_af ._af"
585,"Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. ",sirolimus,diltiazem,mechanism,"Apparent_bf oral_bf clearance_bf volume_bf distribution_bf DRUG decreased_be 38%_be 45%_be ,_be respectively_be ,_be DRUG given_af OTHER_DRUG ._af"
596,"CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. ",diltiazem,sirolimus,mechanism,"CONCLUSIONS:_bf Single-dose_bf DRUG coadministration_be leads_be higher_be OTHER_DRUG exposure_af ,_af presumably_af inhibition_af first-pass_af metabolism_af OTHER_DRUG ._af"
602,"Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.
",Fluvoxamine,tolbutamide,mechanism,DRUG inhibits_be CYP2C9_be catalyzed_be biotransformation_be OTHER_DRUG ._af
612,"RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. ",fluvoxamine,tolbutamide,mechanism,"RESULTS:_bf During_bf treatment_bf DRUG ,_be statistically_be significant_be decrease_be median_be total_be clearance_be OTHER_DRUG ,_af 845_af mL/h_af 688_af mL/h_af ,_af among_af volunteers_af received_af 75_af mg/d_af ._af"
643,"DISCUSSION: Clarithromycin is a potent inhibitor of CYP3A4, the major enzyme responsible for simvastatin metabolism. ",Clarithromycin,simvastatin,mechanism,"DISCUSSION:_bf DRUG potent_be inhibitor_be CYP3A4_be ,_be major_be enzyme_be responsible_be OTHER_DRUG metabolism_af ._af"
646,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",Macrolide antibiotics,atorvastatin,mechanism,"CONCLUSIONS:_bf Macrolide_bf antibiotics_bf inhibit_bf metabolism_bf HMG-CoA_bf reductase_bf inhibitors_bf metabolized_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf OTHER_DRUG ,_be cerivastatin_be ,_be lovastatin_be ,_be simvastatin)_be ._be"
647,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",Macrolide antibiotics,cerivastatin,mechanism,"CONCLUSIONS:_bf Macrolide_bf antibiotics_bf inhibit_bf metabolism_bf HMG-CoA_bf reductase_bf inhibitors_bf metabolized_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf atorvastatin_bf ,_bf OTHER_DRUG ,_be lovastatin_be ,_be simvastatin)_be ._be"
648,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",Macrolide antibiotics,lovastatin,mechanism,"CONCLUSIONS:_bf Macrolide_bf antibiotics_bf inhibit_bf metabolism_bf HMG-CoA_bf reductase_bf inhibitors_bf metabolized_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf atorvastatin_bf ,_bf cerivastatin_bf ,_bf OTHER_DRUG ,_be simvastatin)_be ._be"
649,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",Macrolide antibiotics,simvastatin,mechanism,"CONCLUSIONS:_bf Macrolide_bf antibiotics_bf inhibit_bf metabolism_bf HMG-CoA_bf reductase_bf inhibitors_bf metabolized_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf atorvastatin_bf ,_bf cerivastatin_bf ,_bf lovastatin_bf ,_bf simvastatin)_bf ._bf"
664,"This study demonstrated that the potent cytochrome P450 enzyme-inducer phenytoin did indeed have a marked effect on the metabolism of quetiapine, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. ",phenytoin,quetiapine,mechanism,"This_bf study_bf demonstrated_bf potent_bf cytochrome_bf P450_bf enzyme-inducer_bf DRUG indeed_be marked_be effect_be metabolism_be OTHER_DRUG ,_af resulting_af 5-fold_af increase_af clearance_af administered_af concomitantly_af patients_af DSM-IV-diagnosed_af schizophrenia_af ,_af schizoaffective_af disorder_af ,_af bipolar_af disorder_af ._af"
778,"Acetaminophen diminished the binding of theophylline to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L. ",Acetaminophen,theophylline,mechanism,"DRUG diminished_be binding_be OTHER_DRUG human_af serum_af net_af change_af 5_af ._af 7%_af (percentage_af increase_af free_af drug_af fraction_af [FDF]_af ,_af 11_af ._af 0%)_af 662_af micromol/L_af net_af change_af 7_af ._af 1%_af (percentage_af increase_af FDF_af ,_af 13_af ._af 7%)_af 1324_af micromol/L_af ._af"
779,"Theophylline decreased the binding of acetaminophen by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L; ",Theophylline,acetaminophen,mechanism,"DRUG decreased_be binding_be OTHER_DRUG net_af change_af 6_af ._af 8%_af (percentage_af increase_af FDF_af ,_af 8_af ._af 8%)_af 277_af ._af 5_af micromol/L;_af"
780,"Valproic acid diminished binding of phenobarbital by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. ",Valproic acid,phenobarbital,mechanism,"Valproic_bf acid_bf diminished_bf binding_bf OTHER_DRUG net_be change_be 9_be ._be 9%_be (percentage_be increase_be FDF_be ,_be 21_be ._be 2%)_be 1732_be micromol/L_be ._be"
865,Coadministration of fluoxetine significantly decreased cisapride plasma concentrations. ,fluoxetine,cisapride,mechanism,Coadministration_bf DRUG significantly_be decreased_be OTHER_DRUG plasma_af concentrations_af ._af
1000,"An intravenous injection of perchlorate given later also produces a complete and immediately beginning depletion of pertechnetate already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels. ",perchlorate,pertechnetate,mechanism,"An_bf intravenous_bf injection_bf DRUG given_be later_be also_be produces_be complete_be immediately_be beginning_be depletion_be OTHER_DRUG already_af accumulated_af thyroid_af ,_af within_af period_af 195_af min_af 99m-TcO-4-injection_af corresponding_af increase_af blood_af levels_af ._af"
1034,"Cholestyramine, an anionic-binding resin, has a considerable effect in lowering the rate and extent of fluvastatin bioavailability. ",Cholestyramine,fluvastatin,mechanism,"DRUG ,_be anionic-binding_be resin_be ,_be considerable_be effect_be lowering_be rate_be extent_be OTHER_DRUG bioavailability_af ._af"
1151,"Vitamin D3 administration to rachitic chicks was effective in significantly elevating duodenal arsenate absorption, acting primarily to enhance serosal transport.",Vitamin D3,arsenate,mechanism,"Vitamin_bf D3_bf administration_bf rachitic_bf chicks_bf effective_bf significantly_bf elevating_bf duodenal_bf OTHER_DRUG absorption_be ,_be acting_be primarily_be enhance_be serosal_be transport_be ._be"
1258,Amiodarone is known to raise serum digoxin levels. ,Amiodarone,digoxin,mechanism,DRUG known_be raise_be serum_be OTHER_DRUG levels_af ._af
1262,"During amiodarone administration, systemic clearance of digoxin was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01). ",amiodarone,digoxin,mechanism,"During_bf DRUG administration_be ,_be systemic_be clearance_be OTHER_DRUG reduced_af 234_af +/-_af 72_af ml/min_af (mean_af +/-_af standard_af deviation)_af 172_af +/-_af 33_af ml/min_af (p_af less_af 0_af ._af 01)_af ._af"
1264,These alterations in digoxin pharmacokinetics produced by amiodarone explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.,digoxin,amiodarone,mechanism,These_bf alterations_bf DRUG pharmacokinetics_be produced_be OTHER_DRUG explain_af increase_af serum_af DRUG level_af observed_af drug_af combination_af used_af clinically_af ._af
1275,Misonidazole has a complex effect on oral CCNU pharmacokinetics. ,Misonidazole,CCNU,mechanism,DRUG complex_be effect_be oral_be OTHER_DRUG pharmacokinetics_af ._af
1276,We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral CCNU cytotoxicity by misonidazole. ,CCNU,misonidazole,mechanism,We_bf propose_bf pharmacokinetic_bf changes_bf underlying_bf mechanism_bf reduction_bf oral_bf DRUG cytotoxicity_be OTHER_DRUG ._af
1277,"Enhanced theophylline clearance secondary to phenytoin therapy.
",theophylline,phenytoin,mechanism,Enhanced_bf DRUG clearance_be secondary_be OTHER_DRUG therapy_af ._af
1278,This report describes two cases in which theophylline clearance accelerated markedly with concomitant phenytoin administration. ,theophylline,phenytoin,mechanism,This_bf report_bf describes_bf two_bf cases_bf DRUG clearance_be accelerated_be markedly_be concomitant_be OTHER_DRUG administration_af ._af
1340,This study demonstrates that concurrent administration of thiosulfate permits at least a twofold increase in dose and total exposure to cisplatin.,thiosulfate,cisplatin,mechanism,This_bf study_bf demonstrates_bf concurrent_bf administration_bf DRUG permits_be least_be twofold_be increase_be dose_be total_be exposure_be OTHER_DRUG ._af
1410,"Interactions of cobalt and iron in absorption and retention.
",cobalt,iron,mechanism,Interactions_bf DRUG OTHER_DRUG absorption_af retention_af ._af
1418,Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. ,iron,cobalt,mechanism,Additional_bf DRUG significantly_be inhibited_be absorption_be OTHER_DRUG dietary_af OTHER_DRUG treatments_af ._af
1419,Additional iron significantly inhibited the absorption of cobalt in both dietary cobalt treatments. ,iron,cobalt,mechanism,Additional_bf DRUG significantly_be inhibited_be absorption_be OTHER_DRUG dietary_af OTHER_DRUG treatments_af ._af
1422,The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt. ,Fe,cobalt,mechanism,The_bf lower_bf rate_bf absorption_bf groups_bf receiving_bf 446_bf mg_bf DRUG instead_be 48_be mg_be DRUG per_af kg_af diet_af resulted_af decreased_af renal_af excretion_af OTHER_DRUG ._af
1424,"Consequently, the effect of iron on the retention of cobalt was lower than on absorption. ",iron,cobalt,mechanism,"Consequently_bf ,_bf effect_bf DRUG retention_be OTHER_DRUG lower_af absorption_af ._af"
1434,"Due to its nephrotoxicity, gentamicin may cause abnormal renal uptake to be seen on 99mTc-MDP bone scintigraphy. ",gentamicin,99mTc-MDP,mechanism,"Due_bf nephrotoxicity_bf ,_bf DRUG may_be cause_be abnormal_be renal_be uptake_be seen_be OTHER_DRUG bone_af scintigraphy_af ._af"
1477,[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ,cimetidine,verografine,mechanism,[The_bf effect_bf DRUG renal_be excretion_be verografin_be iodamide_be dogs]_be The_be intravenous_be injection_be DRUG dose_af 20_af mg/kg_af enhanced_af OTHER_DRUG iodamide_af excretion_af chronic_af canine_af experiments_af ._af
1478,[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs] The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. ,cimetidine,iodamide,mechanism,[The_bf effect_bf DRUG renal_be excretion_be verografin_be OTHER_DRUG dogs]_af The_af intravenous_af injection_af DRUG dose_af 20_af mg/kg_af enhanced_af verografine_af OTHER_DRUG excretion_af chronic_af canine_af experiments_af ._af
1538,Acid-catalyzed ethanolysis of temazepam in anhydrous and aqueous ethanol solutions.,temazepam,ethanol,mechanism,Acid-catalyzed_bf ethanolysis_bf DRUG anhydrous_be aqueous_be OTHER_DRUG solutions_af ._af
1543,"In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a benzodiazepine) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. ",temazepam,ethanol,mechanism,"In_bf addition_bf pharmacological_bf interaction_bf ,_bf report_bf describes_bf novel_bf chemical_bf reaction_bf DRUG (a_be benzodiazepine)_be OTHER_DRUG acidic_af conditions_af similar_af found_af vivo_af ,_af resulting_af 3-ethoxylated_af product_af ._af"
1545,"The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume alcohol and 3-hydroxy-1,4-benzodiazepine on a regular basis. ",alcohol,"3-hydroxy-1,4-benzodiazepine",mechanism,"The_bf results_bf raise_bf possibility_bf ethanolysis_bf reaction_bf may_bf occur_bf stomach_bf people_bf consume_bf DRUG 3-hydroxy-1_be ,_be 4-benzodiazepine_be regular_be basis_be ._be"
1672,Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.,naltrexone,Acamprosate,mechanism,Co-administration_bf DRUG OTHER_DRUG produced_af 25%_af increase_af AUC_af 33%_af increase_af Cmax_af OTHER_DRUG ._af
1767,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",Intestinal adsorbents,Acarbose,mechanism,"Intestinal_bf adsorbents_bf (e_bf ._bf g_bf ._bf ,_bf charcoal)_bf digestive_bf enzyme_bf preparations_bf containing_bf carbohydrate-splitting_bf enzymes_bf (e_bf ._bf g_bf ._bf ,_bf amylase_bf ,_bf pancreatin)_bf may_bf reduce_bf effect_bf OTHER_DRUG taken_be concomitantly_be ._be"
1771,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",charcoal,Acarbose,mechanism,"Intestinal_bf adsorbents_bf (e_bf ._bf g_bf ._bf ,_bf charcoal)_bf digestive_bf enzyme_bf preparations_bf containing_bf carbohydrate-splitting_bf enzymes_bf (e_bf ._bf g_bf ._bf ,_bf amylase_bf ,_bf pancreatin)_bf may_bf reduce_bf effect_bf OTHER_DRUG taken_be concomitantly_be ._be"
1776,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",amylase,Acarbose,mechanism,"Intestinal_bf adsorbents_bf (e_bf ._bf g_bf ._bf ,_bf charcoal)_bf digestive_bf enzyme_bf preparations_bf containing_bf carbohydrate-splitting_bf enzymes_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be pancreatin)_be may_be reduce_be effect_be OTHER_DRUG taken_af concomitantly_af ._af"
1777,"Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.",pancreatin,Acarbose,mechanism,"Intestinal_bf adsorbents_bf (e_bf ._bf g_bf ._bf ,_bf charcoal)_bf digestive_bf enzyme_bf preparations_bf containing_bf carbohydrate-splitting_bf enzymes_bf (e_bf ._bf g_bf ._bf ,_bf amylase_bf ,_bf pancreatin)_bf may_bf reduce_bf effect_bf OTHER_DRUG taken_be concomitantly_be ._be"
1778,"Acarbose has been shown to change the bioavailabillty digoxin when they are co-administered, which may require digoxin dose adjustment.",Acarbose,digoxin,mechanism,"DRUG shown_be change_be bioavailabillty_be OTHER_DRUG co-administered_af ,_af may_af require_af OTHER_DRUG dose_af adjustment_af ._af"
1805,"However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.",metformin,Acarbose,mechanism,"However_bf ,_bf peak_bf plasma_bf level_bf DRUG reduced_be approximately_be 20%_be taking_be OTHER_DRUG due_af slight_af delay_af absorption_af DRUG ._af"
1807,"However, the peak plasma level of metformin was reduced by approximately 20% when taking Acarbose due to a slight delay in the absorption of metformin.",Acarbose,metformin,mechanism,"However_bf ,_bf peak_bf plasma_bf level_bf OTHER_DRUG reduced_be approximately_be 20%_be taking_be DRUG due_af slight_af delay_af absorption_af OTHER_DRUG ._af"
1836,DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.,DIAMOX,phenytoin,mechanism,DRUG modifies_be OTHER_DRUG metabolism_af increased_af serum_af levels_af OTHER_DRUG ._af
1837,DIAMOX modifies phenytoin metabolism with increased serum levels of phenytoin.,DIAMOX,phenytoin,mechanism,DRUG modifies_be OTHER_DRUG metabolism_af increased_af serum_af levels_af OTHER_DRUG ._af
1841,"By decreasing the gastrointestinal absorption of primidone, DIAMOX may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect.",DIAMOX,primidone,mechanism,"By_bf decreasing_bf gastrointestinal_bf absorption_bf OTHER_DRUG ,_be DRUG may_af decrease_af serum_af concentrations_af OTHER_DRUG metabolites_af ,_af consequent_af possible_af decrease_af anticonvulsant_af effect_af ._af"
1844,Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.,Acetazolamide,amphetamine,mechanism,DRUG decreases_be urinary_be excretion_be OTHER_DRUG may_af enhance_af magnitude_af duration_af effect_af ._af
1845,Acetazolamide reduces urinary excretion of quinidine and may enhance its effect.,Acetazolamide,quinidine,mechanism,DRUG reduces_be urinary_be excretion_be OTHER_DRUG may_af enhance_af effect_af ._af
1847,Acetazolamide increases lithium excretion and the lithium may be decreased.,Acetazolamide,lithium,mechanism,DRUG increases_be OTHER_DRUG excretion_af OTHER_DRUG may_af decreased_af ._af
1851,Acetazolamide may elevate cyclosporine levels.,Acetazolamide,cyclosporine,mechanism,DRUG may_be elevate_be OTHER_DRUG levels_af ._af
1853,Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.,probenecid,acyclovir,mechanism,Co-administration_bf DRUG OTHER_DRUG shown_af increase_af mean_af half-life_af area_af concentration-time_af curve_af ._af
1859,Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.,acitretin,ethanol,mechanism,Ethanol:Clinical_bf evidence_bf shown_bf etretinate_bf formed_bf concurrent_bf ingestion_bf DRUG OTHER_DRUG ._af
1884,"Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.",acitretin,phenytoin,mechanism,"Phenytoin:_bf If_bf DRUG given_be concurrently_be OTHER_DRUG ,_af protein_af binding_af OTHER_DRUG may_af reduced_af ._af"
2020,Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.,dexamethasone,albendazole,mechanism,Dexamethasone:_bf Steady-state_bf trough_bf concentrations_bf OTHER_DRUG sulfoxide_be 56%_be higher_be 8_be mg_be DRUG coadministered_af dose_af OTHER_DRUG (15_af mg/kg/day)_af eight_af neurocysticercosis_af patients_af ._af
2024,"Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.",praziquantel,albendazole sulfoxide,mechanism,"Praziquantel:_bf In_bf fed_bf state_bf ,_bf DRUG (40_be mg/kg)_be increased_be mean_be maximum_be plasma_be concentration_be area_be curve_be albendazole_be sulfoxide_be 50%_be healthy_be subjects_be (n=10)_be compared_be separate_be group_be subjects_be (n=6)_be given_be albendazole_be alone_be ._be"
2031,Cimetidine: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).,Albendazole sulfoxide,cimetidine,mechanism,Cimetidine:_bf Albendazole_bf sulfoxide_bf concentrations_bf bile_bf cystic_bf fluid_bf increased_bf (about_bf 2-fold)_bf hydatid_bf cyst_bf patients_bf treated_bf OTHER_DRUG (10_be mg/kg/day)_be (n=7)_be compared_be albendazole_be (20_be mg/kg/day)_be alone_be (n=12)_be ._be
2192,Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.,irbesartan,aliskiren,mechanism,Co-administration_bf DRUG reduced_be OTHER_DRUG Cmax_af 50%_af multiple_af dosing_af ._af
2193,Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.,atorvastatin,aliskiren,mechanism,Co-administration_bf DRUG resulted_be 50%_be increase_be OTHER_DRUG Cmax_af AUC_af multiple_af dosing_af ._af
2197,Ketoconazole: Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.,ketoconazole,aliskiren,mechanism,Ketoconazole:_bf Co-administration_bf 200_bf mg_bf twice-daily_bf DRUG OTHER_DRUG resulted_af approximate_af 80%_af increase_af plasma_af levels_af OTHER_DRUG ._af
2262,"Furosemide: When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.",aliskiren,furosemide,mechanism,"Furosemide:_bf When_bf DRUG co-administered_be OTHER_DRUG ,_af AUC_af Cmax_af OTHER_DRUG reduced_af 30%_af 50%_af ,_af respectively_af ._af"
2274,Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.,Allopurinol,mercaptopurine,mechanism,Mercaptopurine/Azathioprine:_bf DRUG inhibits_be enzymatic_be oxidation_be OTHER_DRUG azathioprine_af 6-thiouric_af acid_af ._af
2275,Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.,Allopurinol,azathioprine,mechanism,Mercaptopurine/Azathioprine:_bf DRUG inhibits_be enzymatic_be oxidation_be mercaptopurine_be OTHER_DRUG 6-thiouric_af acid_af ._af
2306,"Dicumarol: It has been reported that allopurinol prolongs the half-life of the anticoagulant, dicumarol.",allopurinol,dicumarol,mechanism,"Dicumarol:_bf It_bf reported_bf DRUG prolongs_be half-life_be anticoagulant_be ,_be OTHER_DRUG ._af"
2314,"Uricosuric Agents: Since the excretion of oxipurinol is similar to that of urate, uricosuric agents, which increase the excretion of urate, are also likely to increase the excretion of oxipurinol and thus lower the degree of inhibition of xanthine oxidase.",uricosuric agents,oxipurinol,mechanism,"Uricosuric_bf Agents:_bf Since_bf excretion_bf OTHER_DRUG similar_be urate_be ,_be uricosuric_be agents_be ,_be increase_be excretion_be urate_be ,_be also_be likely_be increase_be excretion_be OTHER_DRUG thus_af lower_af degree_af inhibition_af xanthine_af oxidase_af ._af"
2315,The concomitant administration of uricosuric agents and allopurinol has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with allopurinol alone.,uricosuric agents,allopurinol,mechanism,The_bf concomitant_bf administration_bf uricosuric_bf agents_bf OTHER_DRUG associated_be decrease_be excretion_be oxypurines_be (hypoxanthine_be xanthine)_be increase_be urinary_be uric_be acid_be excretion_be compared_be observed_be OTHER_DRUG alone_af ._af
2361,"Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.",Chlorpropamide,allopurinol,mechanism,"Chlorpropamide:_bf Chlorpropamides_bf plasma_bf half-life_bf may_bf prolonged_bf OTHER_DRUG ,_be since_be OTHER_DRUG DRUG may_af compete_af excretion_af renal_af tubule_af ._af"
2366,"Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.",allopurinol,chlorpropamide,mechanism,"Chlorpropamide:_bf Chlorpropamides_bf plasma_bf half-life_bf may_bf prolonged_bf DRUG ,_be since_be DRUG OTHER_DRUG may_af compete_af excretion_af renal_af tubule_af ._af"
2370,Cyclosporin: Reports indicate that cyclosporine levels may be increased during concomitant treatment with allopurinol sodium for injection.,cyclosporine,allopurinol sodium,mechanism,Cyclosporin:_bf Reports_bf indicate_bf DRUG levels_be may_be increased_be concomitant_be treatment_be allopurinol_be sodium_be injection_be ._be
2384,Monoamine Oxidase Inhibitors: Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.,moclobemide,almotriptan,mechanism,Monoamine_bf Oxidase_bf Inhibitors:_bf Coadministration_bf DRUG resulted_be 27%_be decrease_be OTHER_DRUG clearance_af increase_af Cmax_af approximately_af 6%_af ._af
2423,Verapamil: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.,almotriptan,verapamil,mechanism,Verapamil:_bf Coadministration_bf DRUG OTHER_DRUG resulted_af 24%_af increase_af plasma_af concentrations_af DRUG ._af
2426,Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.,almotriptan,ketoconazole,mechanism,Coadministration_bf DRUG potent_be CYP3A4_be inhibitor_be OTHER_DRUG (400_af mg_af q_af ._af ._af 3_af days)_af resulted_af approximately_af 60%_af increase_af area_af plasma_af concentration-time_af curve_af maximal_af plasma_af concentrations_af DRUG ._af
2446,Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold.,Fluvoxamine,alosetron,mechanism,DRUG increased_be mean_be OTHER_DRUG plasma_af concentrations_af (AUC)_af approximately_af 6-fold_af prolonged_af half-life_af approximately_af 3-fold_af ._af
2452,Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%.,Ketoconazole,alosetron,mechanism,DRUG increased_be mean_be OTHER_DRUG plasma_af concentrations_af (AUC)_af 29%_af ._af
2510,A case report of one patient taking amiodarone 200 mg and indinavir 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.,amiodarone,indinavir,mechanism,A_bf case_bf report_bf one_bf patient_bf taking_bf DRUG 200_be mg_be OTHER_DRUG 800_af mg_af three_af times_af day_af resulted_af increases_af DRUG concentrations_af 0_af ._af 9_af mg/L_af 1_af ._af 3_af mg/L_af ._af
2516,Histamine H2 antagonists: Cimetidine inhibits CYP3A4 and can increase serum amiodarone levels.,Histamine H2 antagonists,Cimetidine,mechanism,Histamine_bf H2_bf antagonists:_bf OTHER_DRUG inhibits_be CYP3A4_be increase_be serum_be amiodarone_be levels_be ._be
2776,"Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs.",Cimetidine,tricyclic antidepressants,mechanism,"DRUG reported_be reduce_be hepatic_be metabolism_be certain_be tricyclic_be antidepressants_be ,_be thereby_be delaying_be elimination_be increasing_be steady-state_be concentrations_be drugs_be ._be"
2781,"Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen.",tricyclic antidepressants,cimetidine,mechanism,"Increases_bf plasma_bf levels_bf tricyclic_bf antidepressants_bf ,_bf frequency_bf severity_bf side_bf effects_bf ,_bf particularly_bf anticholinergic_bf ,_bf reported_bf OTHER_DRUG added_be drug_be regimen_be ._be"
2789,Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.,tricyclic antidepressants,cimetidine,mechanism,Discontinuation_bf OTHER_DRUG well-controlled_be patients_be receiving_be tricyclic_be antidepressants_be OTHER_DRUG may_af decrease_af plasma_af levels_af efficacy_af antidepressants_af ._af
2870,Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.,Probenecid,ampicillin,mechanism,Probenecid:_bf May_bf decrease_bf renal_bf tubular_bf secretion_bf OTHER_DRUG resulting_be increased_be blood_be levels_be and/or_be OTHER_DRUG toxicity_af ._af
2877,"Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.",Indinavir,amprenavir,mechanism,"DRUG steady-state_be Cmax_be ,_be A_be ._be C_be ._be Cmin_be decreased_be 22%_be ,_be 38%_be ,_be 27%_be ,_be respectively_be ,_be concomitant_be OTHER_DRUG ._af"
2878,"Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.",Saquinavir,amprenavir,mechanism,"DRUG steady-state_be Cmax_be ,_be A_be ._be C_be ._be Cmin_be increased_be 21%_be ,_be decreased_be 19%_be ,_be decreased_be 48%_be ,_be respectively_be ,_be concomitant_be OTHER_DRUG ._af"
2879,"Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.",Nelfinavir,amprenavir,mechanism,"DRUG steady-state_be Cmax_be ,_be A_be ._be C_be ._be Cmin_be increased_be 12%_be ,_be 15%_be ,_be 14%_be ,_be respectively_be ,_be concomitant_be OTHER_DRUG ._af"
2886,"Coadministration of amprenavir and methadone as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum amprenavir AUC, Cmax, andCmin, respectively.",amprenavir,methadone,mechanism,"Coadministration_bf DRUG OTHER_DRUG compared_af non-matched_af historicalcontrol_af group_af resulted_af 30%_af ,_af 27%_af ,_af 25%_af decrease_af serum_af DRUG AUC_af ,_af Cmax_af ,_af andCmin_af ,_af respectively_af ._af"
2940,"It is known that CYP1A2 is inhibited by several medicinal products, including fluvoxamine, and such medicinal products could theoretically adversely influence the clearance of anagrelide.",fluvoxamine,anagrelide,mechanism,"It_bf known_bf CYP1A2_bf inhibited_bf several_bf medicinal_bf products_bf ,_bf including_bf DRUG ,_be medicinal_be products_be could_be theoretically_be adversely_be influence_be clearance_be OTHER_DRUG ._af"
2941,Anagrelide demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. theophylline.,Anagrelide,theophylline,mechanism,DRUG demonstrates_be limited_be inhibitory_be activity_be towards_be CYP1A2_be may_be present_be theoretical_be potential_be interaction_be coadministered_be medicinal_be products_be sharing_be clearance_be mechanism_be ._be g_be ._be OTHER_DRUG ._af
2957,"There is a single case report, which suggests that sucralfate may interfere with anagrelide absorption.",sucralfate,anagrelide,mechanism,"There_bf single_bf case_bf report_bf ,_bf suggests_bf DRUG may_be interfere_be OTHER_DRUG absorption_af ._af"
2972,Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.,anastrozole,tamoxifen,mechanism,Co-administration_bf DRUG OTHER_DRUG resulted_af reduction_af DRUG plasma_af levels_af 27%_af compared_af achieved_af DRUG alone_af ._af
3106,"Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.",Aprepitant,S(-) warfarin,mechanism,"DRUG shown_be induce_be metabolism_be S(-)_be warfarin_be tolbutamide_be ,_be metabolized_be CYP2C9_be ._be"
3107,"Aprepitant has been shown to induce the metabolism of S(-) warfarin and tolbutamide, which are metabolized through CYP2C9.",Aprepitant,tolbutamide,mechanism,"DRUG shown_be induce_be metabolism_be S(-)_be warfarin_be OTHER_DRUG ,_af metabolized_af CYP2C9_af ._af"
3109,"Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.",Aprepitant,phenytoin,mechanism,"Coadministration_bf DRUG drugs_be drugs_be known_be metabolized_be CYP2C9_be ,_be OTHER_DRUG ,_af may_af result_af lower_af plasma_af concentrations_af drugs_af ._af"
3130,"Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.",Aprepitant,dexamethasone,mechanism,"Corticosteroids:_bf Dexamethasone:_bf DRUG ,_be given_be regimen_be 125mg_be OTHER_DRUG coadministered_af orally_af 20_af mg_af Day_af 1_af ,_af DRUG given_af 80_af mg/day_af OTHER_DRUG coadministered_af orally_af 8_af mg_af Days_af 2_af 5_af ,_af increased_af AUC_af OTHER_DRUG ,_af CYP3A4_af substrate_af 2_af ._af 2-fold_af ,_af Days_af 1_af 5_af ._af"
3137,"Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.",Aprepitant,dexamethasone,mechanism,"Corticosteroids:_bf Dexamethasone:_bf DRUG ,_be given_be regimen_be 125mg_be OTHER_DRUG coadministered_af orally_af 20_af mg_af Day_af 1_af ,_af DRUG given_af 80_af mg/day_af OTHER_DRUG coadministered_af orally_af 8_af mg_af Days_af 2_af 5_af ,_af increased_af AUC_af OTHER_DRUG ,_af CYP3A4_af substrate_af 2_af ._af 2-fold_af ,_af Days_af 1_af 5_af ._af"
3146,The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.,dexamethasone,Aprepitant,mechanism,The_bf daily_bf dose_bf DRUG administered_be clinical_be studies_be OTHER_DRUG reflects_af approximate_af 50%_af reduction_af dose_af DRUG ._af
3149,"Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.",Aprepitant,methylprednisolone,mechanism,"DRUG ,_be given_be regimen_be 125_be mg_be Day_be 1_be 80_be mg/day_be Days_be 2_be 3_be ,_be increased_be AUC_be OTHER_DRUG ,_af CYP3A4_af substrate_af ,_af 1_af ._af 34-fold_af Day_af 1_af 2_af ._af 5-fold_af Day_af 3_af ,_af OTHER_DRUG coadministered_af intravenously_af 125_af mg_af Day_af 1_af orally_af 40_af mg_af Days_af 2_af 3_af ._af"
3174,"Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.",S(-)warfarin,Aprepitant,mechanism,"Although_bf effect_bf OTHER_DRUG plasma_be AUC_be R(+)_be S(-)_be warfarin_be determined_be Day_be 3_be ,_be 34%_be decrease_be DRUG (a_af CYP2C9_af substrate)_af trough_af concentration_af accompanied_af 14%_af decrease_af prothrombin_af time_af (reported_af International_af Normalized_af Ratio_af INR)_af 5_af days_af completion_af dosing_af OTHER_DRUG ._af"
3185,"Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.",tolbutamide,Aprepitant,mechanism,"Tolbutamide:_bf OTHER_DRUG ,_be given_be 125_be mg_be Day_be 1_be 80_be mg/day_be Days_be 2_be 3_be ,_be decreased_be AUC_be DRUG (a_af CYP2C9_af substrate)_af 23%_af Day_af 4_af ,_af 28%_af Day_af 8_af ,_af 15%_af Day_af 15_af ,_af single_af dose_af DRUG 500_af mg_af admini_af ,_af stered_af orally_af prior_af administration_af 3-day_af regimen_af OTHER_DRUG Days_af 4_af ,_af 8_af ,_af 15_af ._af"
3193,"Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;",Aprepitant,ethinyl estradiol,mechanism,"Oral_bf contraceptives:_bf DRUG ,_be given_be daily_be 14_be days_be 100-mg_be capsule_be oral_be contraceptive_be containing_be 35_be mcg_be ethinyl_be estradiol_be 1_be mg_be norethindrone_be ,_be decreased_be AUC_be ethinyl_be estradiol_be 43%_be ,_be decreased_be AUC_be norethindrone_be 8%;_be"
3194,"Oral contraceptives: Aprepitant, when given once daily for 14 days as a 100-mg capsule with an oral contraceptive containing 35 mcg of ethinyl estradiol and 1 mg of norethindrone, decreased the AUC of ethinyl estradiol by 43%, and decreased the AUC of norethindrone by 8%;",Aprepitant,norethindrone,mechanism,"Oral_bf contraceptives:_bf DRUG ,_be given_be daily_be 14_be days_be 100-mg_be capsule_be oral_be contraceptive_be containing_be 35_be mcg_be ethinyl_be estradiol_be 1_be mg_be OTHER_DRUG ,_af decreased_af AUC_af ethinyl_af estradiol_af 43%_af ,_af decreased_af AUC_af OTHER_DRUG 8%;_af"
3213,"Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.",Aprepitant,midazolam,mechanism,"Midazolam:_bf DRUG increased_be AUC_be OTHER_DRUG ,_af sensitive_af CYP3A4_af substrate_af ,_af 2_af ._af 3-fold_af Day_af 1_af 3_af ._af 3-fold_af Day_af 5_af ,_af single_af oral_af dose_af OTHER_DRUG 2_af mg_af coadministered_af Day_af 1_af Day_af 5_af regimen_af DRUG 125_af mg_af Day_af 1_af 80_af mg/day_af Days_af 2_af 5_af ._af"
3235,Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.,Aprepitant,midazolam,mechanism,DRUG increased_be AUC_be OTHER_DRUG 25%_af Day_af 4_af decreased_af AUC_af OTHER_DRUG 19%_af Day_af 8_af relative_af dosing_af DRUG Days_af 1_af 3_af ._af
3236,Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.,Aprepitant,midazolam,mechanism,DRUG increased_be AUC_be OTHER_DRUG 25%_af Day_af 4_af decreased_af AUC_af OTHER_DRUG 19%_af Day_af 8_af relative_af dosing_af DRUG Days_af 1_af 3_af ._af
3271,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",Aprepitant,rifampin,mechanism,"therefore_bf ,_bf coadministration_bf DRUG drugs_be strongly_be induce_be CYP3A4_be activity_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af carbamazepine_af ,_af phenytoin)_af may_af result_af reduced_af plasma_af concentrations_af DRUG may_af result_af decreased_af efficacy_af DRUG ._af"
3273,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",Aprepitant,phenytoin,mechanism,"therefore_bf ,_bf coadministration_bf DRUG drugs_be strongly_be induce_be CYP3A4_be activity_be (e_be ._be g_be ._be ,_be rifampin_be ,_be carbamazepine_be ,_be phenytoin)_be may_be result_be reduced_be plasma_be concentrations_be DRUG may_af result_af decreased_af efficacy_af DRUG ._af"
3274,"therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.",Aprepitant,aprepitant,mechanism,"therefore_bf ,_bf coadministration_bf DRUG drugs_be strongly_be induce_be CYP3A4_be activity_be (e_be ._be g_be ._be ,_be rifampin_be ,_be carbamazepine_be ,_be phenytoin)_be may_be result_be reduced_be plasma_be concentrations_be DRUG may_af result_af decreased_af efficacy_af DRUG ._af"
3291,"Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.",Aprepitant,ketoconazole,mechanism,"Ketoconazole:_bf When_bf single_bf 125-mg_bf dose_bf DRUG administered_be Day5_be 10-day_be regimen_be 400_be mg/day_be OTHER_DRUG ,_af strong_af CYP3A4_af inhibitor_af ,_af AUC_af DRUG increased_af approximately_af 5-fold_af mean_af terminal_af half-life_af DRUG increased_af approximately_af 3-fold_af ._af"
3300,"Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.",Aprepitant,rifampin,mechanism,"Rifampin:_bf When_bf single_bf 375-mg_bf dose_bf DRUG administered_be Day9_be 14-day_be regimen_be 600_be mg/day_be OTHER_DRUG ,_af strong_af CYP3A4_af inducer_af ,_af AUC_af DRUG decreased_af approximately_af 11-fold_af mean_af terminal_af half-life_af decreased_af approximately_af 3-fold_af ._af"
3308,"Diltiazem: In patients with mild to moderate hypertension, administration of aprepitant once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with diltiazem 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of aprepitant AUC and a simultaneous 1.7-fold increase of diltiazem AUC.",aprepitant,diltiazem,mechanism,"Diltiazem:_bf In_bf patients_bf mild_bf moderate_bf hypertension_bf ,_bf administration_bf DRUG daily_be ,_be tablet_be formulation_be comparable_be 230_be mg_be capsule_be formulation_be ,_be OTHER_DRUG 120_af mg_af 3_af times_af daily_af 5_af days_af ,_af resulted_af 2-fold_af increase_af DRUG AUC_af simultaneous_af 1_af ._af 7-fold_af increase_af OTHER_DRUG AUC_af ._af"
3318,"Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.",aprepitant,paroxetine,mechanism,"Paroxetine:_bf Coadministration_bf daily_bf doses_bf DRUG ,_be tablet_be formulation_be comparable_be 85_be mg_be 170_be mg_be capsule_be formulation_be ,_be OTHER_DRUG 20_af mg_af daily_af ,_af resulted_af decrease_af AUC_af approximately_af 25%_af Cmax_af ,_af approximately_af 20%_af DRUG OTHER_DRUG ._af"
3382,"Agents that induce CYP3A4 (eg, carbamazepine) could cause an increase in aripiprazole clearance and lower blood levels.",carbamazepine,aripiprazole,mechanism,"Agents_bf induce_bf CYP3A4_bf (eg_bf ,_bf carbamazepine)_bf could_bf cause_bf increase_bf OTHER_DRUG clearance_be lower_be blood_be levels_be ._be"
3386,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",ketoconazole,aripiprazole,mechanism,"Inhibitors_bf CYP3A4_bf (eg_bf ,_bf ketoconazole)_bf CYP2D6_bf (eg_bf ,_bf quinidine_bf ,_bf fluoxetine_bf ,_bf paroxetine)_bf inhibit_bf OTHER_DRUG elimination_be cause_be increased_be blood_be levels_be ._be"
3389,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",quinidine,aripiprazole,mechanism,"Inhibitors_bf CYP3A4_bf (eg_bf ,_bf ketoconazole)_bf CYP2D6_bf (eg_bf ,_bf DRUG ,_be fluoxetine_be ,_be paroxetine)_be inhibit_be OTHER_DRUG elimination_af cause_af increased_af blood_af levels_af ._af"
3391,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",fluoxetine,aripiprazole,mechanism,"Inhibitors_bf CYP3A4_bf (eg_bf ,_bf ketoconazole)_bf CYP2D6_bf (eg_bf ,_bf quinidine_bf ,_bf DRUG ,_be paroxetine)_be inhibit_be OTHER_DRUG elimination_af cause_af increased_af blood_af levels_af ._af"
3392,"Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.",paroxetine,aripiprazole,mechanism,"Inhibitors_bf CYP3A4_bf (eg_bf ,_bf ketoconazole)_bf CYP2D6_bf (eg_bf ,_bf quinidine_bf ,_bf fluoxetine_bf ,_bf paroxetine)_bf inhibit_bf OTHER_DRUG elimination_be cause_be increased_be blood_be levels_be ._be"
3396,"Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.",ketoconazole,aripiprazole,mechanism,"Ketoconazole:_bf Coadministration_bf DRUG (200_be mg/day_be 14_be days)_be 15-mg_be single_be dose_be OTHER_DRUG increased_af AUC_af OTHER_DRUG active_af metabolite_af 63%_af 77%_af ,_af respectively_af ._af"
3406,"Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.",aripiprazole,quinidine,mechanism,"Quinidine:_bf Coadministration_bf 10-mg_bf single_bf dose_bf DRUG OTHER_DRUG (166_af mg/day_af 13_af days)_af ,_af potent_af inhibitor_af CYP2D6_af ,_af increased_af AUC_af DRUG 112%_af decreased_af AUC_af active_af metabolite_af ,_af dehydroaripiprazole_af ,_af 35%_af ._af"
3420,"Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.",carbamazepine,aripiprazole,mechanism,"Carbamazepine:_bf Coadministration_bf DRUG (200_be mg_be BID)_be ,_be potent_be CYP3A4_be inducer_be ,_be OTHER_DRUG (30_af mg_af QD)_af resulted_af approximate_af 70%_af decrease_af Cmax_af AUC_af values_af OTHER_DRUG active_af metabolite_af ,_af dehydro-aripiprazole_af ._af"
3502,Phenobarbital: Decreases aspirin effectiveness by enzyme induction.,Phenobarbital,aspirin,mechanism,Phenobarbital:_bf Decreases_bf OTHER_DRUG effectiveness_be enzyme_be induction_be ._be
3553,"Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.",Antacids,pseudoephedrine,mechanism,"DRUG increase_be rate_be absorption_be OTHER_DRUG ,_af kaolin_af decreases_af ._af"
3555,"Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.",pseudoephedrine,kaolin,mechanism,"Antacids_bf increase_bf rate_bf absorption_bf DRUG ,_be OTHER_DRUG decreases_af ._af"
3558,Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.,azathioprine,allopurinol,mechanism,Use_bf Allopurinol:_bf The_bf principal_bf pathway_bf detoxification_bf DRUG inhibited_be OTHER_DRUG ._af
3575,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,atorvastatin,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be OTHER_DRUG ,_af carbamazepine_af ,_af cetirizine_af ,_af didanosine_af ,_af efavirenz_af ,_af fluconazole_af ,_af indinavir_af ,_af midazolam_af ,_af rifabutin_af ,_af sildenafil_af ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
3576,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,carbamazepine,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be OTHER_DRUG ,_af cetirizine_af ,_af didanosine_af ,_af efavirenz_af ,_af fluconazole_af ,_af indinavir_af ,_af midazolam_af ,_af rifabutin_af ,_af sildenafil_af ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
3577,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,cetirizine,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be OTHER_DRUG ,_af didanosine_af ,_af efavirenz_af ,_af fluconazole_af ,_af indinavir_af ,_af midazolam_af ,_af rifabutin_af ,_af sildenafil_af ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
3578,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,didanosine,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be OTHER_DRUG ,_af efavirenz_af ,_af fluconazole_af ,_af indinavir_af ,_af midazolam_af ,_af rifabutin_af ,_af sildenafil_af ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
3579,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,efavirenz,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be OTHER_DRUG ,_af fluconazole_af ,_af indinavir_af ,_af midazolam_af ,_af rifabutin_af ,_af sildenafil_af ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
3580,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,fluconazole,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be OTHER_DRUG ,_af indinavir_af ,_af midazolam_af ,_af rifabutin_af ,_af sildenafil_af ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
3581,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,indinavir,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be fluconazole_be ,_be OTHER_DRUG ,_af midazolam_af ,_af rifabutin_af ,_af sildenafil_af ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
3582,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,midazolam,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be fluconazole_be ,_be indinavir_be ,_be OTHER_DRUG ,_af rifabutin_af ,_af sildenafil_af ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
3583,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,rifabutin,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be fluconazole_be ,_be indinavir_be ,_be midazolam_be ,_be OTHER_DRUG ,_af sildenafil_af ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
3584,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,sildenafil,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be fluconazole_be ,_be indinavir_be ,_be midazolam_be ,_be rifabutin_be ,_be OTHER_DRUG ,_af theophylline_af (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
3585,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,theophylline,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be fluconazole_be ,_be indinavir_be ,_be midazolam_be ,_be rifabutin_be ,_be sildenafil_be ,_be OTHER_DRUG (intravenous_af oral)_af ,_af triazolam_af ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
3586,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,triazolam,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be fluconazole_be ,_be indinavir_be ,_be midazolam_be ,_be rifabutin_be ,_be sildenafil_be ,_be theophylline_be (intravenous_be oral)_be ,_be OTHER_DRUG ,_af trimethoprim/sulfamethoxazole_af zidovudine_af ._af"
3587,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,trimethoprim,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be fluconazole_be ,_be indinavir_be ,_be midazolam_be ,_be rifabutin_be ,_be sildenafil_be ,_be theophylline_be (intravenous_be oral)_be ,_be triazolam_be ,_be trimethoprim/sulfamethoxazole_be zidovudine_be ._be"
3588,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,sulfamethoxazole,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be fluconazole_be ,_be indinavir_be ,_be midazolam_be ,_be rifabutin_be ,_be sildenafil_be ,_be theophylline_be (intravenous_be oral)_be ,_be triazolam_be ,_be trimethoprim/sulfamethoxazole_be zidovudine_be ._be"
3589,"When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.",azithromycin,zidovudine,mechanism,"When_bf used_bf therapeutic_bf doses_bf ,_bf DRUG modest_be effect_be pharmacokinetics_be atorvastatin_be ,_be carbamazepine_be ,_be cetirizine_be ,_be didanosine_be ,_be efavirenz_be ,_be fluconazole_be ,_be indinavir_be ,_be midazolam_be ,_be rifabutin_be ,_be sildenafil_be ,_be theophylline_be (intravenous_be oral)_be ,_be triazolam_be ,_be trimethoprim/sulfamethoxazole_be OTHER_DRUG ._af"
3696,Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.,efavirenz,azithromycin,mechanism,Co-administration_bf DRUG fluconazole_be modest_be effect_be pharmacokinetics_be OTHER_DRUG ._af
3697,Co-administration with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin.,fluconazole,azithromycin,mechanism,Co-administration_bf efavirenz_bf DRUG modest_be effect_be pharmacokinetics_be OTHER_DRUG ._af
3736,"Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.",Simulect,azathioprine,mechanism,"Total_bf body_bf clearance_bf DRUG reduced_be average_be 22%_be 51%_be OTHER_DRUG mycophenolate_af mofetil_af ,_af respectively_af ,_af added_af regimen_af consisting_af cyclosporine_af ,_af USP_af (MODIFIED)_af corticosteroids_af ._af"
3737,"Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.",Simulect,mycophenolate mofetil,mechanism,"Total_bf body_bf clearance_bf DRUG reduced_be average_be 22%_be 51%_be azathioprine_be mycophenolate_be mofetil_be ,_be respectively_be ,_be added_be regimen_be consisting_be cyclosporine_be ,_be USP_be (MODIFIED)_be corticosteroids_be ._be"
3808,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.,ACE inhibitors,lithium,mechanism,Lithium:_bf Increased_bf serum_bf OTHER_DRUG levels_be symptoms_be OTHER_DRUG toxicity_af reported_af patients_af receiving_af ACE_af inhibitors_af therapy_af OTHER_DRUG ._af
3874,Urinary acidifying agents decrease blood levels and increase excretion of amphetamines.,Urinary acidifying,amphetamines,mechanism,Urinary_bf acidifying_bf agents_bf decrease_bf blood_bf levels_bf increase_bf excretion_bf OTHER_DRUG ._be
3923,"Digoxin: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.",bepridil hydrochloride,digoxin,mechanism,"Digoxin:_bf In_bf controlled_bf studies_bf healthy_bf volunteers_bf ,_bf bepridil_bf hydrochloride_bf either_bf effect_bf (one_bf study)_bf associated_bf modest_bf increases_bf ,_bf 30%_bf (two_bf studies)_bf steady-state_bf serum_bf OTHER_DRUG concentrations_be ._be"
4009,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",ketoconazole,bexarotene,mechanism,"On_bf basis_bf metabolism_bf OTHER_DRUG cytochrome_be P450_be 3A4_be ,_be DRUG ,_af itraconazole_af ,_af erythromycin_af ,_af gemfibrozil_af ,_af grapefruit_af juice_af ,_af inhibitors_af cytochrome_af P450_af 3A4_af would_af expected_af lead_af increase_af plasma_af OTHER_DRUG concentrations_af ._af"
4012,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",itraconazole,bexarotene,mechanism,"On_bf basis_bf metabolism_bf OTHER_DRUG cytochrome_be P450_be 3A4_be ,_be ketoconazole_be ,_be DRUG ,_af erythromycin_af ,_af gemfibrozil_af ,_af grapefruit_af juice_af ,_af inhibitors_af cytochrome_af P450_af 3A4_af would_af expected_af lead_af increase_af plasma_af OTHER_DRUG concentrations_af ._af"
4014,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",erythromycin,bexarotene,mechanism,"On_bf basis_bf metabolism_bf OTHER_DRUG cytochrome_be P450_be 3A4_be ,_be ketoconazole_be ,_be itraconazole_be ,_be DRUG ,_af gemfibrozil_af ,_af grapefruit_af juice_af ,_af inhibitors_af cytochrome_af P450_af 3A4_af would_af expected_af lead_af increase_af plasma_af OTHER_DRUG concentrations_af ._af"
4015,"On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.",gemfibrozil,bexarotene,mechanism,"On_bf basis_bf metabolism_bf OTHER_DRUG cytochrome_be P450_be 3A4_be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be DRUG ,_af grapefruit_af juice_af ,_af inhibitors_af cytochrome_af P450_af 3A4_af would_af expected_af lead_af increase_af plasma_af OTHER_DRUG concentrations_af ._af"
4018,"Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.",rifampin,bexarotene,mechanism,"Furthermore_bf ,_bf DRUG ,_be phenytoin_be ,_be phenobarbital_be ,_be inducers_be cytochrome_be P450_be 3A4_be may_be cause_be reduction_be plasma_be OTHER_DRUG concentrations_af ._af"
4020,"Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.",phenytoin,bexarotene,mechanism,"Furthermore_bf ,_bf rifampin_bf ,_bf DRUG ,_be phenobarbital_be ,_be inducers_be cytochrome_be P450_be 3A4_be may_be cause_be reduction_be plasma_be OTHER_DRUG concentrations_af ._af"
4021,"Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.",phenobarbital,bexarotene,mechanism,"Furthermore_bf ,_bf rifampin_bf ,_bf phenytoin_bf ,_bf DRUG ,_be inducers_be cytochrome_be P450_be 3A4_be may_be cause_be reduction_be plasma_be OTHER_DRUG concentrations_af ._af"
4022,"Concomitant administration of Targretin capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.",Targretin,gemfibrozil,mechanism,"Concomitant_bf administration_bf DRUG capsules_be OTHER_DRUG resulted_af substantial_af increases_af plasma_af concentrations_af bexarotene_af ,_af probably_af least_af partially_af related_af cytochrome_af P450_af 3A4_af inhibition_af OTHER_DRUG ._af"
4071,"In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.",CASODEX,coumarin anticoagulant,mechanism,"In_bf vitro_bf studies_bf shown_bf DRUG displace_be coumarin_be anticoagulants_be ,_be warfarin_be ,_be protein-binding_be sites_be ._be"
4072,"In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.",CASODEX,warfarin,mechanism,"In_bf vitro_bf studies_bf shown_bf DRUG displace_be coumarin_be anticoagulants_be ,_be OTHER_DRUG ,_af protein-binding_af sites_af ._af"
4152,"Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.",bosentan,Ortho-Novum,mechanism,"Hormonal_bf Contraceptives_bf ,_bf Including_bf Oral_bf ,_bf Injectable_bf ,_bf Transdermal_bf ,_bf Implantable_bf Contraceptives:_bf An_bf interaction_bf study_bf demonstrated_bf co-administration_bf DRUG oral_be hormonal_be contraceptive_be OTHER_DRUG produced_af average_af decreases_af norethindrone_af ethinyl_af estradiol_af levels_af 14%_af 31%_af ,_af respectively_af ._af"
4163,Steady-state bosentan plasma concentrations were 3- to 4-fold higher than in the absence of cyclosporine A.,bosentan,cyclosporine A,mechanism,Steady-state_bf DRUG plasma_be concentrations_be 3-_be 4-fold_be higher_be absence_be cyclosporine_be A_be ._be
4165,Co-administration of bosentan decreased the plasma concentrations of cyclosporine A (a CYP3A4 substrate) by approximately 50%.,bosentan,cyclosporine A,mechanism,Co-administration_bf DRUG decreased_be plasma_be concentrations_be cyclosporine_be A_be (a_be CYP3A4_be substrate)_be approximately_be 50%_be ._be
4169,Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.,tacrolimus,bosentan,mechanism,Co-administration_bf DRUG OTHER_DRUG resulted_af markedly_af increased_af plasma_af concentrations_af OTHER_DRUG animals_af ._af
4177,Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.,bosentan,glyburide,mechanism,Co-administration_bf DRUG decreased_be plasma_be concentrations_be OTHER_DRUG approximately_af 40%_af ._af
4178,Bosentan is also expected to reduce plasma concentrations of other oral hypoglycemic agents that are predominantly metabolized by CYP2C9 or CYP3A4.,Bosentan,hypoglycemic agents,mechanism,DRUG also_be expected_be reduce_be plasma_be concentrations_be oral_be hypoglycemic_be agents_be predominantly_be metabolized_be CYP2C9_be CYP3A4_be ._be
4182,"Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.",bosentan,ketoconazole,mechanism,"Ketoconazole:_bf Co-administration_bf DRUG 125_be mg_be b_be ._be ._be ._be OTHER_DRUG ,_af potent_af CYP3A4_af inhibitor_af ,_af increased_af plasma_af concentrations_af DRUG approximately_af 2-fold_af ._af"
4191,"Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.",bosentan,simvastatin,mechanism,"OTHER_DRUG Other_be Statins:_be Co-administration_be DRUG decreased_af plasma_af concentrations_af OTHER_DRUG (a_af CYP3A4_af substrate)_af ,_af active_af -hydroxy_af acid_af metabolite_af ,_af approximately_af 50%_af ._af"
4192,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.",Bosentan,statins,mechanism,"DRUG also_be expected_be reduce_be plasma_be concentrations_be OTHER_DRUG significant_af metabolism_af CYP3A4_af ,_af lovastatin_af atorvastatin_af ._af"
4193,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.",Bosentan,lovastatin,mechanism,"DRUG also_be expected_be reduce_be plasma_be concentrations_be statins_be significant_be metabolism_be CYP3A4_be ,_be OTHER_DRUG atorvastatin_af ._af"
4194,"Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.",Bosentan,atorvastatin,mechanism,"DRUG also_be expected_be reduce_be plasma_be concentrations_be statins_be significant_be metabolism_be CYP3A4_be ,_be lovastatin_be OTHER_DRUG ._af"
4204,"Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.",bosentan,S-warfarin,mechanism,"Warfarin:_bf Co-administration_bf DRUG 500_be mg_be b_be ._be ._be ._be 6_be days_be decreased_be plasma_be concentrations_be OTHER_DRUG (a_af CYP2C9_af substrate)_af R-warfarin_af (a_af CYP3A4_af substrate)_af 29_af 38%_af ,_af respectively_af ._af"
4205,"Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.",bosentan,R-warfarin,mechanism,"Warfarin:_bf Co-administration_bf DRUG 500_be mg_be b_be ._be ._be ._be 6_be days_be decreased_be plasma_be concentrations_be S-warfarin_be (a_be CYP2C9_be substrate)_be OTHER_DRUG (a_af CYP3A4_af substrate)_af 29_af 38%_af ,_af respectively_af ._af"
4379,Concomitant oral administration of ketoconazole (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral budesonide.,ketoconazole,budesonide,mechanism,Concomitant_bf oral_bf administration_bf DRUG (a_be known_be inhibitor_be CYP3A4_be activity_be liver_be intestinal_be mucosa)_be caused_be eight-fold_be increase_be systemic_be exposure_be oral_be OTHER_DRUG ._af
4415,This antagonistic effect of probenecid on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.,probenecid,bumetanide,mechanism,This_bf antagonistic_bf effect_bf DRUG OTHER_DRUG natriuresis_af due_af direct_af action_af sodium_af excretion_af probably_af secondary_af inhibitory_af effect_af renal_af tubular_af secretion_af OTHER_DRUG ._af
4422,#NAME?,Indomethacin,bumetanide,mechanism,-_bf Indomethacin:_bf DRUG blunts_be increases_be urine_be volume_be sodium_be excretion_be seen_be OTHER_DRUG treatment_af inhibits_af bumetanide-induced_af increase_af plasma_af renin_af activity_af ._af
4504,"While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).",bupropion,carbamazepine,mechanism,"While_bf systematically_bf studied_bf ,_bf certain_bf drugs_bf may_bf induce_bf metabolism_bf DRUG (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af phenobarbital_af ,_af phenytoin)_af ._af"
4505,"While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).",bupropion,phenobarbital,mechanism,"While_bf systematically_bf studied_bf ,_bf certain_bf drugs_bf may_bf induce_bf metabolism_bf DRUG (e_be ._be g_be ._be ,_be carbamazepine_be ,_be OTHER_DRUG ,_af phenytoin)_af ._af"
4506,"While not systematically studied, certain drugs may induce the metabolism of bupropion (e.g., carbamazepine, phenobarbital, phenytoin).",bupropion,phenytoin,mechanism,"While_bf systematically_bf studied_bf ,_bf certain_bf drugs_bf may_bf induce_bf metabolism_bf DRUG (e_be ._be g_be ._be ,_be carbamazepine_be ,_be phenobarbital_be ,_be phenytoin)_be ._be"
4523,"In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and t1/2 of desipramine by an average of approximately 2-, 5- and 2-fold, respectively.",bupropion,desipramine,mechanism,"In_bf study_bf 15_bf male_bf subjects_bf (ages_bf 19_bf 35_bf years)_bf extensive_bf metabolizers_bf CYP2D6_bf isoenzyme_bf ,_bf daily_bf doses_bf DRUG given_be 150_be mg_be twice_be daily_be followed_be single_be dose_be 50_be mg_be OTHER_DRUG increased_af Cmax_af ,_af AUC_af ,_af t1/2_af OTHER_DRUG average_af approximately_af 2-_af ,_af 5-_af 2-fold_af ,_af respectively_af ._af"
4711,"In a study in normal volunteers, concomitant administration of buspirone HCl and haloperidol resulted in increased serum haloperidol concentrations.",buspirone HCl,haloperidol,mechanism,"In_bf study_bf normal_bf volunteers_bf ,_bf concomitant_bf administration_bf buspirone_bf HCl_bf OTHER_DRUG resulted_be increased_be serum_be OTHER_DRUG concentrations_af ._af"
4727,"In vitro, buspirone may displace less firmly bound drugs like digoxin.",buspirone,digoxin,mechanism,"In_bf vitro_bf ,_bf DRUG may_be displace_be less_be firmly_be bound_be drugs_be like_be OTHER_DRUG ._af"
4728,"Itraconazole decreases busulfan clearance by up to 25%, and may produce AUCs   1500  M min in some patients.",Itraconazole,busulfan,mechanism,"DRUG decreases_be OTHER_DRUG clearance_af 25%_af ,_af may_af produce_af AUCs_af 1500_af M_af min_af patients_af ._af"
4750,"Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.",Phenytoin,busulfan,mechanism,"DRUG increases_be clearance_be OTHER_DRUG 15%_af ,_af possibly_af due_af induction_af glutathione-S-transferase_af ._af"
4751,"Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.",BUSULFEX,phenytoin,mechanism,"Since_bf pharmacokinetics_bf DRUG studied_be patients_be treated_be OTHER_DRUG ,_af clearance_af DRUG recommended_af dose_af may_af lower_af exposure_af (AUC)_af higher_af patients_af treated_af OTHER_DRUG ._af"
4761,"Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.",acetaminophen,BUSULFEX,mechanism,"Because_bf busulfan_bf eliminated_bf body_bf via_bf conjugation_bf glutathione_bf ,_bf use_bf DRUG prior_be (_be 72_be hours)_be concurrent_be OTHER_DRUG may_af result_af reduced_af busulfan_af clearance_af based_af upon_af known_af property_af DRUG decrease_af glutathione_af levels_af blood_af tissues_af ._af"
4932,"However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.",STADOL NS,sumatriptan,mechanism,"However_bf ,_bf another_bf study_bf healthy_bf volunteers_bf ,_bf pharmacokinetics_bf butorphanol_bf significantly_bf altered_bf (29%_bf decrease_bf AUC_bf 38%_bf decrease_bf Cmax)_bf 1-mg_bf dose_bf STADOL_bf NS_bf administered_bf 1_bf minute_bf 20-mg_bf dose_bf OTHER_DRUG nasal_be spray_be ._be"
4933,"When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.",STADOL NS,sumatriptan,mechanism,"When_bf STADOL_bf NS_bf administered_bf 30_bf minutes_bf OTHER_DRUG nasal_be spray_be ,_be AUC_be butorphanol_be increased_be 11%_be Cmax_be decreased_be 18%_be ._be"
5020,"Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;",Cholestyramine,fat soluble vitamins,mechanism,"Interactions_bf vitamin_bf D_bf analogues_bf (Vitamin_bf D2_bf ,_bf Vitamin_bf D3_bf ,_bf Calcitriol_bf ,_bf Calcidiol):_bf Cholestyramine:_bf DRUG reported_be reduce_be intestinal_be absorption_be fat_be soluble_be vitamins;_be"
5032,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenytoin,calcitriol,mechanism,"Phenytoin/Phenobarbital:_bf The_bf coadministration_bf DRUG phenobarbital_be affect_be plasma_be concentrations_be vitamin_be D_be ,_be may_be reduce_be endogenous_be plasma_be levels_be calcitriol/ergocalcitriol_be accelerating_be metabolism_be ._be"
5034,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenobarbital,calcitriol,mechanism,"Phenytoin/Phenobarbital:_bf The_bf coadministration_bf phenytoin_bf DRUG affect_be plasma_be concentrations_be vitamin_be D_be ,_be may_be reduce_be endogenous_be plasma_be levels_be calcitriol/ergocalcitriol_be accelerating_be metabolism_be ._be"
5044,Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.,Ketoconazole,vitamin D,mechanism,Ketoconazole:_bf DRUG may_be inhibit_be synthetic_be catabolic_be enzymes_be vitamin_be D_be ._be
5048,"Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.",vitamin D analogues,corticosteroids,mechanism,"Corticosteroids:_bf A_bf relationship_bf functional_bf antagonism_bf exists_bf vitamin_bf D_bf analogues_bf ,_bf promote_bf calcium_bf absorption_bf ,_bf OTHER_DRUG ,_be inhibit_be calcium_be absorption_be ._be"
5084,"Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;",Cholestyramine,fat soluble vitamins,mechanism,"Interactions_bf vitamin_bf D_bf analogues_bf (Vitamin_bf D2_bf ,_bf Vitamin_bf D3_bf ,_bf Calcitriol_bf ,_bf Calcidiol):_bf Cholestyramine:_bf DRUG reported_be reduce_be intestinal_be absorption_be fat_be soluble_be vitamins;_be"
5096,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenytoin,calcitriol,mechanism,"Phenytoin/Phenobarbital:_bf The_bf coadministration_bf DRUG phenobarbital_be affect_be plasma_be concentrations_be vitamin_be D_be ,_be may_be reduce_be endogenous_be plasma_be levels_be calcitriol/ergocalcitriol_be accelerating_be metabolism_be ._be"
5098,"Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.",phenobarbital,calcitriol,mechanism,"Phenytoin/Phenobarbital:_bf The_bf coadministration_bf phenytoin_bf DRUG affect_be plasma_be concentrations_be vitamin_be D_be ,_be may_be reduce_be endogenous_be plasma_be levels_be calcitriol/ergocalcitriol_be accelerating_be metabolism_be ._be"
5110,Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.,Ketoconazole,vitamin D,mechanism,Ketoconazole:_bf DRUG may_be inhibit_be synthetic_be catabolic_be enzymes_be vitamin_be D_be ._be
5114,"Corticosteroids: A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption.",vitamin D analogues,corticosteroids,mechanism,"Corticosteroids:_bf A_bf relationship_bf functional_bf antagonism_bf exists_bf vitamin_bf D_bf analogues_bf ,_bf promote_bf calcium_bf absorption_bf ,_bf OTHER_DRUG ,_be inhibit_be calcium_be absorption_be ._be"
5158,"Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.",lithium,ACE inhibitors,mechanism,"DRUG Reversible_be increases_be serum_be DRUG concentrations_af toxicity_af reported_af concomitant_af administration_af DRUG ACE_af inhibitors_af ,_af angiotensin_af II_af receptor_af antagonists_af ._af"
5159,"Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.",lithium,angiotensin II receptor antagonists,mechanism,"DRUG Reversible_be increases_be serum_be DRUG concentrations_af toxicity_af reported_af concomitant_af administration_af DRUG ACE_af inhibitors_af ,_af angiotensin_af II_af receptor_af antagonists_af ._af"
5164,"An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.",lithium,ATACAND,mechanism,"An_bf increase_bf serum_bf DRUG concentration_be reported_be concomitant_be administration_be DRUG OTHER_DRUG ,_af careful_af monitoring_af serum_af DRUG levels_af recommended_af concomitant_af use_af ._af"
5199,Leucovorin: The concentration of 5-fluorouracil is increased and its toxicity may be enhanced by leucovorin.,5-fluorouracil,leucovorin,mechanism,Leucovorin:_bf The_bf concentration_bf DRUG increased_be toxicity_be may_be enhanced_be OTHER_DRUG ._af
5202,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,Acetazolamide,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be OTHER_DRUG ,_af azole_af antifungals_af ,_af cimetidine_af ,_af clarithromycin(1)_af ,_af dalfopristin_af ,_af danazol_af ,_af delavirdine_af ,_af diltiazem_af ,_af erythromycin(1)_af ,_af fluoxetine_af ,_af fluvoxamine_af ,_af grapefruit_af juice_af ,_af isoniazid_af ,_af itraconazole_af ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
5203,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,azole antifungals,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be quinine_be ,_be quinupristin_be ,_be troleandomycin_be ,_be valproate(1)_be ,_be verapamil_be ,_be zileuton_be ._be"
5204,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,cimetidine,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be OTHER_DRUG ,_af clarithromycin(1)_af ,_af dalfopristin_af ,_af danazol_af ,_af delavirdine_af ,_af diltiazem_af ,_af erythromycin(1)_af ,_af fluoxetine_af ,_af fluvoxamine_af ,_af grapefruit_af juice_af ,_af isoniazid_af ,_af itraconazole_af ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
5205,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,clarithromycin,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be quinine_be ,_be quinupristin_be ,_be troleandomycin_be ,_be valproate(1)_be ,_be verapamil_be ,_be zileuton_be ._be"
5206,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,dalfopristin,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be OTHER_DRUG ,_af danazol_af ,_af delavirdine_af ,_af diltiazem_af ,_af erythromycin(1)_af ,_af fluoxetine_af ,_af fluvoxamine_af ,_af grapefruit_af juice_af ,_af isoniazid_af ,_af itraconazole_af ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
5207,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,danazol,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be OTHER_DRUG ,_af delavirdine_af ,_af diltiazem_af ,_af erythromycin(1)_af ,_af fluoxetine_af ,_af fluvoxamine_af ,_af grapefruit_af juice_af ,_af isoniazid_af ,_af itraconazole_af ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
5208,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,delavirdine,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be OTHER_DRUG ,_af diltiazem_af ,_af erythromycin(1)_af ,_af fluoxetine_af ,_af fluvoxamine_af ,_af grapefruit_af juice_af ,_af isoniazid_af ,_af itraconazole_af ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
5209,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,diltiazem,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be OTHER_DRUG ,_af erythromycin(1)_af ,_af fluoxetine_af ,_af fluvoxamine_af ,_af grapefruit_af juice_af ,_af isoniazid_af ,_af itraconazole_af ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
5210,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,erythromycin,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be quinine_be ,_be quinupristin_be ,_be troleandomycin_be ,_be valproate(1)_be ,_be verapamil_be ,_be zileuton_be ._be"
5211,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,fluoxetine,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be OTHER_DRUG ,_af fluvoxamine_af ,_af grapefruit_af juice_af ,_af isoniazid_af ,_af itraconazole_af ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
5212,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,fluvoxamine,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be OTHER_DRUG ,_af grapefruit_af juice_af ,_af isoniazid_af ,_af itraconazole_af ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
5213,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,isoniazid,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be OTHER_DRUG ,_af itraconazole_af ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
5214,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,itraconazole,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be OTHER_DRUG ,_af ketoconazole_af ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
5215,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,ketoconazole,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be OTHER_DRUG ,_af loratadine_af ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
5216,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,loratadine,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be OTHER_DRUG ,_af nefazodone_af ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
5217,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,nefazodone,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be OTHER_DRUG ,_af niacinamide_af ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
5218,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,niacinamide,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be OTHER_DRUG ,_af nicotinamide_af ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
5219,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,nicotinamide,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be OTHER_DRUG ,_af protease_af inhibitors_af ,_af propoxyphene_af ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
5220,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,protease inhibitors,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be quinine_be ,_be quinupristin_be ,_be troleandomycin_be ,_be valproate(1)_be ,_be verapamil_be ,_be zileuton_be ._be"
5221,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,propoxyphene,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be OTHER_DRUG ,_af quinine_af ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
5222,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,quinine,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be OTHER_DRUG ,_af quinupristin_af ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
5223,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,quinupristin,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be quinine_be ,_be OTHER_DRUG ,_af troleandomycin_af ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
5224,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,troleandomycin,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be quinine_be ,_be quinupristin_be ,_be OTHER_DRUG ,_af valproate(1)_af ,_af verapamil_af ,_af zileuton_af ._af"
5225,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,valproate,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be quinine_be ,_be quinupristin_be ,_be troleandomycin_be ,_be valproate(1)_be ,_be verapamil_be ,_be zileuton_be ._be"
5226,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,verapamil,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be quinine_be ,_be quinupristin_be ,_be troleandomycin_be ,_be valproate(1)_be ,_be OTHER_DRUG ,_af zileuton_af ._af"
5227,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.",EQUETROTM,zileuton,mechanism,"Agents_bf CYP3A4_bf inhibitors_bf found_bf ,_bf expected_bf ,_bf increase_bf plasma_bf levels_bf DRUG following:_be Acetazolamide_be ,_be azole_be antifungals_be ,_be cimetidine_be ,_be clarithromycin(1)_be ,_be dalfopristin_be ,_be danazol_be ,_be delavirdine_be ,_be diltiazem_be ,_be erythromycin(1)_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be grapefruit_be juice_be ,_be isoniazid_be ,_be itraconazole_be ,_be ketoconazole_be ,_be loratadine_be ,_be nefazodone_be ,_be niacinamide_be ,_be nicotinamide_be ,_be protease_be inhibitors_be ,_be propoxyphene_be ,_be quinine_be ,_be quinupristin_be ,_be troleandomycin_be ,_be valproate(1)_be ,_be verapamil_be ,_be OTHER_DRUG ._af"
5554,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,Cisplatin,mechanism,"Agents_bf CYP_bf inducers_bf found_bf ,_bf expected_bf ,_bf decrease_bf plasma_bf levels_bf DRUG following:_be OTHER_DRUG ,_af doxorubicin_af HCL_af ,_af felbamate_af ,_af rifampin_af ,_af phenobarbital_af ,_af Phenytoin(2)_af ,_af primidone_af ,_af methsuximide_af ,_af theophylline_af Thus_af ,_af patient_af titrated_af stable_af dosage_af DRUG ,_af begins_af course_af treatment_af one_af CYP3A4_af inducers_af ,_af reasonable_af expect_af dose_af increase_af DRUG may_af necessary_af ._af"
5555,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,doxorubicin HCL,mechanism,"Agents_bf CYP_bf inducers_bf found_bf ,_bf expected_bf ,_bf decrease_bf plasma_bf levels_bf DRUG following:_be Cisplatin_be ,_be doxorubicin_be HCL_be ,_be felbamate_be ,_be rifampin_be ,_be phenobarbital_be ,_be Phenytoin(2)_be ,_be primidone_be ,_be methsuximide_be ,_be theophylline_be Thus_be ,_be patient_be titrated_be stable_be dosage_be DRUG ,_af begins_af course_af treatment_af one_af CYP3A4_af inducers_af ,_af reasonable_af expect_af dose_af increase_af DRUG may_af necessary_af ._af"
5556,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,felbamate,mechanism,"Agents_bf CYP_bf inducers_bf found_bf ,_bf expected_bf ,_bf decrease_bf plasma_bf levels_bf DRUG following:_be Cisplatin_be ,_be doxorubicin_be HCL_be ,_be OTHER_DRUG ,_af rifampin_af ,_af phenobarbital_af ,_af Phenytoin(2)_af ,_af primidone_af ,_af methsuximide_af ,_af theophylline_af Thus_af ,_af patient_af titrated_af stable_af dosage_af DRUG ,_af begins_af course_af treatment_af one_af CYP3A4_af inducers_af ,_af reasonable_af expect_af dose_af increase_af DRUG may_af necessary_af ._af"
5557,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,rifampin,mechanism,"Agents_bf CYP_bf inducers_bf found_bf ,_bf expected_bf ,_bf decrease_bf plasma_bf levels_bf DRUG following:_be Cisplatin_be ,_be doxorubicin_be HCL_be ,_be felbamate_be ,_be OTHER_DRUG ,_af phenobarbital_af ,_af Phenytoin(2)_af ,_af primidone_af ,_af methsuximide_af ,_af theophylline_af Thus_af ,_af patient_af titrated_af stable_af dosage_af DRUG ,_af begins_af course_af treatment_af one_af CYP3A4_af inducers_af ,_af reasonable_af expect_af dose_af increase_af DRUG may_af necessary_af ._af"
5558,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,phenobarbital,mechanism,"Agents_bf CYP_bf inducers_bf found_bf ,_bf expected_bf ,_bf decrease_bf plasma_bf levels_bf DRUG following:_be Cisplatin_be ,_be doxorubicin_be HCL_be ,_be felbamate_be ,_be rifampin_be ,_be OTHER_DRUG ,_af Phenytoin(2)_af ,_af primidone_af ,_af methsuximide_af ,_af theophylline_af Thus_af ,_af patient_af titrated_af stable_af dosage_af DRUG ,_af begins_af course_af treatment_af one_af CYP3A4_af inducers_af ,_af reasonable_af expect_af dose_af increase_af DRUG may_af necessary_af ._af"
5559,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,Phenytoin,mechanism,"Agents_bf CYP_bf inducers_bf found_bf ,_bf expected_bf ,_bf decrease_bf plasma_bf levels_bf DRUG following:_be Cisplatin_be ,_be doxorubicin_be HCL_be ,_be felbamate_be ,_be rifampin_be ,_be phenobarbital_be ,_be Phenytoin(2)_be ,_be primidone_be ,_be methsuximide_be ,_be theophylline_be Thus_be ,_be patient_be titrated_be stable_be dosage_be DRUG ,_af begins_af course_af treatment_af one_af CYP3A4_af inducers_af ,_af reasonable_af expect_af dose_af increase_af DRUG may_af necessary_af ._af"
5560,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,primidone,mechanism,"Agents_bf CYP_bf inducers_bf found_bf ,_bf expected_bf ,_bf decrease_bf plasma_bf levels_bf DRUG following:_be Cisplatin_be ,_be doxorubicin_be HCL_be ,_be felbamate_be ,_be rifampin_be ,_be phenobarbital_be ,_be Phenytoin(2)_be ,_be OTHER_DRUG ,_af methsuximide_af ,_af theophylline_af Thus_af ,_af patient_af titrated_af stable_af dosage_af DRUG ,_af begins_af course_af treatment_af one_af CYP3A4_af inducers_af ,_af reasonable_af expect_af dose_af increase_af DRUG may_af necessary_af ._af"
5561,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,methsuximide,mechanism,"Agents_bf CYP_bf inducers_bf found_bf ,_bf expected_bf ,_bf decrease_bf plasma_bf levels_bf DRUG following:_be Cisplatin_be ,_be doxorubicin_be HCL_be ,_be felbamate_be ,_be rifampin_be ,_be phenobarbital_be ,_be Phenytoin(2)_be ,_be primidone_be ,_be OTHER_DRUG ,_af theophylline_af Thus_af ,_af patient_af titrated_af stable_af dosage_af DRUG ,_af begins_af course_af treatment_af one_af CYP3A4_af inducers_af ,_af reasonable_af expect_af dose_af increase_af DRUG may_af necessary_af ._af"
5562,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of EQUETROTM are the following: Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, Phenytoin(2), primidone, methsuximide, and theophylline Thus, if a patient has been titrated to a stable dosage on EQUETROTM, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for EQUETROTM may be necessary.",EQUETROTM,theophylline,mechanism,"Agents_bf CYP_bf inducers_bf found_bf ,_bf expected_bf ,_bf decrease_bf plasma_bf levels_bf DRUG following:_be Cisplatin_be ,_be doxorubicin_be HCL_be ,_be felbamate_be ,_be rifampin_be ,_be phenobarbital_be ,_be Phenytoin(2)_be ,_be primidone_be ,_be methsuximide_be ,_be OTHER_DRUG Thus_af ,_af patient_af titrated_af stable_af dosage_af DRUG ,_af begins_af course_af treatment_af one_af CYP3A4_af inducers_af ,_af reasonable_af expect_af dose_af increase_af DRUG may_af necessary_af ._af"
5621,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,Acetaminophen,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be OTHER_DRUG ,_af alprazolam_af ,_af amitriptyline_af ,_af bupropion_af ,_af buspirone_af ,_af citalopram_af ,_af clobazam_af ,_af clonazepam_af ,_af clozapine_af ,_af cyclosporin_af ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5622,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,alprazolam,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be OTHER_DRUG ,_af amitriptyline_af ,_af bupropion_af ,_af buspirone_af ,_af citalopram_af ,_af clobazam_af ,_af clonazepam_af ,_af clozapine_af ,_af cyclosporin_af ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5623,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,amitriptyline,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be OTHER_DRUG ,_af bupropion_af ,_af buspirone_af ,_af citalopram_af ,_af clobazam_af ,_af clonazepam_af ,_af clozapine_af ,_af cyclosporin_af ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5624,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,bupropion,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be OTHER_DRUG ,_af buspirone_af ,_af citalopram_af ,_af clobazam_af ,_af clonazepam_af ,_af clozapine_af ,_af cyclosporin_af ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5625,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,buspirone,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be OTHER_DRUG ,_af citalopram_af ,_af clobazam_af ,_af clonazepam_af ,_af clozapine_af ,_af cyclosporin_af ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5626,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,citalopram,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be OTHER_DRUG ,_af clobazam_af ,_af clonazepam_af ,_af clozapine_af ,_af cyclosporin_af ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5627,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,clobazam,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be OTHER_DRUG ,_af clonazepam_af ,_af clozapine_af ,_af cyclosporin_af ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5628,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,clonazepam,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be OTHER_DRUG ,_af clozapine_af ,_af cyclosporin_af ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5629,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,clozapine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be OTHER_DRUG ,_af cyclosporin_af ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5630,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,cyclosporin,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be OTHER_DRUG ,_af delavirdine_af ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5631,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,delavirdine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be OTHER_DRUG ,_af desipramine_af ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5632,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,desipramine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be OTHER_DRUG ,_af diazepam_af ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5633,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,diazepam,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be OTHER_DRUG ,_af dicumarol_af ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5634,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,dicumarol,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be OTHER_DRUG ,_af doxycycline_af ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5635,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,doxycycline,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be OTHER_DRUG ,_af ethosuximide_af ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5636,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,ethosuximide,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be OTHER_DRUG ,_af felbamate_af ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5637,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,felbamate,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be OTHER_DRUG ,_af felodipine_af ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5638,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,felodipine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be OTHER_DRUG ,_af glucocorticoids_af ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5639,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,glucocorticoids,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be OTHER_DRUG ,_af haloperidol_af ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5640,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,haloperidol,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be OTHER_DRUG ,_af itraconazole_af ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5641,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,itraconazole,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be OTHER_DRUG ,_af lamotrigine_af ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5642,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,lamotrigine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be OTHER_DRUG ,_af levothyroxine_af ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5643,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,levothyroxine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be OTHER_DRUG ,_af lorazepam_af ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5644,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,lorazepam,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be OTHER_DRUG ,_af methadone_af ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5645,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,methadone,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be OTHER_DRUG ,_af midazolam_af ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5646,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,midazolam,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be OTHER_DRUG ,_af mirtazapine_af ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5647,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,mirtazapine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be OTHER_DRUG ,_af nortriptyline_af ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5648,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,nortriptyline,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be OTHER_DRUG ,_af olanzapine_af ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5649,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,olanzapine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be OTHER_DRUG ,_af oral_af contraceptives(3)_af ,_af oxcarbazepine_af ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5650,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,contraceptives,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be tiagabine_be ,_be tramadol_be ,_be triazolam_be ,_be valproate_be ,_be warfarin(5)_be ,_be ziprasidone_be ,_be zonisamide_be ._be"
5651,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,oxcarbazepine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be OTHER_DRUG ,_af Phenytoin(4)_af ,_af praziquantel_af ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5652,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,Phenytoin,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be tiagabine_be ,_be tramadol_be ,_be triazolam_be ,_be valproate_be ,_be warfarin(5)_be ,_be ziprasidone_be ,_be zonisamide_be ._be"
5653,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,praziquantel,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be OTHER_DRUG ,_af protease_af inhibitors_af ,_af quetiapine_af ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5654,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,protease inhibitors,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be tiagabine_be ,_be tramadol_be ,_be triazolam_be ,_be valproate_be ,_be warfarin(5)_be ,_be ziprasidone_be ,_be zonisamide_be ._be"
5655,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,quetiapine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be OTHER_DRUG ,_af risperidone_af ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5656,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,risperidone,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be OTHER_DRUG ,_af theophylline_af ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5657,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,theophylline,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be OTHER_DRUG ,_af topiramate_af ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5658,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,topiramate,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be OTHER_DRUG ,_af tiagabine_af ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5659,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,tiagabine,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be OTHER_DRUG ,_af tramadol_af ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5660,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,tramadol,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be tiagabine_be ,_be OTHER_DRUG ,_af triazolam_af ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5661,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,triazolam,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be tiagabine_be ,_be tramadol_be ,_be OTHER_DRUG ,_af valproate_af ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5662,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,valproate,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be tiagabine_be ,_be tramadol_be ,_be triazolam_be ,_be OTHER_DRUG ,_af warfarin(5)_af ,_af ziprasidone_af ,_af zonisamide_af ._af"
5663,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,warfarin,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be tiagabine_be ,_be tramadol_be ,_be triazolam_be ,_be valproate_be ,_be warfarin(5)_be ,_be ziprasidone_be ,_be zonisamide_be ._be"
5664,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,ziprasidone,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be tiagabine_be ,_be tramadol_be ,_be triazolam_be ,_be valproate_be ,_be warfarin(5)_be ,_be OTHER_DRUG ,_af zonisamide_af ._af"
5665,"Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.",EQUETROTM,zonisamide,mechanism,"Agents_bf found_bf ,_bf expected_bf decreased_bf plasma_bf levels_bf presence_bf DRUG due_be induction_be CYP_be enzymes_be following:_be Acetaminophen_be ,_be alprazolam_be ,_be amitriptyline_be ,_be bupropion_be ,_be buspirone_be ,_be citalopram_be ,_be clobazam_be ,_be clonazepam_be ,_be clozapine_be ,_be cyclosporin_be ,_be delavirdine_be ,_be desipramine_be ,_be diazepam_be ,_be dicumarol_be ,_be doxycycline_be ,_be ethosuximide_be ,_be felbamate_be ,_be felodipine_be ,_be glucocorticoids_be ,_be haloperidol_be ,_be itraconazole_be ,_be lamotrigine_be ,_be levothyroxine_be ,_be lorazepam_be ,_be methadone_be ,_be midazolam_be ,_be mirtazapine_be ,_be nortriptyline_be ,_be olanzapine_be ,_be oral_be contraceptives(3)_be ,_be oxcarbazepine_be ,_be Phenytoin(4)_be ,_be praziquantel_be ,_be protease_be inhibitors_be ,_be quetiapine_be ,_be risperidone_be ,_be theophylline_be ,_be topiramate_be ,_be tiagabine_be ,_be tramadol_be ,_be triazolam_be ,_be valproate_be ,_be warfarin(5)_be ,_be ziprasidone_be ,_be OTHER_DRUG ._af"
6661,"Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.",EQUETROTM,Clomipramine HCl,mechanism,"Agents_bf Increased_bf Levels_bf Presence_bf Carbamazepine:_bf DRUG increases_be plasma_be levels_be following_be agents:_be Clomipramine_be HCl_be ,_be Phenytoin(6)_be ,_be primidone_be Thus_be ,_be patient_be titrated_be stable_be dosage_be one_be agents_be category_be ,_be begins_be course_be treatment_be DRUG ,_af reasonable_af expect_af dose_af decrease_af concomitant_af agent_af may_af necessary_af ._af"
6662,"Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.",EQUETROTM,Phenytoin,mechanism,"Agents_bf Increased_bf Levels_bf Presence_bf Carbamazepine:_bf DRUG increases_be plasma_be levels_be following_be agents:_be Clomipramine_be HCl_be ,_be Phenytoin(6)_be ,_be primidone_be Thus_be ,_be patient_be titrated_be stable_be dosage_be one_be agents_be category_be ,_be begins_be course_be treatment_be DRUG ,_af reasonable_af expect_af dose_af decrease_af concomitant_af agent_af may_af necessary_af ._af"
6663,"Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.",EQUETROTM,primidone,mechanism,"Agents_bf Increased_bf Levels_bf Presence_bf Carbamazepine:_bf DRUG increases_be plasma_be levels_be following_be agents:_be Clomipramine_be HCl_be ,_be Phenytoin(6)_be ,_be OTHER_DRUG Thus_af ,_af patient_af titrated_af stable_af dosage_af one_af agents_af category_af ,_af begins_af course_af treatment_af DRUG ,_af reasonable_af expect_af dose_af decrease_af concomitant_af agent_af may_af necessary_af ._af"
6687,Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.,Geocillin,probenecid,mechanism,DRUG (carbenicillin_be indanyl_be sodium)_be blood_be levels_be may_be increased_be prolonged_be concurrent_be administration_be OTHER_DRUG ._af
6688,Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.,carbenicillin indanyl sodium,probenecid,mechanism,Geocillin_bf (carbenicillin_bf indanyl_bf sodium)_bf blood_bf levels_bf may_bf increased_bf prolonged_bf concurrent_bf administration_bf OTHER_DRUG ._be
6700,Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.,digoxin,antithyroid agents,mechanism,Serum_bf concentration_bf DRUG digitoxin_be may_be increase_be patients_be take_be antithyroid_be agents_be ._be
6701,Serum concentration of digoxin and digitoxin may increase when patients take antithyroid agents.,digitoxin,antithyroid agents,mechanism,Serum_bf concentration_bf digoxin_bf DRUG may_be increase_be patients_be take_be antithyroid_be agents_be ._be
6764,Cyclosporine: Modest increases in mean trough cyclosporine concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.,cyclosporine,carvedilol,mechanism,Cyclosporine:_bf Modest_bf increases_bf mean_bf trough_bf DRUG concentrations_be observed_be following_be initiation_be OTHER_DRUG treatment_af 21_af renal_af transplant_af patients_af suffering_af chronic_af vascular_af rejection_af ._af
6774,Digoxin: Digoxin concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.,digoxin,carvedilol,mechanism,Digoxin:_bf DRUG concentrations_be increased_be 15%_be DRUG OTHER_DRUG administered_af concomitantly_af ._af
6777,Inducers and Inhibitors of Hepatic Metabolism: Rifampin reduced plasma concentrations of carvedilol by about 70%.,Rifampin,carvedilol,mechanism,Inducers_bf Inhibitors_bf Hepatic_bf Metabolism:_bf DRUG reduced_be plasma_be concentrations_be OTHER_DRUG 70%_af ._af
6820,"CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.",CANCIDAS,tacrolimus,mechanism,"DRUG reduced_be blood_be AUC0-12_be OTHER_DRUG approximately_af 20%_af ,_af peak_af blood_af concentration_af (Cmax)_af 16%_af ,_af 12-hour_af blood_af concentration_af (C12hr)_af 26%_af healthy_af subjects_af OTHER_DRUG (2_af doses_af 0_af ._af 1_af mg/kg_af 12_af hours_af apart)_af administered_af 10th_af day_af DRUG 70_af mg_af daily_af ,_af compared_af results_af control_af period_af OTHER_DRUG administered_af alone_af ._af"
6831,"In two clinical studies, cyclosporine (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of caspofungin by approximately 35%.",cyclosporine,caspofungin,mechanism,"In_bf two_bf clinical_bf studies_bf ,_bf DRUG (one_be 4_be mg/kg_be dose_be two_be 3_be mg/kg_be doses)_be increased_be AUC_be OTHER_DRUG approximately_af 35%_af ._af"
6834,A drug-drug interaction study with rifampin in healthy volunteers has shown a 30% decrease in caspofungin trough concentrations.,rifampin,caspofungin,mechanism,A_bf drug-drug_bf interaction_bf study_bf DRUG healthy_be volunteers_be shown_be 30%_be decrease_be OTHER_DRUG trough_af concentrations_af ._af
6840,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",efavirenz,CANCIDAS,mechanism,"In_bf addition_bf ,_bf results_bf regression_bf analyses_bf patient_bf pharmacokinetic_bf data_bf suggest_bf co-administration_bf inducers_bf drug_bf clearance_bf (efavirenz_bf ,_bf nevirapine_bf ,_bf phenytoin_bf ,_bf dexamethasone_bf ,_bf carbamazepine)_bf OTHER_DRUG may_be result_be clinically_be meaningful_be reductions_be caspofungin_be concentrations_be ._be"
6845,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",nevirapine,CANCIDAS,mechanism,"In_bf addition_bf ,_bf results_bf regression_bf analyses_bf patient_bf pharmacokinetic_bf data_bf suggest_bf co-administration_bf inducers_bf drug_bf clearance_bf (efavirenz_bf ,_bf DRUG ,_be phenytoin_be ,_be dexamethasone_be ,_be carbamazepine)_be OTHER_DRUG may_af result_af clinically_af meaningful_af reductions_af caspofungin_af concentrations_af ._af"
6849,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",phenytoin,CANCIDAS,mechanism,"In_bf addition_bf ,_bf results_bf regression_bf analyses_bf patient_bf pharmacokinetic_bf data_bf suggest_bf co-administration_bf inducers_bf drug_bf clearance_bf (efavirenz_bf ,_bf nevirapine_bf ,_bf DRUG ,_be dexamethasone_be ,_be carbamazepine)_be OTHER_DRUG may_af result_af clinically_af meaningful_af reductions_af caspofungin_af concentrations_af ._af"
6852,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",dexamethasone,CANCIDAS,mechanism,"In_bf addition_bf ,_bf results_bf regression_bf analyses_bf patient_bf pharmacokinetic_bf data_bf suggest_bf co-administration_bf inducers_bf drug_bf clearance_bf (efavirenz_bf ,_bf nevirapine_bf ,_bf phenytoin_bf ,_bf DRUG ,_be carbamazepine)_be OTHER_DRUG may_af result_af clinically_af meaningful_af reductions_af caspofungin_af concentrations_af ._af"
6854,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.",carbamazepine,CANCIDAS,mechanism,"In_bf addition_bf ,_bf results_bf regression_bf analyses_bf patient_bf pharmacokinetic_bf data_bf suggest_bf co-administration_bf inducers_bf drug_bf clearance_bf (efavirenz_bf ,_bf nevirapine_bf ,_bf phenytoin_bf ,_bf dexamethasone_bf ,_bf carbamazepine)_bf OTHER_DRUG may_be result_be clinically_be meaningful_be reductions_be caspofungin_be concentrations_be ._be"
6878,"Probenecid may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.",Probenecid,cephalosporins,mechanism,"DRUG may_be decrease_be renal_be tubular_be secretion_be OTHER_DRUG used_af concurrently_af ,_af resulting_af increased_af prolonged_af cephalosporin_af blood_af levels_af ._af"
6890,"H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.",famotidine,cefditoren pivoxil,mechanism,"H2-Receptor_bf Antagonists:_bf Co-administration_bf single_bf dose_bf intravenously_bf administered_bf DRUG (20_be mg)_be reduced_be oral_be absorption_be single_be 400_be mg_be dose_be cefditoren_be pivoxil_be administered_be following_be meal_be ,_be evidenced_be 27%_be decrease_be mean_be Cmax_be 22%_be decrease_be mean_be AUC_be ._be"
6897,"Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.",b-lactam antibiotics,cefditoren pivoxil,mechanism,"Probenecid:_bf As_bf b-lactam_bf antibiotics_bf ,_bf co-administration_bf probenecid_bf cefditoren_bf pivoxil_bf resulted_bf increase_bf plasma_bf exposure_bf cefditoren_bf ,_bf 49%_bf increase_bf mean_bf Cmax_bf ,_bf 122%_bf increase_bf mean_bf AUC_bf ,_bf 53%_bf increase_bf half-life_bf ._bf"
6899,"Probenecid: As with other b-lactam antibiotics, co-administration of probenecid with cefditoren pivoxil resulted in an increase in the plasma exposure of cefditoren, with a 49% increase in mean Cmax, a 122% increase in mean AUC, and a 53% increase in half-life.",probenecid,cefditoren pivoxil,mechanism,"Probenecid:_bf As_bf b-lactam_bf antibiotics_bf ,_bf co-administration_bf DRUG cefditoren_be pivoxil_be resulted_be increase_be plasma_be exposure_be cefditoren_be ,_be 49%_be increase_be mean_be Cmax_be ,_be 122%_be increase_be mean_be AUC_be ,_be 53%_be increase_be half-life_be ._be"
6910,Carbamazepine: Elevated carbamazepine levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.,carbamazepine,SUPRAX,mechanism,Carbamazepine:_bf Elevated_bf DRUG levels_be reported_be postmarketing_be experience_be OTHER_DRUG administered_af concomitantly_af ._af
6922,Concomitant administration of probenecid doubled the AUC for cefprozil.,probenecid,cefprozil,mechanism,Concomitant_bf administration_bf DRUG doubled_be AUC_be OTHER_DRUG ._af
6941,"however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.",ranitidine,ceftibuten,mechanism,"however_bf ,_bf 150_bf mg_bf DRUG q12h_be 3_be days_be increased_be OTHER_DRUG C_af max_af 23%_af OTHER_DRUG AUC_af 16%_af ._af"
6942,"however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.",ranitidine,ceftibuten,mechanism,"however_bf ,_bf 150_bf mg_bf DRUG q12h_be 3_be days_be increased_be OTHER_DRUG C_af max_af 23%_af OTHER_DRUG AUC_af 16%_af ._af"
6997,Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.,fluconazole,celecoxib,mechanism,Fluconazole:_bf Concomitant_bf administration_bf DRUG 200_be mg_be QD_be resulted_be two-fold_be increase_be OTHER_DRUG plasma_af concentration_af ._af
6998,This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).,celecoxib,fluconazole,mechanism,This_bf increase_bf due_bf inhibition_bf DRUG metabolism_be via_be P450_be 2C9_be OTHER_DRUG (see_af CLINICAL_af PHARMACOLOGY_af -_af Pharmacokinetics:_af Metabolism)_af ._af
7007,"Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.",lithium,CELEBREX,mechanism,"Lithium:_bf In_bf study_bf conducted_bf healthy_bf subjects_bf ,_bf mean_bf steady-state_bf DRUG plasma_be levels_be increased_be approximately_be 17%_be subjects_be receiving_be DRUG 450_af mg_af BID_af OTHER_DRUG 200_af mg_af BID_af compared_af subjects_af receiving_af DRUG alone_af ._af"
7029,"Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.",cephalexin,metformin,mechanism,"Metformin:_bf In_bf healthy_bf subjects_bf given_bf single_bf 500_bf mg_bf doses_bf DRUG OTHER_DRUG ,_af plasma_af OTHER_DRUG mean_af cmax_af AUC_af increased_af average_af 34%_af 24%_af ,_af respectively_af ,_af OTHER_DRUG mean_af renal_af clearance_af decreased_af 14%_af ._af"
7036,"Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.",cephalexin,metformin,mechanism,"Although_bf observed_bf study_bf ,_bf adverse_bf effects_bf could_bf potentially_bf arise_bf co-administration_bf DRUG OTHER_DRUG inhibition_af tubular_af secretion_af via_af organic_af cationic_af transporter_af systems_af ._af"
7045,"Probenecid: As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.",cephalexin,probenecid,mechanism,"Probenecid:_bf As_bf b-lactams_bf ,_bf renal_bf excretion_bf DRUG inhibited_be OTHER_DRUG ._af"
7073,"In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.",cerivastatin sodium,cholestyramine,mechanism,"In_bf first_bf study_bf ,_bf concomitant_bf administration_bf 0_bf ._bf 2_bf mg_bf cerivastatin_bf sodium_bf 12_bf g_bf OTHER_DRUG resulted_be decreases_be 22%_be AUC_be 40%_be Cmax_be compared_be dosing_be cerivastatin_be sodium_be alone_be ._be"
7076,"However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.",cholestyramine,cerivastatin sodium,mechanism,"However_bf ,_bf second_bf study_bf ,_bf administration_bf 12_bf g_bf DRUG 1_be hour_be evening_be meal_be 0_be ._be 3_be mg_be cerivastatin_be sodium_be approximately_be 4_be hours_be evening_be meal_be resulted_be decrease_be cerivastatin_be AUC_be less_be 8%_be ,_be decrease_be Cmax_be 30%_be compared_be dosing_be cerivastatin_be sodium_be alone_be ._be"
7104,"ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.",cerivastatin,erythromycin,mechanism,"ERYTHROMYCIN:_bf In_bf hypercholesterolemic_bf patients_bf ,_bf steady-state_bf DRUG AUC_be Cmax_be increased_be approximately_be 50%_be 24%_be respectively_be 10_be days_be co-administration_be OTHER_DRUG ,_af known_af inhibitor_af cytochrome_af P450_af 3A4_af ._af"
7141,"In a multiple dose study of theophylline (400 mg once daily for 3 days) and cetirizine (20 mg once daily for 3 days), a 16% decrease in the clearance of cetirizine was observed.",theophylline,cetirizine,mechanism,"In_bf multiple_bf dose_bf study_bf DRUG (400_be mg_be daily_be 3_be days)_be OTHER_DRUG (20_af mg_af daily_af 3_af days)_af ,_af 16%_af decrease_af clearance_af OTHER_DRUG observed_af ._af"
7155,There was a small decrease in the clearance of cetirizine caused by a 400-mg dose of theophylline;,cetirizine,theophylline,mechanism,There_bf small_bf decrease_bf clearance_bf DRUG caused_be 400-mg_be dose_be theophylline;_be
7186,Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;,Antacids,chloroquine,mechanism,DRUG kaolin:_be DRUG kaolin_af reduce_af absorption_af chloroquine;_af
7187,Antacids and kaolin: Antacids and kaolin can reduce absorption of chloroquine;,kaolin,chloroquine,mechanism,Antacids_bf kaolin:_bf Antacids_bf DRUG reduce_be absorption_be chloroquine;_be
7190,"Cimetidine: Cimetidine can inhibit the metabolism of chloroquine, increasing its plasma level.",Cimetidine,chloroquine,mechanism,"Cimetidine:_bf DRUG inhibit_be metabolism_be OTHER_DRUG ,_af increasing_af plasma_af level_af ._af"
7193,"Ampicillin: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin.",chloroquine,ampicillin,mechanism,"Ampicillin:_bf In_bf study_bf healthy_bf volunteers_bf ,_bf DRUG significantly_be reduced_be bioavailability_be OTHER_DRUG ._af"
7196,"Cyclosporin: After introduction of chloroquine (oral form), a sudden increase in serum cyclosporin level has been reported.",chloroquine,cyclosporin,mechanism,"Cyclosporin:_bf After_bf introduction_bf DRUG (oral_be form)_be ,_be sudden_be increase_be serum_be OTHER_DRUG level_af reported_af ._af"
7224,#NAME?,Cholestytamine,thiazide diuretics,mechanism,#NAME?
7227,#NAME?,colestipol,thiazide diuretics,mechanism,#NAME?
7237,Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.,Diuretic agents,lithium,mechanism,Diuretic_bf agents_bf reduce_bf renal_bf clearance_bf OTHER_DRUG add_be high_be risk_be OTHER_DRUG toxicity_af ._af
7238,Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.,Diuretic agents,lithium,mechanism,Diuretic_bf agents_bf reduce_bf renal_bf clearance_bf OTHER_DRUG add_be high_be risk_be OTHER_DRUG toxicity_af ._af
7562,Chlorprothixene may increase the plasma-level of concomitantly given lithium.,Chlorprothixene,lithium,mechanism,DRUG may_be increase_be plasma-level_be concomitantly_be given_be OTHER_DRUG ._af
7614,"Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;",Cholestyramine,fat soluble vitamins,mechanism,"Interactions_bf vitamin_bf D_bf analogues_bf (Vitamin_bf D2_bf ,_bf Vitamin_bf D3_bf ,_bf Calcitriol_bf ,_bf Calcidiol):_bf Cholestyramine:_bf DRUG reported_be reduce_be intestinal_be absorption_be fat_be soluble_be vitamins;_be"
7638,Ketoconazole: Ketoconazole may inhibit both synthetic and catabolic enzymes of vitamin D.,Ketoconazole,vitamin D,mechanism,Ketoconazole:_bf DRUG may_be inhibit_be synthetic_be catabolic_be enzymes_be vitamin_be D_be ._be
7652,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,phenylbutazone,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be OTHER_DRUG ,_af warfarin_af ,_af thiazide_af diuretics_af (acidic)_af propranolol_af (basic)_af ,_af well_af tetracycline_af penicillin_af G_af ,_af phenobarbital_af ,_af thyroid_af thyroxine_af preparations_af ,_af estrogens_af progestins_af ,_af digitalis_af ._af"
7653,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,warfarin,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be OTHER_DRUG ,_af thiazide_af diuretics_af (acidic)_af propranolol_af (basic)_af ,_af well_af tetracycline_af penicillin_af G_af ,_af phenobarbital_af ,_af thyroid_af thyroxine_af preparations_af ,_af estrogens_af progestins_af ,_af digitalis_af ._af"
7654,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,thiazide diuretics,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be warfarin_be ,_be thiazide_be diuretics_be (acidic)_be propranolol_be (basic)_be ,_be well_be tetracycline_be penicillin_be G_be ,_be phenobarbital_be ,_be thyroid_be thyroxine_be preparations_be ,_be estrogens_be progestins_be ,_be digitalis_be ._be"
7655,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,propranolol,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be warfarin_be ,_be thiazide_be diuretics_be (acidic)_be OTHER_DRUG (basic)_af ,_af well_af tetracycline_af penicillin_af G_af ,_af phenobarbital_af ,_af thyroid_af thyroxine_af preparations_af ,_af estrogens_af progestins_af ,_af digitalis_af ._af"
7656,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,tetracycline,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be warfarin_be ,_be thiazide_be diuretics_be (acidic)_be propranolol_be (basic)_be ,_be well_be OTHER_DRUG penicillin_af G_af ,_af phenobarbital_af ,_af thyroid_af thyroxine_af preparations_af ,_af estrogens_af progestins_af ,_af digitalis_af ._af"
7657,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,penicillin G,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be warfarin_be ,_be thiazide_be diuretics_be (acidic)_be propranolol_be (basic)_be ,_be well_be tetracycline_be penicillin_be G_be ,_be phenobarbital_be ,_be thyroid_be thyroxine_be preparations_be ,_be estrogens_be progestins_be ,_be digitalis_be ._be"
7658,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,phenobarbital,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be warfarin_be ,_be thiazide_be diuretics_be (acidic)_be propranolol_be (basic)_be ,_be well_be tetracycline_be penicillin_be G_be ,_be OTHER_DRUG ,_af thyroid_af thyroxine_af preparations_af ,_af estrogens_af progestins_af ,_af digitalis_af ._af"
7659,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,thyroxine,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be warfarin_be ,_be thiazide_be diuretics_be (acidic)_be propranolol_be (basic)_be ,_be well_be tetracycline_be penicillin_be G_be ,_be phenobarbital_be ,_be thyroid_be OTHER_DRUG preparations_af ,_af estrogens_af progestins_af ,_af digitalis_af ._af"
7660,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,estrogens,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be warfarin_be ,_be thiazide_be diuretics_be (acidic)_be propranolol_be (basic)_be ,_be well_be tetracycline_be penicillin_be G_be ,_be phenobarbital_be ,_be thyroid_be thyroxine_be preparations_be ,_be OTHER_DRUG progestins_af ,_af digitalis_af ._af"
7661,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,progestins,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be warfarin_be ,_be thiazide_be diuretics_be (acidic)_be propranolol_be (basic)_be ,_be well_be tetracycline_be penicillin_be G_be ,_be phenobarbital_be ,_be thyroid_be thyroxine_be preparations_be ,_be estrogens_be OTHER_DRUG ,_af digitalis_af ._af"
7662,"Cholestyramine resin may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic) or propranolol (basic), as well as tetracycline penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis.",Cholestyramine,digitalis,mechanism,"DRUG resin_be may_be delay_be reduce_be absorption_be concomitant_be oral_be medication_be phenylbutazone_be ,_be warfarin_be ,_be thiazide_be diuretics_be (acidic)_be propranolol_be (basic)_be ,_be well_be tetracycline_be penicillin_be G_be ,_be phenobarbital_be ,_be thyroid_be thyroxine_be preparations_be ,_be estrogens_be progestins_be ,_be OTHER_DRUG ._af"
7741,"Cholestyramine resin may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of cholestyramine resin could pose a hazard to health if a potentially toxic drug such as digitalis has been filtrated to a maintenance level while the patient was taking cholestyramine resin.",cholestyramine,digitalis,mechanism,"DRUG resin_be may_be interfere_be pharmacokinetics_be drugs_be undergo_be enterohepatic_be circulation_be ,_be The_be discontinuance_be DRUG resin_af could_af pose_af hazard_af health_af potentially_af toxic_af drug_af OTHER_DRUG filtrated_af maintenance_af level_af patient_af taking_af DRUG resin_af ._af"
7774,"In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.",ciclesonide,ketoconazole,mechanism,"In_bf another_bf drug_bf interaction_bf study_bf ,_bf co-administration_bf orally_bf inhaled_bf DRUG oral_be OTHER_DRUG ,_af potent_af inhibitor_af cytochrome_af P450_af 3A4_af ,_af increased_af exposure_af (AUC)_af des-ciclesonide_af approximately_af 3_af ._af 6-fold_af steady_af state_af ,_af levels_af DRUG remained_af unchanged_af ._af"
7796,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,acetaminophen,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af OTHER_DRUG ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
7797,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,acyclovir,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af OTHER_DRUG ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
7798,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,angiotensin-converting enzyme inhibitors,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
7799,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,aminosalicylic acid,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
7800,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,barbiturates,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af OTHER_DRUG ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
7801,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,benzodiazepines,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af OTHER_DRUG ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
7802,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,bumetanide,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af OTHER_DRUG ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
7803,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,clofibrate,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af OTHER_DRUG ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
7804,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,methotrexate,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af OTHER_DRUG ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
7805,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,famotidine,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af OTHER_DRUG ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
7806,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,furosemide,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af OTHER_DRUG ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
7807,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,nonsteroidal anti-inflammatory,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
7808,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,theophylline,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af OTHER_DRUG ,_af zidovudine)_af ._af"
7809,"Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).",Probenecid,zidovudine,mechanism,"DRUG :_be DRUG known_af interact_af metabolism_af renal_af tubular_af excretion_af many_af drugs_af (e_af ._af g_af ._af ,_af acetaminophen_af ,_af acyclovir_af ,_af angiotensin-converting_af enzyme_af inhibitors_af ,_af aminosalicylic_af acid_af ,_af barbiturates_af ,_af benzodiazepines_af ,_af bumetanide_af ,_af clofibrate_af ,_af methotrexate_af ,_af famotidine_af ,_af furosemide_af ,_af nonsteroidal_af anti-inflammatory_af agents_af ,_af theophylline_af ,_af zidovudine)_af ._af"
7960,Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.,omeprazole,cilostazol,mechanism,Pharmacokinetic_bf studies_bf demonstrated_bf DRUG erythromycin_be significantly_be increased_be systemic_be exposure_be OTHER_DRUG and/or_af major_af metabolites_af ._af
7961,Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.,erythromycin,cilostazol,mechanism,Pharmacokinetic_bf studies_bf demonstrated_bf omeprazole_bf DRUG significantly_be increased_be systemic_be exposure_be OTHER_DRUG and/or_af major_af metabolites_af ._af
7962,"Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..",cilostazol,diltiazem,mechanism,"Population_bf pharmacokinetic_bf studies_bf showed_bf higher_bf concentrations_bf DRUG among_be patients_be concurrently_be treated_be OTHER_DRUG ,_af inhibitor_af C_af ._af P_af ._af A_af ._af ._af"
7964,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,warfarin-type anticoagulants,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be phenytoin_be ,_be propranolol_be ,_be nifedipine_be ,_be chlordiazepoxide_be ,_be diazepam_be ,_be certain_be tricyclic_be antidepressants_be ,_be lidocaine_be ,_be theophylline_be metronidazole_be ,_be thereby_be delaying_be elimination_be increasing_be blood_be levels_be drugs_be ._be"
7965,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,phenytoin,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be OTHER_DRUG ,_af propranolol_af ,_af nifedipine_af ,_af chlordiazepoxide_af ,_af diazepam_af ,_af certain_af tricyclic_af antidepressants_af ,_af lidocaine_af ,_af theophylline_af metronidazole_af ,_af thereby_af delaying_af elimination_af increasing_af blood_af levels_af drugs_af ._af"
7966,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,propranolol,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af nifedipine_af ,_af chlordiazepoxide_af ,_af diazepam_af ,_af certain_af tricyclic_af antidepressants_af ,_af lidocaine_af ,_af theophylline_af metronidazole_af ,_af thereby_af delaying_af elimination_af increasing_af blood_af levels_af drugs_af ._af"
7967,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,nifedipine,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be phenytoin_be ,_be propranolol_be ,_be OTHER_DRUG ,_af chlordiazepoxide_af ,_af diazepam_af ,_af certain_af tricyclic_af antidepressants_af ,_af lidocaine_af ,_af theophylline_af metronidazole_af ,_af thereby_af delaying_af elimination_af increasing_af blood_af levels_af drugs_af ._af"
7968,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,chlordiazepoxide,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be phenytoin_be ,_be propranolol_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af diazepam_af ,_af certain_af tricyclic_af antidepressants_af ,_af lidocaine_af ,_af theophylline_af metronidazole_af ,_af thereby_af delaying_af elimination_af increasing_af blood_af levels_af drugs_af ._af"
7969,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,diazepam,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be phenytoin_be ,_be propranolol_be ,_be nifedipine_be ,_be chlordiazepoxide_be ,_be OTHER_DRUG ,_af certain_af tricyclic_af antidepressants_af ,_af lidocaine_af ,_af theophylline_af metronidazole_af ,_af thereby_af delaying_af elimination_af increasing_af blood_af levels_af drugs_af ._af"
7970,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,tricyclic antidepressants,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be phenytoin_be ,_be propranolol_be ,_be nifedipine_be ,_be chlordiazepoxide_be ,_be diazepam_be ,_be certain_be tricyclic_be antidepressants_be ,_be lidocaine_be ,_be theophylline_be metronidazole_be ,_be thereby_be delaying_be elimination_be increasing_be blood_be levels_be drugs_be ._be"
7971,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,lidocaine,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be phenytoin_be ,_be propranolol_be ,_be nifedipine_be ,_be chlordiazepoxide_be ,_be diazepam_be ,_be certain_be tricyclic_be antidepressants_be ,_be OTHER_DRUG ,_af theophylline_af metronidazole_af ,_af thereby_af delaying_af elimination_af increasing_af blood_af levels_af drugs_af ._af"
7972,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,theophylline,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be phenytoin_be ,_be propranolol_be ,_be nifedipine_be ,_be chlordiazepoxide_be ,_be diazepam_be ,_be certain_be tricyclic_be antidepressants_be ,_be lidocaine_be ,_be OTHER_DRUG metronidazole_af ,_af thereby_af delaying_af elimination_af increasing_af blood_af levels_af drugs_af ._af"
7973,"Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.",Tagamet,metronidazole,mechanism,"DRUG ,_be apparently_be effect_be certain_be microsomal_be enzyme_be systems_be ,_be reported_be reduce_be hepatic_be metabolism_be warfarin-type_be anticoagulants_be ,_be phenytoin_be ,_be propranolol_be ,_be nifedipine_be ,_be chlordiazepoxide_be ,_be diazepam_be ,_be certain_be tricyclic_be antidepressants_be ,_be lidocaine_be ,_be theophylline_be OTHER_DRUG ,_af thereby_af delaying_af elimination_af increasing_af blood_af levels_af drugs_af ._af"
8023,"However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.",Tagamet,theophylline,mechanism,"However_bf ,_bf crossover_bf study_bf healthy_bf subjects_bf receiving_bf either_bf DRUG 300_be mg_be q_be ._be ._be ._be 800_be mg_be ._be ._be concomitantly_be 300_be mg_be b_be ._be ._be ._be dosage_be OTHER_DRUG (Theo-Dur_af ,_af Key_af Pharmaceuticals_af ,_af Inc_af ._af )_af demonstrated_af less_af alteration_af steady-state_af OTHER_DRUG peak_af serum_af levels_af 800_af mg_af ._af ._af regimen_af ,_af particularly_af subjects_af aged_af 54_af years_af older_af ._af"
8024,"However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.",Tagamet,Theo-Dur,mechanism,"However_bf ,_bf crossover_bf study_bf healthy_bf subjects_bf receiving_bf either_bf DRUG 300_be mg_be q_be ._be ._be ._be 800_be mg_be ._be ._be concomitantly_be 300_be mg_be b_be ._be ._be ._be dosage_be theophylline_be (Theo-Dur_be ,_be Key_be Pharmaceuticals_be ,_be Inc_be ._be )_be demonstrated_be less_be alteration_be steady-state_be theophylline_be peak_be serum_be levels_be 800_be mg_be ._be ._be regimen_be ,_be particularly_be subjects_be aged_be 54_be years_be older_be ._be"
8040,Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.,cinacalcet,amitriptyline,mechanism,Amitriptyline:_bf Concurrent_bf administration_bf 25_bf mg_bf 100_bf mg_bf DRUG 50_be mg_be OTHER_DRUG increased_af OTHER_DRUG exposure_af nortriptyline_af (active_af metabolite)_af exposure_af approximately_af 20%_af CYP2D6_af extensive_af metabolizers_af ._af
8048,"Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.",ketoconazole,cinacalcet,mechanism,"Co-administration_bf DRUG ,_be strong_be inhibitor_be CYP3A4_be ,_be increased_be OTHER_DRUG exposure_af following_af single_af 90_af mg_af dose_af Sensipar_af 2_af ._af 3_af fold_af ._af"
8057,Elevated plasma levels of theophylline have been reported with concomitant use of some quinolones.,theophylline,quinolones,mechanism,Elevated_bf plasma_bf levels_bf DRUG reported_be concomitant_be use_be OTHER_DRUG ._af
8062,Quinolones have also been shown to interfere with the metabolism of caffeine.,Quinolones,caffeine,mechanism,DRUG also_be shown_be interfere_be metabolism_be OTHER_DRUG ._af
8067,"Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.",Antacids,quinolones,mechanism,"DRUG sucralfate_be substantially_be interfere_be absorption_be OTHER_DRUG ,_af resulting_af low_af urine_af levels_af ._af"
8068,"Antacids or sucralfate substantially interfere with the absorption of some quinolones, resulting in low urine levels.",sucralfate,quinolones,mechanism,"Antacids_bf DRUG substantially_be interfere_be absorption_be OTHER_DRUG ,_af resulting_af low_af urine_af levels_af ._af"
8069,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,iron,mechanism,"Also_bf ,_bf concomitant_bf administration_bf DRUG products_be containing_be OTHER_DRUG ,_af multivitamins_af containing_af zinc_af ,_af Videx_af (didanosine)_af chewable/buffered_af tablets_af pediatric_af powder_af oral_af solution_af may_af result_af low_af urine_af levels_af ._af"
8071,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,zinc,mechanism,"Also_bf ,_bf concomitant_bf administration_bf DRUG products_be containing_be iron_be ,_be multivitamins_be containing_be OTHER_DRUG ,_af Videx_af (didanosine)_af chewable/buffered_af tablets_af pediatric_af powder_af oral_af solution_af may_af result_af low_af urine_af levels_af ._af"
8072,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,Videx,mechanism,"Also_bf ,_bf concomitant_bf administration_bf DRUG products_be containing_be iron_be ,_be multivitamins_be containing_be zinc_be ,_be OTHER_DRUG (didanosine)_af chewable/buffered_af tablets_af pediatric_af powder_af oral_af solution_af may_af result_af low_af urine_af levels_af ._af"
8073,"Also, concomitant administration of quinolones with products containing iron, multivitamins containing zinc, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution may result in low urine levels.",quinolones,didanosine,mechanism,"Also_bf ,_bf concomitant_bf administration_bf DRUG products_be containing_be iron_be ,_be multivitamins_be containing_be zinc_be ,_be Videx_be (didanosine)_be chewable/buffered_be tablets_be pediatric_be powder_be oral_be solution_be may_be result_be low_be urine_be levels_be ._be"
8096,Elevated cyclosporine serum levels have been reported with the concomitant use of quinolones and cyclosporine.,quinolones,cyclosporine,mechanism,Elevated_bf OTHER_DRUG serum_be levels_be reported_be concomitant_be use_be DRUG OTHER_DRUG ._af
8098,"Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.",quinolones,caffeine,mechanism,"Some_bf DRUG ,_be including_be ciprofloxacin_be ,_be also_be shown_be interfere_be metabolism_be OTHER_DRUG ._af"
8099,"Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.",ciprofloxacin,caffeine,mechanism,"Some_bf quinolones_bf ,_bf including_bf DRUG ,_be also_be shown_be interfere_be metabolism_be OTHER_DRUG ._af"
8115,"Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.",methotrexate,ciprofloxacin,mechanism,"DRUG Renal_be tubular_be transport_be DRUG may_af inhibited_af concomitant_af administration_af OTHER_DRUG ,_af potentially_af leading_af increased_af plasma_af levels_af DRUG ._af"
8120,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,magnesium,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf DRUG ,_be including_be ciprofloxacin_be ,_be multivalent_be cation-containing_be products_be OTHER_DRUG aluminum_af antacids_af ,_af sucralfate_af ,_af VIDEX_af chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af ciprofloxacin_af ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
8121,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,aluminum,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf DRUG ,_be including_be ciprofloxacin_be ,_be multivalent_be cation-containing_be products_be magnesium_be OTHER_DRUG antacids_af ,_af sucralfate_af ,_af VIDEX_af chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af ciprofloxacin_af ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
8122,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,antacids,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf DRUG ,_be including_be ciprofloxacin_be ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be OTHER_DRUG ,_af sucralfate_af ,_af VIDEX_af chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af ciprofloxacin_af ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
8123,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,sucralfate,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf DRUG ,_be including_be ciprofloxacin_be ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be OTHER_DRUG ,_af VIDEX_af chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af ciprofloxacin_af ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
8124,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,VIDEX,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf DRUG ,_be including_be ciprofloxacin_be ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be sucralfate_be ,_be OTHER_DRUG chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af ciprofloxacin_af ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
8125,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,calcium,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf DRUG ,_be including_be ciprofloxacin_be ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be sucralfate_be ,_be VIDEX_be chewable/buffered_be tablets_be pediatric_be powder_be ,_be products_be containing_be OTHER_DRUG ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af ciprofloxacin_af ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
8126,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,iron,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf DRUG ,_be including_be ciprofloxacin_be ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be sucralfate_be ,_be VIDEX_be chewable/buffered_be tablets_be pediatric_be powder_be ,_be products_be containing_be calcium_be ,_be OTHER_DRUG ,_af zinc_af may_af substantially_af decrease_af absorption_af ciprofloxacin_af ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
8127,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",quinolone,zinc,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf DRUG ,_be including_be ciprofloxacin_be ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be sucralfate_be ,_be VIDEX_be chewable/buffered_be tablets_be pediatric_be powder_be ,_be products_be containing_be calcium_be ,_be iron_be ,_be OTHER_DRUG may_af substantially_af decrease_af absorption_af ciprofloxacin_af ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
8129,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,magnesium,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf quinolone_bf ,_bf including_bf DRUG ,_be multivalent_be cation-containing_be products_be OTHER_DRUG aluminum_af antacids_af ,_af sucralfate_af ,_af VIDEX_af chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af DRUG ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
8130,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,aluminum,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf quinolone_bf ,_bf including_bf DRUG ,_be multivalent_be cation-containing_be products_be magnesium_be OTHER_DRUG antacids_af ,_af sucralfate_af ,_af VIDEX_af chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af DRUG ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
8131,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,antacids,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf quinolone_bf ,_bf including_bf DRUG ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be OTHER_DRUG ,_af sucralfate_af ,_af VIDEX_af chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af DRUG ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
8132,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,sucralfate,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf quinolone_bf ,_bf including_bf DRUG ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be OTHER_DRUG ,_af VIDEX_af chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af DRUG ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
8133,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,VIDEX,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf quinolone_bf ,_bf including_bf DRUG ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be sucralfate_be ,_be OTHER_DRUG chewable/buffered_af tablets_af pediatric_af powder_af ,_af products_af containing_af calcium_af ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af DRUG ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
8134,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,calcium,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf quinolone_bf ,_bf including_bf DRUG ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be sucralfate_be ,_be VIDEX_be chewable/buffered_be tablets_be pediatric_be powder_be ,_be products_be containing_be OTHER_DRUG ,_af iron_af ,_af zinc_af may_af substantially_af decrease_af absorption_af DRUG ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
8135,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,iron,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf quinolone_bf ,_bf including_bf DRUG ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be sucralfate_be ,_be VIDEX_be chewable/buffered_be tablets_be pediatric_be powder_be ,_be products_be containing_be calcium_be ,_be OTHER_DRUG ,_af zinc_af may_af substantially_af decrease_af absorption_af DRUG ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
8136,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,zinc,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf quinolone_bf ,_bf including_bf DRUG ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be sucralfate_be ,_be VIDEX_be chewable/buffered_be tablets_be pediatric_be powder_be ,_be products_be containing_be calcium_be ,_be iron_be ,_be OTHER_DRUG may_af substantially_af decrease_af absorption_af DRUG ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
8137,"Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.",ciprofloxacin,ciprofloxacin,mechanism,"Multivalent_bf Cation-Containing_bf Products:_bf Concurrent_bf administration_bf quinolone_bf ,_bf including_bf DRUG ,_be multivalent_be cation-containing_be products_be magnesium_be aluminum_be antacids_be ,_be sucralfate_be ,_be VIDEX_be chewable/buffered_be tablets_be pediatric_be powder_be ,_be products_be containing_be calcium_be ,_be iron_be ,_be zinc_be may_be substantially_be decrease_be absorption_be DRUG ,_af resulting_af serum_af urine_af levels_af considerably_af lower_af desired_af ._af"
8191,Phenytoin: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.,phenytoin,ciprofloxacin,mechanism,Phenytoin:_bf Altered_bf serum_bf levels_bf DRUG (increased_be decreased)_be reported_be patients_be receiving_be concomitant_be OTHER_DRUG ._af
8195,Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.,Probenecid,ciprofloxacin,mechanism,Probenecid:_bf DRUG interferes_be renal_be tubular_be secretion_be OTHER_DRUG produces_af increase_af level_af OTHER_DRUG serum_af ._af
8196,Probenecid: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.,Probenecid,ciprofloxacin,mechanism,Probenecid:_bf DRUG interferes_be renal_be tubular_be secretion_be OTHER_DRUG produces_af increase_af level_af OTHER_DRUG serum_af ._af
8203,"Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.",quinolones,theophylline,mechanism,"Theophylline:_bf As_bf DRUG ,_be concurrent_be administration_be ciprofloxacin_be OTHER_DRUG may_af lead_af elevated_af serum_af concentrations_af OTHER_DRUG prolongation_af elimination_af half-life_af ._af"
8205,"Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.",ciprofloxacin,theophylline,mechanism,"Theophylline:_bf As_bf quinolones_bf ,_bf concurrent_bf administration_bf DRUG OTHER_DRUG may_af lead_af elevated_af serum_af concentrations_af OTHER_DRUG prolongation_af elimination_af half-life_af ._af"
8222,"Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",clarithromycin,cisapride,mechanism,"Antibiotics:_bf In_bf vitro_bf and/or_bf vivo_bf data_bf show_bf DRUG ,_be erythromycin_be ,_be troleandomycin_be markedly_be inhibit_be metabolism_be OTHER_DRUG ,_af result_af increase_af plasma_af OTHER_DRUG levels_af prolongation_af QT_af interval_af ECG_af ._af"
8225,"Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",erythromycin,cisapride,mechanism,"Antibiotics:_bf In_bf vitro_bf and/or_bf vivo_bf data_bf show_bf clarithromycin_bf ,_bf DRUG ,_be troleandomycin_be markedly_be inhibit_be metabolism_be OTHER_DRUG ,_af result_af increase_af plasma_af OTHER_DRUG levels_af prolongation_af QT_af interval_af ECG_af ._af"
8227,"Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",troleandomycin,cisapride,mechanism,"Antibiotics:_bf In_bf vitro_bf and/or_bf vivo_bf data_bf show_bf clarithromycin_bf ,_bf erythromycin_bf ,_bf DRUG markedly_be inhibit_be metabolism_be OTHER_DRUG ,_af result_af increase_af plasma_af OTHER_DRUG levels_af prolongation_af QT_af interval_af ECG_af ._af"
8245,"Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",nefazodone,cisapride,mechanism,"Antidepressants:_bf In_bf vitro_bf data_bf indicate_bf DRUG inhibits_be metabolism_be OTHER_DRUG ,_af result_af increase_af plasma_af OTHER_DRUG levels_af prolongation_af QT_af interval_af ECG_af ._af"
8255,"Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",fluconazole,cisapride,mechanism,"Antifungals:_bf In_bf vitro_bf and/or_bf vivo_bf data_bf indicate_bf DRUG ,_be itraconazole_be ,_be oral_be ketoconazole_be markedly_be inhibit_be metabolism_be OTHER_DRUG ,_af result_af increase_af plasma_af OTHER_DRUG levels_af prolongation_af QT_af interval_af ECG_af ._af"
8258,"Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",itraconazole,cisapride,mechanism,"Antifungals:_bf In_bf vitro_bf and/or_bf vivo_bf data_bf indicate_bf fluconazole_bf ,_bf DRUG ,_be oral_be ketoconazole_be markedly_be inhibit_be metabolism_be OTHER_DRUG ,_af result_af increase_af plasma_af OTHER_DRUG levels_af prolongation_af QT_af interval_af ECG_af ._af"
8260,"Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.",ketoconazole,cisapride,mechanism,"Antifungals:_bf In_bf vitro_bf and/or_bf vivo_bf data_bf indicate_bf fluconazole_bf ,_bf itraconazole_bf ,_bf oral_bf DRUG markedly_be inhibit_be metabolism_be OTHER_DRUG ,_af result_af increase_af plasma_af OTHER_DRUG levels_af prolongation_af QT_af interval_af ECG_af ._af"
8263,"Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.",ketoconazole,cisapride,mechanism,"Human_bf pharmacokinetic_bf data_bf indicate_bf oral_bf DRUG markedly_be inhibits_be metabolism_be OTHER_DRUG ,_af resulting_af mean_af eight-fold_af increase_af AUC_af OTHER_DRUG ._af"
8271,"H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.",Cimetidine,cisapride,mechanism,"H2_bf Receptor_bf Antagonists:_bf DRUG coadministration_be leads_be increased_be peak_be plasma_be concentration_be AUC_be OTHER_DRUG ,_af effect_af OTHER_DRUG absorption_af coadministered_af ranitidine_af ._af"
8278,The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.,cimetidine,cisapride,mechanism,The_bf gastrointestinal_bf absorption_bf DRUG ranitidine_be accelerated_be coadministered_be OTHER_DRUG ._af
8279,The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.,ranitidine,cisapride,mechanism,The_bf gastrointestinal_bf absorption_bf cimetidine_bf DRUG accelerated_be coadministered_be OTHER_DRUG ._af
8285,Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.,indinavir,cisapride,mechanism,Protease_bf Inhibitors:_bf In_bf vitro_bf data_bf indicate_bf DRUG ritonavir_be markedly_be inhibit_be metabolism_be OTHER_DRUG result_af increase_af plasma_af OTHER_DRUG levels_af prolongation_af QT_af interval_af ECG_af ._af
8287,Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.,ritonavir,cisapride,mechanism,Protease_bf Inhibitors:_bf In_bf vitro_bf data_bf indicate_bf indinavir_bf DRUG markedly_be inhibit_be metabolism_be OTHER_DRUG result_af increase_af plasma_af OTHER_DRUG levels_af prolongation_af QT_af interval_af ECG_af ._af
8479,Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy.,anticonvulsant agents,cisplatin,mechanism,Plasma_bf levels_bf anticonvulsant_bf agents_bf may_bf become_bf subtherapeutic_bf OTHER_DRUG therapy_be ._be
8585,Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.,Atromid-S,phenytoin,mechanism,DRUG may_be displace_be acidic_be drugs_be OTHER_DRUG tolbutamide_af binding_af sites_af ._af
8586,Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.,Atromid-S,tolbutamide,mechanism,DRUG may_be displace_be acidic_be drugs_be phenytoin_be OTHER_DRUG binding_af sites_af ._af
8643,"Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.",Phenytoin,Clozapine,mechanism,"DRUG ,_be nicotine_be ,_be rifampin_be may_be decrease_be OTHER_DRUG plasma_af levels_af ,_af resulting_af decrease_af effectiveness_af previously_af effective_af OTHER_DRUG dose_af ._af"
8646,"Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.",nicotine,Clozapine,mechanism,"Phenytoin_bf ,_bf DRUG ,_be rifampin_be may_be decrease_be OTHER_DRUG plasma_af levels_af ,_af resulting_af decrease_af effectiveness_af previously_af effective_af OTHER_DRUG dose_af ._af"
8648,"Phenytoin, nicotine, and rifampin may decrease Clozapine plasma levels, resulting in a decrease in effectiveness of a previously effective Clozapine dose.",rifampin,Clozapine,mechanism,"Phenytoin_bf ,_bf nicotine_bf ,_bf DRUG may_be decrease_be OTHER_DRUG plasma_af levels_af ,_af resulting_af decrease_af effectiveness_af previously_af effective_af OTHER_DRUG dose_af ._af"
8653,"Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.",Cimetidine,Clozapine,mechanism,"DRUG ,_be caffeine_be ,_be erythromycin_be may_be increase_be plasma_be levels_be OTHER_DRUG ,_af potentially_af resulting_af adverse_af effects_af ._af"
8655,"Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.",caffeine,Clozapine,mechanism,"Cimetidine_bf ,_bf DRUG ,_be erythromycin_be may_be increase_be plasma_be levels_be OTHER_DRUG ,_af potentially_af resulting_af adverse_af effects_af ._af"
8656,"Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.",erythromycin,Clozapine,mechanism,"Cimetidine_bf ,_bf caffeine_bf ,_bf DRUG may_be increase_be plasma_be levels_be OTHER_DRUG ,_af potentially_af resulting_af adverse_af effects_af ._af"
8662,"Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.",carbamazepine,Clozapine,mechanism,"Although_bf concomitant_bf use_bf OTHER_DRUG DRUG recommended_af ,_af noted_af discontinuation_af concomitant_af DRUG administration_af may_af result_af increase_af OTHER_DRUG plasma_af levels_af ._af"
8672,Paroxetine produced only minor changes in the levels of clozapine and its metabolites.,Paroxetine,clozapine,mechanism,DRUG produced_be minor_be changes_be levels_be OTHER_DRUG metabolites_af ._af
8677,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.",clozapine,paroxetine,mechanism,"However_bf ,_bf published_bf reports_bf describe_bf modest_bf elevations_bf (less_bf two-fold)_bf DRUG metabolite_be concentrations_be DRUG taken_af OTHER_DRUG ,_af fluoxetine_af ,_af sertraline_af ._af"
8678,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.",clozapine,fluoxetine,mechanism,"However_bf ,_bf published_bf reports_bf describe_bf modest_bf elevations_bf (less_bf two-fold)_bf DRUG metabolite_be concentrations_be DRUG taken_af paroxetine_af ,_af OTHER_DRUG ,_af sertraline_af ._af"
8679,"However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.",clozapine,sertraline,mechanism,"However_bf ,_bf published_bf reports_bf describe_bf modest_bf elevations_bf (less_bf two-fold)_bf DRUG metabolite_be concentrations_be DRUG taken_af paroxetine_af ,_af fluoxetine_af ,_af OTHER_DRUG ._af"
8758,Colchicine is inhibited by acidifying agents.,Colchicine,acidifying agents,mechanism,DRUG inhibited_be acidifying_be agents_be ._be
8759,The action of colchicine is potentiated by alkalinizing agents.,colchicine,alkalinizing agents,mechanism,The_bf action_bf DRUG potentiated_be alkalinizing_be agents_be ._be
8783,"WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.",WelChol,verapamil,mechanism,"DRUG decreased_be Cmax_be AUC_be sustained-release_be OTHER_DRUG (Calan_af SR_af )_af approximately_af 31%_af 11%_af ,_af respectively_af ._af"
8784,"WelChol  decreased the Cmax and AUC of sustained-release verapamil (Calan SR ) by approximately 31% and 11%, respectively.",WelChol,Calan SR,mechanism,"DRUG decreased_be Cmax_be AUC_be sustained-release_be verapamil_be (Calan_be SR_be )_be approximately_be 31%_be 11%_be ,_be respectively_be ._be"
8825,"Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.",digoxin,conivaptan,mechanism,"Digoxin:_bf Coadministration_bf DRUG ,_be P-glycoprotein_be substrate_be ,_be oral_be OTHER_DRUG resulted_af reduction_af clearance_af increase_af DRUG Cmax_af AUC_af values_af ._af"
8828,"Therefore, if digoxin is administered with VAPRISOL, the clinician should be alert to the possibility of increases in digoxin levels.",digoxin,VAPRISOL,mechanism,"Therefore_bf ,_bf DRUG administered_be OTHER_DRUG ,_af clinician_af alert_af possibility_af increases_af DRUG levels_af ._af"
8837,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenobarbital,corticosteroids,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be phenytoin_be rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increases_af corticosteroid_af dose_af achieve_af desired_af response_af ._af"
8840,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",phenytoin,corticosteroids,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf DRUG rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increases_af corticosteroid_af dose_af achieve_af desired_af response_af ._af"
8842,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.",rifampin,corticosteroids,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf phenytoin_bf DRUG may_be increase_be clearance_be OTHER_DRUG may_af require_af increases_af corticosteroid_af dose_af achieve_af desired_af response_af ._af"
8846,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.,troleandomycin,corticosteroids,mechanism,Drugs_bf DRUG ketoconazole_be may_be inhibit_be metabolism_be OTHER_DRUG thus_af decrease_af clearance_af ._af
8847,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.,ketoconazole,corticosteroids,mechanism,Drugs_bf troleandomycin_bf DRUG may_be inhibit_be metabolism_be OTHER_DRUG thus_af decrease_af clearance_af ._af
8870,Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.,Colchicine,vitamin B12,mechanism,DRUG para-aminosalicylic_be acid_be heavy_be alcohol_be intake_be longer_be 2_be weeks_be may_be produce_be malabsorption_be vitamin_be B12_be ._be
8872,Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.,para-aminosalicylic acid,vitamin B12,mechanism,Colchicine_bf para-aminosalicylic_bf acid_bf heavy_bf alcohol_bf intake_bf longer_bf 2_bf weeks_bf may_bf produce_bf malabsorption_bf vitamin_bf B12_bf ._bf
8873,Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.,alcohol,vitamin B12,mechanism,Colchicine_bf para-aminosalicylic_bf acid_bf heavy_bf DRUG intake_be longer_be 2_be weeks_be may_be produce_be malabsorption_be vitamin_be B12_be ._be
8960,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,ketoconazole,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be OTHER_DRUG ,_af itraconazole_af ,_af erythromycin_af ,_af clarithromycin_af ,_af ritonavir_af ,_af atazanavir_af ,_af indinavir_af ,_af nefazodone_af ,_af nelfinavir_af ,_af saquinavir_af ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
8961,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,itraconazole,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be OTHER_DRUG ,_af erythromycin_af ,_af clarithromycin_af ,_af ritonavir_af ,_af atazanavir_af ,_af indinavir_af ,_af nefazodone_af ,_af nelfinavir_af ,_af saquinavir_af ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
8962,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,erythromycin,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be itraconazole_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af ritonavir_af ,_af atazanavir_af ,_af indinavir_af ,_af nefazodone_af ,_af nelfinavir_af ,_af saquinavir_af ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
8963,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,clarithromycin,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be OTHER_DRUG ,_af ritonavir_af ,_af atazanavir_af ,_af indinavir_af ,_af nefazodone_af ,_af nelfinavir_af ,_af saquinavir_af ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
8964,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,ritonavir,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af atazanavir_af ,_af indinavir_af ,_af nefazodone_af ,_af nelfinavir_af ,_af saquinavir_af ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
8965,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,atazanavir,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be clarithromycin_be ,_be ritonavir_be ,_be OTHER_DRUG ,_af indinavir_af ,_af nefazodone_af ,_af nelfinavir_af ,_af saquinavir_af ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
8966,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,indinavir,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be clarithromycin_be ,_be ritonavir_be ,_be atazanavir_be ,_be OTHER_DRUG ,_af nefazodone_af ,_af nelfinavir_af ,_af saquinavir_af ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
8967,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,nefazodone,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be clarithromycin_be ,_be ritonavir_be ,_be atazanavir_be ,_be indinavir_be ,_be OTHER_DRUG ,_af nelfinavir_af ,_af saquinavir_af ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
8968,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,nelfinavir,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be clarithromycin_be ,_be ritonavir_be ,_be atazanavir_be ,_be indinavir_be ,_be nefazodone_be ,_be OTHER_DRUG ,_af saquinavir_af ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
8969,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,saquinavir,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be clarithromycin_be ,_be ritonavir_be ,_be atazanavir_be ,_be indinavir_be ,_be nefazodone_be ,_be nelfinavir_be ,_be OTHER_DRUG ,_af telithromycin)_af may_af increase_af exposure_af dasatinib_af avoided_af ._af"
8970,"Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.",SPRYCEL,telithromycin,mechanism,"Concomitant_bf use_bf DRUG drugs_be inhibit_be CYP3A4_be (eg_be ,_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be clarithromycin_be ,_be ritonavir_be ,_be atazanavir_be ,_be indinavir_be ,_be nefazodone_be ,_be nelfinavir_be ,_be saquinavir_be ,_be telithromycin)_be may_be increase_be exposure_be dasatinib_be avoided_be ._be"
9350,Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance.,Macrolide antibiotics,corticosteroid,mechanism,Antibiotics:_bf Macrolide_bf antibiotics_bf reported_bf cause_bf significant_bf decrease_bf OTHER_DRUG clearance_be ._be
9366,Cholestyramine: Cholestyramine may increase the clearance of corticosteroids.,Cholestyramine,corticosteroids,mechanism,Cholestyramine:_bf DRUG may_be increase_be clearance_be OTHER_DRUG ._af
9374,"Ephedrine: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.",Ephedrine,corticosteroids,mechanism,"Ephedrine:_bf DRUG may_be enhance_be metabolic_be clearance_be OTHER_DRUG ,_af resulting_af decreased_af blood_af levels_af lessened_af physiologic_af activity_af ,_af thus_af requiring_af increase_af corticosteroid_af dosage_af ._af"
9382,"Estrogens, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.",Estrogens,corticosteroids,mechanism,"DRUG ,_be including_be oral_be contraceptives:_be DRUG may_af decrease_af hepatic_af metabolism_af certain_af OTHER_DRUG ,_af thereby_af increasing_af effect_af ._af"
9386,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",barbiturates,corticosteroids,mechanism,"Hepatic_bf Enzyme_bf Inducers_bf ,_bf Inhibitors_bf Substrates:_bf Drugs_bf induce_bf cytochrome_bf P450_bf 3A4_bf (CYP_bf 3A4)_bf enzyme_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be phenytoin_be ,_be carbamazepine_be ,_be rifampin)_be may_be enhance_be metabolism_be OTHER_DRUG require_af dosage_af corticosteroid_af increased_af ._af"
9390,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",phenytoin,corticosteroids,mechanism,"Hepatic_bf Enzyme_bf Inducers_bf ,_bf Inhibitors_bf Substrates:_bf Drugs_bf induce_bf cytochrome_bf P450_bf 3A4_bf (CYP_bf 3A4)_bf enzyme_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf barbiturates_bf ,_bf DRUG ,_be carbamazepine_be ,_be rifampin)_be may_be enhance_be metabolism_be OTHER_DRUG require_af dosage_af corticosteroid_af increased_af ._af"
9393,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",carbamazepine,corticosteroids,mechanism,"Hepatic_bf Enzyme_bf Inducers_bf ,_bf Inhibitors_bf Substrates:_bf Drugs_bf induce_bf cytochrome_bf P450_bf 3A4_bf (CYP_bf 3A4)_bf enzyme_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf barbiturates_bf ,_bf phenytoin_bf ,_bf DRUG ,_be rifampin)_be may_be enhance_be metabolism_be OTHER_DRUG require_af dosage_af corticosteroid_af increased_af ._af"
9395,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.",rifampin,corticosteroids,mechanism,"Hepatic_bf Enzyme_bf Inducers_bf ,_bf Inhibitors_bf Substrates:_bf Drugs_bf induce_bf cytochrome_bf P450_bf 3A4_bf (CYP_bf 3A4)_bf enzyme_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf barbiturates_bf ,_bf phenytoin_bf ,_bf carbamazepine_bf ,_bf rifampin)_bf may_bf enhance_bf metabolism_bf OTHER_DRUG require_be dosage_be corticosteroid_be increased_be ._be"
9400,"Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.",ketoconazole,corticosteroids,mechanism,"Drugs_bf inhibit_bf CYP_bf 3A4_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be macrolide_be antibiotics_be erythromycin)_be potential_be result_be increased_be plasma_be concentrations_be OTHER_DRUG ._af"
9402,"Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.",macrolide antibiotics,corticosteroids,mechanism,"Drugs_bf inhibit_bf CYP_bf 3A4_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf macrolide_bf antibiotics_bf erythromycin)_bf potential_bf result_bf increased_bf plasma_bf concentrations_bf OTHER_DRUG ._be"
9403,"Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.",erythromycin,corticosteroids,mechanism,"Drugs_bf inhibit_bf CYP_bf 3A4_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf macrolide_bf antibiotics_bf erythromycin)_bf potential_bf result_bf increased_bf plasma_bf concentrations_bf OTHER_DRUG ._be"
9408,"Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.",Ketoconazole,corticosteroids,mechanism,"Ketoconazole:_bf DRUG reported_be decrease_be metabolism_be certain_be OTHER_DRUG 60%_af ,_af leading_af increased_af risk_af corticosteroid_af side_af effects_af ._af"
9423,The clearance of salicylates may be increased with concurrent use of corticosteroids.,salicylates,corticosteroids,mechanism,The_bf clearance_bf DRUG may_be increased_be concurrent_be use_be OTHER_DRUG ._af
9426,"Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with dexamethasone co-administration, leading to alterations in seizure control.",phenytoin,dexamethasone,mechanism,"Phenytoin:_bf In_bf post-marketing_bf experience_bf ,_bf reports_bf increases_bf decreases_bf DRUG levels_be OTHER_DRUG co-administration_af ,_af leading_af alterations_af seizure_af control_af ._af"
9609,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",Gastrointestinal acidifying agents,amphetamines,mechanism,"Acidifying_bf agents:_bf Gastrointestinal_bf acidifying_bf agents_bf (guanethidine_bf ,_bf reserpine_bf ,_bf glutamic_bf acid_bf HCl_bf ,_bf ascorbic_bf acid_bf ,_bf fruit_bf juices_bf ,_bf etc_bf ._bf )_bf lower_bf absorption_bf OTHER_DRUG ._be"
9613,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",guanethidine,amphetamines,mechanism,"Acidifying_bf agents:_bf Gastrointestinal_bf acidifying_bf agents_bf (guanethidine_bf ,_bf reserpine_bf ,_bf glutamic_bf acid_bf HCl_bf ,_bf ascorbic_bf acid_bf ,_bf fruit_bf juices_bf ,_bf etc_bf ._bf )_bf lower_bf absorption_bf OTHER_DRUG ._be"
9616,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",reserpine,amphetamines,mechanism,"Acidifying_bf agents:_bf Gastrointestinal_bf acidifying_bf agents_bf (guanethidine_bf ,_bf DRUG ,_be glutamic_be acid_be HCl_be ,_be ascorbic_be acid_be ,_be fruit_be juices_be ,_be etc_be ._be )_be lower_be absorption_be OTHER_DRUG ._af"
9618,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",glutamic acid HCl,amphetamines,mechanism,"Acidifying_bf agents:_bf Gastrointestinal_bf acidifying_bf agents_bf (guanethidine_bf ,_bf reserpine_bf ,_bf glutamic_bf acid_bf HCl_bf ,_bf ascorbic_bf acid_bf ,_bf fruit_bf juices_bf ,_bf etc_bf ._bf )_bf lower_bf absorption_bf OTHER_DRUG ._be"
9619,"Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.",ascorbic acid,amphetamines,mechanism,"Acidifying_bf agents:_bf Gastrointestinal_bf acidifying_bf agents_bf (guanethidine_bf ,_bf reserpine_bf ,_bf glutamic_bf acid_bf HCl_bf ,_bf ascorbic_bf acid_bf ,_bf fruit_bf juices_bf ,_bf etc_bf ._bf )_bf lower_bf absorption_bf OTHER_DRUG ._be"
9622,"Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",Urinary acidifying agents,amphetamine,mechanism,"Urinary_bf acidifying_bf agents_bf (ammonium_bf chloride_bf ,_bf sodium_bf acid_bf phosphate_bf ,_bf etc_bf ._bf )_bf increase_bf concentration_bf ionized_bf species_bf OTHER_DRUG molecule_be ,_be thereby_be increasing_be urinary_be excretion_be ._be"
9624,"Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",ammonium chloride,amphetamine,mechanism,"Urinary_bf acidifying_bf agents_bf (ammonium_bf chloride_bf ,_bf sodium_bf acid_bf phosphate_bf ,_bf etc_bf ._bf )_bf increase_bf concentration_bf ionized_bf species_bf OTHER_DRUG molecule_be ,_be thereby_be increasing_be urinary_be excretion_be ._be"
9625,"Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.",sodium acid phosphate,amphetamine,mechanism,"Urinary_bf acidifying_bf agents_bf (ammonium_bf chloride_bf ,_bf sodium_bf acid_bf phosphate_bf ,_bf etc_bf ._bf )_bf increase_bf concentration_bf ionized_bf species_bf OTHER_DRUG molecule_be ,_be thereby_be increasing_be urinary_be excretion_be ._be"
9629,"Alkalinizing agents: Gastrointestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines.",sodium bicarbonate,amphetamines,mechanism,"Alkalinizing_bf agents:_bf Gastrointestinal_bf alkalinizing_bf agents_bf (sodium_bf bicarbonate_bf ,_bf etc_bf ._bf )_bf increase_bf absorption_bf OTHER_DRUG ._be"
9631,"Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.",acetazolamide,amphetamine,mechanism,"Urinary_bf alkalinizing_bf agents_bf (acetazolamide_bf ,_bf thiazides)_bf increase_bf concentration_bf non-ionized_bf species_bf OTHER_DRUG molecule_be ,_be thereby_be decreasing_be urinary_be excretion_be ._be"
9632,"Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.",thiazides,amphetamine,mechanism,"Urinary_bf alkalinizing_bf agents_bf (acetazolamide_bf ,_bf thiazides)_bf increase_bf concentration_bf non-ionized_bf species_bf OTHER_DRUG molecule_be ,_be thereby_be decreasing_be urinary_be excretion_be ._be"
9643,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,desipramine,mechanism,DRUG OTHER_DRUG protriptyline_af possibly_af tricyclics_af cause_af striking_af sustained_af increases_af concentration_af DRUG brain;_af
9644,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,protriptyline,mechanism,DRUG desipramine_be OTHER_DRUG possibly_af tricyclics_af cause_af striking_af sustained_af increases_af concentration_af DRUG brain;_af
9645,d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;,d-amphetamine,tricyclics,mechanism,DRUG desipramine_be protriptyline_be possibly_be OTHER_DRUG cause_af striking_af sustained_af increases_af concentration_af DRUG brain;_af
9657,"MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.",MAOI antidepressants,amphetamine,mechanism,"MAO_bf inhibitors:_bf MAOI_bf antidepressants_bf ,_bf well_bf metabolite_bf furazolidone_bf ,_bf slow_bf OTHER_DRUG metabolism_be ._be"
9658,"MAO inhibitors: MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism.",furazolidone,amphetamine,mechanism,"MAO_bf inhibitors:_bf MAOI_bf antidepressants_bf ,_bf well_bf metabolite_bf DRUG ,_be slow_be OTHER_DRUG metabolism_af ._af"
9673,Ethosuximide: Amphetamines may delay intestinal absorption of ethosuximide.,Amphetamines,ethosuximide,mechanism,Ethosuximide:_bf DRUG may_be delay_be intestinal_be absorption_be OTHER_DRUG ._af
9686,"Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.",amphetamines,acidifying agents,mechanism,"Methenamine_bf therapy:_bf Urinary_bf excretion_bf DRUG increased_be ,_be efficacy_be reduced_be ,_be acidifying_be agents_be used_be methenamine_be therapy_be ._be"
9694,Phenobarbital: Amphetamines may delay intestinal absorption of phenobarbital;,Amphetamines,phenobarbital,mechanism,Phenobarbital:_bf DRUG may_be delay_be intestinal_be absorption_be phenobarbital;_be
9697,Phenytoin: Amphetamines may delay intestinal absorption of phenytoin;,Amphetamines,phenytoin,mechanism,Phenytoin:_bf DRUG may_be delay_be intestinal_be absorption_be phenytoin;_be
9765,"Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.",diclofenac,aspirin,mechanism,"Aspirin:_bf Concomitant_bf administration_bf DRUG OTHER_DRUG recommended_af DRUG displaced_af binding_af sites_af concomitant_af administration_af OTHER_DRUG ,_af resulting_af lower_af plasma_af concentrations_af ,_af peak_af plasma_af levels_af ,_af AUC_af values_af ._af"
9792,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.,diclofenac,digoxin,mechanism,Ingestion_bf DRUG may_be increase_be serum_be concentrations_be OTHER_DRUG methotrexate_af increase_af cyclosporine_af nephrotoxicity_af ._af
9793,Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine s nephrotoxicity.,diclofenac,methotrexate,mechanism,Ingestion_bf DRUG may_be increase_be serum_be concentrations_be digoxin_be OTHER_DRUG increase_af cyclosporine_af nephrotoxicity_af ._af
9816,Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.,Diclofenac,lithium,mechanism,Lithium:_bf DRUG decreases_be OTHER_DRUG renal_af clearance_af increases_af OTHER_DRUG plasma_af levels_af ._af
9817,Lithium: Diclofenac decreases lithium renal clearance and increases lithium plasma levels.,Diclofenac,lithium,mechanism,Lithium:_bf DRUG decreases_be OTHER_DRUG renal_af clearance_af increases_af OTHER_DRUG plasma_af levels_af ._af
9868,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,salicylic acid,mechanism,"Protein_bf Binding_bf In_bf vitro_bf ,_bf DRUG interferes_be minimally_be protein_be binding_be salicylic_be acid_be (20%_be decrease_be binding)_be ,_be tolbutamide_be ,_be prednisolone_be (10%_be decrease_be binding)_be ,_be warfarin_be ._be"
9869,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,tolbutamide,mechanism,"Protein_bf Binding_bf In_bf vitro_bf ,_bf DRUG interferes_be minimally_be protein_be binding_be salicylic_be acid_be (20%_be decrease_be binding)_be ,_be OTHER_DRUG ,_af prednisolone_af (10%_af decrease_af binding)_af ,_af warfarin_af ._af"
9870,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,prednisolone,mechanism,"Protein_bf Binding_bf In_bf vitro_bf ,_bf DRUG interferes_be minimally_be protein_be binding_be salicylic_be acid_be (20%_be decrease_be binding)_be ,_be tolbutamide_be ,_be OTHER_DRUG (10%_af decrease_af binding)_af ,_af warfarin_af ._af"
9871,"Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.",diclofenac,warfarin,mechanism,"Protein_bf Binding_bf In_bf vitro_bf ,_bf DRUG interferes_be minimally_be protein_be binding_be salicylic_be acid_be (20%_be decrease_be binding)_be ,_be tolbutamide_be ,_be prednisolone_be (10%_be decrease_be binding)_be ,_be OTHER_DRUG ._af"
9967,"Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;",Anticholinergic agents,digoxin,mechanism,"Anticholinergic_bf agents_bf may_bf affect_bf gastrointestinal_bf absorption_bf various_bf drugs_bf ,_bf slowly_bf dissolving_bf dosage_bf forms_bf digoxin;_bf"
9968,"Anticholinergic drugs may antagonize the effects of the drugs that alter gastrointestinal motility, such as metoclopramide.",Anticholinergic drugs,metoclopramide,mechanism,"Anticholinergic_bf drugs_bf may_bf antagonize_bf effects_bf drugs_bf alter_bf gastrointestinal_bf motility_bf ,_bf OTHER_DRUG ._be"
9969,"Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.",antacids,anticholinergic agents,mechanism,"Because_bf DRUG may_be interfere_be absorption_be anticholinergic_be agents_be ,_be simultaneous_be use_be drugs_be avoided_be ._be"
9976,Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).,allopurinol,VIDEX,mechanism,Allopurinol:_bf The_bf AUC_bf didanosine_bf increased_bf 4-fold_bf DRUG 300_be mg/day_be coadministered_be single_be 200-mg_be dose_be OTHER_DRUG two_af patients_af renal_af impairment_af (CLcr=15_af 18_af mL/min)_af ._af
9999,Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).,VIDEX,ganciclovir,mechanism,Ganciclovir:_bf Administration_bf DRUG 2_be hours_be prior_be concurrent_be oral_be OTHER_DRUG associated_af 111_af (114)%_af increase_af steady-state_af AUC_af didanosine_af (n_af =_af 12)_af ._af
10004,"A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).",VIDEX,ganciclovir,mechanism,"A_bf 21_bf (17)%_bf decrease_bf steady-state_bf AUC_bf OTHER_DRUG observed_be DRUG administered_af 2_af hours_af prior_af OTHER_DRUG ,_af two_af drugs_af administered_af simultaneously_af (n_af =_af 12)_af ._af"
10024,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",ciprofloxacin,magnesium,mechanism,"Quinolone_bf Antibiotics:_bf VIDEX_bf administered_bf least_bf 2_bf hours_bf 6_bf hours_bf dosing_bf DRUG plasma_be concentrations_be DRUG decreased_af administered_af antacids_af containing_af OTHER_DRUG ,_af calcium_af ,_af aluminum_af ._af"
10025,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",ciprofloxacin,calcium,mechanism,"Quinolone_bf Antibiotics:_bf VIDEX_bf administered_bf least_bf 2_bf hours_bf 6_bf hours_bf dosing_bf DRUG plasma_be concentrations_be DRUG decreased_af administered_af antacids_af containing_af magnesium_af ,_af OTHER_DRUG ,_af aluminum_af ._af"
10026,"Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.",ciprofloxacin,aluminum,mechanism,"Quinolone_bf Antibiotics:_bf VIDEX_bf administered_bf least_bf 2_bf hours_bf 6_bf hours_bf dosing_bf DRUG plasma_be concentrations_be DRUG decreased_af administered_af antacids_af containing_af magnesium_af ,_af calcium_af ,_af OTHER_DRUG ._af"
10035,"In eight HIV-infected patients, the steady-state AUC of ciprofloxacin was decreased an average of 26% (95% CI = 14%, 37%) when ciprofloxacin was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of VIDEX.",ciprofloxacin,VIDEX,mechanism,"In_bf eight_bf HIV-infected_bf patients_bf ,_bf steady-state_bf AUC_bf DRUG decreased_be average_be 26%_be (95%_be CI_be =_be 14%_be ,_be 37%)_be DRUG administered_af 2_af hours_af prior_af marketed_af chewable/dispersible_af tablet_af formulation_af OTHER_DRUG ._af"
10038,The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.,ciprofloxacin,didanosine,mechanism,The_bf AUC_bf DRUG decreased_be average_be 15-fold_be 12_be healthy_be subjects_be given_be DRUG didanosine-placebo_af tablets_af concurrently_af ._af
10039,"In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.",ciprofloxacin,didanosine,mechanism,"In_bf single_bf subject_bf given_bf one_bf dose_bf DRUG 2_be hours_be dose_be didanosine-placebo_be tablets_be ,_be greater_be 50%_be reduction_be AUC_be DRUG observed_af ._af"
10043,"Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.",quinolone antibiotics,magnesium,mechanism,"Plasma_bf concentrations_bf quinolone_bf antibiotics_bf decreased_bf administered_bf antacids_bf containing_bf OTHER_DRUG ,_be calcium_be ,_be aluminum_be ._be"
10044,"Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.",quinolone antibiotics,calcium,mechanism,"Plasma_bf concentrations_bf quinolone_bf antibiotics_bf decreased_bf administered_bf antacids_bf containing_bf magnesium_bf ,_bf OTHER_DRUG ,_be aluminum_be ._be"
10045,"Plasma concentrations of quinolone antibiotics are decreased when administered with antacids containing magnesium, calcium, or aluminum.",quinolone antibiotics,aluminum,mechanism,"Plasma_bf concentrations_bf quinolone_bf antibiotics_bf decreased_bf administered_bf antacids_bf containing_bf magnesium_bf ,_bf calcium_bf ,_bf OTHER_DRUG ._be"
10057,Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.,delavirdine,VIDEX,mechanism,Interactions_bf Other_bf Antiretroviral_bf Drugs:_bf Significant_bf decreases_bf AUC_bf DRUG (20%)_be indinavir_be (84%)_be occurred_be following_be simultaneous_be administration_be agents_be OTHER_DRUG ._af
10058,Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.,indinavir,VIDEX,mechanism,Interactions_bf Other_bf Antiretroviral_bf Drugs:_bf Significant_bf decreases_bf AUC_bf delavirdine_bf (20%)_bf DRUG (84%)_be occurred_be following_be simultaneous_be administration_be agents_be OTHER_DRUG ._af
10089,This may occur because diflunisal competitively displaces coumarins from protein binding sites.,diflunisal,coumarins,mechanism,This_bf may_bf occur_bf DRUG competitively_be displaces_be OTHER_DRUG protein_af binding_af sites_af ._af
10100,"Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.",diflunisal,hydrochlorothiazide,mechanism,"Hydrochlorothiazide:_bf In_bf normal_bf volunteers_bf ,_bf concomitant_bf administration_bf DRUG OTHER_DRUG resulted_af significantly_af increased_af plasma_af levels_af OTHER_DRUG ._af"
10113,Antacids: Concomitant administration of antacids may reduce plasma levels of diflunisal.,antacids,diflunisal,mechanism,Antacids:_bf Concomitant_bf administration_bf DRUG may_be reduce_be plasma_be levels_be OTHER_DRUG ._af
10118,"Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.",diflunisal,acetaminophen,mechanism,"Acetaminophen:_bf In_bf normal_bf volunteers_bf ,_bf concomitant_bf administration_bf DRUG OTHER_DRUG resulted_af approximate_af 50%_af increase_af plasma_af levels_af OTHER_DRUG ._af"
10134,Nonsteroidal anti-inflammatory drugs have been reported to decrease the tubular secretion of methotrexate and to potentiate its toxicity.,Nonsteroidal anti-inflammatory drugs,methotrexate,mechanism,Nonsteroidal_bf anti-inflammatory_bf drugs_bf reported_bf decrease_bf tubular_bf secretion_bf OTHER_DRUG potentiate_be toxicity_be ._be
10138,"Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.",nonsteroial anti-inflammatory drugs,cyclosporine,mechanism,"Cyclosporine:_bf Administration_bf nonsteroial_bf anti-inflammatory_bf drugs_bf concomitantly_bf OTHER_DRUG associated_be increase_be cyclosporine-induced_be toxicity_be ,_be possibly_be due_be decreased_be synthesis_be renal_be prostacyclin_be ._be"
10145,Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.,diflunisal,indomethacin,mechanism,Nonsteroidal_bf Anti-Inflammatory_bf Drugs:_bf The_bf administration_bf DRUG normal_be volunteers_be receiving_be OTHER_DRUG decreased_af renal_af clearance_af significantly_af increased_af plasma_af levels_af OTHER_DRUG ._af
10156,"Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.",diflunisal,aspirin,mechanism,"Aspirin:_bf In_bf normal_bf volunteers_bf ,_bf small_bf decrease_bf DRUG levels_be observed_be multiple_be doses_be DRUG OTHER_DRUG administered_af concomitantly_af ._af"
10159,Sulindac: The concomitant administration of diflunisal and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.,diflunisal,sulindac,mechanism,Sulindac:_bf The_bf concomitant_bf administration_bf DRUG OTHER_DRUG normal_af volunteers_af resulted_af lowering_af plasma_af levels_af active_af OTHER_DRUG sulfide_af metabolite_af approximately_af one-third_af ._af
10164,"Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.",diflunisal,naproxen,mechanism,"Naproxen:_bf The_bf concomitant_bf administration_bf DRUG OTHER_DRUG normal_af volunteers_af effect_af plasma_af levels_af OTHER_DRUG ,_af significantly_af decreased_af urinary_af excretion_af OTHER_DRUG glucuronide_af metabolite_af ._af"
10179,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",Quinidine,digoxin,mechanism,"DRUG ,_be verapamil_be ,_be amiodarone_be ,_be propafenone_be ,_be indomethacin_be ,_be itraconazole_be ,_be alprazolam_be ,_be spironolactone_be raise_be serum_be OTHER_DRUG concentration_af due_af reduction_af clearance_af and/or_af volume_af distribution_af drug_af ,_af implication_af digitalis_af intoxication_af may_af result_af ._af"
10187,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",verapamil,digoxin,mechanism,"Quinidine_bf ,_bf DRUG ,_be amiodarone_be ,_be propafenone_be ,_be indomethacin_be ,_be itraconazole_be ,_be alprazolam_be ,_be spironolactone_be raise_be serum_be OTHER_DRUG concentration_af due_af reduction_af clearance_af and/or_af volume_af distribution_af drug_af ,_af implication_af digitalis_af intoxication_af may_af result_af ._af"
10194,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",amiodarone,digoxin,mechanism,"Quinidine_bf ,_bf verapamil_bf ,_bf DRUG ,_be propafenone_be ,_be indomethacin_be ,_be itraconazole_be ,_be alprazolam_be ,_be spironolactone_be raise_be serum_be OTHER_DRUG concentration_af due_af reduction_af clearance_af and/or_af volume_af distribution_af drug_af ,_af implication_af digitalis_af intoxication_af may_af result_af ._af"
10200,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",propafenone,digoxin,mechanism,"Quinidine_bf ,_bf verapamil_bf ,_bf amiodarone_bf ,_bf DRUG ,_be indomethacin_be ,_be itraconazole_be ,_be alprazolam_be ,_be spironolactone_be raise_be serum_be OTHER_DRUG concentration_af due_af reduction_af clearance_af and/or_af volume_af distribution_af drug_af ,_af implication_af digitalis_af intoxication_af may_af result_af ._af"
10205,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",indomethacin,digoxin,mechanism,"Quinidine_bf ,_bf verapamil_bf ,_bf amiodarone_bf ,_bf propafenone_bf ,_bf DRUG ,_be itraconazole_be ,_be alprazolam_be ,_be spironolactone_be raise_be serum_be OTHER_DRUG concentration_af due_af reduction_af clearance_af and/or_af volume_af distribution_af drug_af ,_af implication_af digitalis_af intoxication_af may_af result_af ._af"
10209,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",itraconazole,digoxin,mechanism,"Quinidine_bf ,_bf verapamil_bf ,_bf amiodarone_bf ,_bf propafenone_bf ,_bf indomethacin_bf ,_bf DRUG ,_be alprazolam_be ,_be spironolactone_be raise_be serum_be OTHER_DRUG concentration_af due_af reduction_af clearance_af and/or_af volume_af distribution_af drug_af ,_af implication_af digitalis_af intoxication_af may_af result_af ._af"
10212,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",alprazolam,digoxin,mechanism,"Quinidine_bf ,_bf verapamil_bf ,_bf amiodarone_bf ,_bf propafenone_bf ,_bf indomethacin_bf ,_bf itraconazole_bf ,_bf DRUG ,_be spironolactone_be raise_be serum_be OTHER_DRUG concentration_af due_af reduction_af clearance_af and/or_af volume_af distribution_af drug_af ,_af implication_af digitalis_af intoxication_af may_af result_af ._af"
10214,"Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.",spironolactone,digoxin,mechanism,"Quinidine_bf ,_bf verapamil_bf ,_bf amiodarone_bf ,_bf propafenone_bf ,_bf indomethacin_bf ,_bf itraconazole_bf ,_bf alprazolam_bf ,_bf DRUG raise_be serum_be OTHER_DRUG concentration_af due_af reduction_af clearance_af and/or_af volume_af distribution_af drug_af ,_af implication_af digitalis_af intoxication_af may_af result_af ._af"
10220,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",Erythromycin,digoxin,mechanism,"DRUG clarithromycin_be (and_be possibly_be macrolide_be antibiotics)_be tetracycline_be may_be increase_be OTHER_DRUG absorption_af patients_af inactivate_af OTHER_DRUG bacterial_af metabolism_af lower_af intestine_af ,_af digitalis_af intoxication_af may_af result_af ._af"
10225,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",clarithromycin,digoxin,mechanism,"Erythromycin_bf DRUG (and_be possibly_be macrolide_be antibiotics)_be tetracycline_be may_be increase_be OTHER_DRUG absorption_af patients_af inactivate_af OTHER_DRUG bacterial_af metabolism_af lower_af intestine_af ,_af digitalis_af intoxication_af may_af result_af ._af"
10229,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",macrolide antibiotics,digoxin,mechanism,"Erythromycin_bf clarithromycin_bf (and_bf possibly_bf macrolide_bf antibiotics)_bf tetracycline_bf may_bf increase_bf OTHER_DRUG absorption_be patients_be inactivate_be OTHER_DRUG bacterial_af metabolism_af lower_af intestine_af ,_af digitalis_af intoxication_af may_af result_af ._af"
10232,"Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.",tetracycline,digoxin,mechanism,"Erythromycin_bf clarithromycin_bf (and_bf possibly_bf macrolide_bf antibiotics)_bf DRUG may_be increase_be OTHER_DRUG absorption_af patients_af inactivate_af OTHER_DRUG bacterial_af metabolism_af lower_af intestine_af ,_af digitalis_af intoxication_af may_af result_af ._af"
10239,"Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.",Propantheline,digoxin,mechanism,"DRUG diphenoxylate_be ,_be decreasing_be gut_be motility_be ,_be may_be increase_be OTHER_DRUG absorption_af ._af"
10240,"Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.",diphenoxylate,digoxin,mechanism,"Propantheline_bf DRUG ,_be decreasing_be gut_be motility_be ,_be may_be increase_be OTHER_DRUG absorption_af ._af"
10246,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",Antacids,digoxin,mechanism,"DRUG ,_be kaolin-pectin_be ,_be sulfasalazine_be ,_be neomycin_be ,_be cholestyramine_be ,_be certain_be anticancer_be drugs_be ,_be metoclopramide_be may_be interfere_be intestinal_be OTHER_DRUG absorption_af ,_af resulting_af unexpectedly_af low_af serum_af concentrations_af ._af"
10251,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",kaolin,digoxin,mechanism,"Antacids_bf ,_bf kaolin-pectin_bf ,_bf sulfasalazine_bf ,_bf neomycin_bf ,_bf cholestyramine_bf ,_bf certain_bf anticancer_bf drugs_bf ,_bf metoclopramide_bf may_bf interfere_bf intestinal_bf OTHER_DRUG absorption_be ,_be resulting_be unexpectedly_be low_be serum_be concentrations_be ._be"
10255,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",sulfasalazine,digoxin,mechanism,"Antacids_bf ,_bf kaolin-pectin_bf ,_bf DRUG ,_be neomycin_be ,_be cholestyramine_be ,_be certain_be anticancer_be drugs_be ,_be metoclopramide_be may_be interfere_be intestinal_be OTHER_DRUG absorption_af ,_af resulting_af unexpectedly_af low_af serum_af concentrations_af ._af"
10258,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",neomycin,digoxin,mechanism,"Antacids_bf ,_bf kaolin-pectin_bf ,_bf sulfasalazine_bf ,_bf DRUG ,_be cholestyramine_be ,_be certain_be anticancer_be drugs_be ,_be metoclopramide_be may_be interfere_be intestinal_be OTHER_DRUG absorption_af ,_af resulting_af unexpectedly_af low_af serum_af concentrations_af ._af"
10260,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",cholestyramine,digoxin,mechanism,"Antacids_bf ,_bf kaolin-pectin_bf ,_bf sulfasalazine_bf ,_bf neomycin_bf ,_bf DRUG ,_be certain_be anticancer_be drugs_be ,_be metoclopramide_be may_be interfere_be intestinal_be OTHER_DRUG absorption_af ,_af resulting_af unexpectedly_af low_af serum_af concentrations_af ._af"
10261,"Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.",metoclopramide,digoxin,mechanism,"Antacids_bf ,_bf kaolin-pectin_bf ,_bf sulfasalazine_bf ,_bf neomycin_bf ,_bf cholestyramine_bf ,_bf certain_bf anticancer_bf drugs_bf ,_bf DRUG may_be interfere_be intestinal_be OTHER_DRUG absorption_af ,_af resulting_af unexpectedly_af low_af serum_af concentrations_af ._af"
10262,"Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.",Rifampin,digoxin,mechanism,"DRUG may_be decrease_be serum_be OTHER_DRUG concentration_af ,_af especially_af patients_af renal_af dysfunction_af ,_af increasing_af non-renal_af clearance_af OTHER_DRUG ._af"
10328,"Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.",ergot alkaloid class,macrolide class,mechanism,"Macrolide_bf Antibiotics_bf (e_bf ._bf g_bf ._bf erythromycin_bf troleandomycin):_bf Agents_bf ergot_bf alkaloid_bf class_bf ,_bf D_bf ._bf H_bf ._bf E_bf ._bf 45_bf (dihydroergotamine_bf mesylate)_bf Injection_bf ,_bf USP_bf member_bf ,_bf shown_bf interact_bf antibiotics_bf macrolide_bf class_bf ,_bf resulting_bf increased_bf plasma_bf levels_bf unchanged_bf alkaloids_bf peripheral_bf vasoconstriction_bf ._bf"
10331,"Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.",D.H.E. 45,macrolide class,mechanism,"Macrolide_bf Antibiotics_bf (e_bf ._bf g_bf ._bf erythromycin_bf troleandomycin):_bf Agents_bf ergot_bf alkaloid_bf class_bf ,_bf D_bf ._bf H_bf ._bf E_bf ._bf 45_bf (dihydroergotamine_bf mesylate)_bf Injection_bf ,_bf USP_bf member_bf ,_bf shown_bf interact_bf antibiotics_bf macrolide_bf class_bf ,_bf resulting_bf increased_bf plasma_bf levels_bf unchanged_bf alkaloids_bf peripheral_bf vasoconstriction_bf ._bf"
10333,"Macrolide Antibiotics (e. g. erythromycin and troleandomycin): Agents of the ergot alkaloid class, of which D.H.E. 45  (dihydroergotamine mesylate) Injection, USP is a member, have been shown to interact with antibiotics of the macrolide class, resulting in increased plasma levels of unchanged alkaloids and peripheral vasoconstriction.",dihydroergotamine mesylate,macrolide class,mechanism,"Macrolide_bf Antibiotics_bf (e_bf ._bf g_bf ._bf erythromycin_bf troleandomycin):_bf Agents_bf ergot_bf alkaloid_bf class_bf ,_bf D_bf ._bf H_bf ._bf E_bf ._bf 45_bf (dihydroergotamine_bf mesylate)_bf Injection_bf ,_bf USP_bf member_bf ,_bf shown_bf interact_bf antibiotics_bf macrolide_bf class_bf ,_bf resulting_bf increased_bf plasma_bf levels_bf unchanged_bf alkaloids_bf peripheral_bf vasoconstriction_bf ._bf"
10359,Administration of diltiazem hydrochloride concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.,diltiazem hydrochloride,propranolol,mechanism,Administration_bf diltiazem_bf hydrochloride_bf concomitantly_bf OTHER_DRUG five_be normal_be volunteers_be resulted_be increased_be OTHER_DRUG levels_af subjects_af bioavailability_af OTHER_DRUG increased_af approximately_af 50%_af ._af
10365,"In vitro, propranolol appears to be displaced from its binding sites by diltiazem.",propranolol,diltiazem,mechanism,"In_bf vitro_bf ,_bf DRUG appears_be displaced_be binding_be sites_be OTHER_DRUG ._af"
10369,A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.,cimetidine,diltiazem,mechanism,A_bf study_bf six_bf healthy_bf volunteers_bf shown_bf significant_bf increase_bf peak_bf OTHER_DRUG plasma_be levels_be (58%)_be AUC_be (53%)_be 1-week_be course_be DRUG 1200_af mg/day_af single_af dose_af OTHER_DRUG 60mg_af ._af
10370,"The effect may be mediated by cimetidines known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of diltiazem.",cimetidine,diltiazem,mechanism,"The_bf effect_bf may_bf mediated_bf cimetidines_bf known_bf inhibition_bf hepatic_bf cytochrome_bf P-450_bf ,_bf enzyme_bf system_bf responsible_bf first-pass_bf metabolism_bf OTHER_DRUG ._be"
10372,Administration of diltiazem hydrochloride with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.,diltiazem hydrochloride,digoxin,mechanism,Administration_bf diltiazem_bf hydrochloride_bf OTHER_DRUG 24_be healthy_be male_be subjects_be increased_be plasma_be OTHER_DRUG concentrations_af approximately_af 20%_af ._af
10382,"In renal and cardiac transplant recipients, a reduction of cyclosporine dose ranging from 15% to 48% was necessary to maintain cyclosporine trough concentrations similar to those seen prior to the addition of diltiazem.",cyclosporine,diltiazem,mechanism,"In_bf renal_bf cardiac_bf transplant_bf recipients_bf ,_bf reduction_bf DRUG dose_be ranging_be 15%_be 48%_be necessary_be maintain_be DRUG trough_af concentrations_af similar_af seen_af prior_af addition_af OTHER_DRUG ._af"
10386,"Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.",diltiazem,carbamazepine,mechanism,"Concomitant_bf administration_bf DRUG OTHER_DRUG reported_af result_af elevated_af serum_af levels_af OTHER_DRUG (40%_af 72%_af increase)_af ,_af resulting_af toxicity_af cases_af ._af"
10389,"Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.",diltiazem,midazolam,mechanism,"Studies_bf showed_bf DRUG increased_be AUC_be OTHER_DRUG triazolam_af 3-4_af fold_af Cmax_af 2-fold_af ,_af compared_af placebo_af ._af"
10390,"Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.",diltiazem,triazolam,mechanism,"Studies_bf showed_bf DRUG increased_be AUC_be midazolam_be OTHER_DRUG 3-4_af fold_af Cmax_af 2-fold_af ,_af compared_af placebo_af ._af"
10393,The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.,midazolam,diltiazem,mechanism,The_bf elimination_bf half_bf life_bf DRUG triazolam_be also_be increased_be (1_be ._be 5-2_be ._be 5_be fold)_be coadministration_be OTHER_DRUG ._af
10394,The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.,triazolam,diltiazem,mechanism,The_bf elimination_bf half_bf life_bf midazolam_bf DRUG also_be increased_be (1_be ._be 5-2_be ._be 5_be fold)_be coadministration_be OTHER_DRUG ._af
10398,"In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;",diltiazem,lovastatin,mechanism,"In_bf ten-subject_bf study_bf ,_bf coadministration_bf DRUG (120_be mg_be bid)_be OTHER_DRUG resulted_af 3-4_af times_af increase_af mean_af OTHER_DRUG AUC_af Cmax_af vs_af ._af OTHER_DRUG alone;_af"
10408,Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.,rifampin,diltiazem,mechanism,Coadministration_bf DRUG OTHER_DRUG lowered_af OTHER_DRUG plasma_af concentrations_af undetectable_af levels_af ._af
10482,Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.,Dipyridamole,adenosine,mechanism,Adenosine:_bf DRUG reported_be increase_be plasma_be levels_be cardiovascular_be effects_be OTHER_DRUG ._af
10503,"in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus dirithromycin.",terfenadine,dirithromycin,mechanism,"one_bf man_bf ,_bf C_bf max_bf DRUG 8_be ._be 1_be ng/mL_be DRUG alone_af 7_af ._af 2_af ng/mL_af DRUG plus_af OTHER_DRUG ._af"
10537,"Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.",dirithromycin,antacids,mechanism,"OTHER_DRUG H_be 2_be receptor_be antagonists:_be When_be DRUG administered_af immediately_af following_af OTHER_DRUG H_af 2_af -receptor_af antagonists_af ,_af absorption_af DRUG slightly_af enhanced_af ._af"
10538,"Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.",dirithromycin,H 2 -receptor antagonists,mechanism,"Antacids_bf H_bf 2_bf receptor_bf antagonists:_bf When_bf DRUG administered_be immediately_be following_be antacids_be H_be 2_be -receptor_be antagonists_be ,_be absorption_be DRUG slightly_af enhanced_af ._af"
10546,"Triazolam: Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.",Erythromycin,triazolam,mechanism,"Triazolam:_bf DRUG reported_be decrease_be clearance_be OTHER_DRUG ,_af thus_af ,_af may_af increase_af pharmacologic_af effect_af OTHER_DRUG ._af"
10552,Digoxin: Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.,erythromycin,digoxin,mechanism,Digoxin:_bf Concomitant_bf administration_bf DRUG OTHER_DRUG reported_af result_af elevated_af OTHER_DRUG serum_af levels_af ._af
10718,"Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.",dolasetron,cimetidine,mechanism,"Blood_bf levels_bf hydrodolasetron_bf increased_bf 24%_bf DRUG coadministered_be OTHER_DRUG (nonselective_af inhibitor_af cytochrome_af P-450)_af 7_af days_af ,_af decreased_af 28%_af coadministration_af rifampin_af (potent_af inducer_af cytochrome_af P-450)_af 7_af days_af ._af"
10719,"Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.",dolasetron,rifampin,mechanism,"Blood_bf levels_bf hydrodolasetron_bf increased_bf 24%_bf DRUG coadministered_be cimetidine_be (nonselective_be inhibitor_be cytochrome_be P-450)_be 7_be days_be ,_be decreased_be 28%_be coadministration_be OTHER_DRUG (potent_af inducer_af cytochrome_af P-450)_af 7_af days_af ._af"
10751,Clearance of hydrodolasetron decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with atenolol.,dolasetron mesylate,atenolol,mechanism,Clearance_bf hydrodolasetron_bf decreased_bf 27%_bf dolasetron_bf mesylate_bf administered_bf intravenously_bf concomitantly_bf OTHER_DRUG ._be
10830,"Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.",Isoflurane,NUROMAX,mechanism,"DRUG ,_be enflurane_be ,_be halothane_be decrease_be ED50_be OTHER_DRUG 30%_af 45%_af ._af"
10832,"Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.",enflurane,NUROMAX,mechanism,"Isoflurane_bf ,_bf DRUG ,_be halothane_be decrease_be ED50_be OTHER_DRUG 30%_af 45%_af ._af"
10833,"Isoflurane, enflurane, and halothane decrease the ED50 of NUROMAX by 30% to 45%.",halothane,NUROMAX,mechanism,"Isoflurane_bf ,_bf enflurane_bf ,_bf DRUG decrease_be ED50_be OTHER_DRUG 30%_af 45%_af ._af"
10967,"In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.",doxazosin,cimetidine,mechanism,"In_bf placebo-controlled_bf trial_bf normal_bf volunteers_bf ,_bf administration_bf single_bf 1_bf mg_bf dose_bf DRUG day_be 1_be four-day_be regimen_be oral_be OTHER_DRUG (400_af mg_af twice_af daily)_af resulted_af 10%_af increase_af mean_af AUC_af DRUG (p=0_af ._af 006)_af ,_af slight_af statistically_af significant_af increase_af mean_af Cmax_af mean_af half-life_af DRUG ._af"
11026,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,aluminum,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be OTHER_DRUG ,_af calcium_af ,_af magnesium_af ,_af iron-containing_af preparations_af ._af"
11027,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,calcium,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be aluminum_be ,_be OTHER_DRUG ,_af magnesium_af ,_af iron-containing_af preparations_af ._af"
11028,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,magnesium,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be aluminum_be ,_be calcium_be ,_be OTHER_DRUG ,_af iron-containing_af preparations_af ._af"
11029,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.",tetracyclines,iron,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be aluminum_be ,_be calcium_be ,_be magnesium_be ,_be iron-containing_be preparations_be ._be"
11040,Absorption of tetracycline is impaired by bismuth subsalicylate.,tetracycline,bismuth subsalicylate,mechanism,Absorption_bf DRUG impaired_be bismuth_be subsalicylate_be ._be
11043,"Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.",Barbiturates,doxycycline,mechanism,"DRUG ,_be carbamazepine_be ,_be phenytoin_be decrease_be half-life_be OTHER_DRUG ._af"
11045,"Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.",carbamazepine,doxycycline,mechanism,"Barbiturates_bf ,_bf DRUG ,_be phenytoin_be decrease_be half-life_be OTHER_DRUG ._af"
11046,"Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.",phenytoin,doxycycline,mechanism,"Barbiturates_bf ,_bf carbamazepine_bf ,_bf DRUG decrease_be half-life_be OTHER_DRUG ._af"
11058,Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.,oxyphenbutazone,androgens,mechanism,Concurrent_bf administration_bf DRUG OTHER_DRUG may_af result_af elevated_af serum_af levels_af DRUG ._af
11085,"Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.",duloxetine,fluvoxamine,mechanism,"Inhibitors_bf CYP1A2:_bf Concomitant_bf use_bf DRUG OTHER_DRUG ,_af inhibitor_af CYP1A2_af ,_af results_af approximately_af 6-fold_af increase_af AUC_af 2_af ._af 5-fold_af increase_af Cmax_af DRUG ._af"
11091,"Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.",Paroxetine,duloxetine,mechanism,"DRUG (20_be mg_be QD)_be increased_be concentration_be OTHER_DRUG (40_af mg_af QD)_af 60%_af ,_af greater_af degrees_af inhibition_af expected_af higher_af doses_af DRUG ._af"
11096,"When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.",duloxetine,desipramine,mechanism,"When_bf DRUG administered_be (at_be dose_be 60_be mg_be BID)_be conjunction_be single_be 50-mg_be dose_be OTHER_DRUG ,_af CYP2D6_af substrate_af ,_af AUC_af OTHER_DRUG increased_af 3-fold_af ._af"
11207,"Concurrent administration of dyphylline and probenecid, which competes for tubular secretion, has been shown to increase the plasma half-life of dyphylline .",dyphylline,probenecid,mechanism,"Concurrent_bf administration_bf DRUG OTHER_DRUG ,_af competes_af tubular_af secretion_af ,_af shown_af increase_af plasma_af half-life_af DRUG ._af"
11217,Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7,Edetate calcium disodium,zinc insulin,mechanism,Steroids_bf enhance_bf renal_bf toxicity_bf edetate_bf calcium_bf disodium_bf animals_bf ._bf 7_bf Edetate_bf calcium_bf disodium_bf interferes_bf action_bf zinc_bf insulin_bf preparations_bf chelating_bf zinc_bf ._bf 7_bf
11231,"Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.",phenobarbital,efavirenz,mechanism,"Drugs_bf induce_bf CYP3A4_bf activity_bf (eg_bf ,_bf DRUG ,_be rifampin_be ,_be rifabutin)_be would_be expected_be increase_be clearance_be OTHER_DRUG resulting_af lowered_af plasma_af concentrations_af ._af"
11233,"Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.",rifampin,efavirenz,mechanism,"Drugs_bf induce_bf CYP3A4_bf activity_bf (eg_bf ,_bf phenobarbital_bf ,_bf DRUG ,_be rifabutin)_be would_be expected_be increase_be clearance_be OTHER_DRUG resulting_af lowered_af plasma_af concentrations_af ._af"
11234,"Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.",rifabutin,efavirenz,mechanism,"Drugs_bf induce_bf CYP3A4_bf activity_bf (eg_bf ,_bf phenobarbital_bf ,_bf rifampin_bf ,_bf rifabutin)_bf would_bf expected_bf increase_bf clearance_bf OTHER_DRUG resulting_be lowered_be plasma_be concentrations_be ._be"
11267,Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to SUSTIVA.,indinavir,SUSTIVA,mechanism,Increasing_bf DRUG dose_be 1000_be mg_be every_be 8_be hours_be compensate_be increased_be DRUG metabolism_af due_af OTHER_DRUG ._af
11268,"When indinavir at an increased dose (1000 mg every 8 hours) was given with SUSTIVA (600 mg once daily), the indinavir AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when indinavir (800 mg every 8 hours) was given alone.",indinavir,SUSTIVA,mechanism,"When_bf DRUG increased_be dose_be (1000_be mg_be every_be 8_be hours)_be given_be OTHER_DRUG (600_af mg_af daily)_af ,_af DRUG AUC_af Cmin_af decreased_af average_af 33-46%_af 39-57%_af ,_af respectively_af ,_af compared_af DRUG (800_af mg_af every_af 8_af hours)_af given_af alone_af ._af"
11293,Potential for reduction in anticonvulsant and/or efavirenz plasma levels;,anticonvulsant,efavirenz,mechanism,Potential_bf reduction_bf DRUG and/or_be OTHER_DRUG plasma_af levels;_af
11300,SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.,SUSTIVA,itraconazole,mechanism,DRUG potential_be decrease_be plasma_be concentrations_be OTHER_DRUG ketoconazole_af ._af
11301,SUSTIVA has the potential to decrease plasma concentrations of itraconazole and ketoconazole.,SUSTIVA,ketoconazole,mechanism,DRUG potential_be decrease_be plasma_be concentrations_be itraconazole_be OTHER_DRUG ._af
11484,"Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.",Bismuth subsalicylate,enoxacin,mechanism,"Bismuth:_bf Bismuth_bf subsalicylate_bf ,_bf given_bf concomitantly_bf OTHER_DRUG 60_be minutes_be following_be OTHER_DRUG administration_af ,_af decreased_af OTHER_DRUG bioavailability_af approximately_af 25%_af ._af"
11493,Caffeine: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.,Enoxacin,methylxanthines,mechanism,Caffeine:_bf DRUG potent_be inhibitor_be cytochrome_be P-450_be isozymes_be responsible_be metabolism_be OTHER_DRUG ._af
11494,"In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.",enoxacin,caffeine,mechanism,"In_bf multiple-dose_bf study_bf ,_bf DRUG caused_be dose-related_be increase_be mean_be elimination_be half-life_be OTHER_DRUG ,_af thereby_af decreasing_af clearance_af OTHER_DRUG 80%_af leading_af five-fold_af increase_af AUC_af half-life_af OTHER_DRUG ._af"
11502,Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.,caffeine,enoxacin,mechanism,Trough_bf plasma_bf OTHER_DRUG levels_be also_be 20%_be higher_be DRUG OTHER_DRUG administered_af concomitantly_af ._af
11511,Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the quinolone class.,cyclosporine,quinolone class,mechanism,Cyclosporine:_bf Elevated_bf serum_bf levels_bf DRUG reported_be concomitant_be use_be DRUG members_af quinolone_af class_af ._af
11514,Digoxin: Enoxacin may raise serum digoxin levels in some individuals.,Enoxacin,digoxin,mechanism,Digoxin:_bf DRUG may_be raise_be serum_be OTHER_DRUG levels_af individuals_af ._af
11546,or with multivitamins containing zinc may substantially interfere with drug absorption and result in insufficient plasma and tissue quinolone concentrations.,zinc,quinolone,mechanism,multivitamins_bf containing_bf DRUG may_be substantially_be interfere_be drug_be absorption_be result_be insufficient_be plasma_be tissue_be OTHER_DRUG concentrations_af ._af
11551,Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.,aluminum hydroxide,enoxacin,mechanism,Antacids_bf containing_bf aluminum_bf hydroxide_bf magnesium_bf hydroxide_bf reduce_bf oral_bf absorption_bf OTHER_DRUG 75%_be ._be
11552,Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.,magnesium hydroxide,enoxacin,mechanism,Antacids_bf containing_bf aluminum_bf hydroxide_bf magnesium_bf hydroxide_bf reduce_bf oral_bf absorption_bf OTHER_DRUG 75%_be ._be
11553,The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.,enoxacin,ranitidine,mechanism,The_bf oral_bf bioavailability_bf DRUG reduced_be 60%_be coadministration_be OTHER_DRUG ._af
11556,Theophylline: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.,Enoxacin,methylxanthines,mechanism,Theophylline:_bf DRUG potent_be inhibitor_be cytochrome_be P-450_be isozymes_be responsible_be metabolism_be OTHER_DRUG ._af
11557,Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.,Enoxacin,theophylline,mechanism,DRUG interferes_be metabolism_be OTHER_DRUG resulting_af 42%_af 74%_af dose-related_af decrease_af OTHER_DRUG clearance_af subsequent_af 260%_af 350%_af increase_af serum_af OTHER_DRUG levels_af ._af
11568,"Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.",Quinolones,R-warfarin,mechanism,"Warfarin:_bf DRUG ,_be including_be enoxacin_be ,_be decrease_be clearance_be OTHER_DRUG ,_af less_af active_af isomer_af racemic_af warfarin_af ._af"
11570,"Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.",enoxacin,R-warfarin,mechanism,"Warfarin:_bf Quinolones_bf ,_bf including_bf DRUG ,_be decrease_be clearance_be OTHER_DRUG ,_af less_af active_af isomer_af racemic_af warfarin_af ._af"
11682,Cimetidine increased the AUC of epirubicin by 50%.,Cimetidine,epirubicin,mechanism,DRUG increased_be AUC_be OTHER_DRUG 50%_af ._af
11684,"A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.",INSPRA,ketoconazole,mechanism,"A_bf pharmacokinetic_bf study_bf evaluating_bf administration_bf single_bf dose_bf DRUG 100_be mg_be OTHER_DRUG 200_af mg_af BID_af ,_af potent_af inhibitor_af CYP3A4_af pathway_af ,_af showed_af 1_af ._af 7-fold_af increase_af Cmax_af eplerenone_af 5_af ._af 4-fold_af increase_af AUC_af eplerenone_af ._af"
11690,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,erythromycin,mechanism,"Administration_bf DRUG CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be OTHER_DRUG 500_af mg_af BID_af ,_af verapamil_af 240_af mg_af QD_af ,_af saquinavir_af 1200_af mg_af TID_af ,_af fluconazole_af 200_af mg_af QD)_af resulted_af increases_af Cmax_af DRUG ranging_af 1_af ._af 4-_af 1_af ._af 6-_af fold_af AUC_af 2_af ._af 0-_af 2_af ._af 9-_af fold_af ._af"
11691,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,verapamil,mechanism,"Administration_bf DRUG CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be erythromycin_be 500_be mg_be BID_be ,_be OTHER_DRUG 240_af mg_af QD_af ,_af saquinavir_af 1200_af mg_af TID_af ,_af fluconazole_af 200_af mg_af QD)_af resulted_af increases_af Cmax_af DRUG ranging_af 1_af ._af 4-_af 1_af ._af 6-_af fold_af AUC_af 2_af ._af 0-_af 2_af ._af 9-_af fold_af ._af"
11692,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,saquinavir,mechanism,"Administration_bf DRUG CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be erythromycin_be 500_be mg_be BID_be ,_be verapamil_be 240_be mg_be QD_be ,_be OTHER_DRUG 1200_af mg_af TID_af ,_af fluconazole_af 200_af mg_af QD)_af resulted_af increases_af Cmax_af DRUG ranging_af 1_af ._af 4-_af 1_af ._af 6-_af fold_af AUC_af 2_af ._af 0-_af 2_af ._af 9-_af fold_af ._af"
11693,"Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.",eplerenone,fluconazole,mechanism,"Administration_bf DRUG CYP3A4_be inhibitors_be (e_be ._be g_be ._be ,_be erythromycin_be 500_be mg_be BID_be ,_be verapamil_be 240_be mg_be QD_be ,_be saquinavir_be 1200_be mg_be TID_be ,_be OTHER_DRUG 200_af mg_af QD)_af resulted_af increases_af Cmax_af DRUG ranging_af 1_af ._af 4-_af 1_af ._af 6-_af fold_af AUC_af 2_af ._af 0-_af 2_af ._af 9-_af fold_af ._af"
11813,"In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",furosemide,FLOLAN,mechanism,"In_bf clinical_bf trials_bf ,_bf OTHER_DRUG used_be digoxin_be ,_be diuretics_be ,_be anticoagulants_be ,_be oral_be vasodilators_be ,_be supplemental_be oxygen_be ._be In_be pharmacokinetic_be substudy_be patients_be congestive_be heart_be failure_be receiving_be DRUG digoxin_af therapy_af OTHER_DRUG initiated_af ,_af apparent_af oral_af clearance_af values_af DRUG (n_af =_af 23)_af digoxin_af (n_af =_af 30)_af decreased_af 13%_af 15%_af ,_af respectively_af ,_af second_af day_af therapy_af returned_af baseline_af values_af day_af 87_af ._af"
11816,"In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.",digoxin,FLOLAN,mechanism,"In_bf clinical_bf trials_bf ,_bf OTHER_DRUG used_be DRUG ,_af diuretics_af ,_af anticoagulants_af ,_af oral_af vasodilators_af ,_af supplemental_af oxygen_af ._af In_af pharmacokinetic_af substudy_af patients_af congestive_af heart_af failure_af receiving_af furosemide_af DRUG therapy_af OTHER_DRUG initiated_af ,_af apparent_af oral_af clearance_af values_af furosemide_af (n_af =_af 23)_af DRUG (n_af =_af 30)_af decreased_af 13%_af 15%_af ,_af respectively_af ,_af second_af day_af therapy_af returned_af baseline_af values_af day_af 87_af ._af"
29,"To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. ",ampicillin,oxytetracycline,No interaction,"To_bf investigate_bf effects_bf antimicrobial_bf combinations_bf GL_bf four_bf kinds_bf antibiotics_bf (ampicillin_bf ,_bf cefazolin_bf ,_bf OTHER_DRUG chloramphenicol)_be ,_be fractional_be inhibitory_be concentration_be index_be (FICI)_be determined_be checkerboard_be assay_be strain_be ._be"
30,"To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. ",ampicillin,chloramphenicol,No interaction,"To_bf investigate_bf effects_bf antimicrobial_bf combinations_bf GL_bf four_bf kinds_bf antibiotics_bf (ampicillin_bf ,_bf cefazolin_bf ,_bf oxytetracycline_bf chloramphenicol)_bf ,_bf fractional_bf inhibitory_bf concentration_bf index_bf (FICI)_bf determined_bf checkerboard_bf assay_bf strain_bf ._bf"
31,"To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. ",cefazolin,oxytetracycline,No interaction,"To_bf investigate_bf effects_bf antimicrobial_bf combinations_bf GL_bf four_bf kinds_bf antibiotics_bf (ampicillin_bf ,_bf DRUG ,_be OTHER_DRUG chloramphenicol)_af ,_af fractional_af inhibitory_af concentration_af index_af (FICI)_af determined_af checkerboard_af assay_af strain_af ._af"
32,"To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. ",cefazolin,chloramphenicol,No interaction,"To_bf investigate_bf effects_bf antimicrobial_bf combinations_bf GL_bf four_bf kinds_bf antibiotics_bf (ampicillin_bf ,_bf DRUG ,_be oxytetracycline_be chloramphenicol)_be ,_be fractional_be inhibitory_be concentration_be index_be (FICI)_be determined_be checkerboard_be assay_be strain_be ._be"
33,"To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. ",oxytetracycline,chloramphenicol,No interaction,"To_bf investigate_bf effects_bf antimicrobial_bf combinations_bf GL_bf four_bf kinds_bf antibiotics_bf (ampicillin_bf ,_bf cefazolin_bf ,_bf DRUG chloramphenicol)_be ,_be fractional_be inhibitory_be concentration_be index_be (FICI)_be determined_be checkerboard_be assay_be strain_be ._be"
36,"On the basis of the estimated number of regular users of intravenous amphetamine in Ontario, the mortality rate in such users is at least four times as high as in the general population of the same age, and is comparable to that in alcoholics and heroin addicts. ",amphetamine,heroin,No interaction,"On_bf basis_bf estimated_bf number_bf regular_bf users_bf intravenous_bf DRUG Ontario_be ,_be mortality_be rate_be users_be least_be four_be times_be high_be general_be population_be age_be ,_be comparable_be alcoholics_be OTHER_DRUG addicts_af ._af"
37,"However, the absolute number of alcohol-related deaths is far greater than the number of deaths in amphetamine or heroin users.",alcohol,amphetamine,No interaction,"However_bf ,_bf absolute_bf number_bf alcohol-related_bf deaths_bf far_bf greater_bf number_bf deaths_bf OTHER_DRUG heroin_be users_be ._be"
38,"However, the absolute number of alcohol-related deaths is far greater than the number of deaths in amphetamine or heroin users.",alcohol,heroin,No interaction,"However_bf ,_bf absolute_bf number_bf alcohol-related_bf deaths_bf far_bf greater_bf number_bf deaths_bf amphetamine_bf OTHER_DRUG users_be ._be"
39,"However, the absolute number of alcohol-related deaths is far greater than the number of deaths in amphetamine or heroin users.",amphetamine,heroin,No interaction,"However_bf ,_bf absolute_bf number_bf alcohol-related_bf deaths_bf far_bf greater_bf number_bf deaths_bf DRUG OTHER_DRUG users_af ._af"
40,"Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin.",contortrostatin,echistatin,No interaction,"Differential_bf regulation_bf tyrosine_bf phosphorylation_bf tumor_bf cells_bf DRUG ,_be homodimeric_be disintegrin_be ,_be monomeric_be disintegrins_be OTHER_DRUG flavoridin_af ._af"
41,"Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin.",contortrostatin,flavoridin,No interaction,"Differential_bf regulation_bf tyrosine_bf phosphorylation_bf tumor_bf cells_bf DRUG ,_be homodimeric_be disintegrin_be ,_be monomeric_be disintegrins_be echistatin_be OTHER_DRUG ._af"
42,"Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins echistatin and flavoridin.",echistatin,flavoridin,No interaction,"Differential_bf regulation_bf tyrosine_bf phosphorylation_bf tumor_bf cells_bf contortrostatin_bf ,_bf homodimeric_bf disintegrin_bf ,_bf monomeric_bf disintegrins_bf DRUG OTHER_DRUG ._af"
43,The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells. ,contortrostatin,echistatin,No interaction,The_bf homodimeric_bf disintegrin_bf DRUG compared_be directly_be monomeric_be disintegrins_be OTHER_DRUG flavoridin_af ability_af affect_af protein_af tyrosine_af phosphorylation_af tumor_af cells_af ._af
44,The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells. ,contortrostatin,flavoridin,No interaction,The_bf homodimeric_bf disintegrin_bf DRUG compared_be directly_be monomeric_be disintegrins_be echistatin_be OTHER_DRUG ability_af affect_af protein_af tyrosine_af phosphorylation_af tumor_af cells_af ._af
45,The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins echistatin and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells. ,echistatin,flavoridin,No interaction,The_bf homodimeric_bf disintegrin_bf contortrostatin_bf compared_bf directly_bf monomeric_bf disintegrins_bf DRUG OTHER_DRUG ability_af affect_af protein_af tyrosine_af phosphorylation_af tumor_af cells_af ._af
48,"Diethyl pyrocarbonate, at pH 7.0, was used to chemically modify exposed histidine residues on toxin A. ",Diethyl pyrocarbonate,toxin A,No interaction,"Diethyl_bf pyrocarbonate_bf ,_bf pH_bf 7_bf ._bf 0_bf ,_bf used_bf chemically_bf modify_bf exposed_bf histidine_bf residues_bf toxin_bf A_bf ._bf"
49,Modification of toxin A with diethyl pyrocarbonate abolished both its cytotoxic activity and the ability of the toxin to bind Zn-Sepharose gel. ,toxin A,diethyl pyrocarbonate,No interaction,Modification_bf toxin_bf A_bf diethyl_bf pyrocarbonate_bf abolished_bf cytotoxic_bf activity_bf ability_bf toxin_bf bind_bf Zn-Sepharose_bf gel_bf ._bf
50,Treatment of toxin A with [(14)C]-diethyl pyrocarbonate revealed concentration dependent labelling of histidine residues on the toxin molecules. ,toxin A,diethyl pyrocarbonate,No interaction,Treatment_bf toxin_bf A_bf [(14)C]-diethyl_bf pyrocarbonate_bf revealed_bf concentration_bf dependent_bf labelling_bf histidine_bf residues_bf toxin_bf molecules_bf ._bf
51,The effects of diethyl pyrocarbonate could be reversed by hydroxylamine treatment. ,diethyl pyrocarbonate,hydroxylamine,No interaction,The_bf effects_bf diethyl_bf pyrocarbonate_bf could_bf reversed_bf OTHER_DRUG treatment_be ._be
52,"Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.",toxin A,zinc,No interaction,"Exposed_bf histidines_bf toxin_bf A_bf available_bf OTHER_DRUG chelation_be ,_be exploited_be development_be novel_be purification_be protocol_be toxin_be A_be using_be zinc-chelating_be chromatography_be ._be"
53,"Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.",toxin A,toxin A,No interaction,"Exposed_bf histidines_bf toxin_bf A_bf available_bf zinc_bf chelation_bf ,_bf exploited_bf development_bf novel_bf purification_bf protocol_bf toxin_bf A_bf using_bf zinc-chelating_bf chromatography_bf ._bf"
54,"Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.",toxin A,zinc,No interaction,"Exposed_bf histidines_bf toxin_bf A_bf available_bf OTHER_DRUG chelation_be ,_be exploited_be development_be novel_be purification_be protocol_be toxin_be A_be using_be zinc-chelating_be chromatography_be ._be"
55,"Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.",zinc,toxin A,No interaction,"Exposed_bf histidines_bf toxin_bf A_bf available_bf DRUG chelation_be ,_be exploited_be development_be novel_be purification_be protocol_be toxin_be A_be using_be zinc-chelating_be chromatography_be ._be"
56,"Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.",zinc,zinc,No interaction,"Exposed_bf histidines_bf toxin_bf A_bf available_bf DRUG chelation_be ,_be exploited_be development_be novel_be purification_be protocol_be toxin_be A_be using_be zinc-chelating_be chromatography_be ._be"
57,"Exposed histidines on toxin A are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using zinc-chelating chromatography.",toxin A,zinc,No interaction,"Exposed_bf histidines_bf toxin_bf A_bf available_bf OTHER_DRUG chelation_be ,_be exploited_be development_be novel_be purification_be protocol_be toxin_be A_be using_be zinc-chelating_be chromatography_be ._be"
58,"Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.
",budesonide,Survanta,No interaction,"Note:_bf dissolution_bf aerosol_bf particles_bf DRUG OTHER_DRUG ,_af model_af lung_af surfactant_af ._af"
59,"Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.
",budesonide,lung surfactant,No interaction,"Note:_bf dissolution_bf aerosol_bf particles_bf DRUG Survanta_be ,_be model_be lung_be surfactant_be ._be"
60,"Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.
",Survanta,lung surfactant,No interaction,"Note:_bf dissolution_bf aerosol_bf particles_bf budesonide_bf DRUG ,_be model_be lung_be surfactant_be ._be"
61,"The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined. ",pulmonary surfactant,Survanta,No interaction,"The_bf effect_bf pulmonary_bf surfactant_bf extract_bf bovine_bf lung_bf ,_bf OTHER_DRUG ,_be dissolution_be rate_be aerosol_be particles_be budesonide_be determined_be ._be"
62,"The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined. ",pulmonary surfactant,budesonide,No interaction,"The_bf effect_bf pulmonary_bf surfactant_bf extract_bf bovine_bf lung_bf ,_bf Survanta_bf ,_bf dissolution_bf rate_bf aerosol_bf particles_bf OTHER_DRUG determined_be ._be"
63,"The effect of a pulmonary surfactant extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of budesonide was determined. ",Survanta,budesonide,No interaction,"The_bf effect_bf pulmonary_bf surfactant_bf extract_bf bovine_bf lung_bf ,_bf DRUG ,_be dissolution_be rate_be aerosol_be particles_be OTHER_DRUG determined_af ._af"
64,"Aerosol particles of budesonide were generated from an ethanol solution, dried, and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments. ",budesonide,ethanol,No interaction,"Aerosol_bf particles_bf DRUG generated_be OTHER_DRUG solution_af ,_af dried_af ,_af collected_af cascade_af impactor_af characterization_af liquid_af impinger_af dissolution_af experiments_af ._af"
65,"Survanta increased the extent of dissolution of budesonide in proportion to the added concentration, which was also verified by equilibrium solubilization studies. ",Survanta,budesonide,No interaction,"DRUG increased_be extent_be dissolution_be OTHER_DRUG proportion_af added_af concentration_af ,_af also_af verified_af equilibrium_af solubilization_af studies_af ._af"
66,"Survanta also increased rate of dissolution, in a manner similar to sodium dodecyl sulfate. ",Survanta,sodium dodecyl sulfate,No interaction,"DRUG also_be increased_be rate_be dissolution_be ,_be manner_be similar_be sodium_be dodecyl_be sulfate_be ._be"
67,Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase. ,budesonide,budesonide,No interaction,Analysis_bf concentration_bf DRUG following_be ultracentrifugation_be indicated_be rapid_be equilibration_be DRUG Survanta_af aqueous_af phase_af ._af
68,Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase. ,budesonide,Survanta,No interaction,Analysis_bf concentration_bf DRUG following_be ultracentrifugation_be indicated_be rapid_be equilibration_be DRUG OTHER_DRUG aqueous_af phase_af ._af
69,Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of budesonide between the Survanta and aqueous phase. ,budesonide,Survanta,No interaction,Analysis_bf concentration_bf DRUG following_be ultracentrifugation_be indicated_be rapid_be equilibration_be DRUG OTHER_DRUG aqueous_af phase_af ._af
70,"As immediate-early genes (IEGs) are thought to play a critical role in mediating stimulus-induced neural plasticity, IEG response induced by methamphetamine (METH) has been characterized to define the changes in gene expression that may underlie its long-lasting behavioral effects. ",methamphetamine,METH,No interaction,"As_bf immediate-early_bf genes_bf (IEGs)_bf thought_bf play_bf critical_bf role_bf mediating_bf stimulus-induced_bf neural_bf plasticity_bf ,_bf IEG_bf response_bf induced_bf DRUG (METH)_be characterized_be define_be changes_be gene_be expression_be may_be underlie_be long-lasting_be behavioral_be effects_be ._be"
72,"Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. ",METH,atypical neuroleptic,No interaction,"Using_bf situ_bf hybridization_bf ,_bf observed_bf DRUG caused_be rapid_be transient_be dose-dependent_be increase_be arc_be mRNA_be level_be striatum_be cortex_be abolished_be pretreatment_be specific_be dopamine_be D1_be receptor_be antagonist_be SCH-23390_be atypical_be neuroleptic_be clozapine_be ._be"
73,"Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. ",METH,clozapine,No interaction,"Using_bf situ_bf hybridization_bf ,_bf observed_bf DRUG caused_be rapid_be transient_be dose-dependent_be increase_be arc_be mRNA_be level_be striatum_be cortex_be abolished_be pretreatment_be specific_be dopamine_be D1_be receptor_be antagonist_be SCH-23390_be atypical_be neuroleptic_be OTHER_DRUG ._af"
74,"Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. ",SCH-23390,atypical neuroleptic,No interaction,"Using_bf situ_bf hybridization_bf ,_bf observed_bf METH_bf caused_bf rapid_bf transient_bf dose-dependent_bf increase_bf arc_bf mRNA_bf level_bf striatum_bf cortex_bf abolished_bf pretreatment_bf specific_bf dopamine_bf D1_bf receptor_bf antagonist_bf DRUG atypical_be neuroleptic_be clozapine_be ._be"
75,"Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. ",SCH-23390,clozapine,No interaction,"Using_bf situ_bf hybridization_bf ,_bf observed_bf METH_bf caused_bf rapid_bf transient_bf dose-dependent_bf increase_bf arc_bf mRNA_bf level_bf striatum_bf cortex_bf abolished_bf pretreatment_bf specific_bf dopamine_bf D1_bf receptor_bf antagonist_bf DRUG atypical_be neuroleptic_be OTHER_DRUG ._af"
76,"Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic clozapine. ",atypical neuroleptic,clozapine,No interaction,"Using_bf situ_bf hybridization_bf ,_bf observed_bf METH_bf caused_bf rapid_bf transient_bf dose-dependent_bf increase_bf arc_bf mRNA_bf level_bf striatum_bf cortex_bf abolished_bf pretreatment_bf specific_bf dopamine_bf D1_bf receptor_bf antagonist_bf SCH-23390_bf atypical_bf neuroleptic_bf OTHER_DRUG ._be"
77,"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
",DCG-IV,L-CCG-1,No interaction,The_bf effects_bf DRUG OTHER_DRUG upon_af phencyclidine_af (PCP)-induced_af locomotion_af behavioral_af changes_af mice_af ._af
78,"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
",DCG-IV,phencyclidine,No interaction,The_bf effects_bf DRUG L-CCG-1_be upon_be OTHER_DRUG (PCP)-induced_af locomotion_af behavioral_af changes_af mice_af ._af
79,"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
",DCG-IV,PCP,No interaction,The_bf effects_bf DRUG L-CCG-1_be upon_be phencyclidine_be (PCP)-induced_be locomotion_be behavioral_be changes_be mice_be ._be
80,"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
",L-CCG-1,phencyclidine,No interaction,The_bf effects_bf DCG-IV_bf DRUG upon_be OTHER_DRUG (PCP)-induced_af locomotion_af behavioral_af changes_af mice_af ._af
81,"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
",L-CCG-1,PCP,No interaction,The_bf effects_bf DCG-IV_bf DRUG upon_be phencyclidine_be (PCP)-induced_be locomotion_be behavioral_be changes_be mice_be ._be
82,"The effects of DCG-IV and L-CCG-1 upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
",phencyclidine,PCP,No interaction,The_bf effects_bf DCG-IV_bf L-CCG-1_bf upon_bf DRUG (PCP)-induced_be locomotion_be behavioral_be changes_be mice_be ._be
83,injection of phencyclidine (PCP) were observed by measuring locomotor activity and stereotyped behavior. ,phencyclidine,PCP,No interaction,injection_bf DRUG (PCP)_be observed_be measuring_be locomotor_be activity_be stereotyped_be behavior_be ._be
84,"Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1, on the above behavioral changes induced by PCP were found. ",DCG-IV,L-CCG-1,No interaction,"Then_bf ,_bf effects_bf metabotropic_bf glutamate_bf receptor_bf (mGluR)_bf agonists_bf ,_bf DRUG OTHER_DRUG ,_af behavioral_af changes_af induced_af PCP_af found_af ._af"
85,"Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1, on the above behavioral changes induced by PCP were found. ",DCG-IV,PCP,No interaction,"Then_bf ,_bf effects_bf metabotropic_bf glutamate_bf receptor_bf (mGluR)_bf agonists_bf ,_bf DRUG L-CCG-1_be ,_be behavioral_be changes_be induced_be OTHER_DRUG found_af ._af"
86,"Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and L-CCG-1, on the above behavioral changes induced by PCP were found. ",L-CCG-1,PCP,No interaction,"Then_bf ,_bf effects_bf metabotropic_bf glutamate_bf receptor_bf (mGluR)_bf agonists_bf ,_bf DCG-IV_bf DRUG ,_be behavioral_be changes_be induced_be OTHER_DRUG found_af ._af"
88,"In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.",PCP,PCP,No interaction,"In_bf order_bf examine_bf molecular_bf mechanisms_bf PCP-induced_bf behavioral_bf changes_bf ,_bf Northern_bf blot_bf analysis_bf total_bf RNA_bf prefrontal_bf cortical_bf tissues_bf mice_bf treated_bf DRUG ,_be DCG-IV_be ,_be L-CCG-1_be carried_be ._be"
89,"In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.",PCP,DCG-IV,No interaction,"In_bf order_bf examine_bf molecular_bf mechanisms_bf PCP-induced_bf behavioral_bf changes_bf ,_bf Northern_bf blot_bf analysis_bf total_bf RNA_bf prefrontal_bf cortical_bf tissues_bf mice_bf treated_bf DRUG ,_be OTHER_DRUG ,_af L-CCG-1_af carried_af ._af"
90,"In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.",PCP,L-CCG-1,No interaction,"In_bf order_bf examine_bf molecular_bf mechanisms_bf PCP-induced_bf behavioral_bf changes_bf ,_bf Northern_bf blot_bf analysis_bf total_bf RNA_bf prefrontal_bf cortical_bf tissues_bf mice_bf treated_bf DRUG ,_be DCG-IV_be ,_be OTHER_DRUG carried_af ._af"
91,"In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.",PCP,DCG-IV,No interaction,"In_bf order_bf examine_bf molecular_bf mechanisms_bf PCP-induced_bf behavioral_bf changes_bf ,_bf Northern_bf blot_bf analysis_bf total_bf RNA_bf prefrontal_bf cortical_bf tissues_bf mice_bf treated_bf DRUG ,_be OTHER_DRUG ,_af L-CCG-1_af carried_af ._af"
92,"In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.",PCP,L-CCG-1,No interaction,"In_bf order_bf examine_bf molecular_bf mechanisms_bf PCP-induced_bf behavioral_bf changes_bf ,_bf Northern_bf blot_bf analysis_bf total_bf RNA_bf prefrontal_bf cortical_bf tissues_bf mice_bf treated_bf DRUG ,_be DCG-IV_be ,_be OTHER_DRUG carried_af ._af"
93,"In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and L-CCG-1 was carried out.",DCG-IV,L-CCG-1,No interaction,"In_bf order_bf examine_bf molecular_bf mechanisms_bf PCP-induced_bf behavioral_bf changes_bf ,_bf Northern_bf blot_bf analysis_bf total_bf RNA_bf prefrontal_bf cortical_bf tissues_bf mice_bf treated_bf PCP_bf ,_bf DRUG ,_be OTHER_DRUG carried_af ._af"
94,"Behavioral responses to repeated cocaine exposure in mice selectively bred for differential sensitivity to pentobarbital.
",cocaine,pentobarbital,No interaction,Behavioral_bf responses_bf repeated_bf DRUG exposure_be mice_be selectively_be bred_be differential_be sensitivity_be OTHER_DRUG ._af
95,"Mice from the 20th generation of three lines divergently selected for response to pentobarbital-induced sedation times [long-sedation time (LST), short sedation time (SST), and randomly bred control (RBC)] were used to study cocaine-induced behavioral sensitization. ",pentobarbital,cocaine,No interaction,"Mice_bf 20th_bf generation_bf three_bf lines_bf divergently_bf selected_bf response_bf pentobarbital-induced_bf sedation_bf times_bf [long-sedation_bf time_bf (LST)_bf ,_bf short_bf sedation_bf time_bf (SST)_bf ,_bf randomly_bf bred_bf control_bf (RBC)]_bf used_bf study_bf cocaine-induced_bf behavioral_bf sensitization_bf ._bf"
96,"18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
",18-Methoxycoronaridine,18-MC,No interaction,"DRUG (18-MC)_be ibogaine:_be comparison_be antiaddictive_be efficacy_be ,_be toxicity_be ,_be mechanisms_be action_be ._be"
97,"18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
",18-Methoxycoronaridine,ibogaine,No interaction,"DRUG (18-MC)_be ibogaine:_be comparison_be antiaddictive_be efficacy_be ,_be toxicity_be ,_be mechanisms_be action_be ._be"
98,"18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
",18-MC,ibogaine,No interaction,"18-Methoxycoronaridine_bf (18-MC)_bf ibogaine:_bf comparison_bf antiaddictive_bf efficacy_bf ,_bf toxicity_bf ,_bf mechanisms_bf action_bf ._bf"
99,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ",ibogaine,18-MC,No interaction,"Like_bf DRUG (40_be mg/kg)_be ,_be OTHER_DRUG (40_af mg/kg)_af decreases_af intravenous_af self-administration_af morphine_af cocaine_af oral_af self-administration_af ethanol_af nicotine_af rats;_af"
100,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ",ibogaine,morphine,No interaction,"Like_bf DRUG (40_be mg/kg)_be ,_be 18-MC_be (40_be mg/kg)_be decreases_be intravenous_be self-administration_be OTHER_DRUG cocaine_af oral_af self-administration_af ethanol_af nicotine_af rats;_af"
101,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ",ibogaine,cocaine,No interaction,"Like_bf DRUG (40_be mg/kg)_be ,_be 18-MC_be (40_be mg/kg)_be decreases_be intravenous_be self-administration_be morphine_be OTHER_DRUG oral_af self-administration_af ethanol_af nicotine_af rats;_af"
102,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ",ibogaine,ethanol,No interaction,"Like_bf DRUG (40_be mg/kg)_be ,_be 18-MC_be (40_be mg/kg)_be decreases_be intravenous_be self-administration_be morphine_be cocaine_be oral_be self-administration_be OTHER_DRUG nicotine_af rats;_af"
103,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ",ibogaine,nicotine,No interaction,"Like_bf DRUG (40_be mg/kg)_be ,_be 18-MC_be (40_be mg/kg)_be decreases_be intravenous_be self-administration_be morphine_be cocaine_be oral_be self-administration_be ethanol_be OTHER_DRUG rats;_af"
104,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ",18-MC,morphine,No interaction,"Like_bf ibogaine_bf (40_bf mg/kg)_bf ,_bf DRUG (40_be mg/kg)_be decreases_be intravenous_be self-administration_be OTHER_DRUG cocaine_af oral_af self-administration_af ethanol_af nicotine_af rats;_af"
105,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ",18-MC,cocaine,No interaction,"Like_bf ibogaine_bf (40_bf mg/kg)_bf ,_bf DRUG (40_be mg/kg)_be decreases_be intravenous_be self-administration_be morphine_be OTHER_DRUG oral_af self-administration_af ethanol_af nicotine_af rats;_af"
106,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ",18-MC,ethanol,No interaction,"Like_bf ibogaine_bf (40_bf mg/kg)_bf ,_bf DRUG (40_be mg/kg)_be decreases_be intravenous_be self-administration_be morphine_be cocaine_be oral_be self-administration_be OTHER_DRUG nicotine_af rats;_af"
107,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ",18-MC,nicotine,No interaction,"Like_bf ibogaine_bf (40_bf mg/kg)_bf ,_bf DRUG (40_be mg/kg)_be decreases_be intravenous_be self-administration_be morphine_be cocaine_be oral_be self-administration_be ethanol_be OTHER_DRUG rats;_af"
108,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ",morphine,cocaine,No interaction,"Like_bf ibogaine_bf (40_bf mg/kg)_bf ,_bf 18-MC_bf (40_bf mg/kg)_bf decreases_bf intravenous_bf self-administration_bf DRUG OTHER_DRUG oral_af self-administration_af ethanol_af nicotine_af rats;_af"
109,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ",morphine,ethanol,No interaction,"Like_bf ibogaine_bf (40_bf mg/kg)_bf ,_bf 18-MC_bf (40_bf mg/kg)_bf decreases_bf intravenous_bf self-administration_bf DRUG cocaine_be oral_be self-administration_be OTHER_DRUG nicotine_af rats;_af"
110,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ",morphine,nicotine,No interaction,"Like_bf ibogaine_bf (40_bf mg/kg)_bf ,_bf 18-MC_bf (40_bf mg/kg)_bf decreases_bf intravenous_bf self-administration_bf DRUG cocaine_be oral_be self-administration_be ethanol_be OTHER_DRUG rats;_af"
111,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ",cocaine,ethanol,No interaction,"Like_bf ibogaine_bf (40_bf mg/kg)_bf ,_bf 18-MC_bf (40_bf mg/kg)_bf decreases_bf intravenous_bf self-administration_bf morphine_bf DRUG oral_be self-administration_be OTHER_DRUG nicotine_af rats;_af"
112,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ",cocaine,nicotine,No interaction,"Like_bf ibogaine_bf (40_bf mg/kg)_bf ,_bf 18-MC_bf (40_bf mg/kg)_bf decreases_bf intravenous_bf self-administration_bf morphine_bf DRUG oral_be self-administration_be ethanol_be OTHER_DRUG rats;_af"
113,"Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; ",ethanol,nicotine,No interaction,"Like_bf ibogaine_bf (40_bf mg/kg)_bf ,_bf 18-MC_bf (40_bf mg/kg)_bf decreases_bf intravenous_bf self-administration_bf morphine_bf cocaine_bf oral_bf self-administration_bf DRUG OTHER_DRUG rats;_af"
114,"unlike ibogaine, 18-MC does not affect responding for a nondrug reinforcer (water). ",ibogaine,18-MC,No interaction,"unlike_bf DRUG ,_be OTHER_DRUG affect_af responding_af nondrug_af reinforcer_af (water)_af ._af"
115,Both ibogaine and 18-MC ameliorate opioid withdrawal signs. ,ibogaine,18-MC,No interaction,Both_bf DRUG OTHER_DRUG ameliorate_af opioid_af withdrawal_af signs_af ._af
116,Both ibogaine and 18-MC ameliorate opioid withdrawal signs. ,ibogaine,opioid,No interaction,Both_bf DRUG 18-MC_be ameliorate_be OTHER_DRUG withdrawal_af signs_af ._af
117,Both ibogaine and 18-MC ameliorate opioid withdrawal signs. ,18-MC,opioid,No interaction,Both_bf ibogaine_bf DRUG ameliorate_be OTHER_DRUG withdrawal_af signs_af ._af
118,"Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens. ",ibogaine,18-MC,No interaction,"Both_bf DRUG OTHER_DRUG decrease_af extracellular_af levels_af dopamine_af nucleus_af accumbens_af ,_af DRUG increases_af extracellular_af levels_af serotonin_af nucleus_af accumbens_af ._af"
119,"Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens. ",ibogaine,ibogaine,No interaction,"Both_bf DRUG 18-MC_be decrease_be extracellular_be levels_be dopamine_be nucleus_be accumbens_be ,_be DRUG increases_af extracellular_af levels_af serotonin_af nucleus_af accumbens_af ._af"
120,"Both ibogaine and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens. ",18-MC,ibogaine,No interaction,"Both_bf OTHER_DRUG DRUG decrease_af extracellular_af levels_af dopamine_af nucleus_af accumbens_af ,_af OTHER_DRUG increases_af extracellular_af levels_af serotonin_af nucleus_af accumbens_af ._af"
121,Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ,ibogaine,18-MC,No interaction,Both_bf DRUG OTHER_DRUG block_af morphine-induced_af nicotine-induced_af dopamine_af release_af nucleus_af accumbens;_af
126,Both ibogaine and 18-MC block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens; ,morphine,nicotine,No interaction,Both_bf ibogaine_bf 18-MC_bf block_bf morphine-induced_bf nicotine-induced_bf dopamine_bf release_bf nucleus_bf accumbens;_bf
128,Both ibogaine and 18-MC enhance the locomotor and/or stereotypic effects of stimulants. ,ibogaine,18-MC,No interaction,Both_bf DRUG OTHER_DRUG enhance_af locomotor_af and/or_af stereotypic_af effects_af stimulants_af ._af
129,"Ibogaine attenuates, but 18-MC potentiates, the acute locomotor effects of morphine; ",Ibogaine,18-MC,No interaction,"DRUG attenuates_be ,_be OTHER_DRUG potentiates_af ,_af acute_af locomotor_af effects_af morphine;_af"
132,both compounds attenuate morphine-induced locomotion in morphine-experienced rats. ,morphine,morphine,No interaction,compounds_bf attenuate_bf morphine-induced_bf locomotion_bf morphine-experienced_bf rats_bf ._bf
133,"Ibogaine, but not 18-MC, decreases heart rate at high doses. ",Ibogaine,18-MC,No interaction,"DRUG ,_be OTHER_DRUG ,_af decreases_af heart_af rate_af high_af doses_af ._af"
134,"While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. ",18-MC,ibogaine,No interaction,"While_bf DRUG OTHER_DRUG similar_af affinities_af kappa_af opioid_af possibly_af nicotinic_af receptors_af ,_af DRUG much_af lower_af affinities_af OTHER_DRUG NMDA_af sigma-2_af receptors_af ,_af sodium_af channels_af ,_af 5-HT_af transporter_af ._af"
135,"While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. ",18-MC,18-MC,No interaction,"While_bf DRUG ibogaine_be similar_be affinities_be kappa_be opioid_be possibly_be nicotinic_be receptors_be ,_be DRUG much_af lower_af affinities_af ibogaine_af NMDA_af sigma-2_af receptors_af ,_af sodium_af channels_af ,_af 5-HT_af transporter_af ._af"
136,"While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. ",18-MC,ibogaine,No interaction,"While_bf DRUG OTHER_DRUG similar_af affinities_af kappa_af opioid_af possibly_af nicotinic_af receptors_af ,_af DRUG much_af lower_af affinities_af OTHER_DRUG NMDA_af sigma-2_af receptors_af ,_af sodium_af channels_af ,_af 5-HT_af transporter_af ._af"
137,"While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. ",ibogaine,18-MC,No interaction,"While_bf OTHER_DRUG DRUG similar_af affinities_af kappa_af opioid_af possibly_af nicotinic_af receptors_af ,_af OTHER_DRUG much_af lower_af affinities_af DRUG NMDA_af sigma-2_af receptors_af ,_af sodium_af channels_af ,_af 5-HT_af transporter_af ._af"
138,"While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. ",ibogaine,ibogaine,No interaction,"While_bf 18-MC_bf DRUG similar_be affinities_be kappa_be opioid_be possibly_be nicotinic_be receptors_be ,_be 18-MC_be much_be lower_be affinities_be DRUG NMDA_af sigma-2_af receptors_af ,_af sodium_af channels_af ,_af 5-HT_af transporter_af ._af"
139,"While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. ",18-MC,ibogaine,No interaction,"While_bf DRUG OTHER_DRUG similar_af affinities_af kappa_af opioid_af possibly_af nicotinic_af receptors_af ,_af DRUG much_af lower_af affinities_af OTHER_DRUG NMDA_af sigma-2_af receptors_af ,_af sodium_af channels_af ,_af 5-HT_af transporter_af ._af"
140,"Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. ",18-MC,ibogaine,No interaction,"Both_bf DRUG OTHER_DRUG sequestered_af fat_af ,_af like_af OTHER_DRUG ,_af DRUG probably_af active_af metabolite_af ._af"
141,"Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. ",18-MC,ibogaine,No interaction,"Both_bf DRUG OTHER_DRUG sequestered_af fat_af ,_af like_af OTHER_DRUG ,_af DRUG probably_af active_af metabolite_af ._af"
142,"Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. ",18-MC,18-MC,No interaction,"Both_bf DRUG ibogaine_be sequestered_be fat_be ,_be like_be ibogaine_be ,_be DRUG probably_af active_af metabolite_af ._af"
143,"Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. ",ibogaine,ibogaine,No interaction,"Both_bf 18-MC_bf DRUG sequestered_be fat_be ,_be like_be DRUG ,_af 18-MC_af probably_af active_af metabolite_af ._af"
144,"Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. ",ibogaine,18-MC,No interaction,"Both_bf OTHER_DRUG DRUG sequestered_af fat_af ,_af like_af DRUG ,_af OTHER_DRUG probably_af active_af metabolite_af ._af"
145,"Both 18-MC and ibogaine are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. ",ibogaine,18-MC,No interaction,"Both_bf OTHER_DRUG DRUG sequestered_af fat_af ,_af like_af DRUG ,_af OTHER_DRUG probably_af active_af metabolite_af ._af"
146,The data suggest that 18-MC has a narrower spectrum of actions and will have a substantially greater therapeutic index than ibogaine.,18-MC,ibogaine,No interaction,The_bf data_bf suggest_bf DRUG narrower_be spectrum_be actions_be substantially_be greater_be therapeutic_be index_be OTHER_DRUG ._af
148,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",anticoagulant,phenobarbital,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf DRUG interference_be OTHER_DRUG ,_af secobarbital_af ,_af glutethimide_af ,_af chloral_af hydrate_af methaqualone_af systematically_af investigated_af 16_af patients_af receiving_af coumarin_af therapy_af ._af"
149,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",anticoagulant,secobarbital,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf DRUG interference_be phenobarbital_be ,_be OTHER_DRUG ,_af glutethimide_af ,_af chloral_af hydrate_af methaqualone_af systematically_af investigated_af 16_af patients_af receiving_af coumarin_af therapy_af ._af"
150,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",anticoagulant,glutethimide,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf DRUG interference_be phenobarbital_be ,_be secobarbital_be ,_be OTHER_DRUG ,_af chloral_af hydrate_af methaqualone_af systematically_af investigated_af 16_af patients_af receiving_af coumarin_af therapy_af ._af"
151,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",anticoagulant,chloral hydrate,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf DRUG interference_be phenobarbital_be ,_be secobarbital_be ,_be glutethimide_be ,_be chloral_be hydrate_be methaqualone_be systematically_be investigated_be 16_be patients_be receiving_be coumarin_be therapy_be ._be"
152,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",anticoagulant,methaqualone,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf DRUG interference_be phenobarbital_be ,_be secobarbital_be ,_be glutethimide_be ,_be chloral_be hydrate_be OTHER_DRUG systematically_af investigated_af 16_af patients_af receiving_af coumarin_af therapy_af ._af"
153,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",anticoagulant,coumarin,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf DRUG interference_be phenobarbital_be ,_be secobarbital_be ,_be glutethimide_be ,_be chloral_be hydrate_be methaqualone_be systematically_be investigated_be 16_be patients_be receiving_be OTHER_DRUG therapy_af ._af"
154,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",phenobarbital,secobarbital,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf anticoagulant_bf interference_bf DRUG ,_be OTHER_DRUG ,_af glutethimide_af ,_af chloral_af hydrate_af methaqualone_af systematically_af investigated_af 16_af patients_af receiving_af coumarin_af therapy_af ._af"
155,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",phenobarbital,glutethimide,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf anticoagulant_bf interference_bf DRUG ,_be secobarbital_be ,_be OTHER_DRUG ,_af chloral_af hydrate_af methaqualone_af systematically_af investigated_af 16_af patients_af receiving_af coumarin_af therapy_af ._af"
156,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",phenobarbital,chloral hydrate,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf anticoagulant_bf interference_bf DRUG ,_be secobarbital_be ,_be glutethimide_be ,_be chloral_be hydrate_be methaqualone_be systematically_be investigated_be 16_be patients_be receiving_be coumarin_be therapy_be ._be"
157,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",phenobarbital,methaqualone,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf anticoagulant_bf interference_bf DRUG ,_be secobarbital_be ,_be glutethimide_be ,_be chloral_be hydrate_be OTHER_DRUG systematically_af investigated_af 16_af patients_af receiving_af coumarin_af therapy_af ._af"
158,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",phenobarbital,coumarin,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf anticoagulant_bf interference_bf DRUG ,_be secobarbital_be ,_be glutethimide_be ,_be chloral_be hydrate_be methaqualone_be systematically_be investigated_be 16_be patients_be receiving_be OTHER_DRUG therapy_af ._af"
159,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",secobarbital,glutethimide,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf anticoagulant_bf interference_bf phenobarbital_bf ,_bf DRUG ,_be OTHER_DRUG ,_af chloral_af hydrate_af methaqualone_af systematically_af investigated_af 16_af patients_af receiving_af coumarin_af therapy_af ._af"
160,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",secobarbital,chloral hydrate,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf anticoagulant_bf interference_bf phenobarbital_bf ,_bf DRUG ,_be glutethimide_be ,_be chloral_be hydrate_be methaqualone_be systematically_be investigated_be 16_be patients_be receiving_be coumarin_be therapy_be ._be"
161,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",secobarbital,methaqualone,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf anticoagulant_bf interference_bf phenobarbital_bf ,_bf DRUG ,_be glutethimide_be ,_be chloral_be hydrate_be OTHER_DRUG systematically_af investigated_af 16_af patients_af receiving_af coumarin_af therapy_af ._af"
162,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",secobarbital,coumarin,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf anticoagulant_bf interference_bf phenobarbital_bf ,_bf DRUG ,_be glutethimide_be ,_be chloral_be hydrate_be methaqualone_be systematically_be investigated_be 16_be patients_be receiving_be OTHER_DRUG therapy_af ._af"
163,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",glutethimide,chloral hydrate,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf anticoagulant_bf interference_bf phenobarbital_bf ,_bf secobarbital_bf ,_bf DRUG ,_be chloral_be hydrate_be methaqualone_be systematically_be investigated_be 16_be patients_be receiving_be coumarin_be therapy_be ._be"
164,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",glutethimide,methaqualone,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf anticoagulant_bf interference_bf phenobarbital_bf ,_bf secobarbital_bf ,_bf DRUG ,_be chloral_be hydrate_be OTHER_DRUG systematically_af investigated_af 16_af patients_af receiving_af coumarin_af therapy_af ._af"
165,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",glutethimide,coumarin,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf anticoagulant_bf interference_bf phenobarbital_bf ,_bf secobarbital_bf ,_bf DRUG ,_be chloral_be hydrate_be methaqualone_be systematically_be investigated_be 16_be patients_be receiving_be OTHER_DRUG therapy_af ._af"
166,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",chloral hydrate,methaqualone,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf anticoagulant_bf interference_bf phenobarbital_bf ,_bf secobarbital_bf ,_bf glutethimide_bf ,_bf chloral_bf hydrate_bf OTHER_DRUG systematically_be investigated_be 16_be patients_be receiving_be coumarin_be therapy_be ._be"
167,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",chloral hydrate,coumarin,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf anticoagulant_bf interference_bf phenobarbital_bf ,_bf secobarbital_bf ,_bf glutethimide_bf ,_bf chloral_bf hydrate_bf methaqualone_bf systematically_bf investigated_bf 16_bf patients_bf receiving_bf OTHER_DRUG therapy_be ._be"
168,"The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. ",methaqualone,coumarin,No interaction,"The_bf intensity_bf ,_bf uniformity_bf time_bf course_bf anticoagulant_bf interference_bf phenobarbital_bf ,_bf secobarbital_bf ,_bf glutethimide_bf ,_bf chloral_bf hydrate_bf DRUG systematically_be investigated_be 16_be patients_be receiving_be OTHER_DRUG therapy_af ._af"
169,"Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide; ",phenobarbital,secobarbital,No interaction,"Anticoagulant_bf inhibition_bf observed_bf administration_bf DRUG ,_be OTHER_DRUG glutethimide;_af"
170,"Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide; ",phenobarbital,glutethimide,No interaction,"Anticoagulant_bf inhibition_bf observed_bf administration_bf DRUG ,_be secobarbital_be glutethimide;_be"
171,"Anticoagulant inhibition was observed during the administration of phenobarbital, secobarbital and glutethimide; ",secobarbital,glutethimide,No interaction,"Anticoagulant_bf inhibition_bf observed_bf administration_bf phenobarbital_bf ,_bf DRUG glutethimide;_be"
172,there was no significant change in prothrombin test results during the trials of chloral hydrate and methaqualone. ,chloral hydrate,methaqualone,No interaction,significant_bf change_bf prothrombin_bf test_bf results_bf trials_bf chloral_bf hydrate_bf OTHER_DRUG ._be
173,Barbiturates and glutethimide should not be administered to patients receiving coumarin drugs. ,Barbiturates,glutethimide,No interaction,DRUG OTHER_DRUG administered_af patients_af receiving_af coumarin_af drugs_af ._af
176,"Chloral hydrate and methaqualone interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant. ",Chloral hydrate,methaqualone,No interaction,"Chloral_bf hydrate_bf OTHER_DRUG interact_be pharmacologically_be orally_be administered_be anticoagulant_be agents_be ,_be effect_be clinically_be significant_be ._be"
179,It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.,chloral hydrate,methaqualone,No interaction,It_bf concluded_bf chloral_bf hydrate_bf OTHER_DRUG may_be administered_be safely_be without_be additional_be caution_be prothrombin_be test_be monitoring_be oral_be anticoagulant_be therapy_be ._be
180,It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.,chloral hydrate,anticoagulant,No interaction,It_bf concluded_bf chloral_bf hydrate_bf methaqualone_bf may_bf administered_bf safely_bf without_bf additional_bf caution_bf prothrombin_bf test_bf monitoring_bf oral_bf OTHER_DRUG therapy_be ._be
181,It is concluded that chloral hydrate and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.,methaqualone,anticoagulant,No interaction,It_bf concluded_bf chloral_bf hydrate_bf DRUG may_be administered_be safely_be without_be additional_be caution_be prothrombin_be test_be monitoring_be oral_be OTHER_DRUG therapy_af ._af
182,Concomitantly given thiazide diuretics did not interfere with the absorption of a tablet of digoxin. ,thiazide diuretics,digoxin,No interaction,Concomitantly_bf given_bf thiazide_bf diuretics_bf interfere_bf absorption_bf tablet_bf OTHER_DRUG ._be
183,Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. ,Resveratrol,noradrenaline,No interaction,DRUG (5-35_be micromol/l)_be induced_be concentration-dependent_be relaxation_be mesenteric_be arteries_be preconstricted_be OTHER_DRUG (8_af micromol/l)_af KCl_af (125_af mmol/l)_af lean_af dietary-obese_af rats_af ._af
184,Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. ,Resveratrol,KCl,No interaction,DRUG (5-35_be micromol/l)_be induced_be concentration-dependent_be relaxation_be mesenteric_be arteries_be preconstricted_be noradrenaline_be (8_be micromol/l)_be OTHER_DRUG (125_af mmol/l)_af lean_af dietary-obese_af rats_af ._af
185,Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats. ,noradrenaline,KCl,No interaction,Resveratrol_bf (5-35_bf micromol/l)_bf induced_bf concentration-dependent_bf relaxation_bf mesenteric_bf arteries_bf preconstricted_bf DRUG (8_be micromol/l)_be OTHER_DRUG (125_af mmol/l)_af lean_af dietary-obese_af rats_af ._af
186,"However, L-NAME (100 and 300 micromol/l) did not alter the effects of reseveratrol on arteries from dietary-obese rats, giving superimposed concentration-responses curves. ",L-NAME,reseveratrol,No interaction,"However_bf ,_bf DRUG (100_be 300_be micromol/l)_be alter_be effects_be OTHER_DRUG arteries_af dietary-obese_af rats_af ,_af giving_af superimposed_af concentration-responses_af curves_af ._af"
187,Indomethacin was also ineffective in altering resveratrol activity in arteries from both lean and dietary-obese rats. ,Indomethacin,resveratrol,No interaction,DRUG also_be ineffective_be altering_be OTHER_DRUG activity_af arteries_af lean_af dietary-obese_af rats_af ._af
188,"In noradrenaline-precontracted arteries from dietary-obese rats, responses to resveratrol were not attenuated by endothelial denudation, indicating an action independent of the endothelium. ",noradrenaline,resveratrol,No interaction,"In_bf noradrenaline-precontracted_bf arteries_bf dietary-obese_bf rats_bf ,_bf responses_bf OTHER_DRUG attenuated_be endothelial_be denudation_be ,_be indicating_be action_be independent_be endothelium_be ._be"
189,"This study indicates that: (a) the maximal effects of resveratrol on resistance arteries from lean and dietary-obese rats are not effected by endothelial dysfunction, and (b) the effects of resveratrol in lean animals (where endothelial function is not impaired), but not in dietary-obese rats, are mediated via NO.",resveratrol,resveratrol,No interaction,"This_bf study_bf indicates_bf that:_bf (a)_bf maximal_bf effects_bf DRUG resistance_be arteries_be lean_be dietary-obese_be rats_be effected_be endothelial_be dysfunction_be ,_be (b)_be effects_be DRUG lean_af animals_af (where_af endothelial_af function_af impaired)_af ,_af dietary-obese_af rats_af ,_af mediated_af via_af NO_af ._af"
190,"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
",indinavir,IDV,No interaction,"If_bf taken_bf 1_bf hour_bf DRUG (IDV)_be ,_be didanosine_be affect_be OTHER_DRUG exposure_af ,_af despite_af persistent_af buffering_af effects_af ._af"
191,"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
",indinavir,didanosine,No interaction,"If_bf taken_bf 1_bf hour_bf DRUG (IDV)_be ,_be OTHER_DRUG affect_af IDV_af exposure_af ,_af despite_af persistent_af buffering_af effects_af ._af"
192,"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
",indinavir,IDV,No interaction,"If_bf taken_bf 1_bf hour_bf DRUG (IDV)_be ,_be didanosine_be affect_be OTHER_DRUG exposure_af ,_af despite_af persistent_af buffering_af effects_af ._af"
193,"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
",IDV,didanosine,No interaction,"If_bf taken_bf 1_bf hour_bf indinavir_bf (IDV)_bf ,_bf OTHER_DRUG affect_be DRUG exposure_af ,_af despite_af persistent_af buffering_af effects_af ._af"
194,"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
",IDV,IDV,No interaction,"If_bf taken_bf 1_bf hour_bf indinavir_bf (IDV)_bf ,_bf didanosine_bf affect_bf DRUG exposure_be ,_be despite_be persistent_be buffering_be effects_be ._be"
195,"If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
",didanosine,IDV,No interaction,"If_bf taken_bf 1_bf hour_bf indinavir_bf (IDV)_bf ,_bf DRUG affect_be OTHER_DRUG exposure_af ,_af despite_af persistent_af buffering_af effects_af ._af"
197,"Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ",indinavir,indinavir,No interaction,"Concurrent_bf administration_bf DRUG didanosine_be significantly_be reduces_be level_be exposure_be DRUG ,_af unclear_af soon_af didanosine_af administration_af DRUG may_af given_af safely_af ._af"
198,"Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ",indinavir,didanosine,No interaction,"Concurrent_bf administration_bf DRUG OTHER_DRUG significantly_af reduces_af level_af exposure_af DRUG ,_af unclear_af soon_af OTHER_DRUG administration_af DRUG may_af given_af safely_af ._af"
199,"Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ",indinavir,indinavir,No interaction,"Concurrent_bf administration_bf DRUG didanosine_be significantly_be reduces_be level_be exposure_be DRUG ,_af unclear_af soon_af didanosine_af administration_af DRUG may_af given_af safely_af ._af"
200,"Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ",didanosine,indinavir,No interaction,"Concurrent_bf administration_bf OTHER_DRUG DRUG significantly_af reduces_af level_af exposure_af OTHER_DRUG ,_af unclear_af soon_af DRUG administration_af OTHER_DRUG may_af given_af safely_af ._af"
201,"Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ",didanosine,didanosine,No interaction,"Concurrent_bf administration_bf indinavir_bf DRUG significantly_be reduces_be level_be exposure_be indinavir_be ,_be unclear_be soon_be DRUG administration_af indinavir_af may_af given_af safely_af ._af"
202,"Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ",didanosine,indinavir,No interaction,"Concurrent_bf administration_bf OTHER_DRUG DRUG significantly_af reduces_af level_af exposure_af OTHER_DRUG ,_af unclear_af soon_af DRUG administration_af OTHER_DRUG may_af given_af safely_af ._af"
203,"Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ",indinavir,didanosine,No interaction,"Concurrent_bf administration_bf DRUG OTHER_DRUG significantly_af reduces_af level_af exposure_af DRUG ,_af unclear_af soon_af OTHER_DRUG administration_af DRUG may_af given_af safely_af ._af"
204,"Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ",indinavir,indinavir,No interaction,"Concurrent_bf administration_bf DRUG didanosine_be significantly_be reduces_be level_be exposure_be DRUG ,_af unclear_af soon_af didanosine_af administration_af DRUG may_af given_af safely_af ._af"
205,"Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. ",didanosine,indinavir,No interaction,"Concurrent_bf administration_bf OTHER_DRUG DRUG significantly_af reduces_af level_af exposure_af OTHER_DRUG ,_af unclear_af soon_af DRUG administration_af OTHER_DRUG may_af given_af safely_af ._af"
206,We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. ,indinavir,indinavir,No interaction,We_bf compared_bf DRUG pharmacokinetics_be gastric_be pH_be 12_be human_be immunodeficiency_be virus-positive_be patients_be use_be 800_be mg_be DRUG alone_af versus_af 800_af mg_af DRUG administered_af 1_af didanosine_af administration_af ._af
207,We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. ,indinavir,indinavir,No interaction,We_bf compared_bf DRUG pharmacokinetics_be gastric_be pH_be 12_be human_be immunodeficiency_be virus-positive_be patients_be use_be 800_be mg_be DRUG alone_af versus_af 800_af mg_af DRUG administered_af 1_af didanosine_af administration_af ._af
208,We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. ,indinavir,didanosine,No interaction,We_bf compared_bf DRUG pharmacokinetics_be gastric_be pH_be 12_be human_be immunodeficiency_be virus-positive_be patients_be use_be 800_be mg_be DRUG alone_af versus_af 800_af mg_af DRUG administered_af 1_af OTHER_DRUG administration_af ._af
209,We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. ,indinavir,indinavir,No interaction,We_bf compared_bf DRUG pharmacokinetics_be gastric_be pH_be 12_be human_be immunodeficiency_be virus-positive_be patients_be use_be 800_be mg_be DRUG alone_af versus_af 800_af mg_af DRUG administered_af 1_af didanosine_af administration_af ._af
210,We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. ,indinavir,didanosine,No interaction,We_bf compared_bf DRUG pharmacokinetics_be gastric_be pH_be 12_be human_be immunodeficiency_be virus-positive_be patients_be use_be 800_be mg_be DRUG alone_af versus_af 800_af mg_af DRUG administered_af 1_af OTHER_DRUG administration_af ._af
211,We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after didanosine administration. ,indinavir,didanosine,No interaction,We_bf compared_bf DRUG pharmacokinetics_be gastric_be pH_be 12_be human_be immunodeficiency_be virus-positive_be patients_be use_be 800_be mg_be DRUG alone_af versus_af 800_af mg_af DRUG administered_af 1_af OTHER_DRUG administration_af ._af
216,"The percentage of neurons hyperpolarized by mu-, delta(1)-, and kappa-selective opioids was significantly reduced when 1% but not < ",mu-selective opioids,delta(1)-selective opioids,No interaction,"The_bf percentage_bf neurons_bf hyperpolarized_bf mu-_bf ,_bf delta(1)-_bf ,_bf kappa-selective_bf opioids_bf significantly_bf reduced_bf 1%_bf <_bf"
217,"The percentage of neurons hyperpolarized by mu-, delta(1)-, and kappa-selective opioids was significantly reduced when 1% but not < ",mu-selective opioids,kappa-selective opioids,No interaction,"The_bf percentage_bf neurons_bf hyperpolarized_bf mu-_bf ,_bf delta(1)-_bf ,_bf kappa-selective_bf opioids_bf significantly_bf reduced_bf 1%_bf <_bf"
218,"The percentage of neurons hyperpolarized by mu-, delta(1)-, and kappa-selective opioids was significantly reduced when 1% but not < ",delta(1)-selective opioids,kappa-selective opioids,No interaction,"The_bf percentage_bf neurons_bf hyperpolarized_bf mu-_bf ,_bf delta(1)-_bf ,_bf kappa-selective_bf opioids_bf significantly_bf reduced_bf 1%_bf <_bf"
220,"Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
",verapamil,azoxymethane,No interaction,Suppression_bf DRUG bombesin-enhanced_be peritoneal_be metastasis_be intestinal_be adenocarcinomas_be induced_be OTHER_DRUG wistar_af rats_af ._af
221,"Suppression by verapamil of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
",bombesin,azoxymethane,No interaction,Suppression_bf verapamil_bf bombesin-enhanced_bf peritoneal_bf metastasis_bf intestinal_bf adenocarcinomas_bf induced_bf OTHER_DRUG wistar_be rats_be ._be
222,"BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ",bombesin,verapamil hydrochloride,No interaction,"BACKGROUND:_bf The_bf effects_bf combined_bf administration_bf DRUG verapamil_be hydrochloride_be (verapamil)_be ,_be calcium_be channel_be blocker_be ,_be incidence_be peritoneal_be metastasis_be intestinal_be adenocarcinomas_be induced_be azoxymethane_be (AOM)_be labeling_be index_be intestinal_be cancers_be investigated_be male_be Wistar_be rats_be ._be"
223,"BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ",bombesin,verapamil,No interaction,"BACKGROUND:_bf The_bf effects_bf combined_bf administration_bf DRUG OTHER_DRUG hydrochloride_af (verapamil)_af ,_af calcium_af channel_af blocker_af ,_af incidence_af peritoneal_af metastasis_af intestinal_af adenocarcinomas_af induced_af azoxymethane_af (AOM)_af labeling_af index_af intestinal_af cancers_af investigated_af male_af Wistar_af rats_af ._af"
224,"BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ",bombesin,calcium channel blocker,No interaction,"BACKGROUND:_bf The_bf effects_bf combined_bf administration_bf DRUG verapamil_be hydrochloride_be (verapamil)_be ,_be calcium_be channel_be blocker_be ,_be incidence_be peritoneal_be metastasis_be intestinal_be adenocarcinomas_be induced_be azoxymethane_be (AOM)_be labeling_be index_be intestinal_be cancers_be investigated_be male_be Wistar_be rats_be ._be"
225,"BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ",bombesin,azoxymethane,No interaction,"BACKGROUND:_bf The_bf effects_bf combined_bf administration_bf DRUG verapamil_be hydrochloride_be (verapamil)_be ,_be calcium_be channel_be blocker_be ,_be incidence_be peritoneal_be metastasis_be intestinal_be adenocarcinomas_be induced_be OTHER_DRUG (AOM)_af labeling_af index_af intestinal_af cancers_af investigated_af male_af Wistar_af rats_af ._af"
226,"BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ",bombesin,AOM,No interaction,"BACKGROUND:_bf The_bf effects_bf combined_bf administration_bf DRUG verapamil_be hydrochloride_be (verapamil)_be ,_be calcium_be channel_be blocker_be ,_be incidence_be peritoneal_be metastasis_be intestinal_be adenocarcinomas_be induced_be azoxymethane_be (AOM)_be labeling_be index_be intestinal_be cancers_be investigated_be male_be Wistar_be rats_be ._be"
227,"BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ",verapamil hydrochloride,verapamil,No interaction,"BACKGROUND:_bf The_bf effects_bf combined_bf administration_bf bombesin_bf OTHER_DRUG hydrochloride_be (verapamil)_be ,_be calcium_be channel_be blocker_be ,_be incidence_be peritoneal_be metastasis_be intestinal_be adenocarcinomas_be induced_be azoxymethane_be (AOM)_be labeling_be index_be intestinal_be cancers_be investigated_be male_be Wistar_be rats_be ._be"
228,"BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ",verapamil hydrochloride,calcium channel blocker,No interaction,"BACKGROUND:_bf The_bf effects_bf combined_bf administration_bf bombesin_bf verapamil_bf hydrochloride_bf (verapamil)_bf ,_bf calcium_bf channel_bf blocker_bf ,_bf incidence_bf peritoneal_bf metastasis_bf intestinal_bf adenocarcinomas_bf induced_bf azoxymethane_bf (AOM)_bf labeling_bf index_bf intestinal_bf cancers_bf investigated_bf male_bf Wistar_bf rats_bf ._bf"
229,"BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ",verapamil hydrochloride,azoxymethane,No interaction,"BACKGROUND:_bf The_bf effects_bf combined_bf administration_bf bombesin_bf verapamil_bf hydrochloride_bf (verapamil)_bf ,_bf calcium_bf channel_bf blocker_bf ,_bf incidence_bf peritoneal_bf metastasis_bf intestinal_bf adenocarcinomas_bf induced_bf OTHER_DRUG (AOM)_be labeling_be index_be intestinal_be cancers_be investigated_be male_be Wistar_be rats_be ._be"
230,"BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ",verapamil hydrochloride,AOM,No interaction,"BACKGROUND:_bf The_bf effects_bf combined_bf administration_bf bombesin_bf verapamil_bf hydrochloride_bf (verapamil)_bf ,_bf calcium_bf channel_bf blocker_bf ,_bf incidence_bf peritoneal_bf metastasis_bf intestinal_bf adenocarcinomas_bf induced_bf azoxymethane_bf (AOM)_bf labeling_bf index_bf intestinal_bf cancers_bf investigated_bf male_bf Wistar_bf rats_bf ._bf"
231,"BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ",verapamil,calcium channel blocker,No interaction,"BACKGROUND:_bf The_bf effects_bf combined_bf administration_bf bombesin_bf DRUG hydrochloride_be (verapamil)_be ,_be calcium_be channel_be blocker_be ,_be incidence_be peritoneal_be metastasis_be intestinal_be adenocarcinomas_be induced_be azoxymethane_be (AOM)_be labeling_be index_be intestinal_be cancers_be investigated_be male_be Wistar_be rats_be ._be"
232,"BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ",verapamil,azoxymethane,No interaction,"BACKGROUND:_bf The_bf effects_bf combined_bf administration_bf bombesin_bf DRUG hydrochloride_be (verapamil)_be ,_be calcium_be channel_be blocker_be ,_be incidence_be peritoneal_be metastasis_be intestinal_be adenocarcinomas_be induced_be OTHER_DRUG (AOM)_af labeling_af index_af intestinal_af cancers_af investigated_af male_af Wistar_af rats_af ._af"
233,"BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ",verapamil,AOM,No interaction,"BACKGROUND:_bf The_bf effects_bf combined_bf administration_bf bombesin_bf DRUG hydrochloride_be (verapamil)_be ,_be calcium_be channel_be blocker_be ,_be incidence_be peritoneal_be metastasis_be intestinal_be adenocarcinomas_be induced_be azoxymethane_be (AOM)_be labeling_be index_be intestinal_be cancers_be investigated_be male_be Wistar_be rats_be ._be"
234,"BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ",calcium channel blocker,azoxymethane,No interaction,"BACKGROUND:_bf The_bf effects_bf combined_bf administration_bf bombesin_bf verapamil_bf hydrochloride_bf (verapamil)_bf ,_bf calcium_bf channel_bf blocker_bf ,_bf incidence_bf peritoneal_bf metastasis_bf intestinal_bf adenocarcinomas_bf induced_bf OTHER_DRUG (AOM)_be labeling_be index_be intestinal_be cancers_be investigated_be male_be Wistar_be rats_be ._be"
235,"BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ",calcium channel blocker,AOM,No interaction,"BACKGROUND:_bf The_bf effects_bf combined_bf administration_bf bombesin_bf verapamil_bf hydrochloride_bf (verapamil)_bf ,_bf calcium_bf channel_bf blocker_bf ,_bf incidence_bf peritoneal_bf metastasis_bf intestinal_bf adenocarcinomas_bf induced_bf azoxymethane_bf (AOM)_bf labeling_bf index_bf intestinal_bf cancers_bf investigated_bf male_bf Wistar_bf rats_bf ._bf"
236,"BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. ",azoxymethane,AOM,No interaction,"BACKGROUND:_bf The_bf effects_bf combined_bf administration_bf bombesin_bf verapamil_bf hydrochloride_bf (verapamil)_bf ,_bf calcium_bf channel_bf blocker_bf ,_bf incidence_bf peritoneal_bf metastasis_bf intestinal_bf adenocarcinomas_bf induced_bf DRUG (AOM)_be labeling_be index_be intestinal_be cancers_be investigated_be male_be Wistar_be rats_be ._be"
237,"METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. ",AOM,bombesin,No interaction,"METHODS:_bf From_bf beginning_bf experiment_bf ,_bf rats_bf given_bf 10_bf weekly_bf subcutaneous_bf injections_bf DRUG (7_be ._be 4_be mg/kg_be body_be weight)_be subcutaneous_be injections_be OTHER_DRUG (40_af microg/kg_af body_af weight)_af every_af day_af ,_af week_af 16_af ,_af intraperitoneal_af injections_af verapamil_af (10_af 20_af mg/kg_af body_af weight)_af every_af day_af end_af fo_af experiment_af week_af 45_af ._af"
238,"METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. ",AOM,verapamil,No interaction,"METHODS:_bf From_bf beginning_bf experiment_bf ,_bf rats_bf given_bf 10_bf weekly_bf subcutaneous_bf injections_bf DRUG (7_be ._be 4_be mg/kg_be body_be weight)_be subcutaneous_be injections_be bombesin_be (40_be microg/kg_be body_be weight)_be every_be day_be ,_be week_be 16_be ,_be intraperitoneal_be injections_be OTHER_DRUG (10_af 20_af mg/kg_af body_af weight)_af every_af day_af end_af fo_af experiment_af week_af 45_af ._af"
239,"METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. ",bombesin,verapamil,No interaction,"METHODS:_bf From_bf beginning_bf experiment_bf ,_bf rats_bf given_bf 10_bf weekly_bf subcutaneous_bf injections_bf AOM_bf (7_bf ._bf 4_bf mg/kg_bf body_bf weight)_bf subcutaneous_bf injections_bf DRUG (40_be microg/kg_be body_be weight)_be every_be day_be ,_be week_be 16_be ,_be intraperitoneal_be injections_be OTHER_DRUG (10_af 20_af mg/kg_af body_af weight)_af every_af day_af end_af fo_af experiment_af week_af 45_af ._af"
240,"Although verapamil administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by bombesin or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis. ",verapamil,bombesin,No interaction,"Although_bf DRUG administered_be either_be dose_be little_be effect_be enhancement_be intestinal_be carcinogenesis_be OTHER_DRUG location_af ,_af histologic_af type_af ,_af depth_af involvement_af ,_af labeling_af index_af ,_af apoptotic_af index_af tumor_af vascularity_af intestinal_af cancers_af ,_af significantly_af decreased_af incidence_af cancer_af metastasis_af ._af"
243,The interaction of prostaglandin F2alpha and synthetic oxytocin on placental vessels was studied in vitro. ,prostaglandin F2alpha,oxytocin,No interaction,The_bf interaction_bf prostaglandin_bf F2alpha_bf synthetic_bf OTHER_DRUG placental_be vessels_be studied_be vitro_be ._be
244,In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha. ,norepinephrine,oxytocin,No interaction,In_bf seven_bf experiments_bf reactions_bf DRUG OTHER_DRUG PGF2alpha_af ._af
245,In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha. ,norepinephrine,PGF2alpha,No interaction,In_bf seven_bf experiments_bf reactions_bf DRUG oxytocin_be OTHER_DRUG ._af
246,In seven experiments reactions to norepinephrine and oxytocin were PGF2alpha. ,oxytocin,PGF2alpha,No interaction,In_bf seven_bf experiments_bf reactions_bf norepinephrine_bf DRUG OTHER_DRUG ._af
249,"Carbamazepine overdose recognized by a tricyclic antidepressant assay.
",Carbamazepine,tricyclic antidepressant,No interaction,DRUG overdose_be recognized_be tricyclic_be antidepressant_be assay_be ._be
251,We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.,carbamazepine,carbamazepine,No interaction,We_bf report_bf case_bf adolescent_bf altered_bf consciousness_bf caused_bf DRUG overdose_be positive_be tricyclic_be antidepressant_be level_be alert_be clinicians_be cross-reactivity_be DRUG toxicology_af screen_af tricyclic_af antidepressants_af ._af
252,We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.,carbamazepine,tricyclic antidepressants,No interaction,We_bf report_bf case_bf adolescent_bf altered_bf consciousness_bf caused_bf DRUG overdose_be positive_be tricyclic_be antidepressant_be level_be alert_be clinicians_be cross-reactivity_be DRUG toxicology_af screen_af tricyclic_af antidepressants_af ._af
253,We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.,tricyclic antidepressant,carbamazepine,No interaction,We_bf report_bf case_bf adolescent_bf altered_bf consciousness_bf caused_bf OTHER_DRUG overdose_be positive_be tricyclic_be antidepressant_be level_be alert_be clinicians_be cross-reactivity_be OTHER_DRUG toxicology_af screen_af tricyclic_af antidepressants_af ._af
254,We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.,tricyclic antidepressant,tricyclic antidepressants,No interaction,We_bf report_bf case_bf adolescent_bf altered_bf consciousness_bf caused_bf carbamazepine_bf overdose_bf positive_bf tricyclic_bf antidepressant_bf level_bf alert_bf clinicians_bf cross-reactivity_bf carbamazepine_bf toxicology_bf screen_bf tricyclic_bf antidepressants_bf ._bf
256,"In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ",ginsenosides,selective Ca(2+) channel blockers,No interaction,"In_bf study_bf investigated_bf effect_bf DRUG high_be threshold_be voltage-dependent_be Ca(2+)_be channel_be subtypes_be using_be selective_be Ca(2+)_be channel_be blockers_be nimodipine_be (L-type)_be ,_be omega-conotoxin_be GVIA_be (N-type)_be ,_be omega-agatoxin_be IVA_be (P-type)_be bovine_be chromaffin_be cells_be ._be"
257,"In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ",ginsenosides,nimodipine,No interaction,"In_bf study_bf investigated_bf effect_bf DRUG high_be threshold_be voltage-dependent_be Ca(2+)_be channel_be subtypes_be using_be selective_be Ca(2+)_be channel_be blockers_be OTHER_DRUG (L-type)_af ,_af omega-conotoxin_af GVIA_af (N-type)_af ,_af omega-agatoxin_af IVA_af (P-type)_af bovine_af chromaffin_af cells_af ._af"
258,"In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ",ginsenosides,omega-conotoxin GVIA,No interaction,"In_bf study_bf investigated_bf effect_bf DRUG high_be threshold_be voltage-dependent_be Ca(2+)_be channel_be subtypes_be using_be selective_be Ca(2+)_be channel_be blockers_be nimodipine_be (L-type)_be ,_be omega-conotoxin_be GVIA_be (N-type)_be ,_be omega-agatoxin_be IVA_be (P-type)_be bovine_be chromaffin_be cells_be ._be"
259,"In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ",ginsenosides,omega-agatoxin IVA,No interaction,"In_bf study_bf investigated_bf effect_bf DRUG high_be threshold_be voltage-dependent_be Ca(2+)_be channel_be subtypes_be using_be selective_be Ca(2+)_be channel_be blockers_be nimodipine_be (L-type)_be ,_be omega-conotoxin_be GVIA_be (N-type)_be ,_be omega-agatoxin_be IVA_be (P-type)_be bovine_be chromaffin_be cells_be ._be"
260,"In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ",selective Ca(2+) channel blockers,nimodipine,No interaction,"In_bf study_bf investigated_bf effect_bf ginsenosides_bf high_bf threshold_bf voltage-dependent_bf Ca(2+)_bf channel_bf subtypes_bf using_bf selective_bf Ca(2+)_bf channel_bf blockers_bf OTHER_DRUG (L-type)_be ,_be omega-conotoxin_be GVIA_be (N-type)_be ,_be omega-agatoxin_be IVA_be (P-type)_be bovine_be chromaffin_be cells_be ._be"
261,"In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ",selective Ca(2+) channel blockers,omega-conotoxin GVIA,No interaction,"In_bf study_bf investigated_bf effect_bf ginsenosides_bf high_bf threshold_bf voltage-dependent_bf Ca(2+)_bf channel_bf subtypes_bf using_bf selective_bf Ca(2+)_bf channel_bf blockers_bf nimodipine_bf (L-type)_bf ,_bf omega-conotoxin_bf GVIA_bf (N-type)_bf ,_bf omega-agatoxin_bf IVA_bf (P-type)_bf bovine_bf chromaffin_bf cells_bf ._bf"
262,"In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ",selective Ca(2+) channel blockers,omega-agatoxin IVA,No interaction,"In_bf study_bf investigated_bf effect_bf ginsenosides_bf high_bf threshold_bf voltage-dependent_bf Ca(2+)_bf channel_bf subtypes_bf using_bf selective_bf Ca(2+)_bf channel_bf blockers_bf nimodipine_bf (L-type)_bf ,_bf omega-conotoxin_bf GVIA_bf (N-type)_bf ,_bf omega-agatoxin_bf IVA_bf (P-type)_bf bovine_bf chromaffin_bf cells_bf ._bf"
263,"In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ",nimodipine,omega-conotoxin GVIA,No interaction,"In_bf study_bf investigated_bf effect_bf ginsenosides_bf high_bf threshold_bf voltage-dependent_bf Ca(2+)_bf channel_bf subtypes_bf using_bf selective_bf Ca(2+)_bf channel_bf blockers_bf DRUG (L-type)_be ,_be omega-conotoxin_be GVIA_be (N-type)_be ,_be omega-agatoxin_be IVA_be (P-type)_be bovine_be chromaffin_be cells_be ._be"
264,"In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ",nimodipine,omega-agatoxin IVA,No interaction,"In_bf study_bf investigated_bf effect_bf ginsenosides_bf high_bf threshold_bf voltage-dependent_bf Ca(2+)_bf channel_bf subtypes_bf using_bf selective_bf Ca(2+)_bf channel_bf blockers_bf DRUG (L-type)_be ,_be omega-conotoxin_be GVIA_be (N-type)_be ,_be omega-agatoxin_be IVA_be (P-type)_be bovine_be chromaffin_be cells_be ._be"
265,"In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. ",omega-conotoxin GVIA,omega-agatoxin IVA,No interaction,"In_bf study_bf investigated_bf effect_bf ginsenosides_bf high_bf threshold_bf voltage-dependent_bf Ca(2+)_bf channel_bf subtypes_bf using_bf selective_bf Ca(2+)_bf channel_bf blockers_bf nimodipine_bf (L-type)_bf ,_bf omega-conotoxin_bf GVIA_bf (N-type)_bf ,_bf omega-agatoxin_bf IVA_bf (P-type)_bf bovine_bf chromaffin_bf cells_bf ._bf"
266,Nimodipine had no effect on ginsenosides response. ,Nimodipine,ginsenosides,No interaction,DRUG effect_be OTHER_DRUG response_af ._af
267,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. ",ginsenosides,omega-conotoxin GVIA,No interaction,"These_bf data_bf suggest_bf DRUG negatively_be coupled_be three_be types_be calcium_be channels_be bovine_be chromaffin_be cell_be ,_be including_be omega-conotoxin_be GVIA-sensitive_be (N-type)_be channel_be ,_be omega-agatoxin_be IVA-sensitive_be (P-type)_be channel_be nimodipine/omega-conotoxin_be GVIA/omega-agatoxin_be VIA-resistant_be (presumptive_be Q-type)_be channel_be ._be"
268,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. ",ginsenosides,omega-agatoxin IVA,No interaction,"These_bf data_bf suggest_bf DRUG negatively_be coupled_be three_be types_be calcium_be channels_be bovine_be chromaffin_be cell_be ,_be including_be omega-conotoxin_be GVIA-sensitive_be (N-type)_be channel_be ,_be omega-agatoxin_be IVA-sensitive_be (P-type)_be channel_be nimodipine/omega-conotoxin_be GVIA/omega-agatoxin_be VIA-resistant_be (presumptive_be Q-type)_be channel_be ._be"
269,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. ",ginsenosides,nimodipine,No interaction,"These_bf data_bf suggest_bf DRUG negatively_be coupled_be three_be types_be calcium_be channels_be bovine_be chromaffin_be cell_be ,_be including_be omega-conotoxin_be GVIA-sensitive_be (N-type)_be channel_be ,_be omega-agatoxin_be IVA-sensitive_be (P-type)_be channel_be nimodipine/omega-conotoxin_be GVIA/omega-agatoxin_be VIA-resistant_be (presumptive_be Q-type)_be channel_be ._be"
270,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. ",ginsenosides,omega-conotoxin GVIA,No interaction,"These_bf data_bf suggest_bf DRUG negatively_be coupled_be three_be types_be calcium_be channels_be bovine_be chromaffin_be cell_be ,_be including_be omega-conotoxin_be GVIA-sensitive_be (N-type)_be channel_be ,_be omega-agatoxin_be IVA-sensitive_be (P-type)_be channel_be nimodipine/omega-conotoxin_be GVIA/omega-agatoxin_be VIA-resistant_be (presumptive_be Q-type)_be channel_be ._be"
271,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. ",ginsenosides,omega-agatoxin VIA,No interaction,"These_bf data_bf suggest_bf DRUG negatively_be coupled_be three_be types_be calcium_be channels_be bovine_be chromaffin_be cell_be ,_be including_be omega-conotoxin_be GVIA-sensitive_be (N-type)_be channel_be ,_be omega-agatoxin_be IVA-sensitive_be (P-type)_be channel_be nimodipine/omega-conotoxin_be GVIA/omega-agatoxin_be VIA-resistant_be (presumptive_be Q-type)_be channel_be ._be"
272,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. ",omega-conotoxin GVIA,omega-agatoxin IVA,No interaction,"These_bf data_bf suggest_bf ginsenosides_bf negatively_bf coupled_bf three_bf types_bf calcium_bf channels_bf bovine_bf chromaffin_bf cell_bf ,_bf including_bf omega-conotoxin_bf GVIA-sensitive_bf (N-type)_bf channel_bf ,_bf omega-agatoxin_bf IVA-sensitive_bf (P-type)_bf channel_bf nimodipine/omega-conotoxin_bf GVIA/omega-agatoxin_bf VIA-resistant_bf (presumptive_bf Q-type)_bf channel_bf ._bf"
273,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. ",omega-conotoxin GVIA,nimodipine,No interaction,"These_bf data_bf suggest_bf ginsenosides_bf negatively_bf coupled_bf three_bf types_bf calcium_bf channels_bf bovine_bf chromaffin_bf cell_bf ,_bf including_bf omega-conotoxin_bf GVIA-sensitive_bf (N-type)_bf channel_bf ,_bf omega-agatoxin_bf IVA-sensitive_bf (P-type)_bf channel_bf nimodipine/omega-conotoxin_bf GVIA/omega-agatoxin_bf VIA-resistant_bf (presumptive_bf Q-type)_bf channel_bf ._bf"
274,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. ",omega-conotoxin GVIA,omega-conotoxin GVIA,No interaction,"These_bf data_bf suggest_bf ginsenosides_bf negatively_bf coupled_bf three_bf types_bf calcium_bf channels_bf bovine_bf chromaffin_bf cell_bf ,_bf including_bf omega-conotoxin_bf GVIA-sensitive_bf (N-type)_bf channel_bf ,_bf omega-agatoxin_bf IVA-sensitive_bf (P-type)_bf channel_bf nimodipine/omega-conotoxin_bf GVIA/omega-agatoxin_bf VIA-resistant_bf (presumptive_bf Q-type)_bf channel_bf ._bf"
275,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. ",omega-conotoxin GVIA,omega-agatoxin VIA,No interaction,"These_bf data_bf suggest_bf ginsenosides_bf negatively_bf coupled_bf three_bf types_bf calcium_bf channels_bf bovine_bf chromaffin_bf cell_bf ,_bf including_bf omega-conotoxin_bf GVIA-sensitive_bf (N-type)_bf channel_bf ,_bf omega-agatoxin_bf IVA-sensitive_bf (P-type)_bf channel_bf nimodipine/omega-conotoxin_bf GVIA/omega-agatoxin_bf VIA-resistant_bf (presumptive_bf Q-type)_bf channel_bf ._bf"
276,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. ",omega-agatoxin IVA,nimodipine,No interaction,"These_bf data_bf suggest_bf ginsenosides_bf negatively_bf coupled_bf three_bf types_bf calcium_bf channels_bf bovine_bf chromaffin_bf cell_bf ,_bf including_bf omega-conotoxin_bf GVIA-sensitive_bf (N-type)_bf channel_bf ,_bf omega-agatoxin_bf IVA-sensitive_bf (P-type)_bf channel_bf nimodipine/omega-conotoxin_bf GVIA/omega-agatoxin_bf VIA-resistant_bf (presumptive_bf Q-type)_bf channel_bf ._bf"
277,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. ",omega-agatoxin IVA,omega-conotoxin GVIA,No interaction,"These_bf data_bf suggest_bf ginsenosides_bf negatively_bf coupled_bf three_bf types_bf calcium_bf channels_bf bovine_bf chromaffin_bf cell_bf ,_bf including_bf omega-conotoxin_bf GVIA-sensitive_bf (N-type)_bf channel_bf ,_bf omega-agatoxin_bf IVA-sensitive_bf (P-type)_bf channel_bf nimodipine/omega-conotoxin_bf GVIA/omega-agatoxin_bf VIA-resistant_bf (presumptive_bf Q-type)_bf channel_bf ._bf"
278,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. ",omega-agatoxin IVA,omega-agatoxin VIA,No interaction,"These_bf data_bf suggest_bf ginsenosides_bf negatively_bf coupled_bf three_bf types_bf calcium_bf channels_bf bovine_bf chromaffin_bf cell_bf ,_bf including_bf omega-conotoxin_bf GVIA-sensitive_bf (N-type)_bf channel_bf ,_bf omega-agatoxin_bf IVA-sensitive_bf (P-type)_bf channel_bf nimodipine/omega-conotoxin_bf GVIA/omega-agatoxin_bf VIA-resistant_bf (presumptive_bf Q-type)_bf channel_bf ._bf"
279,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. ",nimodipine,omega-conotoxin GVIA,No interaction,"These_bf data_bf suggest_bf ginsenosides_bf negatively_bf coupled_bf three_bf types_bf calcium_bf channels_bf bovine_bf chromaffin_bf cell_bf ,_bf including_bf omega-conotoxin_bf GVIA-sensitive_bf (N-type)_bf channel_bf ,_bf omega-agatoxin_bf IVA-sensitive_bf (P-type)_bf channel_bf nimodipine/omega-conotoxin_bf GVIA/omega-agatoxin_bf VIA-resistant_bf (presumptive_bf Q-type)_bf channel_bf ._bf"
280,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. ",nimodipine,omega-agatoxin VIA,No interaction,"These_bf data_bf suggest_bf ginsenosides_bf negatively_bf coupled_bf three_bf types_bf calcium_bf channels_bf bovine_bf chromaffin_bf cell_bf ,_bf including_bf omega-conotoxin_bf GVIA-sensitive_bf (N-type)_bf channel_bf ,_bf omega-agatoxin_bf IVA-sensitive_bf (P-type)_bf channel_bf nimodipine/omega-conotoxin_bf GVIA/omega-agatoxin_bf VIA-resistant_bf (presumptive_bf Q-type)_bf channel_bf ._bf"
281,"These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. ",omega-conotoxin GVIA,omega-agatoxin VIA,No interaction,"These_bf data_bf suggest_bf ginsenosides_bf negatively_bf coupled_bf three_bf types_bf calcium_bf channels_bf bovine_bf chromaffin_bf cell_bf ,_bf including_bf omega-conotoxin_bf GVIA-sensitive_bf (N-type)_bf channel_bf ,_bf omega-agatoxin_bf IVA-sensitive_bf (P-type)_bf channel_bf nimodipine/omega-conotoxin_bf GVIA/omega-agatoxin_bf VIA-resistant_bf (presumptive_bf Q-type)_bf channel_bf ._bf"
282,"Thus, the selective regulation of voltage-dependent Ca(2+) subtypes by ginsenosides in bovine chromaffin cell could be the cellular basis of antistress effects induced by ginseng.",ginsenosides,ginseng,No interaction,"Thus_bf ,_bf selective_bf regulation_bf voltage-dependent_bf Ca(2+)_bf subtypes_bf DRUG bovine_be chromaffin_be cell_be could_be cellular_be basis_be antistress_be effects_be induced_be OTHER_DRUG ._af"
283,"In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans.
",KRM-1648,ofloxacin,No interaction,"In_bf vitro_bf activity_bf DRUG ,_be either_be singly_be combination_be OTHER_DRUG ,_af Mycobacterium_af ulcerans_af ._af"
284,"The antimicrobial effect of a benzoxazinorifamycin, KRM-1648, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. ",benzoxazinorifamycin,KRM-1648,No interaction,"The_bf antimicrobial_bf effect_bf DRUG ,_be OTHER_DRUG ,_af either_af alone_af combination_af ofloxacin_af ,_af evaluated_af vitro_af two_af type_af strains_af six_af clinical_af isolates_af Mycobacterium_af ulcerans_af ._af"
285,"The antimicrobial effect of a benzoxazinorifamycin, KRM-1648, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. ",benzoxazinorifamycin,ofloxacin,No interaction,"The_bf antimicrobial_bf effect_bf DRUG ,_be KRM-1648_be ,_be either_be alone_be combination_be OTHER_DRUG ,_af evaluated_af vitro_af two_af type_af strains_af six_af clinical_af isolates_af Mycobacterium_af ulcerans_af ._af"
286,"The antimicrobial effect of a benzoxazinorifamycin, KRM-1648, either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. ",KRM-1648,ofloxacin,No interaction,"The_bf antimicrobial_bf effect_bf benzoxazinorifamycin_bf ,_bf DRUG ,_be either_be alone_be combination_be OTHER_DRUG ,_af evaluated_af vitro_af two_af type_af strains_af six_af clinical_af isolates_af Mycobacterium_af ulcerans_af ._af"
287,"ulcerans was between 0.012 and 0.025 mg/l, while corresponding values for rifampicin and rifabutin were in the range of 0.1-0.8 mg/l and 0.1-0.4 mg/l respectively. ",rifampicin,rifabutin,No interaction,"ulcerans_bf 0_bf ._bf 012_bf 0_bf ._bf 025_bf mg/l_bf ,_bf corresponding_bf values_bf DRUG OTHER_DRUG range_af 0_af ._af 1-0_af ._af 8_af mg/l_af 0_af ._af 1-0_af ._af 4_af mg/l_af respectively_af ._af"
289,"When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ",ofloxacin,rifampicin,No interaction,"When_bf combined_bf DRUG ,_be KRM-1648_be exhibited_be strong_be synergistic_be activity_be additive_be effects_be observed_be combination_be OTHER_DRUG (or_af rifabutin)_af DRUG ._af"
290,"When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ",ofloxacin,rifabutin,No interaction,"When_bf combined_bf DRUG ,_be KRM-1648_be exhibited_be strong_be synergistic_be activity_be additive_be effects_be observed_be combination_be rifampicin_be (or_be rifabutin)_be DRUG ._af"
291,"When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ",ofloxacin,ofloxacin,No interaction,"When_bf combined_bf DRUG ,_be KRM-1648_be exhibited_be strong_be synergistic_be activity_be additive_be effects_be observed_be combination_be rifampicin_be (or_be rifabutin)_be DRUG ._af"
292,"When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ",KRM-1648,rifampicin,No interaction,"When_bf combined_bf ofloxacin_bf ,_bf DRUG exhibited_be strong_be synergistic_be activity_be additive_be effects_be observed_be combination_be OTHER_DRUG (or_af rifabutin)_af ofloxacin_af ._af"
293,"When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ",KRM-1648,rifabutin,No interaction,"When_bf combined_bf ofloxacin_bf ,_bf DRUG exhibited_be strong_be synergistic_be activity_be additive_be effects_be observed_be combination_be rifampicin_be (or_be rifabutin)_be ofloxacin_be ._be"
294,"When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ",KRM-1648,ofloxacin,No interaction,"When_bf combined_bf OTHER_DRUG ,_be DRUG exhibited_af strong_af synergistic_af activity_af additive_af effects_af observed_af combination_af rifampicin_af (or_af rifabutin)_af OTHER_DRUG ._af"
295,"When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. ",rifampicin,rifabutin,No interaction,"When_bf combined_bf ofloxacin_bf ,_bf KRM-1648_bf exhibited_bf strong_bf synergistic_bf activity_bf additive_bf effects_bf observed_bf combination_bf DRUG (or_be rifabutin)_be ofloxacin_be ._be"
298,"The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. ",ruthenium red,RR,No interaction,"The_bf effects_bf ruthenium_bf red_bf (RR)_bf inositol_bf 1_bf ,_bf 4_bf ,_bf 5-trisphosphate_bf (InsP(3))-induced_bf responses_bf studied_bf rat_bf bone_bf marrow_bf megakaryocytes_bf patch-clamp_bf whole-cell_bf recording_bf technique_bf combination_bf fura-2_bf microfluorometry_bf ._bf"
299,"The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. ",ruthenium red,"inositol 1,4,5-trisphosphate",No interaction,"The_bf effects_bf ruthenium_bf red_bf (RR)_bf inositol_bf 1_bf ,_bf 4_bf ,_bf 5-trisphosphate_bf (InsP(3))-induced_bf responses_bf studied_bf rat_bf bone_bf marrow_bf megakaryocytes_bf patch-clamp_bf whole-cell_bf recording_bf technique_bf combination_bf fura-2_bf microfluorometry_bf ._bf"
300,"The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. ",ruthenium red,InsP(3),No interaction,"The_bf effects_bf ruthenium_bf red_bf (RR)_bf inositol_bf 1_bf ,_bf 4_bf ,_bf 5-trisphosphate_bf (InsP(3))-induced_bf responses_bf studied_bf rat_bf bone_bf marrow_bf megakaryocytes_bf patch-clamp_bf whole-cell_bf recording_bf technique_bf combination_bf fura-2_bf microfluorometry_bf ._bf"
301,"The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. ",RR,"inositol 1,4,5-trisphosphate",No interaction,"The_bf effects_bf ruthenium_bf red_bf (RR)_bf inositol_bf 1_bf ,_bf 4_bf ,_bf 5-trisphosphate_bf (InsP(3))-induced_bf responses_bf studied_bf rat_bf bone_bf marrow_bf megakaryocytes_bf patch-clamp_bf whole-cell_bf recording_bf technique_bf combination_bf fura-2_bf microfluorometry_bf ._bf"
302,"The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. ",RR,InsP(3),No interaction,"The_bf effects_bf ruthenium_bf red_bf (RR)_bf inositol_bf 1_bf ,_bf 4_bf ,_bf 5-trisphosphate_bf (InsP(3))-induced_bf responses_bf studied_bf rat_bf bone_bf marrow_bf megakaryocytes_bf patch-clamp_bf whole-cell_bf recording_bf technique_bf combination_bf fura-2_bf microfluorometry_bf ._bf"
303,"The effects of ruthenium red (RR) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. ","inositol 1,4,5-trisphosphate",InsP(3),No interaction,"The_bf effects_bf ruthenium_bf red_bf (RR)_bf inositol_bf 1_bf ,_bf 4_bf ,_bf 5-trisphosphate_bf (InsP(3))-induced_bf responses_bf studied_bf rat_bf bone_bf marrow_bf megakaryocytes_bf patch-clamp_bf whole-cell_bf recording_bf technique_bf combination_bf fura-2_bf microfluorometry_bf ._bf"
306,"In contrast, in isolated single pancreatic acinar cells, RR had no effect on InsP(3)-induced responses. ",RR,InsP(3),No interaction,"In_bf contrast_bf ,_bf isolated_bf single_bf pancreatic_bf acinar_bf cells_bf ,_bf DRUG effect_be InsP(3)-induced_be responses_be ._be"
307,"In addition, we have shown that RR is a useful pharmacological tool with which to examine the InsP(3)-mediated responses of megakaryocytes.",RR,InsP(3),No interaction,"In_bf addition_bf ,_bf shown_bf DRUG useful_be pharmacological_be tool_be examine_be InsP(3)-mediated_be responses_be megakaryocytes_be ._be"
308,"Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.
",rofecoxib,digoxin,No interaction,Effect_bf DRUG pharmacokinetics_be OTHER_DRUG healthy_af volunteers_af ._af
309,"The authors examined the effect of the cyclooxygenase-2 (COX-2) inhibitor, rofecoxib, at steady state on the pharmacokinetics of digoxin following a single dose in healthy subjects. ",rofecoxib,digoxin,No interaction,"The_bf authors_bf examined_bf effect_bf cyclooxygenase-2_bf (COX-2)_bf inhibitor_bf ,_bf DRUG ,_be steady_be state_be pharmacokinetics_be OTHER_DRUG following_af single_af dose_af healthy_af subjects_af ._af"
310,Samples for plasma and urine immunoreactive digoxin concentrations were collected through 120 hours following the digoxin dose. ,digoxin,digoxin,No interaction,Samples_bf plasma_bf urine_bf immunoreactive_bf DRUG concentrations_be collected_be 120_be hours_be following_be DRUG dose_af ._af
311,"For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. ",digoxin,rofecoxib,No interaction,"For_bf DRUG AUC(0-infinity)_be ,_be AUC(0-24)_be ,_be Cmax_be ,_be geometric_be mean_be ratios_be (90%_be confidence_be interval)_be (rofecoxib_be +_be digoxin/placebo_be +_be digoxin)_be 1_be ._be 04_be (0_be ._be 94_be ,_be 1_be ._be 14)_be ,_be 1_be ._be 02_be (0_be ._be 94_be ,_be 1_be ._be 09)_be ,_be 1_be ._be 00_be (0_be ._be 91_be ,_be 1_be ._be 10)_be ,_be respectively_be ._be"
312,"For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. ",digoxin,digoxin,No interaction,"For_bf DRUG AUC(0-infinity)_be ,_be AUC(0-24)_be ,_be Cmax_be ,_be geometric_be mean_be ratios_be (90%_be confidence_be interval)_be (rofecoxib_be +_be digoxin/placebo_be +_be digoxin)_be 1_be ._be 04_be (0_be ._be 94_be ,_be 1_be ._be 14)_be ,_be 1_be ._be 02_be (0_be ._be 94_be ,_be 1_be ._be 09)_be ,_be 1_be ._be 00_be (0_be ._be 91_be ,_be 1_be ._be 10)_be ,_be respectively_be ._be"
313,"For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. ",digoxin,digoxin,No interaction,"For_bf DRUG AUC(0-infinity)_be ,_be AUC(0-24)_be ,_be Cmax_be ,_be geometric_be mean_be ratios_be (90%_be confidence_be interval)_be (rofecoxib_be +_be digoxin/placebo_be +_be digoxin)_be 1_be ._be 04_be (0_be ._be 94_be ,_be 1_be ._be 14)_be ,_be 1_be ._be 02_be (0_be ._be 94_be ,_be 1_be ._be 09)_be ,_be 1_be ._be 00_be (0_be ._be 91_be ,_be 1_be ._be 10)_be ,_be respectively_be ._be"
314,"For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. ",rofecoxib,digoxin,No interaction,"For_bf OTHER_DRUG AUC(0-infinity)_be ,_be AUC(0-24)_be ,_be Cmax_be ,_be geometric_be mean_be ratios_be (90%_be confidence_be interval)_be (rofecoxib_be +_be digoxin/placebo_be +_be digoxin)_be 1_be ._be 04_be (0_be ._be 94_be ,_be 1_be ._be 14)_be ,_be 1_be ._be 02_be (0_be ._be 94_be ,_be 1_be ._be 09)_be ,_be 1_be ._be 00_be (0_be ._be 91_be ,_be 1_be ._be 10)_be ,_be respectively_be ._be"
315,"For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. ",rofecoxib,digoxin,No interaction,"For_bf OTHER_DRUG AUC(0-infinity)_be ,_be AUC(0-24)_be ,_be Cmax_be ,_be geometric_be mean_be ratios_be (90%_be confidence_be interval)_be (rofecoxib_be +_be digoxin/placebo_be +_be digoxin)_be 1_be ._be 04_be (0_be ._be 94_be ,_be 1_be ._be 14)_be ,_be 1_be ._be 02_be (0_be ._be 94_be ,_be 1_be ._be 09)_be ,_be 1_be ._be 00_be (0_be ._be 91_be ,_be 1_be ._be 10)_be ,_be respectively_be ._be"
316,"For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. ",digoxin,digoxin,No interaction,"For_bf DRUG AUC(0-infinity)_be ,_be AUC(0-24)_be ,_be Cmax_be ,_be geometric_be mean_be ratios_be (90%_be confidence_be interval)_be (rofecoxib_be +_be digoxin/placebo_be +_be digoxin)_be 1_be ._be 04_be (0_be ._be 94_be ,_be 1_be ._be 14)_be ,_be 1_be ._be 02_be (0_be ._be 94_be ,_be 1_be ._be 09)_be ,_be 1_be ._be 00_be (0_be ._be 91_be ,_be 1_be ._be 10)_be ,_be respectively_be ._be"
317,"The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively. ",rofecoxib,digoxin,No interaction,"The_bf harmonic_bf mean_bf elimination_bf half-life_bf 45_bf ._bf 7_bf 43_bf ._bf 4_bf hours_bf DRUG +_be OTHER_DRUG placebo_af +_af OTHER_DRUG treatments_af ,_af respectively_af ._af"
318,"The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively. ",rofecoxib,digoxin,No interaction,"The_bf harmonic_bf mean_bf elimination_bf half-life_bf 45_bf ._bf 7_bf 43_bf ._bf 4_bf hours_bf DRUG +_be OTHER_DRUG placebo_af +_af OTHER_DRUG treatments_af ,_af respectively_af ._af"
319,"The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib + digoxin and placebo + digoxin treatments, respectively. ",digoxin,digoxin,No interaction,"The_bf harmonic_bf mean_bf elimination_bf half-life_bf 45_bf ._bf 7_bf 43_bf ._bf 4_bf hours_bf rofecoxib_bf +_bf DRUG placebo_be +_be DRUG treatments_af ,_af respectively_af ._af"
320,"The mean (SD) cumulative urinary excretion of immunoreactive digoxin after concurrent treatment with rofecoxib or placebo was 228.2 (+/- 30.8) and 235.1 (+/- 39.1) micrograms/120 hours, respectively. ",digoxin,rofecoxib,No interaction,"The_bf mean_bf (SD)_bf cumulative_bf urinary_bf excretion_bf immunoreactive_bf DRUG concurrent_be treatment_be OTHER_DRUG placebo_af 228_af ._af 2_af (+/-_af 30_af ._af 8)_af 235_af ._af 1_af (+/-_af 39_af ._af 1)_af micrograms/120_af hours_af ,_af respectively_af ._af"
321,Rofecoxib did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of digoxin.,Rofecoxib,digoxin,No interaction,DRUG influence_be plasma_be pharmacokinetics_be renal_be elimination_be single_be oral_be dose_be OTHER_DRUG ._af
322,"Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.",cyclophosphamide,doxorubicin,No interaction,"Concomitant_bf DRUG ,_be OTHER_DRUG ,_af vincristine_af ,_af prednisone_af chemotherapy_af plus_af highly_af active_af antiretroviral_af therapy_af patients_af human_af immunodeficiency_af virus-related_af ,_af non-Hodgkin_af lymphoma_af ._af"
323,"Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.",cyclophosphamide,vincristine,No interaction,"Concomitant_bf DRUG ,_be doxorubicin_be ,_be OTHER_DRUG ,_af prednisone_af chemotherapy_af plus_af highly_af active_af antiretroviral_af therapy_af patients_af human_af immunodeficiency_af virus-related_af ,_af non-Hodgkin_af lymphoma_af ._af"
324,"Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.",cyclophosphamide,prednisone,No interaction,"Concomitant_bf DRUG ,_be doxorubicin_be ,_be vincristine_be ,_be OTHER_DRUG chemotherapy_af plus_af highly_af active_af antiretroviral_af therapy_af patients_af human_af immunodeficiency_af virus-related_af ,_af non-Hodgkin_af lymphoma_af ._af"
325,"Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.",cyclophosphamide,highly active antiretroviral,No interaction,"Concomitant_bf DRUG ,_be doxorubicin_be ,_be vincristine_be ,_be prednisone_be chemotherapy_be plus_be highly_be active_be antiretroviral_be therapy_be patients_be human_be immunodeficiency_be virus-related_be ,_be non-Hodgkin_be lymphoma_be ._be"
326,"Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.",doxorubicin,vincristine,No interaction,"Concomitant_bf cyclophosphamide_bf ,_bf DRUG ,_be OTHER_DRUG ,_af prednisone_af chemotherapy_af plus_af highly_af active_af antiretroviral_af therapy_af patients_af human_af immunodeficiency_af virus-related_af ,_af non-Hodgkin_af lymphoma_af ._af"
327,"Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.",doxorubicin,prednisone,No interaction,"Concomitant_bf cyclophosphamide_bf ,_bf DRUG ,_be vincristine_be ,_be OTHER_DRUG chemotherapy_af plus_af highly_af active_af antiretroviral_af therapy_af patients_af human_af immunodeficiency_af virus-related_af ,_af non-Hodgkin_af lymphoma_af ._af"
328,"Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.",doxorubicin,highly active antiretroviral,No interaction,"Concomitant_bf cyclophosphamide_bf ,_bf DRUG ,_be vincristine_be ,_be prednisone_be chemotherapy_be plus_be highly_be active_be antiretroviral_be therapy_be patients_be human_be immunodeficiency_be virus-related_be ,_be non-Hodgkin_be lymphoma_be ._be"
329,"Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.",vincristine,prednisone,No interaction,"Concomitant_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf DRUG ,_be OTHER_DRUG chemotherapy_af plus_af highly_af active_af antiretroviral_af therapy_af patients_af human_af immunodeficiency_af virus-related_af ,_af non-Hodgkin_af lymphoma_af ._af"
330,"Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.",vincristine,highly active antiretroviral,No interaction,"Concomitant_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf DRUG ,_be prednisone_be chemotherapy_be plus_be highly_be active_be antiretroviral_be therapy_be patients_be human_be immunodeficiency_be virus-related_be ,_be non-Hodgkin_be lymphoma_be ._be"
331,"Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.",prednisone,highly active antiretroviral,No interaction,"Concomitant_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf vincristine_bf ,_bf DRUG chemotherapy_be plus_be highly_be active_be antiretroviral_be therapy_be patients_be human_be immunodeficiency_be virus-related_be ,_be non-Hodgkin_be lymphoma_be ._be"
332,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",cyclophosphamide,doxorubicin,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf DRUG ,_be OTHER_DRUG ,_af vincristine_af ,_af prednisone_af (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af DRUG ,_af OTHER_DRUG ,_af teniposide_af ,_af prednisone_af vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
333,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",cyclophosphamide,vincristine,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf DRUG ,_be doxorubicin_be ,_be OTHER_DRUG ,_af prednisone_af (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af DRUG ,_af doxorubicin_af ,_af teniposide_af ,_af prednisone_af OTHER_DRUG plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
334,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",cyclophosphamide,prednisone,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf DRUG ,_be doxorubicin_be ,_be vincristine_be ,_be OTHER_DRUG (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af DRUG ,_af doxorubicin_af ,_af teniposide_af ,_af OTHER_DRUG vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
335,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",cyclophosphamide,cyclophosphamide,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf DRUG ,_be doxorubicin_be ,_be vincristine_be ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be DRUG ,_af doxorubicin_af ,_af teniposide_af ,_af prednisone_af vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
336,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",cyclophosphamide,doxorubicin,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf DRUG ,_be OTHER_DRUG ,_af vincristine_af ,_af prednisone_af (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af DRUG ,_af OTHER_DRUG ,_af teniposide_af ,_af prednisone_af vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
337,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",cyclophosphamide,teniposide,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf DRUG ,_be doxorubicin_be ,_be vincristine_be ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be DRUG ,_af doxorubicin_af ,_af OTHER_DRUG ,_af prednisone_af vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
338,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",cyclophosphamide,prednisone,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf DRUG ,_be doxorubicin_be ,_be vincristine_be ,_be OTHER_DRUG (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af DRUG ,_af doxorubicin_af ,_af teniposide_af ,_af OTHER_DRUG vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
339,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",cyclophosphamide,vincristine,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf DRUG ,_be doxorubicin_be ,_be OTHER_DRUG ,_af prednisone_af (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af DRUG ,_af doxorubicin_af ,_af teniposide_af ,_af prednisone_af OTHER_DRUG plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
340,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",cyclophosphamide,bleomycin,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf DRUG ,_be doxorubicin_be ,_be vincristine_be ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be DRUG ,_af doxorubicin_af ,_af teniposide_af ,_af prednisone_af vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
341,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",cyclophosphamide,antiretroviral,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf DRUG ,_be doxorubicin_be ,_be vincristine_be ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be DRUG ,_af doxorubicin_af ,_af teniposide_af ,_af prednisone_af vincristine_af plus_af bleomycin)_af without_af receiving_af OTHER_DRUG therapy_af ._af"
342,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",doxorubicin,vincristine,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf DRUG ,_be OTHER_DRUG ,_af prednisone_af (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af cyclophosphamide_af ,_af DRUG ,_af teniposide_af ,_af prednisone_af OTHER_DRUG plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
343,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",doxorubicin,prednisone,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf DRUG ,_be vincristine_be ,_be OTHER_DRUG (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af cyclophosphamide_af ,_af DRUG ,_af teniposide_af ,_af OTHER_DRUG vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
344,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",doxorubicin,cyclophosphamide,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf OTHER_DRUG ,_be DRUG ,_af vincristine_af ,_af prednisone_af (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af OTHER_DRUG ,_af DRUG ,_af teniposide_af ,_af prednisone_af vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
345,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",doxorubicin,doxorubicin,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf DRUG ,_be vincristine_be ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be DRUG ,_af teniposide_af ,_af prednisone_af vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
346,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",doxorubicin,teniposide,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf DRUG ,_be vincristine_be ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be DRUG ,_af OTHER_DRUG ,_af prednisone_af vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
347,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",doxorubicin,prednisone,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf DRUG ,_be vincristine_be ,_be OTHER_DRUG (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af cyclophosphamide_af ,_af DRUG ,_af teniposide_af ,_af OTHER_DRUG vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
348,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",doxorubicin,vincristine,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf DRUG ,_be OTHER_DRUG ,_af prednisone_af (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af cyclophosphamide_af ,_af DRUG ,_af teniposide_af ,_af prednisone_af OTHER_DRUG plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
349,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",doxorubicin,bleomycin,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf DRUG ,_be vincristine_be ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be DRUG ,_af teniposide_af ,_af prednisone_af vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
350,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",doxorubicin,antiretroviral,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf DRUG ,_be vincristine_be ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be DRUG ,_af teniposide_af ,_af prednisone_af vincristine_af plus_af bleomycin)_af without_af receiving_af OTHER_DRUG therapy_af ._af"
351,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",vincristine,prednisone,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf DRUG ,_be OTHER_DRUG (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af cyclophosphamide_af ,_af doxorubicin_af ,_af teniposide_af ,_af OTHER_DRUG DRUG plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
352,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",vincristine,cyclophosphamide,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf OTHER_DRUG ,_be doxorubicin_be ,_be DRUG ,_af prednisone_af (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af OTHER_DRUG ,_af doxorubicin_af ,_af teniposide_af ,_af prednisone_af DRUG plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
353,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",vincristine,doxorubicin,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf OTHER_DRUG ,_be DRUG ,_af prednisone_af (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af cyclophosphamide_af ,_af OTHER_DRUG ,_af teniposide_af ,_af prednisone_af DRUG plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
354,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",vincristine,teniposide,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf DRUG ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be doxorubicin_be ,_be OTHER_DRUG ,_af prednisone_af DRUG plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
355,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",vincristine,prednisone,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf DRUG ,_be OTHER_DRUG (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af cyclophosphamide_af ,_af doxorubicin_af ,_af teniposide_af ,_af OTHER_DRUG DRUG plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
356,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",vincristine,vincristine,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf DRUG ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be doxorubicin_be ,_be teniposide_be ,_be prednisone_be DRUG plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
357,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",vincristine,bleomycin,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf DRUG ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be doxorubicin_be ,_be teniposide_be ,_be prednisone_be DRUG plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
358,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",vincristine,antiretroviral,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf DRUG ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be doxorubicin_be ,_be teniposide_be ,_be prednisone_be DRUG plus_af bleomycin)_af without_af receiving_af OTHER_DRUG therapy_af ._af"
359,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",prednisone,cyclophosphamide,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf OTHER_DRUG ,_be doxorubicin_be ,_be vincristine_be ,_be DRUG (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af OTHER_DRUG ,_af doxorubicin_af ,_af teniposide_af ,_af DRUG vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
360,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",prednisone,doxorubicin,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf OTHER_DRUG ,_be vincristine_be ,_be DRUG (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af cyclophosphamide_af ,_af OTHER_DRUG ,_af teniposide_af ,_af DRUG vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
361,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",prednisone,teniposide,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf vincristine_bf ,_bf DRUG (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be doxorubicin_be ,_be OTHER_DRUG ,_af DRUG vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
362,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",prednisone,prednisone,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf vincristine_bf ,_bf DRUG (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be doxorubicin_be ,_be teniposide_be ,_be DRUG vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
363,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",prednisone,vincristine,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf OTHER_DRUG ,_be DRUG (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af cyclophosphamide_af ,_af doxorubicin_af ,_af teniposide_af ,_af DRUG OTHER_DRUG plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
364,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",prednisone,bleomycin,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf vincristine_bf ,_bf DRUG (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be doxorubicin_be ,_be teniposide_be ,_be DRUG vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
365,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",prednisone,antiretroviral,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf vincristine_bf ,_bf DRUG (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be doxorubicin_be ,_be teniposide_be ,_be DRUG vincristine_af plus_af bleomycin)_af without_af receiving_af OTHER_DRUG therapy_af ._af"
366,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",cyclophosphamide,doxorubicin,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf DRUG ,_be OTHER_DRUG ,_af vincristine_af ,_af prednisone_af (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af DRUG ,_af OTHER_DRUG ,_af teniposide_af ,_af prednisone_af vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
367,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",cyclophosphamide,teniposide,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf DRUG ,_be doxorubicin_be ,_be vincristine_be ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be DRUG ,_af doxorubicin_af ,_af OTHER_DRUG ,_af prednisone_af vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
368,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",cyclophosphamide,prednisone,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf DRUG ,_be doxorubicin_be ,_be vincristine_be ,_be OTHER_DRUG (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af DRUG ,_af doxorubicin_af ,_af teniposide_af ,_af OTHER_DRUG vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
369,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",cyclophosphamide,vincristine,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf DRUG ,_be doxorubicin_be ,_be OTHER_DRUG ,_af prednisone_af (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af DRUG ,_af doxorubicin_af ,_af teniposide_af ,_af prednisone_af OTHER_DRUG plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
370,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",cyclophosphamide,bleomycin,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf DRUG ,_be doxorubicin_be ,_be vincristine_be ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be DRUG ,_af doxorubicin_af ,_af teniposide_af ,_af prednisone_af vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
371,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",cyclophosphamide,antiretroviral,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf DRUG ,_be doxorubicin_be ,_be vincristine_be ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be DRUG ,_af doxorubicin_af ,_af teniposide_af ,_af prednisone_af vincristine_af plus_af bleomycin)_af without_af receiving_af OTHER_DRUG therapy_af ._af"
372,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",doxorubicin,teniposide,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf DRUG ,_be vincristine_be ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be DRUG ,_af OTHER_DRUG ,_af prednisone_af vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
373,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",doxorubicin,prednisone,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf DRUG ,_be vincristine_be ,_be OTHER_DRUG (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af cyclophosphamide_af ,_af DRUG ,_af teniposide_af ,_af OTHER_DRUG vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
374,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",doxorubicin,vincristine,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf DRUG ,_be OTHER_DRUG ,_af prednisone_af (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af cyclophosphamide_af ,_af DRUG ,_af teniposide_af ,_af prednisone_af OTHER_DRUG plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
375,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",doxorubicin,bleomycin,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf DRUG ,_be vincristine_be ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be DRUG ,_af teniposide_af ,_af prednisone_af vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
376,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",doxorubicin,antiretroviral,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf DRUG ,_be vincristine_be ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be DRUG ,_af teniposide_af ,_af prednisone_af vincristine_af plus_af bleomycin)_af without_af receiving_af OTHER_DRUG therapy_af ._af"
377,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",teniposide,prednisone,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf vincristine_bf ,_bf OTHER_DRUG (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be doxorubicin_be ,_be DRUG ,_af OTHER_DRUG vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
378,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",teniposide,vincristine,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf OTHER_DRUG ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be doxorubicin_be ,_be DRUG ,_af prednisone_af OTHER_DRUG plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
379,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",teniposide,bleomycin,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf vincristine_bf ,_bf prednisone_bf (CHOP)_bf chemotherapy_bf regimen_bf plus_bf HAART_bf group_bf 80_bf patients_bf treated_bf CHOP_bf chemotherapy_bf CHOP-like_bf regimen_bf (i_bf ._bf ._bf ,_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf DRUG ,_be prednisone_be vincristine_be plus_be bleomycin)_be without_be receiving_be antiretroviral_be therapy_be ._be"
380,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",teniposide,antiretroviral,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf vincristine_bf ,_bf prednisone_bf (CHOP)_bf chemotherapy_bf regimen_bf plus_bf HAART_bf group_bf 80_bf patients_bf treated_bf CHOP_bf chemotherapy_bf CHOP-like_bf regimen_bf (i_bf ._bf ._bf ,_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf DRUG ,_be prednisone_be vincristine_be plus_be bleomycin)_be without_be receiving_be OTHER_DRUG therapy_af ._af"
381,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",prednisone,vincristine,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf OTHER_DRUG ,_be DRUG (CHOP)_af chemotherapy_af regimen_af plus_af HAART_af group_af 80_af patients_af treated_af CHOP_af chemotherapy_af CHOP-like_af regimen_af (i_af ._af ._af ,_af cyclophosphamide_af ,_af doxorubicin_af ,_af teniposide_af ,_af DRUG OTHER_DRUG plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
382,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",prednisone,bleomycin,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf vincristine_bf ,_bf DRUG (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be doxorubicin_be ,_be teniposide_be ,_be DRUG vincristine_af plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
383,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",prednisone,antiretroviral,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf vincristine_bf ,_bf DRUG (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be doxorubicin_be ,_be teniposide_be ,_be DRUG vincristine_af plus_af bleomycin)_af without_af receiving_af OTHER_DRUG therapy_af ._af"
384,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",vincristine,bleomycin,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf DRUG ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be doxorubicin_be ,_be teniposide_be ,_be prednisone_be DRUG plus_af bleomycin)_af without_af receiving_af antiretroviral_af therapy_af ._af"
385,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",vincristine,antiretroviral,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf DRUG ,_be prednisone_be (CHOP)_be chemotherapy_be regimen_be plus_be HAART_be group_be 80_be patients_be treated_be CHOP_be chemotherapy_be CHOP-like_be regimen_be (i_be ._be ._be ,_be cyclophosphamide_be ,_be doxorubicin_be ,_be teniposide_be ,_be prednisone_be DRUG plus_af bleomycin)_af without_af receiving_af OTHER_DRUG therapy_af ._af"
386,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. ",bleomycin,antiretroviral,No interaction,"To_bf evaluate_bf impact_bf chemotherapy_bf plus_bf HAART_bf clinical_bf course_bf patients_bf HIV-related_bf ,_bf systemic_bf ,_bf non-Hodgkin_bf lymphoma_bf (HIV-NHL)_bf ,_bf authors_bf compared_bf retrospectively_bf group_bf 24_bf patients_bf HIV-NHL_bf treated_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf vincristine_bf ,_bf prednisone_bf (CHOP)_bf chemotherapy_bf regimen_bf plus_bf HAART_bf group_bf 80_bf patients_bf treated_bf CHOP_bf chemotherapy_bf CHOP-like_bf regimen_bf (i_bf ._bf ._bf ,_bf cyclophosphamide_bf ,_bf doxorubicin_bf ,_bf teniposide_bf ,_bf prednisone_bf vincristine_bf plus_bf bleomycin)_bf without_bf receiving_bf OTHER_DRUG therapy_be ._be"
387,Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor. ,Antiretroviral,reverse transcriptase inhibitors,No interaction,DRUG regimens_be consisted_be two_be reverse_be transcriptase_be inhibitors_be one_be protease_be inhibitor_be ._be
388,Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor. ,Antiretroviral,protease inhibitor,No interaction,DRUG regimens_be consisted_be two_be reverse_be transcriptase_be inhibitors_be one_be protease_be inhibitor_be ._be
389,Antiretroviral regimens consisted of two reverse transcriptase inhibitors and one protease inhibitor. ,reverse transcriptase inhibitors,protease inhibitor,No interaction,Antiretroviral_bf regimens_bf consisted_bf two_bf reverse_bf transcriptase_bf inhibitors_bf one_bf protease_bf inhibitor_bf ._bf
392,"Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. ",Imipramine,moclobemide,No interaction,"DRUG (5_be mg/kg)_be ,_be OTHER_DRUG (30_af mg/kg)_af ,_af clonazepam_af (0_af ._af 25_af mg/kg)_af ,_af fluoxetine_af (20_af mg/kg)_af sertraline_af (30_af mg/kg)_af vehicle_af administered_af ._af"
393,"Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. ",Imipramine,clonazepam,No interaction,"DRUG (5_be mg/kg)_be ,_be moclobemide_be (30_be mg/kg)_be ,_be OTHER_DRUG (0_af ._af 25_af mg/kg)_af ,_af fluoxetine_af (20_af mg/kg)_af sertraline_af (30_af mg/kg)_af vehicle_af administered_af ._af"
394,"Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. ",Imipramine,fluoxetine,No interaction,"DRUG (5_be mg/kg)_be ,_be moclobemide_be (30_be mg/kg)_be ,_be clonazepam_be (0_be ._be 25_be mg/kg)_be ,_be OTHER_DRUG (20_af mg/kg)_af sertraline_af (30_af mg/kg)_af vehicle_af administered_af ._af"
395,"Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. ",Imipramine,sertraline,No interaction,"DRUG (5_be mg/kg)_be ,_be moclobemide_be (30_be mg/kg)_be ,_be clonazepam_be (0_be ._be 25_be mg/kg)_be ,_be fluoxetine_be (20_be mg/kg)_be OTHER_DRUG (30_af mg/kg)_af vehicle_af administered_af ._af"
396,"Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. ",moclobemide,clonazepam,No interaction,"Imipramine_bf (5_bf mg/kg)_bf ,_bf DRUG (30_be mg/kg)_be ,_be OTHER_DRUG (0_af ._af 25_af mg/kg)_af ,_af fluoxetine_af (20_af mg/kg)_af sertraline_af (30_af mg/kg)_af vehicle_af administered_af ._af"
397,"Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. ",moclobemide,fluoxetine,No interaction,"Imipramine_bf (5_bf mg/kg)_bf ,_bf DRUG (30_be mg/kg)_be ,_be clonazepam_be (0_be ._be 25_be mg/kg)_be ,_be OTHER_DRUG (20_af mg/kg)_af sertraline_af (30_af mg/kg)_af vehicle_af administered_af ._af"
398,"Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. ",moclobemide,sertraline,No interaction,"Imipramine_bf (5_bf mg/kg)_bf ,_bf DRUG (30_be mg/kg)_be ,_be clonazepam_be (0_be ._be 25_be mg/kg)_be ,_be fluoxetine_be (20_be mg/kg)_be OTHER_DRUG (30_af mg/kg)_af vehicle_af administered_af ._af"
399,"Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. ",clonazepam,fluoxetine,No interaction,"Imipramine_bf (5_bf mg/kg)_bf ,_bf moclobemide_bf (30_bf mg/kg)_bf ,_bf DRUG (0_be ._be 25_be mg/kg)_be ,_be OTHER_DRUG (20_af mg/kg)_af sertraline_af (30_af mg/kg)_af vehicle_af administered_af ._af"
400,"Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. ",clonazepam,sertraline,No interaction,"Imipramine_bf (5_bf mg/kg)_bf ,_bf moclobemide_bf (30_bf mg/kg)_bf ,_bf DRUG (0_be ._be 25_be mg/kg)_be ,_be fluoxetine_be (20_be mg/kg)_be OTHER_DRUG (30_af mg/kg)_af vehicle_af administered_af ._af"
401,"Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. ",fluoxetine,sertraline,No interaction,"Imipramine_bf (5_bf mg/kg)_bf ,_bf moclobemide_bf (30_bf mg/kg)_bf ,_bf clonazepam_bf (0_bf ._bf 25_bf mg/kg)_bf ,_bf DRUG (20_be mg/kg)_be OTHER_DRUG (30_af mg/kg)_af vehicle_af administered_af ._af"
402,"An oral glucose overload of 1 ml of a 50% glucose solution was given to rats and blood glucose was determined after 30, 60 and 90 min. ",glucose,glucose,No interaction,"An_bf oral_bf DRUG overload_be 1_be ml_be 50%_be DRUG solution_af given_af rats_af blood_af DRUG determined_af 30_af ,_af 60_af 90_af min_af ._af"
403,Imipramine and clonazepam did not change fasting or overload glycemia. ,Imipramine,clonazepam,No interaction,DRUG OTHER_DRUG change_af fasting_af overload_af glycemia_af ._af
404,Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. ,Fluoxetine,moclobemide,No interaction,DRUG OTHER_DRUG increased_af blood_af glucose_af different_af times_af glucose_af overload_af ._af
405,Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. ,Fluoxetine,glucose,No interaction,DRUG moclobemide_be increased_be blood_be OTHER_DRUG different_af times_af OTHER_DRUG overload_af ._af
406,Fluoxetine and moclobemide increased blood glucose at different times after the glucose overload. ,moclobemide,glucose,No interaction,Fluoxetine_bf DRUG increased_be blood_be OTHER_DRUG different_af times_af OTHER_DRUG overload_af ._af
407,Sertraline neutralized the increase of glycemia induced by oral glucose overload. ,Sertraline,glucose,No interaction,DRUG neutralized_be increase_be glycemia_be induced_be oral_be OTHER_DRUG overload_af ._af
408,"In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of glucose tolerance 30 min after glucose overload. ",glucose,glucose,No interaction,"In_bf second_bf experiment_bf ,_bf non-diabetic_bf streptozotocin-induced_bf diabetic_bf rats_bf fasted_bf ,_bf procedures_bf followed_bf estimation_bf DRUG tolerance_be 30_be min_be DRUG overload_af ._af"
409,"Again, sertraline neutralized the increase in glycemia after glucose overload both in diabetic and non-diabetic rats. ",sertraline,glucose,No interaction,"Again_bf ,_bf DRUG neutralized_be increase_be glycemia_be OTHER_DRUG overload_af diabetic_af non-diabetic_af rats_af ._af"
410,"Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.
",buforin II,azithromycin,No interaction,Activity_bf buforin_bf II_bf alone_bf combination_bf OTHER_DRUG minocycline_be Cryptosporidium_be parvum_be cell_be culture_be ._be
411,"Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.
",buforin II,minocycline,No interaction,Activity_bf buforin_bf II_bf alone_bf combination_bf azithromycin_bf OTHER_DRUG Cryptosporidium_be parvum_be cell_be culture_be ._be
412,"Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture.
",azithromycin,minocycline,No interaction,Activity_bf buforin_bf II_bf alone_bf combination_bf DRUG OTHER_DRUG Cryptosporidium_af parvum_af cell_af culture_af ._af
413,The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated. ,buforin II,azithromycin,No interaction,The_bf vitro_bf anti-cryptosporidial_bf activity_bf buforin_bf II_bf alone_bf combination_bf OTHER_DRUG minocycline_be investigated_be ._be
414,The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated. ,buforin II,minocycline,No interaction,The_bf vitro_bf anti-cryptosporidial_bf activity_bf buforin_bf II_bf alone_bf combination_bf azithromycin_bf OTHER_DRUG investigated_be ._be
415,The in vitro anti-cryptosporidial activity of buforin II alone and in combination with azithromycin and minocycline was investigated. ,azithromycin,minocycline,No interaction,The_bf vitro_bf anti-cryptosporidial_bf activity_bf buforin_bf II_bf alone_bf combination_bf DRUG OTHER_DRUG investigated_af ._af
416,"Moreover, its activity was enhanced when it was combined with either azithromycin or minocycline with 90% parasite reduction at the highest concentration tested. ",azithromycin,minocycline,No interaction,"Moreover_bf ,_bf activity_bf enhanced_bf combined_bf either_bf DRUG OTHER_DRUG 90%_af parasite_af reduction_af highest_af concentration_af tested_af ._af"
419,Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or minocycline.,azithromycin,minocycline,No interaction,Buforin_bf II_bf may_bf active_bf inhibiting_bf Cryptosporidium_bf parvum_bf growth_bf vitro_bf upon_bf combination_bf either_bf DRUG OTHER_DRUG ._af
420,"Effect of dofetillide on the pharmacokinetics of digoxin.
",dofetillide,digoxin,No interaction,Effect_bf DRUG pharmacokinetics_be OTHER_DRUG ._af
421,"The effect of dofetilide on the steady-state pharmacokinetics of digoxin was evaluated in a randomized, double-blind study. ",dofetilide,digoxin,No interaction,"The_bf effect_bf DRUG steady-state_be pharmacokinetics_be OTHER_DRUG evaluated_af randomized_af ,_af double-blind_af study_af ._af"
422,Five days of dofetilide treatment did not significantly affect steady-state pharmacokinetic variables of digoxin compared with placebo; ,dofetilide,digoxin,No interaction,Five_bf days_bf DRUG treatment_be significantly_be affect_be steady-state_be pharmacokinetic_be variables_be OTHER_DRUG compared_af placebo;_af
423,"therefore, the use of dofetilide does not necessitate an adjustment in digoxin dose to maintain therapeutic digoxin levels.",dofetilide,digoxin,No interaction,"therefore_bf ,_bf use_bf DRUG necessitate_be adjustment_be OTHER_DRUG dose_af maintain_af therapeutic_af OTHER_DRUG levels_af ._af"
424,"Numerous drug interactions are possible with some anticonvulsant agents, such as phenobarbitone and phenytoin, which affect hepatic microsomal enzyme systems. ",anticonvulsant agents,phenobarbitone,No interaction,"Numerous_bf drug_bf interactions_bf possible_bf anticonvulsant_bf agents_bf ,_bf OTHER_DRUG phenytoin_be ,_be affect_be hepatic_be microsomal_be enzyme_be systems_be ._be"
425,"Numerous drug interactions are possible with some anticonvulsant agents, such as phenobarbitone and phenytoin, which affect hepatic microsomal enzyme systems. ",anticonvulsant agents,phenytoin,No interaction,"Numerous_bf drug_bf interactions_bf possible_bf anticonvulsant_bf agents_bf ,_bf phenobarbitone_bf OTHER_DRUG ,_be affect_be hepatic_be microsomal_be enzyme_be systems_be ._be"
426,"Numerous drug interactions are possible with some anticonvulsant agents, such as phenobarbitone and phenytoin, which affect hepatic microsomal enzyme systems. ",phenobarbitone,phenytoin,No interaction,"Numerous_bf drug_bf interactions_bf possible_bf anticonvulsant_bf agents_bf ,_bf DRUG OTHER_DRUG ,_af affect_af hepatic_af microsomal_af enzyme_af systems_af ._af"
428,The interaction of intramuscularly injected ketamine and its N-demethylated metabolite (metabolite I) with halothane was evaluated in rats. ,ketamine,halothane,No interaction,The_bf interaction_bf intramuscularly_bf injected_bf DRUG N-demethylated_be metabolite_be (metabolite_be I)_be OTHER_DRUG evaluated_af rats_af ._af
430,"The reduction in MAC was correlated with brain levels of ketamine or metabolite I, suggesting a ketamine:metabolite I potency ration of 3:1. ",ketamine,ketamine,No interaction,"The_bf reduction_bf MAC_bf correlated_bf brain_bf levels_bf DRUG metabolite_be I_be ,_be suggesting_be ketamine:metabolite_be I_be potency_be ration_be 3:1_be ._be"
432,The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone. ,ketamine,ketamine,No interaction,The_bf half-life_bf DRUG plasma_be brain_be longer_be presence_be halothane_be DRUG given_af alone_af ._af
433,The half-life of ketamine in plasma and brain was longer in the presence of halothane than when ketamine was given alone. ,halothane,ketamine,No interaction,The_bf half-life_bf OTHER_DRUG plasma_be brain_be longer_be presence_be DRUG OTHER_DRUG given_af alone_af ._af
439,The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. ,rifampin,warfarin,No interaction,The_bf concomitant_bf administration_bf DRUG OTHER_DRUG resulted_af need_af unusually_af high_af maintenance_af dose_af OTHER_DRUG (20_af mg_af per_af day)_af order_af produce_af therapeutic_af effect_af ._af
440,The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. ,warfarin,warfarin,No interaction,The_bf concomitant_bf administration_bf rifampin_bf DRUG resulted_be need_be unusually_be high_be maintenance_be dose_be DRUG (20_af mg_af per_af day)_af order_af produce_af therapeutic_af effect_af ._af
444,The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ,rifampin,rifampin,No interaction,The_bf effect_bf DRUG warfarin_be requirement_be patient_be appeared_be maximal_be 5_be 7_be days_be initiation_be DRUG extended_af similar_af length_af time_af DRUG withdrawal_af ._af
445,The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ,rifampin,rifampin,No interaction,The_bf effect_bf DRUG warfarin_be requirement_be patient_be appeared_be maximal_be 5_be 7_be days_be initiation_be DRUG extended_af similar_af length_af time_af DRUG withdrawal_af ._af
446,The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ,warfarin,rifampin,No interaction,The_bf effect_bf OTHER_DRUG DRUG requirement_af patient_af appeared_af maximal_af 5_af 7_af days_af initiation_af OTHER_DRUG extended_af similar_af length_af time_af OTHER_DRUG withdrawal_af ._af
447,The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ,warfarin,rifampin,No interaction,The_bf effect_bf OTHER_DRUG DRUG requirement_af patient_af appeared_af maximal_af 5_af 7_af days_af initiation_af OTHER_DRUG extended_af similar_af length_af time_af OTHER_DRUG withdrawal_af ._af
448,The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. ,rifampin,rifampin,No interaction,The_bf effect_bf DRUG warfarin_be requirement_be patient_be appeared_be maximal_be 5_be 7_be days_be initiation_be DRUG extended_af similar_af length_af time_af DRUG withdrawal_af ._af
449,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",sodium carboxymethylcellulose,NaCMC,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf bacitracin_bf insulin_bf ._bf"
450,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",sodium carboxymethylcellulose,carboxymethylcellulose-cysteine,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf OTHER_DRUG (CMC-Cys)_be conjugates_be intestinal_be permeation_be sodium_be fluorescein_be (NaFlu)_be model_be peptide_be drugs_be ,_be bacitracin_be insulin_be ._be"
451,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",sodium carboxymethylcellulose,CMC-Cys,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf bacitracin_bf insulin_bf ._bf"
452,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",sodium carboxymethylcellulose,sodium fluorescein,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf bacitracin_bf insulin_bf ._bf"
453,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",sodium carboxymethylcellulose,NaFlu,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf bacitracin_bf insulin_bf ._bf"
454,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",sodium carboxymethylcellulose,bacitracin,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf OTHER_DRUG insulin_be ._be"
455,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",sodium carboxymethylcellulose,insulin,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf bacitracin_bf OTHER_DRUG ._be"
456,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",NaCMC,carboxymethylcellulose-cysteine,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf OTHER_DRUG (CMC-Cys)_be conjugates_be intestinal_be permeation_be sodium_be fluorescein_be (NaFlu)_be model_be peptide_be drugs_be ,_be bacitracin_be insulin_be ._be"
457,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",NaCMC,CMC-Cys,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf bacitracin_bf insulin_bf ._bf"
458,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",NaCMC,sodium fluorescein,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf bacitracin_bf insulin_bf ._bf"
459,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",NaCMC,NaFlu,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf bacitracin_bf insulin_bf ._bf"
460,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",NaCMC,bacitracin,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf OTHER_DRUG insulin_be ._be"
461,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",NaCMC,insulin,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf bacitracin_bf OTHER_DRUG ._be"
462,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",carboxymethylcellulose-cysteine,CMC-Cys,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf DRUG (CMC-Cys)_be conjugates_be intestinal_be permeation_be sodium_be fluorescein_be (NaFlu)_be model_be peptide_be drugs_be ,_be bacitracin_be insulin_be ._be"
463,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",carboxymethylcellulose-cysteine,sodium fluorescein,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf DRUG (CMC-Cys)_be conjugates_be intestinal_be permeation_be sodium_be fluorescein_be (NaFlu)_be model_be peptide_be drugs_be ,_be bacitracin_be insulin_be ._be"
464,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",carboxymethylcellulose-cysteine,NaFlu,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf DRUG (CMC-Cys)_be conjugates_be intestinal_be permeation_be sodium_be fluorescein_be (NaFlu)_be model_be peptide_be drugs_be ,_be bacitracin_be insulin_be ._be"
465,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",carboxymethylcellulose-cysteine,bacitracin,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf DRUG (CMC-Cys)_be conjugates_be intestinal_be permeation_be sodium_be fluorescein_be (NaFlu)_be model_be peptide_be drugs_be ,_be OTHER_DRUG insulin_af ._af"
466,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",carboxymethylcellulose-cysteine,insulin,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf DRUG (CMC-Cys)_be conjugates_be intestinal_be permeation_be sodium_be fluorescein_be (NaFlu)_be model_be peptide_be drugs_be ,_be bacitracin_be OTHER_DRUG ._af"
467,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",CMC-Cys,sodium fluorescein,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf bacitracin_bf insulin_bf ._bf"
468,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",CMC-Cys,NaFlu,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf bacitracin_bf insulin_bf ._bf"
469,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",CMC-Cys,bacitracin,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf OTHER_DRUG insulin_be ._be"
470,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",CMC-Cys,insulin,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf bacitracin_bf OTHER_DRUG ._be"
471,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",sodium fluorescein,NaFlu,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf bacitracin_bf insulin_bf ._bf"
472,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",sodium fluorescein,bacitracin,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf OTHER_DRUG insulin_be ._be"
473,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",sodium fluorescein,insulin,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf bacitracin_bf OTHER_DRUG ._be"
474,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",NaFlu,bacitracin,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf OTHER_DRUG insulin_be ._be"
475,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",NaFlu,insulin,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf bacitracin_bf OTHER_DRUG ._be"
476,"The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. ",bacitracin,insulin,No interaction,"The_bf purpose_bf study_bf evaluate_bf effect_bf sodium_bf carboxymethylcellulose_bf (NaCMC)_bf carboxymethylcellulose-cysteine_bf (CMC-Cys)_bf conjugates_bf intestinal_bf permeation_bf sodium_bf fluorescein_bf (NaFlu)_bf model_bf peptide_bf drugs_bf ,_bf DRUG OTHER_DRUG ._af"
477,Cysteine was covalently linked to carbodiimide activated NaCMC. ,Cysteine,NaCMC,No interaction,DRUG covalently_be linked_be carbodiimide_be activated_be OTHER_DRUG ._af
478,Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. ,NaCMC,NaFlu,No interaction,Unmodified_bf DRUG (1%_be m/v)_be significantly_be improved_be transport_be ratio_be (R=_be P(app)_be polymer/_be P(app)_be control)_be OTHER_DRUG 1_af ._af 3_af 1%_af (m/v)_af DRUG conjugated_af cysteine_af enhanced_af permeation_af ._af
479,Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. ,NaCMC,NaCMC,No interaction,Unmodified_bf DRUG (1%_be m/v)_be significantly_be improved_be transport_be ratio_be (R=_be P(app)_be polymer/_be P(app)_be control)_be NaFlu_be 1_be ._be 3_be 1%_be (m/v)_be DRUG conjugated_af cysteine_af enhanced_af permeation_af ._af
480,Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. ,NaCMC,cysteine,No interaction,Unmodified_bf DRUG (1%_be m/v)_be significantly_be improved_be transport_be ratio_be (R=_be P(app)_be polymer/_be P(app)_be control)_be NaFlu_be 1_be ._be 3_be 1%_be (m/v)_be DRUG conjugated_af OTHER_DRUG enhanced_af permeation_af ._af
481,Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. ,NaFlu,NaCMC,No interaction,Unmodified_bf OTHER_DRUG (1%_be m/v)_be significantly_be improved_be transport_be ratio_be (R=_be P(app)_be polymer/_be P(app)_be control)_be DRUG 1_af ._af 3_af 1%_af (m/v)_af OTHER_DRUG conjugated_af cysteine_af enhanced_af permeation_af ._af
482,Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. ,NaFlu,cysteine,No interaction,Unmodified_bf NaCMC_bf (1%_bf m/v)_bf significantly_bf improved_bf transport_bf ratio_bf (R=_bf P(app)_bf polymer/_bf P(app)_bf control)_bf DRUG 1_be ._be 3_be 1%_be (m/v)_be NaCMC_be conjugated_be OTHER_DRUG enhanced_af permeation_af ._af
483,Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. ,NaCMC,cysteine,No interaction,Unmodified_bf DRUG (1%_be m/v)_be significantly_be improved_be transport_be ratio_be (R=_be P(app)_be polymer/_be P(app)_be control)_be NaFlu_be 1_be ._be 3_be 1%_be (m/v)_be DRUG conjugated_af OTHER_DRUG enhanced_af permeation_af ._af
484,"Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised cysteine (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of NaFlu from 1.8 to 1.2. ",CMC-Cys,cysteine,No interaction,"Decreasing_bf concentration_bf DRUG ,_be exhibiting_be 7_be ._be 3%_be (m/m)_be immobilised_be OTHER_DRUG (CMC-Cys7_af ._af 3)_af 1%_af (m/v)_af 0_af ._af 5%_af (m/v)_af decreased_af R-value_af NaFlu_af 1_af ._af 8_af 1_af ._af 2_af ._af"
485,"Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised cysteine (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of NaFlu from 1.8 to 1.2. ",CMC-Cys,NaFlu,No interaction,"Decreasing_bf concentration_bf DRUG ,_be exhibiting_be 7_be ._be 3%_be (m/m)_be immobilised_be cysteine_be (CMC-Cys7_be ._be 3)_be 1%_be (m/v)_be 0_be ._be 5%_be (m/v)_be decreased_be R-value_be OTHER_DRUG 1_af ._af 8_af 1_af ._af 2_af ._af"
486,"Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised cysteine (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of NaFlu from 1.8 to 1.2. ",cysteine,NaFlu,No interaction,"Decreasing_bf concentration_bf CMC-Cys_bf ,_bf exhibiting_bf 7_bf ._bf 3%_bf (m/m)_bf immobilised_bf DRUG (CMC-Cys7_be ._be 3)_be 1%_be (m/v)_be 0_be ._be 5%_be (m/v)_be decreased_be R-value_be OTHER_DRUG 1_af ._af 8_af 1_af ._af 2_af ._af"
487,NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. ,NaCMC,cysteine,No interaction,DRUG 1%_be (m/v)_be presence_be free_be OTHER_DRUG significant_af effect_af R-value_af NaFlu_af compared_af DRUG alone_af ._af
488,NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. ,NaCMC,NaFlu,No interaction,DRUG 1%_be (m/v)_be presence_be free_be cysteine_be significant_be effect_be R-value_be OTHER_DRUG compared_af DRUG alone_af ._af
489,NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. ,NaCMC,NaCMC,No interaction,DRUG 1%_be (m/v)_be presence_be free_be cysteine_be significant_be effect_be R-value_be NaFlu_be compared_be DRUG alone_af ._af
490,NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. ,cysteine,NaFlu,No interaction,NaCMC_bf 1%_bf (m/v)_bf presence_bf free_bf DRUG significant_be effect_be R-value_be OTHER_DRUG compared_af NaCMC_af alone_af ._af
491,NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. ,cysteine,NaCMC,No interaction,OTHER_DRUG 1%_be (m/v)_be presence_be free_be DRUG significant_af effect_af R-value_af NaFlu_af compared_af OTHER_DRUG alone_af ._af
492,NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to NaCMC alone. ,NaFlu,NaCMC,No interaction,OTHER_DRUG 1%_be (m/v)_be presence_be free_be cysteine_be significant_be effect_be R-value_be DRUG compared_af OTHER_DRUG alone_af ._af
493,"Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). ",bacitracin,insulin,No interaction,"Formulation_bf fluorescence_bf labelled_bf DRUG OTHER_DRUG unconjugated_af NaCMC_af (1%_af m/v)_af significantly_af improve_af permeation_af ,_af however_af presence_af 1%_af (m/v)_af CMC-Cys7_af ._af 3_af significantly_af improved_af permeation_af observed_af (R=_af 1_af ._af 3)_af ._af"
494,"Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). ",bacitracin,NaCMC,No interaction,"Formulation_bf fluorescence_bf labelled_bf DRUG insulin_be unconjugated_be OTHER_DRUG (1%_af m/v)_af significantly_af improve_af permeation_af ,_af however_af presence_af 1%_af (m/v)_af CMC-Cys7_af ._af 3_af significantly_af improved_af permeation_af observed_af (R=_af 1_af ._af 3)_af ._af"
495,"Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). ",bacitracin,CMC-Cys,No interaction,"Formulation_bf fluorescence_bf labelled_bf DRUG insulin_be unconjugated_be NaCMC_be (1%_be m/v)_be significantly_be improve_be permeation_be ,_be however_be presence_be 1%_be (m/v)_be CMC-Cys7_be ._be 3_be significantly_be improved_be permeation_be observed_be (R=_be 1_be ._be 3)_be ._be"
496,"Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). ",insulin,NaCMC,No interaction,"Formulation_bf fluorescence_bf labelled_bf bacitracin_bf DRUG unconjugated_be OTHER_DRUG (1%_af m/v)_af significantly_af improve_af permeation_af ,_af however_af presence_af 1%_af (m/v)_af CMC-Cys7_af ._af 3_af significantly_af improved_af permeation_af observed_af (R=_af 1_af ._af 3)_af ._af"
497,"Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). ",insulin,CMC-Cys,No interaction,"Formulation_bf fluorescence_bf labelled_bf bacitracin_bf DRUG unconjugated_be NaCMC_be (1%_be m/v)_be significantly_be improve_be permeation_be ,_be however_be presence_be 1%_be (m/v)_be CMC-Cys7_be ._be 3_be significantly_be improved_be permeation_be observed_be (R=_be 1_be ._be 3)_be ._be"
498,"Formulation of fluorescence labelled bacitracin and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). ",NaCMC,CMC-Cys,No interaction,"Formulation_bf fluorescence_bf labelled_bf bacitracin_bf insulin_bf unconjugated_bf DRUG (1%_be m/v)_be significantly_be improve_be permeation_be ,_be however_be presence_be 1%_be (m/v)_be CMC-Cys7_be ._be 3_be significantly_be improved_be permeation_be observed_be (R=_be 1_be ._be 3)_be ._be"
499,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.",NaCMC,cysteine,No interaction,"Conjugation_bf DRUG OTHER_DRUG moieties_af significantly_af improves_af intestinal_af permeation_af hydrophilic_af molecule_af NaFlu_af model_af peptide_af drugs_af bacitracin_af insulin_af vitro_af ,_af therefore_af conjugated_af system_af maybe_af useful_af peroral_af administration_af peptide_af drugs_af future_af ._af"
500,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.",NaCMC,NaFlu,No interaction,"Conjugation_bf DRUG cysteine_be moieties_be significantly_be improves_be intestinal_be permeation_be hydrophilic_be molecule_be OTHER_DRUG model_af peptide_af drugs_af bacitracin_af insulin_af vitro_af ,_af therefore_af conjugated_af system_af maybe_af useful_af peroral_af administration_af peptide_af drugs_af future_af ._af"
501,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.",NaCMC,bacitracin,No interaction,"Conjugation_bf DRUG cysteine_be moieties_be significantly_be improves_be intestinal_be permeation_be hydrophilic_be molecule_be NaFlu_be model_be peptide_be drugs_be OTHER_DRUG insulin_af vitro_af ,_af therefore_af conjugated_af system_af maybe_af useful_af peroral_af administration_af peptide_af drugs_af future_af ._af"
502,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.",NaCMC,insulin,No interaction,"Conjugation_bf DRUG cysteine_be moieties_be significantly_be improves_be intestinal_be permeation_be hydrophilic_be molecule_be NaFlu_be model_be peptide_be drugs_be bacitracin_be OTHER_DRUG vitro_af ,_af therefore_af conjugated_af system_af maybe_af useful_af peroral_af administration_af peptide_af drugs_af future_af ._af"
503,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.",cysteine,NaFlu,No interaction,"Conjugation_bf NaCMC_bf DRUG moieties_be significantly_be improves_be intestinal_be permeation_be hydrophilic_be molecule_be OTHER_DRUG model_af peptide_af drugs_af bacitracin_af insulin_af vitro_af ,_af therefore_af conjugated_af system_af maybe_af useful_af peroral_af administration_af peptide_af drugs_af future_af ._af"
504,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.",cysteine,bacitracin,No interaction,"Conjugation_bf NaCMC_bf DRUG moieties_be significantly_be improves_be intestinal_be permeation_be hydrophilic_be molecule_be NaFlu_be model_be peptide_be drugs_be OTHER_DRUG insulin_af vitro_af ,_af therefore_af conjugated_af system_af maybe_af useful_af peroral_af administration_af peptide_af drugs_af future_af ._af"
505,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.",cysteine,insulin,No interaction,"Conjugation_bf NaCMC_bf DRUG moieties_be significantly_be improves_be intestinal_be permeation_be hydrophilic_be molecule_be NaFlu_be model_be peptide_be drugs_be bacitracin_be OTHER_DRUG vitro_af ,_af therefore_af conjugated_af system_af maybe_af useful_af peroral_af administration_af peptide_af drugs_af future_af ._af"
506,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.",NaFlu,bacitracin,No interaction,"Conjugation_bf NaCMC_bf cysteine_bf moieties_bf significantly_bf improves_bf intestinal_bf permeation_bf hydrophilic_bf molecule_bf DRUG model_be peptide_be drugs_be OTHER_DRUG insulin_af vitro_af ,_af therefore_af conjugated_af system_af maybe_af useful_af peroral_af administration_af peptide_af drugs_af future_af ._af"
507,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.",NaFlu,insulin,No interaction,"Conjugation_bf NaCMC_bf cysteine_bf moieties_bf significantly_bf improves_bf intestinal_bf permeation_bf hydrophilic_bf molecule_bf DRUG model_be peptide_be drugs_be bacitracin_be OTHER_DRUG vitro_af ,_af therefore_af conjugated_af system_af maybe_af useful_af peroral_af administration_af peptide_af drugs_af future_af ._af"
508,"Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.",bacitracin,insulin,No interaction,"Conjugation_bf NaCMC_bf cysteine_bf moieties_bf significantly_bf improves_bf intestinal_bf permeation_bf hydrophilic_bf molecule_bf NaFlu_bf model_bf peptide_bf drugs_bf DRUG OTHER_DRUG vitro_af ,_af therefore_af conjugated_af system_af maybe_af useful_af peroral_af administration_af peptide_af drugs_af future_af ._af"
509,"Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
",amprenavir,rifabutin,No interaction,Pharmacokinetic_bf Interaction_bf DRUG OTHER_DRUG rifampin_af healthy_af males_af ._af
510,"Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
",amprenavir,rifampin,No interaction,Pharmacokinetic_bf Interaction_bf DRUG rifabutin_be OTHER_DRUG healthy_af males_af ._af
511,"Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.
",rifabutin,rifampin,No interaction,Pharmacokinetic_bf Interaction_bf amprenavir_bf DRUG OTHER_DRUG healthy_af males_af ._af
512,The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). ,amprenavir,rifabutin,No interaction,The_bf objective_bf study_bf determine_bf pharmacokinetic_bf interaction_bf DRUG given_be OTHER_DRUG rifampin_af determine_af effects_af drugs_af erythromycin_af breath_af test_af (ERMBT)_af ._af
513,The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). ,amprenavir,rifampin,No interaction,The_bf objective_bf study_bf determine_bf pharmacokinetic_bf interaction_bf DRUG given_be rifabutin_be OTHER_DRUG determine_af effects_af drugs_af erythromycin_af breath_af test_af (ERMBT)_af ._af
514,The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with rifabutin or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). ,rifabutin,rifampin,No interaction,The_bf objective_bf study_bf determine_bf pharmacokinetic_bf interaction_bf amprenavir_bf given_bf DRUG OTHER_DRUG determine_af effects_af drugs_af erythromycin_af breath_af test_af (ERMBT)_af ._af
515,"All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. ",amprenavir,rifabutin,No interaction,"All_bf subjects_bf received_bf DRUG (1_be ,_be 200_be mg_be twice_be day)_be 4_be days_be ,_be followed_be 7-day_be washout_be period_be ,_be followed_be either_be OTHER_DRUG (300_af mg_af day_af [QD])_af (cohort_af 1)_af rifampin_af (600_af mg_af QD)_af (cohort_af 2)_af 14_af days_af ._af"
516,"All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. ",amprenavir,rifampin,No interaction,"All_bf subjects_bf received_bf DRUG (1_be ,_be 200_be mg_be twice_be day)_be 4_be days_be ,_be followed_be 7-day_be washout_be period_be ,_be followed_be either_be rifabutin_be (300_be mg_be day_be [QD])_be (cohort_be 1)_be OTHER_DRUG (600_af mg_af QD)_af (cohort_af 2)_af 14_af days_af ._af"
517,"All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. ",rifabutin,rifampin,No interaction,"All_bf subjects_bf received_bf amprenavir_bf (1_bf ,_bf 200_bf mg_bf twice_bf day)_bf 4_bf days_bf ,_bf followed_bf 7-day_bf washout_bf period_bf ,_bf followed_bf either_bf DRUG (300_be mg_be day_be [QD])_be (cohort_be 1)_be OTHER_DRUG (600_af mg_af QD)_af (cohort_af 2)_af 14_af days_af ._af"
518,"Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. ",amprenavir,rifabutin,No interaction,"Cohort_bf 1_bf received_bf DRUG plus_be OTHER_DRUG 10_af days_af ,_af cohort_af 2_af received_af DRUG plus_af rifampin_af 4_af days_af ._af"
519,"Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. ",amprenavir,amprenavir,No interaction,"Cohort_bf 1_bf received_bf DRUG plus_be rifabutin_be 10_be days_be ,_be cohort_be 2_be received_be DRUG plus_af rifampin_af 4_af days_af ._af"
520,"Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. ",amprenavir,rifampin,No interaction,"Cohort_bf 1_bf received_bf DRUG plus_be rifabutin_be 10_be days_be ,_be cohort_be 2_be received_be DRUG plus_af OTHER_DRUG 4_af days_af ._af"
521,"Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. ",rifabutin,amprenavir,No interaction,"Cohort_bf 1_bf received_bf OTHER_DRUG plus_be DRUG 10_af days_af ,_af cohort_af 2_af received_af OTHER_DRUG plus_af rifampin_af 4_af days_af ._af"
522,"Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. ",rifabutin,rifampin,No interaction,"Cohort_bf 1_bf received_bf amprenavir_bf plus_bf DRUG 10_be days_be ,_be cohort_be 2_be received_be amprenavir_be plus_be OTHER_DRUG 4_af days_af ._af"
523,"Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. ",amprenavir,rifampin,No interaction,"Cohort_bf 1_bf received_bf DRUG plus_be rifabutin_be 10_be days_be ,_be cohort_be 2_be received_be DRUG plus_af OTHER_DRUG 4_af days_af ._af"
524,"Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. ",amprenavir,rifabutin,No interaction,"Serial_bf plasma_bf urine_bf samples_bf measurement_bf DRUG ,_be OTHER_DRUG ,_af rifampin_af 25-O-desacetyl_af metabolites_af ,_af measured_af high-performance_af liquid_af chromatography_af ._af"
525,"Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. ",amprenavir,rifampin,No interaction,"Serial_bf plasma_bf urine_bf samples_bf measurement_bf DRUG ,_be rifabutin_be ,_be OTHER_DRUG 25-O-desacetyl_af metabolites_af ,_af measured_af high-performance_af liquid_af chromatography_af ._af"
526,"Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. ",amprenavir,25-O-desacetyl metabolites,No interaction,"Serial_bf plasma_bf urine_bf samples_bf measurement_bf DRUG ,_be rifabutin_be ,_be rifampin_be 25-O-desacetyl_be metabolites_be ,_be measured_be high-performance_be liquid_be chromatography_be ._be"
527,"Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. ",rifabutin,rifampin,No interaction,"Serial_bf plasma_bf urine_bf samples_bf measurement_bf amprenavir_bf ,_bf DRUG ,_be OTHER_DRUG 25-O-desacetyl_af metabolites_af ,_af measured_af high-performance_af liquid_af chromatography_af ._af"
528,"Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. ",rifabutin,25-O-desacetyl metabolites,No interaction,"Serial_bf plasma_bf urine_bf samples_bf measurement_bf amprenavir_bf ,_bf DRUG ,_be rifampin_be 25-O-desacetyl_be metabolites_be ,_be measured_be high-performance_be liquid_be chromatography_be ._be"
529,"Serial plasma and urine samples for measurement of amprenavir, rifabutin, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. ",rifampin,25-O-desacetyl metabolites,No interaction,"Serial_bf plasma_bf urine_bf samples_bf measurement_bf amprenavir_bf ,_bf rifabutin_bf ,_bf DRUG 25-O-desacetyl_be metabolites_be ,_be measured_be high-performance_be liquid_be chromatography_be ._be"
530,Rifabutin did not significantly affect amprenavir's pharmacokinetics. ,Rifabutin,amprenavir,No interaction,DRUG significantly_be affect_be amprenavir's_be pharmacokinetics_be ._be
533,Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. ,rifabutin,25-O-desacetylrifabutin,No interaction,Amprenavir_bf significantly_bf increased_bf area_bf curve_bf steady_bf state_bf (AUC(ss))_bf DRUG 2_be ._be 93-fold_be AUC(ss)_be OTHER_DRUG 13_af ._af 3-fold_af ._af
535,"Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. ",Rifampin,amprenavir,No interaction,"DRUG significantly_be decreased_be AUC(ss)_be OTHER_DRUG 82%_af ,_af OTHER_DRUG effect_af DRUG pharmacokinetics_af ._af"
536,"Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. ",Rifampin,rifampin,No interaction,"DRUG significantly_be decreased_be AUC(ss)_be amprenavir_be 82%_be ,_be amprenavir_be effect_be DRUG pharmacokinetics_af ._af"
537,"Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. ",amprenavir,amprenavir,No interaction,"Rifampin_bf significantly_bf decreased_bf AUC(ss)_bf DRUG 82%_be ,_be DRUG effect_af rifampin_af pharmacokinetics_af ._af"
538,"Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. ",amprenavir,rifampin,No interaction,"OTHER_DRUG significantly_be decreased_be AUC(ss)_be DRUG 82%_af ,_af DRUG effect_af OTHER_DRUG pharmacokinetics_af ._af"
539,"Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on rifampin pharmacokinetics. ",amprenavir,rifampin,No interaction,"OTHER_DRUG significantly_be decreased_be AUC(ss)_be DRUG 82%_af ,_af DRUG effect_af OTHER_DRUG pharmacokinetics_af ._af"
540,"The results of the ERMBT after 2 weeks of rifabutin and rifampin therapy were increased 187 and 156%, respectively. ",rifabutin,rifampin,No interaction,"The_bf results_bf ERMBT_bf 2_bf weeks_bf DRUG OTHER_DRUG therapy_af increased_af 187_af 156%_af ,_af respectively_af ._af"
541,Amprenavir plus rifampin was well tolerated. ,Amprenavir,rifampin,No interaction,DRUG plus_be OTHER_DRUG well_af tolerated_af ._af
546,"Amprenavir significantly decreases clearance of rifabutin and 25-O-desacetylrifabutin, and the combination is poorly tolerated. ",rifabutin,25-O-desacetylrifabutin,No interaction,"Amprenavir_bf significantly_bf decreases_bf clearance_bf DRUG OTHER_DRUG ,_af combination_af poorly_af tolerated_af ._af"
547,"Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.",Amprenavir,rifampin,No interaction,"DRUG inhibits_be ERMBT_be ,_be OTHER_DRUG rifabutin_af equipotent_af inducers_af ERMBT_af ._af"
548,"Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.",Amprenavir,rifabutin,No interaction,"DRUG inhibits_be ERMBT_be ,_be rifampin_be OTHER_DRUG equipotent_af inducers_af ERMBT_af ._af"
549,"Amprenavir inhibits the ERMBT, and rifampin and rifabutin are equipotent inducers of the ERMBT.",rifampin,rifabutin,No interaction,"Amprenavir_bf inhibits_bf ERMBT_bf ,_bf DRUG OTHER_DRUG equipotent_af inducers_af ERMBT_af ._af"
550,"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" ",thiazolidinediones,rosiglitazone,No interaction,"The_bf DRUG (rosiglitazone_be pioglitazone)_be ,_be new_be class_be oral_be antidiabetic_be agents_be ,_be ""insulin_be sensitizers""_be"
551,"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" ",thiazolidinediones,pioglitazone,No interaction,"The_bf DRUG (rosiglitazone_be pioglitazone)_be ,_be new_be class_be oral_be antidiabetic_be agents_be ,_be ""insulin_be sensitizers""_be"
552,"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" ",thiazolidinediones,antidiabetic agents,No interaction,"The_bf DRUG (rosiglitazone_be pioglitazone)_be ,_be new_be class_be oral_be antidiabetic_be agents_be ,_be ""insulin_be sensitizers""_be"
553,"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" ",rosiglitazone,pioglitazone,No interaction,"The_bf thiazolidinediones_bf (rosiglitazone_bf pioglitazone)_bf ,_bf new_bf class_bf oral_bf antidiabetic_bf agents_bf ,_bf ""insulin_bf sensitizers""_bf"
554,"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" ",rosiglitazone,antidiabetic agents,No interaction,"The_bf thiazolidinediones_bf (rosiglitazone_bf pioglitazone)_bf ,_bf new_bf class_bf oral_bf antidiabetic_bf agents_bf ,_bf ""insulin_bf sensitizers""_bf"
555,"The thiazolidinediones (rosiglitazone and pioglitazone), a new class of oral antidiabetic agents, are ""insulin sensitizers"" ",pioglitazone,antidiabetic agents,No interaction,"The_bf thiazolidinediones_bf (rosiglitazone_bf pioglitazone)_bf ,_bf new_bf class_bf oral_bf antidiabetic_bf agents_bf ,_bf ""insulin_bf sensitizers""_bf"
556,"To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM). ",arginine,glucose,No interaction,"To_bf study_bf pancreatic_bf effects_bf agents_bf ,_bf dynamic_bf insulin_bf glucagon_bf release_bf measured_bf vitro_bf perfused_bf pancreases_bf normal_bf diabetic_bf Chinese_bf hamsters_bf response_bf various_bf combinations_bf DRUG (20mM)_be ,_be OTHER_DRUG (100_af 150_af mg_af ._af per_af 100_af ml_af ._af )_af ,_af theophylline_af (10_af mM)_af ._af"
557,"To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM). ",arginine,theophylline,No interaction,"To_bf study_bf pancreatic_bf effects_bf agents_bf ,_bf dynamic_bf insulin_bf glucagon_bf release_bf measured_bf vitro_bf perfused_bf pancreases_bf normal_bf diabetic_bf Chinese_bf hamsters_bf response_bf various_bf combinations_bf DRUG (20mM)_be ,_be glucose_be (100_be 150_be mg_be ._be per_be 100_be ml_be ._be )_be ,_be OTHER_DRUG (10_af mM)_af ._af"
558,"To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of arginine (20mM), glucose (100 or 150 mg. per 100 ml.), and theophylline (10 mM). ",glucose,theophylline,No interaction,"To_bf study_bf pancreatic_bf effects_bf agents_bf ,_bf dynamic_bf insulin_bf glucagon_bf release_bf measured_bf vitro_bf perfused_bf pancreases_bf normal_bf diabetic_bf Chinese_bf hamsters_bf response_bf various_bf combinations_bf arginine_bf (20mM)_bf ,_bf DRUG (100_be 150_be mg_be ._be per_be 100_be ml_be ._be )_be ,_be OTHER_DRUG (10_af mM)_af ._af"
559,"Glucose, alone and in the presence of theophylline, caused subnormal insulin release and less suppression of glucagon release in the diabectics than in the normals. ",Glucose,theophylline,No interaction,"DRUG ,_be alone_be presence_be OTHER_DRUG ,_af caused_af subnormal_af insulin_af release_af less_af suppression_af glucagon_af release_af diabectics_af normals_af ._af"
560,"Arginine, in the presence of glucose and theophylline, caused excessive glucagon release but nearly normal insulin release in the diabetics. ",Arginine,glucose,No interaction,"DRUG ,_be presence_be OTHER_DRUG theophylline_af ,_af caused_af excessive_af glucagon_af release_af nearly_af normal_af insulin_af release_af diabetics_af ._af"
561,"Arginine, in the presence of glucose and theophylline, caused excessive glucagon release but nearly normal insulin release in the diabetics. ",Arginine,theophylline,No interaction,"DRUG ,_be presence_be glucose_be OTHER_DRUG ,_af caused_af excessive_af glucagon_af release_af nearly_af normal_af insulin_af release_af diabetics_af ._af"
562,"Arginine, in the presence of glucose and theophylline, caused excessive glucagon release but nearly normal insulin release in the diabetics. ",glucose,theophylline,No interaction,"Arginine_bf ,_bf presence_bf DRUG OTHER_DRUG ,_af caused_af excessive_af glucagon_af release_af nearly_af normal_af insulin_af release_af diabetics_af ._af"
563,"Arginine, in the absence of glucose or theophylline, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. ",Arginine,glucose,No interaction,"DRUG ,_be absence_be OTHER_DRUG theophylline_af ,_af caused_af excessive_af glucagon_af release_af diabetics_af undetectable_af insulin_af release_af either_af diabetics_af normals_af ._af"
564,"Arginine, in the absence of glucose or theophylline, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. ",Arginine,theophylline,No interaction,"DRUG ,_be absence_be glucose_be OTHER_DRUG ,_af caused_af excessive_af glucagon_af release_af diabetics_af undetectable_af insulin_af release_af either_af diabetics_af normals_af ._af"
565,"Arginine, in the absence of glucose or theophylline, caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. ",glucose,theophylline,No interaction,"Arginine_bf ,_bf absence_bf DRUG OTHER_DRUG ,_af caused_af excessive_af glucagon_af release_af diabetics_af undetectable_af insulin_af release_af either_af diabetics_af normals_af ._af"
566,"Further, these results confirm that the diabetic Chinese hamster's alpha and beta cells respond normally to theophylline, but are relatively insensitive to glucose.",theophylline,glucose,No interaction,"Further_bf ,_bf results_bf confirm_bf diabetic_bf Chinese_bf hamster's_bf alpha_bf beta_bf cells_bf respond_bf normally_bf DRUG ,_be relatively_be insensitive_be OTHER_DRUG ._af"
567,"In this study, the effects of etofibrate upon chylomicron metabolism was tested by determination of the plasma kinetics of a chylomicron-like emulsion model in 12 patients with coronary artery disease, aged 59+/-11 years, (total cholesterol: 240+/-41 mg/dl; triglycerides: 188+/-42 mg/dl) submitted to a randomized, crossover, double-blind, placebo-controlled study with administration of 1 g per day etofibrate or placebo for 1-month. ",etofibrate,etofibrate,No interaction,"In_bf study_bf ,_bf effects_bf DRUG upon_be chylomicron_be metabolism_be tested_be determination_be plasma_be kinetics_be chylomicron-like_be emulsion_be model_be 12_be patients_be coronary_be artery_be disease_be ,_be aged_be 59+/-11_be years_be ,_be (total_be cholesterol:_be 240+/-41_be mg/dl;_be triglycerides:_be 188+/-42_be mg/dl)_be submitted_be randomized_be ,_be crossover_be ,_be double-blind_be ,_be placebo-controlled_be study_be administration_be 1_be g_be per_be day_be DRUG placebo_af 1-month_af ._af"
569,"Green tea polyphenols as potent enhancers of glucocorticoid-induced mouse mammary tumor virus gene expression.
",Green tea polyphenols,enhancers,No interaction,Green_bf tea_bf polyphenols_bf potent_bf OTHER_DRUG glucocorticoid-induced_be mouse_be mammary_be tumor_be virus_be gene_be expression_be ._be
570,"n-dodecyl gallate showed the most potent inhibition (66% inhibition at 10 microM), which was far more potent than that of crude tannic acid. ",n-dodecyl gallate,tannic acid,No interaction,"n-dodecyl_bf gallate_bf showed_bf potent_bf inhibition_bf (66%_bf inhibition_bf 10_bf microM)_bf ,_bf far_bf potent_bf crude_bf tannic_bf acid_bf ._bf"
572,"AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. ",sirolimus,macrolide immunosuppressant,No interaction,"AIM_bf AND_bf BACKGROUND:_bf The_bf pharmacokinetic_bf interaction_bf DRUG ,_be macrolide_be immunosuppressant_be metabolized_be CYP3A4_be ,_be calcium_be channel_be blocker_be diltiazem_be studied_be 18_be healthy_be subjects_be ._be"
573,"AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. ",sirolimus,calcium channel blocker,No interaction,"AIM_bf AND_bf BACKGROUND:_bf The_bf pharmacokinetic_bf interaction_bf DRUG ,_be macrolide_be immunosuppressant_be metabolized_be CYP3A4_be ,_be calcium_be channel_be blocker_be diltiazem_be studied_be 18_be healthy_be subjects_be ._be"
574,"AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. ",sirolimus,diltiazem,No interaction,"AIM_bf AND_bf BACKGROUND:_bf The_bf pharmacokinetic_bf interaction_bf DRUG ,_be macrolide_be immunosuppressant_be metabolized_be CYP3A4_be ,_be calcium_be channel_be blocker_be OTHER_DRUG studied_af 18_af healthy_af subjects_af ._af"
575,"AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. ",macrolide immunosuppressant,calcium channel blocker,No interaction,"AIM_bf AND_bf BACKGROUND:_bf The_bf pharmacokinetic_bf interaction_bf sirolimus_bf ,_bf macrolide_bf immunosuppressant_bf metabolized_bf CYP3A4_bf ,_bf calcium_bf channel_bf blocker_bf diltiazem_bf studied_bf 18_bf healthy_bf subjects_bf ._bf"
576,"AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. ",macrolide immunosuppressant,diltiazem,No interaction,"AIM_bf AND_bf BACKGROUND:_bf The_bf pharmacokinetic_bf interaction_bf sirolimus_bf ,_bf macrolide_bf immunosuppressant_bf metabolized_bf CYP3A4_bf ,_bf calcium_bf channel_bf blocker_bf OTHER_DRUG studied_be 18_be healthy_be subjects_be ._be"
577,"AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. ",calcium channel blocker,diltiazem,No interaction,"AIM_bf AND_bf BACKGROUND:_bf The_bf pharmacokinetic_bf interaction_bf sirolimus_bf ,_bf macrolide_bf immunosuppressant_bf metabolized_bf CYP3A4_bf ,_bf calcium_bf channel_bf blocker_bf OTHER_DRUG studied_be 18_be healthy_be subjects_be ._be"
578,Several clinically important interactions have previously been reported for other immunosuppressive drugs that are metabolized by the same enzyme and for calcium antagonists. ,immunosuppressive drugs,calcium antagonists,No interaction,Several_bf clinically_bf important_bf interactions_bf previously_bf reported_bf immunosuppressive_bf drugs_bf metabolized_bf enzyme_bf calcium_bf antagonists_bf ._bf
579,"METHODS: Healthy subjects who were 20 to 43 years old participated in an open, three-period, randomized, crossover study of the pharmacokinetics of a single 10-mg oral dose of sirolimus, a single oral 120-mg dose of diltiazem, and the two drugs given together. ",sirolimus,diltiazem,No interaction,"METHODS:_bf Healthy_bf subjects_bf 20_bf 43_bf years_bf old_bf participated_bf open_bf ,_bf three-period_bf ,_bf randomized_bf ,_bf crossover_bf study_bf pharmacokinetics_bf single_bf 10-mg_bf oral_bf dose_bf DRUG ,_be single_be oral_be 120-mg_be dose_be OTHER_DRUG ,_af two_af drugs_af given_af together_af ._af"
581,"RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. ",sirolimus,sirolimus,No interaction,"RESULTS:_bf The_bf geometric_bf mean_bf (90%_bf confidence_bf interval)_bf whole_bf blood_bf DRUG area_be plasma_be concentration_be time-curve_be increased_be 60%_be (35%-90%)_be ,_be 736_be 1178_be ng_be x_be h/mL_be ,_be maximum_be concentration_be increased_be 43%_be (14%-81%)_be ,_be 67_be 96_be ng/mL_be ,_be diltiazem_be coadministration_be ,_be whereas_be mean_be elimination_be half-life_be DRUG decreased_af slightly_af ,_af 79_af 67_af hours_af ._af"
582,"RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. ",diltiazem,sirolimus,No interaction,"RESULTS:_bf The_bf geometric_bf mean_bf (90%_bf confidence_bf interval)_bf whole_bf blood_bf OTHER_DRUG area_be plasma_be concentration_be time-curve_be increased_be 60%_be (35%-90%)_be ,_be 736_be 1178_be ng_be x_be h/mL_be ,_be maximum_be concentration_be increased_be 43%_be (14%-81%)_be ,_be 67_be 96_be ng/mL_be ,_be DRUG coadministration_af ,_af whereas_af mean_af elimination_af half-life_af OTHER_DRUG decreased_af slightly_af ,_af 79_af 67_af hours_af ._af"
583,"Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. ",sirolimus,sirolimus,No interaction,"Apparent_bf oral_bf clearance_bf volume_bf distribution_bf DRUG decreased_be 38%_be 45%_be ,_be respectively_be ,_be DRUG given_af diltiazem_af ._af"
584,"Apparent oral clearance and volume of distribution of sirolimus decreased with 38% and 45%, respectively, when sirolimus was given with diltiazem. ",sirolimus,diltiazem,No interaction,"Apparent_bf oral_bf clearance_bf volume_bf distribution_bf DRUG decreased_be 38%_be 45%_be ,_be respectively_be ,_be DRUG given_af OTHER_DRUG ._af"
586,"The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. ",diltiazem,desacetyldiltiazem,No interaction,"The_bf plasma_bf maximum_bf concentration_bf area_bf plasma_bf concentration-time_bf curve_bf DRUG ,_be OTHER_DRUG ,_af desmethyldiltiazem_af unchanged_af coadministration_af sirolimus_af ,_af potentiation_af effects_af DRUG diastolic_af systolic_af blood_af pressure_af electrocardiographic_af parameters_af seen_af ._af"
587,"The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. ",diltiazem,desmethyldiltiazem,No interaction,"The_bf plasma_bf maximum_bf concentration_bf area_bf plasma_bf concentration-time_bf curve_bf DRUG ,_be desacetyldiltiazem_be ,_be OTHER_DRUG unchanged_af coadministration_af sirolimus_af ,_af potentiation_af effects_af DRUG diastolic_af systolic_af blood_af pressure_af electrocardiographic_af parameters_af seen_af ._af"
588,"The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. ",diltiazem,sirolimus,No interaction,"The_bf plasma_bf maximum_bf concentration_bf area_bf plasma_bf concentration-time_bf curve_bf DRUG ,_be desacetyldiltiazem_be ,_be desmethyldiltiazem_be unchanged_be coadministration_be OTHER_DRUG ,_af potentiation_af effects_af DRUG diastolic_af systolic_af blood_af pressure_af electrocardiographic_af parameters_af seen_af ._af"
589,"The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. ",diltiazem,diltiazem,No interaction,"The_bf plasma_bf maximum_bf concentration_bf area_bf plasma_bf concentration-time_bf curve_bf DRUG ,_be desacetyldiltiazem_be ,_be desmethyldiltiazem_be unchanged_be coadministration_be sirolimus_be ,_be potentiation_be effects_be DRUG diastolic_af systolic_af blood_af pressure_af electrocardiographic_af parameters_af seen_af ._af"
590,"The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. ",desacetyldiltiazem,desmethyldiltiazem,No interaction,"The_bf plasma_bf maximum_bf concentration_bf area_bf plasma_bf concentration-time_bf curve_bf diltiazem_bf ,_bf DRUG ,_be OTHER_DRUG unchanged_af coadministration_af sirolimus_af ,_af potentiation_af effects_af diltiazem_af diastolic_af systolic_af blood_af pressure_af electrocardiographic_af parameters_af seen_af ._af"
591,"The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. ",desacetyldiltiazem,sirolimus,No interaction,"The_bf plasma_bf maximum_bf concentration_bf area_bf plasma_bf concentration-time_bf curve_bf diltiazem_bf ,_bf DRUG ,_be desmethyldiltiazem_be unchanged_be coadministration_be OTHER_DRUG ,_af potentiation_af effects_af diltiazem_af diastolic_af systolic_af blood_af pressure_af electrocardiographic_af parameters_af seen_af ._af"
592,"The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. ",desacetyldiltiazem,diltiazem,No interaction,"The_bf plasma_bf maximum_bf concentration_bf area_bf plasma_bf concentration-time_bf curve_bf OTHER_DRUG ,_be DRUG ,_af desmethyldiltiazem_af unchanged_af coadministration_af sirolimus_af ,_af potentiation_af effects_af OTHER_DRUG diastolic_af systolic_af blood_af pressure_af electrocardiographic_af parameters_af seen_af ._af"
593,"The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. ",desmethyldiltiazem,sirolimus,No interaction,"The_bf plasma_bf maximum_bf concentration_bf area_bf plasma_bf concentration-time_bf curve_bf diltiazem_bf ,_bf desacetyldiltiazem_bf ,_bf DRUG unchanged_be coadministration_be OTHER_DRUG ,_af potentiation_af effects_af diltiazem_af diastolic_af systolic_af blood_af pressure_af electrocardiographic_af parameters_af seen_af ._af"
594,"The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. ",desmethyldiltiazem,diltiazem,No interaction,"The_bf plasma_bf maximum_bf concentration_bf area_bf plasma_bf concentration-time_bf curve_bf OTHER_DRUG ,_be desacetyldiltiazem_be ,_be DRUG unchanged_af coadministration_af sirolimus_af ,_af potentiation_af effects_af OTHER_DRUG diastolic_af systolic_af blood_af pressure_af electrocardiographic_af parameters_af seen_af ._af"
595,"The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. ",sirolimus,diltiazem,No interaction,"The_bf plasma_bf maximum_bf concentration_bf area_bf plasma_bf concentration-time_bf curve_bf OTHER_DRUG ,_be desacetyldiltiazem_be ,_be desmethyldiltiazem_be unchanged_be coadministration_be DRUG ,_af potentiation_af effects_af OTHER_DRUG diastolic_af systolic_af blood_af pressure_af electrocardiographic_af parameters_af seen_af ._af"
597,"CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. ",diltiazem,sirolimus,No interaction,"CONCLUSIONS:_bf Single-dose_bf DRUG coadministration_be leads_be higher_be OTHER_DRUG exposure_af ,_af presumably_af inhibition_af first-pass_af metabolism_af OTHER_DRUG ._af"
598,"CONCLUSIONS: Single-dose diltiazem coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of sirolimus. ",sirolimus,sirolimus,No interaction,"CONCLUSIONS:_bf Single-dose_bf diltiazem_bf coadministration_bf leads_bf higher_bf DRUG exposure_be ,_be presumably_be inhibition_be first-pass_be metabolism_be DRUG ._af"
600,"Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.",sirolimus,sirolimus,No interaction,"Because_bf pronounced_bf intersubject_bf variability_bf extent_bf sirolimus-diltiazem_bf interaction_bf ,_bf whole_bf blood_bf DRUG concentrations_be monitored_be closely_be patients_be treated_be two_be drugs_be ._be"
601,"Because of the pronounced intersubject variability in the extent of the sirolimus-diltiazem interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.",diltiazem,sirolimus,No interaction,"Because_bf pronounced_bf intersubject_bf variability_bf extent_bf sirolimus-diltiazem_bf interaction_bf ,_bf whole_bf blood_bf OTHER_DRUG concentrations_be monitored_be closely_be patients_be treated_be two_be drugs_be ._be"
603,OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. ,fluvoxamine,tolbutamide,No interaction,OBJECTIVE:_bf Our_bf objective_bf examine_bf interaction_bf DRUG OTHER_DRUG confirm_af DRUG inhibits_af CYP2C9_af ._af
604,OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. ,fluvoxamine,fluvoxamine,No interaction,OBJECTIVE:_bf Our_bf objective_bf examine_bf interaction_bf DRUG tolbutamide_be confirm_be DRUG inhibits_af CYP2C9_af ._af
605,OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. ,tolbutamide,fluvoxamine,No interaction,OBJECTIVE:_bf Our_bf objective_bf examine_bf interaction_bf OTHER_DRUG DRUG confirm_af OTHER_DRUG inhibits_af CYP2C9_af ._af
606,"Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. ",tolbutamide,tolbutamide,No interaction,"Plasma_bf analyzed_bf DRUG ,_be urine_be analyzed_be DRUG two_af metabolites_af ,_af 4-hydroxytolbutamide_af carboxytolbutamide_af means_af HPLC_af ._af"
607,"Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. ",tolbutamide,4-hydroxytolbutamide,No interaction,"Plasma_bf analyzed_bf DRUG ,_be urine_be analyzed_be DRUG two_af metabolites_af ,_af OTHER_DRUG carboxytolbutamide_af means_af HPLC_af ._af"
608,"Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. ",tolbutamide,carboxytolbutamide,No interaction,"Plasma_bf analyzed_bf DRUG ,_be urine_be analyzed_be DRUG two_af metabolites_af ,_af 4-hydroxytolbutamide_af OTHER_DRUG means_af HPLC_af ._af"
609,"Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. ",tolbutamide,4-hydroxytolbutamide,No interaction,"Plasma_bf analyzed_bf DRUG ,_be urine_be analyzed_be DRUG two_af metabolites_af ,_af OTHER_DRUG carboxytolbutamide_af means_af HPLC_af ._af"
610,"Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. ",tolbutamide,carboxytolbutamide,No interaction,"Plasma_bf analyzed_bf DRUG ,_be urine_be analyzed_be DRUG two_af metabolites_af ,_af 4-hydroxytolbutamide_af OTHER_DRUG means_af HPLC_af ._af"
611,"Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. ",4-hydroxytolbutamide,carboxytolbutamide,No interaction,"Plasma_bf analyzed_bf tolbutamide_bf ,_bf urine_bf analyzed_bf tolbutamide_bf two_bf metabolites_bf ,_bf DRUG OTHER_DRUG means_af HPLC_af ._af"
613,"The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). ",4-hydroxytolbutamide,carboxytolbutamide,No interaction,"The_bf clearance_bf means_bf DRUG OTHER_DRUG significantly_af reduced_af groups_af (ie_af ,_af 901_af mL/h_af 318_af mL/h_af group_af received_af 150_af mg_af tolbutamide_af per_af day_af 723_af mL/h_af 457_af mL/h_af group_af received_af 75_af mg_af tolbutamide_af per_af day)_af ._af"
614,"The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). ",4-hydroxytolbutamide,tolbutamide,No interaction,"The_bf clearance_bf means_bf DRUG carboxytolbutamide_be significantly_be reduced_be groups_be (ie_be ,_be 901_be mL/h_be 318_be mL/h_be group_be received_be 150_be mg_be OTHER_DRUG per_af day_af 723_af mL/h_af 457_af mL/h_af group_af received_af 75_af mg_af OTHER_DRUG per_af day)_af ._af"
615,"The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). ",4-hydroxytolbutamide,tolbutamide,No interaction,"The_bf clearance_bf means_bf DRUG carboxytolbutamide_be significantly_be reduced_be groups_be (ie_be ,_be 901_be mL/h_be 318_be mL/h_be group_be received_be 150_be mg_be OTHER_DRUG per_af day_af 723_af mL/h_af 457_af mL/h_af group_af received_af 75_af mg_af OTHER_DRUG per_af day)_af ._af"
616,"The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). ",carboxytolbutamide,tolbutamide,No interaction,"The_bf clearance_bf means_bf 4-hydroxytolbutamide_bf DRUG significantly_be reduced_be groups_be (ie_be ,_be 901_be mL/h_be 318_be mL/h_be group_be received_be 150_be mg_be OTHER_DRUG per_af day_af 723_af mL/h_af 457_af mL/h_af group_af received_af 75_af mg_af OTHER_DRUG per_af day)_af ._af"
617,"The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). ",carboxytolbutamide,tolbutamide,No interaction,"The_bf clearance_bf means_bf 4-hydroxytolbutamide_bf DRUG significantly_be reduced_be groups_be (ie_be ,_be 901_be mL/h_be 318_be mL/h_be group_be received_be 150_be mg_be OTHER_DRUG per_af day_af 723_af mL/h_af 457_af mL/h_af group_af received_af 75_af mg_af OTHER_DRUG per_af day)_af ._af"
618,"The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). ",tolbutamide,tolbutamide,No interaction,"The_bf clearance_bf means_bf 4-hydroxytolbutamide_bf carboxytolbutamide_bf significantly_bf reduced_bf groups_bf (ie_bf ,_bf 901_bf mL/h_bf 318_bf mL/h_bf group_bf received_bf 150_bf mg_bf DRUG per_be day_be 723_be mL/h_be 457_be mL/h_be group_be received_be 75_be mg_be DRUG per_af day)_af ._af"
619,"Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.
",everolimus,cyclosporine,No interaction,"Longitudinal_bf assessment_bf DRUG de_be novo_be renal_be transplant_be recipients_be first_be post-transplant_be year:_be pharmacokinetics_be ,_be exposure-response_be relationships_be ,_be influence_be OTHER_DRUG ._af"
620,"OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. ",everolimus,cyclosporine,No interaction,"OBJECTIVE:_bf Our_bf objective_bf characterize_bf steady-state_bf pharmacokinetics_bf DRUG OTHER_DRUG (INN_af ,_af ciclosporin)_af coadministered_af de_af novo_af kidney_af allograft_af recipients_af first_af year_af transplantation_af ._af"
621,"OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. ",everolimus,ciclosporin,No interaction,"OBJECTIVE:_bf Our_bf objective_bf characterize_bf steady-state_bf pharmacokinetics_bf DRUG cyclosporine_be (INN_be ,_be ciclosporin)_be coadministered_be de_be novo_be kidney_be allograft_be recipients_be first_be year_be transplantation_be ._be"
622,"OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and cyclosporine (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. ",cyclosporine,ciclosporin,No interaction,"OBJECTIVE:_bf Our_bf objective_bf characterize_bf steady-state_bf pharmacokinetics_bf everolimus_bf DRUG (INN_be ,_be ciclosporin)_be coadministered_be de_be novo_be kidney_be allograft_be recipients_be first_be year_be transplantation_be ._be"
623,"METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. ",everolimus,cyclosporine,No interaction,"METHOD:_bf This_bf study_bf multicenter_bf randomized_bf double-blind_bf study_bf 101_bf patients_bf randomly_bf assigned_bf 1:1:1_bf receive_bf DRUG tablets_be doses_be 0_be ._be 5_be mg_be ,_be 1_be mg_be ,_be 2_be mg_be twice_be daily_be OTHER_DRUG prednisone_af ._af"
624,"METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. ",everolimus,prednisone,No interaction,"METHOD:_bf This_bf study_bf multicenter_bf randomized_bf double-blind_bf study_bf 101_bf patients_bf randomly_bf assigned_bf 1:1:1_bf receive_bf DRUG tablets_be doses_be 0_be ._be 5_be mg_be ,_be 1_be mg_be ,_be 2_be mg_be twice_be daily_be cyclosporine_be OTHER_DRUG ._af"
625,"METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and prednisone. ",cyclosporine,prednisone,No interaction,"METHOD:_bf This_bf study_bf multicenter_bf randomized_bf double-blind_bf study_bf 101_bf patients_bf randomly_bf assigned_bf 1:1:1_bf receive_bf everolimus_bf tablets_bf doses_bf 0_bf ._bf 5_bf mg_bf ,_bf 1_bf mg_bf ,_bf 2_bf mg_bf twice_bf daily_bf DRUG OTHER_DRUG ._af"
626,"Blood sampling for the pharmacokinetics of everolimus and cyclosporine was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12. ",everolimus,cyclosporine,No interaction,"Blood_bf sampling_bf pharmacokinetics_bf DRUG OTHER_DRUG performed_af day_af 1_af ,_af weeks_af 1_af ,_af 2_af ,_af 3_af ,_af 4_af ,_af months_af 2_af ,_af 3_af ,_af 6_af ,_af 9_af ,_af 12_af ._af"
627,Potential differences in cyclosporine dosing and pharmacokinetics at different levels of everolimus exposure were assessed in the context of ANOVA. ,cyclosporine,everolimus,No interaction,Potential_bf differences_bf DRUG dosing_be pharmacokinetics_be different_be levels_be OTHER_DRUG exposure_af assessed_af context_af ANOVA_af ._af
628,"Cyclosporine doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered everolimus dose level (P = .13, .82, and .76, respectively). ",Cyclosporine,everolimus,No interaction,"DRUG doses_be ,_be trough_be concentrations_be ,_be AUC_be exhibited_be similar_be temporal_be patterns_be course_be study_be regardless_be co-administered_be OTHER_DRUG dose_af level_af (P_af =_af ._af 13_af ,_af ._af 82_af ,_af ._af 76_af ,_af respectively)_af ._af"
629,For a 4-fold range of everolimus doses there were no differential effects on cyclosporine dosing or pharmacokinetics.,everolimus,cyclosporine,No interaction,For_bf 4-fold_bf range_bf DRUG doses_be differential_be effects_be OTHER_DRUG dosing_af pharmacokinetics_af ._af
631,ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. ,ADL-8-2698,peripherally restricted opioid antagonist,No interaction,DRUG novel_be peripherally_be restricted_be opioid_be antagonist_be may_be selectively_be prevent_be opioid-induced_be gastrointestinal_be effects_be without_be reversing_be analgesia_be ._be
633,ADL-8-2698 is a novel peripherally restricted opioid antagonist that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. ,peripherally restricted opioid antagonist,opioid,No interaction,ADL-8-2698_bf novel_bf peripherally_bf restricted_bf OTHER_DRUG antagonist_be may_be selectively_be prevent_be opioid-induced_be gastrointestinal_be effects_be without_be reversing_be analgesia_be ._be
634,"Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study. ",morphine,ADL 8-2698,No interaction,"Gastrointestinal_bf transit_bf time_bf (lactulose_bf hydrogen_bf breath_bf test)_bf measured_bf 14_bf volunteers_bf oral_bf intravenous_bf placebo_bf ,_bf oral_bf placebo_bf intravenous_bf DRUG (0_be ._be 05_be mg_be x_be kg(-1))_be ,_be oral_be ADL_be 8-2698_be (4_be mg)_be intravenous_be DRUG (0_af ._af 05_af mg_af x_af kg(-1))_af double_af blind_af ,_af cross-over_af study_af ._af"
635,"Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study. ",morphine,morphine,No interaction,"Gastrointestinal_bf transit_bf time_bf (lactulose_bf hydrogen_bf breath_bf test)_bf measured_bf 14_bf volunteers_bf oral_bf intravenous_bf placebo_bf ,_bf oral_bf placebo_bf intravenous_bf DRUG (0_be ._be 05_be mg_be x_be kg(-1))_be ,_be oral_be ADL_be 8-2698_be (4_be mg)_be intravenous_be DRUG (0_af ._af 05_af mg_af x_af kg(-1))_af double_af blind_af ,_af cross-over_af study_af ._af"
636,"Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study. ",ADL 8-2698,morphine,No interaction,"Gastrointestinal_bf transit_bf time_bf (lactulose_bf hydrogen_bf breath_bf test)_bf measured_bf 14_bf volunteers_bf oral_bf intravenous_bf placebo_bf ,_bf oral_bf placebo_bf intravenous_bf OTHER_DRUG (0_be ._be 05_be mg_be x_be kg(-1))_be ,_be oral_be ADL_be 8-2698_be (4_be mg)_be intravenous_be OTHER_DRUG (0_af ._af 05_af mg_af x_af kg(-1))_af double_af blind_af ,_af cross-over_af study_af ._af"
638,"Postoperatively, 45 patients were randomly assigned in a double-blind fashion to receive ADL 8-2698 (4 mg) or placebo and intravenous morphine (0.15 mg/kg) or to receive oral and intravenous placebo. ",ADL 8-2698,morphine,No interaction,"Postoperatively_bf ,_bf 45_bf patients_bf randomly_bf assigned_bf double-blind_bf fashion_bf receive_bf ADL_bf 8-2698_bf (4_bf mg)_bf placebo_bf intravenous_bf OTHER_DRUG (0_be ._be 15_be mg/kg)_be receive_be oral_be intravenous_be placebo_be ._be"
639,Morphine analgesia and pupil constriction were unaffected by ADL 8-2698 and differed from placebo (P < .002). ,Morphine,ADL 8-2698,No interaction,DRUG analgesia_be pupil_be constriction_be unaffected_be ADL_be 8-2698_be differed_be placebo_be (P_be <_be ._be 002)_be ._be
642,OBJECTIVE: To report a case of rhabdomyolysis resulting from concomitant use of clarithromycin and simvastatin. ,clarithromycin,simvastatin,No interaction,OBJECTIVE:_bf To_bf report_bf case_bf rhabdomyolysis_bf resulting_bf concomitant_bf use_bf DRUG OTHER_DRUG ._af
645,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",Macrolide antibiotics,HMG-CoA reductase inhibitors,No interaction,"CONCLUSIONS:_bf Macrolide_bf antibiotics_bf inhibit_bf metabolism_bf HMG-CoA_bf reductase_bf inhibitors_bf metabolized_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf atorvastatin_bf ,_bf cerivastatin_bf ,_bf lovastatin_bf ,_bf simvastatin)_bf ._bf"
650,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",HMG-CoA reductase inhibitors,atorvastatin,No interaction,"CONCLUSIONS:_bf Macrolide_bf antibiotics_bf inhibit_bf metabolism_bf HMG-CoA_bf reductase_bf inhibitors_bf metabolized_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf OTHER_DRUG ,_be cerivastatin_be ,_be lovastatin_be ,_be simvastatin)_be ._be"
651,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",HMG-CoA reductase inhibitors,cerivastatin,No interaction,"CONCLUSIONS:_bf Macrolide_bf antibiotics_bf inhibit_bf metabolism_bf HMG-CoA_bf reductase_bf inhibitors_bf metabolized_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf atorvastatin_bf ,_bf OTHER_DRUG ,_be lovastatin_be ,_be simvastatin)_be ._be"
652,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",HMG-CoA reductase inhibitors,lovastatin,No interaction,"CONCLUSIONS:_bf Macrolide_bf antibiotics_bf inhibit_bf metabolism_bf HMG-CoA_bf reductase_bf inhibitors_bf metabolized_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf atorvastatin_bf ,_bf cerivastatin_bf ,_bf OTHER_DRUG ,_be simvastatin)_be ._be"
653,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",HMG-CoA reductase inhibitors,simvastatin,No interaction,"CONCLUSIONS:_bf Macrolide_bf antibiotics_bf inhibit_bf metabolism_bf HMG-CoA_bf reductase_bf inhibitors_bf metabolized_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf atorvastatin_bf ,_bf cerivastatin_bf ,_bf lovastatin_bf ,_bf simvastatin)_bf ._bf"
654,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",atorvastatin,cerivastatin,No interaction,"CONCLUSIONS:_bf Macrolide_bf antibiotics_bf inhibit_bf metabolism_bf HMG-CoA_bf reductase_bf inhibitors_bf metabolized_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf DRUG ,_be OTHER_DRUG ,_af lovastatin_af ,_af simvastatin)_af ._af"
655,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",atorvastatin,lovastatin,No interaction,"CONCLUSIONS:_bf Macrolide_bf antibiotics_bf inhibit_bf metabolism_bf HMG-CoA_bf reductase_bf inhibitors_bf metabolized_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf DRUG ,_be cerivastatin_be ,_be OTHER_DRUG ,_af simvastatin)_af ._af"
656,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",atorvastatin,simvastatin,No interaction,"CONCLUSIONS:_bf Macrolide_bf antibiotics_bf inhibit_bf metabolism_bf HMG-CoA_bf reductase_bf inhibitors_bf metabolized_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf DRUG ,_be cerivastatin_be ,_be lovastatin_be ,_be simvastatin)_be ._be"
657,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",cerivastatin,lovastatin,No interaction,"CONCLUSIONS:_bf Macrolide_bf antibiotics_bf inhibit_bf metabolism_bf HMG-CoA_bf reductase_bf inhibitors_bf metabolized_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf atorvastatin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af simvastatin)_af ._af"
658,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",cerivastatin,simvastatin,No interaction,"CONCLUSIONS:_bf Macrolide_bf antibiotics_bf inhibit_bf metabolism_bf HMG-CoA_bf reductase_bf inhibitors_bf metabolized_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf atorvastatin_bf ,_bf DRUG ,_be lovastatin_be ,_be simvastatin)_be ._be"
659,"CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). ",lovastatin,simvastatin,No interaction,"CONCLUSIONS:_bf Macrolide_bf antibiotics_bf inhibit_bf metabolism_bf HMG-CoA_bf reductase_bf inhibitors_bf metabolized_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf atorvastatin_bf ,_bf cerivastatin_bf ,_bf DRUG ,_be simvastatin)_be ._be"
660,"The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine.
",phenytoin,quetiapine,No interaction,The_bf effects_bf concomitant_bf DRUG administration_be steady-state_be pharmacokinetics_be OTHER_DRUG ._af
661,Quetiapine fumarate ('Seroquel') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia. ,Quetiapine fumarate,Seroquel,No interaction,Quetiapine_bf fumarate_bf ('Seroquel')_bf newly_bf introduced_bf atypical_bf antipsychotic_bf demonstrated_bf efficacy_bf treatment_bf positive_bf negative_bf symptoms_bf schizophrenia_bf ._bf
662,Quetiapine fumarate ('Seroquel') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia. ,Quetiapine fumarate,atypical antipsychotic,No interaction,Quetiapine_bf fumarate_bf ('Seroquel')_bf newly_bf introduced_bf atypical_bf antipsychotic_bf demonstrated_bf efficacy_bf treatment_bf positive_bf negative_bf symptoms_bf schizophrenia_bf ._bf
663,Quetiapine fumarate ('Seroquel') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia. ,Seroquel,atypical antipsychotic,No interaction,Quetiapine_bf fumarate_bf ('Seroquel')_bf newly_bf introduced_bf atypical_bf antipsychotic_bf demonstrated_bf efficacy_bf treatment_bf positive_bf negative_bf symptoms_bf schizophrenia_bf ._bf
665,"Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. ",Acetaminophen,lidocaine,No interaction,"DRUG ,_be OTHER_DRUG ,_af phenobarbital_af ,_af quinidine_af ,_af theophylline_af ,_af valproic_af acid_af added_af pooled_af human_af serum_af therapeutic_af concentrations_af ._af"
666,"Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. ",Acetaminophen,phenobarbital,No interaction,"DRUG ,_be lidocaine_be ,_be OTHER_DRUG ,_af quinidine_af ,_af theophylline_af ,_af valproic_af acid_af added_af pooled_af human_af serum_af therapeutic_af concentrations_af ._af"
667,"Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. ",Acetaminophen,quinidine,No interaction,"DRUG ,_be lidocaine_be ,_be phenobarbital_be ,_be OTHER_DRUG ,_af theophylline_af ,_af valproic_af acid_af added_af pooled_af human_af serum_af therapeutic_af concentrations_af ._af"
668,"Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. ",Acetaminophen,theophylline,No interaction,"DRUG ,_be lidocaine_be ,_be phenobarbital_be ,_be quinidine_be ,_be OTHER_DRUG ,_af valproic_af acid_af added_af pooled_af human_af serum_af therapeutic_af concentrations_af ._af"
669,"Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. ",Acetaminophen,valproic acid,No interaction,"DRUG ,_be lidocaine_be ,_be phenobarbital_be ,_be quinidine_be ,_be theophylline_be ,_be valproic_be acid_be added_be pooled_be human_be serum_be therapeutic_be concentrations_be ._be"
670,"Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. ",lidocaine,phenobarbital,No interaction,"Acetaminophen_bf ,_bf DRUG ,_be OTHER_DRUG ,_af quinidine_af ,_af theophylline_af ,_af valproic_af acid_af added_af pooled_af human_af serum_af therapeutic_af concentrations_af ._af"
671,"Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. ",lidocaine,quinidine,No interaction,"Acetaminophen_bf ,_bf DRUG ,_be phenobarbital_be ,_be OTHER_DRUG ,_af theophylline_af ,_af valproic_af acid_af added_af pooled_af human_af serum_af therapeutic_af concentrations_af ._af"
672,"Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. ",lidocaine,theophylline,No interaction,"Acetaminophen_bf ,_bf DRUG ,_be phenobarbital_be ,_be quinidine_be ,_be OTHER_DRUG ,_af valproic_af acid_af added_af pooled_af human_af serum_af therapeutic_af concentrations_af ._af"
673,"Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. ",lidocaine,valproic acid,No interaction,"Acetaminophen_bf ,_bf DRUG ,_be phenobarbital_be ,_be quinidine_be ,_be theophylline_be ,_be valproic_be acid_be added_be pooled_be human_be serum_be therapeutic_be concentrations_be ._be"
674,"Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. ",phenobarbital,quinidine,No interaction,"Acetaminophen_bf ,_bf lidocaine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af theophylline_af ,_af valproic_af acid_af added_af pooled_af human_af serum_af therapeutic_af concentrations_af ._af"
675,"Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. ",phenobarbital,theophylline,No interaction,"Acetaminophen_bf ,_bf lidocaine_bf ,_bf DRUG ,_be quinidine_be ,_be OTHER_DRUG ,_af valproic_af acid_af added_af pooled_af human_af serum_af therapeutic_af concentrations_af ._af"
676,"Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. ",phenobarbital,valproic acid,No interaction,"Acetaminophen_bf ,_bf lidocaine_bf ,_bf DRUG ,_be quinidine_be ,_be theophylline_be ,_be valproic_be acid_be added_be pooled_be human_be serum_be therapeutic_be concentrations_be ._be"
677,"Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. ",quinidine,theophylline,No interaction,"Acetaminophen_bf ,_bf lidocaine_bf ,_bf phenobarbital_bf ,_bf DRUG ,_be OTHER_DRUG ,_af valproic_af acid_af added_af pooled_af human_af serum_af therapeutic_af concentrations_af ._af"
678,"Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. ",quinidine,valproic acid,No interaction,"Acetaminophen_bf ,_bf lidocaine_bf ,_bf phenobarbital_bf ,_bf DRUG ,_be theophylline_be ,_be valproic_be acid_be added_be pooled_be human_be serum_be therapeutic_be concentrations_be ._be"
679,"Acetaminophen, lidocaine, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. ",theophylline,valproic acid,No interaction,"Acetaminophen_bf ,_bf lidocaine_bf ,_bf phenobarbital_bf ,_bf quinidine_bf ,_bf DRUG ,_be valproic_be acid_be added_be pooled_be human_be serum_be therapeutic_be concentrations_be ._be"
680,The following eight target drug/added drug combinations were studied: acetaminophen/phenobarbital. ,acetaminophen,phenobarbital,No interaction,The_bf following_bf eight_bf target_bf drug/added_bf drug_bf combinations_bf studied:_bf acetaminophen/phenobarbital_bf ._bf
681,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",acetaminophen,theophylline,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
682,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",acetaminophen,lidocaine,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
683,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",acetaminophen,quinidine,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
684,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",acetaminophen,phenobarbital,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
685,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",acetaminophen,acetaminophen,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
686,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",acetaminophen,phenobarbital,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
687,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",acetaminophen,valproic acid,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
688,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",acetaminophen,quinidine,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
689,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",acetaminophen,lidocaine,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
690,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",acetaminophen,theophylline,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
691,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",acetaminophen,acetaminophen,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
692,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",acetaminophen,valproic acid,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
693,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",acetaminophen,phenobarbital,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
694,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",theophylline,lidocaine,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
695,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",theophylline,quinidine,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
696,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",theophylline,phenobarbital,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
697,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",theophylline,acetaminophen,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
698,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",theophylline,phenobarbital,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
699,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",theophylline,valproic acid,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
700,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",theophylline,quinidine,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
701,"acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. ",theophylline,lidocaine,No interaction,"acetaminophen/theophylline_bf ,_bf lidocaine/quinidine_bf ,_bf phenobarbital/acetaminophen_bf ,_bf phenobarbital/valproic_bf acid_bf ,_bf quinidine/lidocaine_bf ,_bf theophylline/acetaminophen_bf ,_bf valproic_bf acid/phenobarbital_bf ._bf"
